
<html lang="en"     class="pb-page"  data-request-id="71d91c5b-afb9-4fdd-ad95-f966fea697b7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c00279;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach" /></meta><meta name="dc.Creator" content="Edwige  Lorthiois" /></meta><meta name="dc.Creator" content="James  Roache" /></meta><meta name="dc.Creator" content="David  Barnes-Seeman" /></meta><meta name="dc.Creator" content="Eva  Altmann" /></meta><meta name="dc.Creator" content="Ulrich  Hassiepen" /></meta><meta name="dc.Creator" content="Gordon  Turner" /></meta><meta name="dc.Creator" content="Rohit  Duvadie" /></meta><meta name="dc.Creator" content="Viktor  Hornak" /></meta><meta name="dc.Creator" content="Rajeshri G.  Karki" /></meta><meta name="dc.Creator" content="Nikolaus  Schiering" /></meta><meta name="dc.Creator" content="Wilhelm A.  Weihofen" /></meta><meta name="dc.Creator" content="Francesca  Perruccio" /></meta><meta name="dc.Creator" content="Amy  Calhoun" /></meta><meta name="dc.Creator" content="Tanzina  Fazal" /></meta><meta name="dc.Creator" content="Darija  Dedic" /></meta><meta name="dc.Creator" content="Corinne  Durand" /></meta><meta name="dc.Creator" content="Solene  Dussauge" /></meta><meta name="dc.Creator" content="Kamal  Fettis" /></meta><meta name="dc.Creator" content="Fabien  Tritsch" /></meta><meta name="dc.Creator" content="Celine  Dentel" /></meta><meta name="dc.Creator" content="Adelaide  Druet" /></meta><meta name="dc.Creator" content="Donglei  Liu" /></meta><meta name="dc.Creator" content="Louise  Kirman" /></meta><meta name="dc.Creator" content="Julie  Lachal" /></meta><meta name="dc.Creator" content="Kenji  Namoto" /></meta><meta name="dc.Creator" content="Douglas  Bevan" /></meta><meta name="dc.Creator" content="Rose  Mo" /></meta><meta name="dc.Creator" content="Gabriela  Monnet" /></meta><meta name="dc.Creator" content="Lionel  Muller" /></meta><meta name="dc.Creator" content="Richard  Zessis" /></meta><meta name="dc.Creator" content="Xueming  Huang" /></meta><meta name="dc.Creator" content="Loren  Lindsley" /></meta><meta name="dc.Creator" content="Treeve  Currie" /></meta><meta name="dc.Creator" content="Yu-Hsin  Chiu" /></meta><meta name="dc.Creator" content="Cary  Fridrich" /></meta><meta name="dc.Creator" content="Peter  Delgado" /></meta><meta name="dc.Creator" content="Shuangxi  Wang" /></meta><meta name="dc.Creator" content="Micah  Hollis-Symynkywicz" /></meta><meta name="dc.Creator" content="Joerg  Berghausen" /></meta><meta name="dc.Creator" content="Eric  Williams" /></meta><meta name="dc.Creator" content="Hong  Liu" /></meta><meta name="dc.Creator" content="Guiqing  Liang" /></meta><meta name="dc.Creator" content="Hyungchul  Kim" /></meta><meta name="dc.Creator" content="Peter  Hoffmann" /></meta><meta name="dc.Creator" content="Andreas  Hein" /></meta><meta name="dc.Creator" content="Paul  Ramage" /></meta><meta name="dc.Creator" content="Allan  D’Arcy" /></meta><meta name="dc.Creator" content="Stefanie  Harlfinger" /></meta><meta name="dc.Creator" content="Martin  Renatus" /></meta><meta name="dc.Creator" content="Simon  Ruedisser" /></meta><meta name="dc.Creator" content="David  Feldman" /></meta><meta name="dc.Creator" content="Jason  Elliott" /></meta><meta name="dc.Creator" content="Richard  Sedrani" /></meta><meta name="dc.Creator" content="Juergen  Maibaum" /></meta><meta name="dc.Creator" content="Christopher M.  Adams" /></meta><meta name="dc.Description" content="The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been describ..." /></meta><meta name="Description" content="The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been describ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 17, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00279" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00279" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00279" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00279" /></link>
        
    
    

<title>Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00279" /></meta><meta property="og:title" content="Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0013.jpeg" /></meta><meta property="og:description" content="The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound 1, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1′ pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound 23 with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00279"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00279">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00279&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00279&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00279&amp;href=/doi/10.1021/acs.jmedchem.0c00279" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8088-8113</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00131" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00298" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Edwige Lorthiois</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edwige Lorthiois</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e98c8d9e808e8cc785869b9d818086809aa987869f889b9d809ac78a8684"><span class="__cf_email__" data-cfemail="274243504e4042094b4855534f4e484e54674948514655534e540944484a">[email protected]</span></a>. Tel: +41616961955.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edwige++Lorthiois">Edwige Lorthiois</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6147-9321" title="Orcid link">http://orcid.org/0000-0002-6147-9321</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Roache</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Roache</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e08a818d8593ce928f81838885a08e8f968192948993ce838f8d"><span class="__cf_email__" data-cfemail="a7cdc6cac2d489d5c8c6c4cfc2e7c9c8d1c6d5d3ced489c4c8ca">[email protected]</span></a>. Tel: +16178717539.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Roache">James Roache</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9515-2394" title="Orcid link">http://orcid.org/0000-0002-9515-2394</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Barnes-Seeman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Barnes-Seeman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Barnes-Seeman">David Barnes-Seeman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eva Altmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eva Altmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eva++Altmann">Eva Altmann</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2749-6347" title="Orcid link">http://orcid.org/0000-0002-2749-6347</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ulrich Hassiepen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ulrich Hassiepen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ulrich++Hassiepen">Ulrich Hassiepen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gordon Turner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gordon Turner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gordon++Turner">Gordon Turner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rohit Duvadie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rohit Duvadie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rohit++Duvadie">Rohit Duvadie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Viktor Hornak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Viktor Hornak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Viktor++Hornak">Viktor Hornak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajeshri G. Karki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajeshri G. Karki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajeshri+G.++Karki">Rajeshri G. Karki</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2210-5789" title="Orcid link">http://orcid.org/0000-0003-2210-5789</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nikolaus Schiering</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nikolaus Schiering</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nikolaus++Schiering">Nikolaus Schiering</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wilhelm A. Weihofen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wilhelm A. Weihofen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wilhelm+A.++Weihofen">Wilhelm A. Weihofen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francesca Perruccio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Perruccio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Perruccio">Francesca Perruccio</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Calhoun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Calhoun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Calhoun">Amy Calhoun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tanzina Fazal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tanzina Fazal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tanzina++Fazal">Tanzina Fazal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darija Dedic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darija Dedic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darija++Dedic">Darija Dedic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Corinne Durand</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Corinne Durand</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Corinne++Durand">Corinne Durand</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Solene Dussauge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Solene Dussauge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Solene++Dussauge">Solene Dussauge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kamal Fettis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kamal Fettis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kamal++Fettis">Kamal Fettis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabien Tritsch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabien Tritsch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabien++Tritsch">Fabien Tritsch</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Celine Dentel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celine Dentel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celine++Dentel">Celine Dentel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adelaide Druet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adelaide Druet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adelaide++Druet">Adelaide Druet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donglei Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donglei Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donglei++Liu">Donglei Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louise Kirman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louise Kirman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louise++Kirman">Louise Kirman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie Lachal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Lachal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Lachal">Julie Lachal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenji Namoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenji Namoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenji++Namoto">Kenji Namoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas Bevan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas Bevan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas++Bevan">Douglas Bevan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rose Mo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rose Mo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rose++Mo">Rose Mo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gabriela Monnet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gabriela Monnet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gabriela++Monnet">Gabriela Monnet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lionel Muller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lionel Muller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lionel++Muller">Lionel Muller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Zessis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Zessis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Zessis">Richard Zessis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xueming Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xueming Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xueming++Huang">Xueming Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Loren Lindsley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Loren Lindsley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Loren++Lindsley">Loren Lindsley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Treeve Currie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Treeve Currie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Treeve++Currie">Treeve Currie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yu-Hsin Chiu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu-Hsin Chiu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Hsin++Chiu">Yu-Hsin Chiu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cary Fridrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cary Fridrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cary++Fridrich">Cary Fridrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Delgado</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Delgado</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Delgado">Peter Delgado</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuangxi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuangxi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuangxi++Wang">Shuangxi Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Micah Hollis-Symynkywicz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Micah Hollis-Symynkywicz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Micah++Hollis-Symynkywicz">Micah Hollis-Symynkywicz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joerg Berghausen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joerg Berghausen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joerg++Berghausen">Joerg Berghausen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Williams">Eric Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Liu">Hong Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guiqing Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guiqing Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guiqing++Liang">Guiqing Liang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hyungchul Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hyungchul Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hyungchul++Kim">Hyungchul Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Hoffmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Hoffmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Hoffmann">Peter Hoffmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Hein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Hein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Hein">Andreas Hein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Ramage</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Ramage</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Ramage">Paul Ramage</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Allan D’Arcy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Allan D’Arcy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Allan++D%E2%80%99Arcy">Allan D’Arcy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefanie Harlfinger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefanie Harlfinger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefanie++Harlfinger">Stefanie Harlfinger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Renatus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Renatus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Renatus">Martin Renatus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Ruedisser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Ruedisser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Ruedisser">Simon Ruedisser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Feldman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Feldman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07396, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Feldman">David Feldman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Elliott</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Elliott</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Elliott">Jason Elliott</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Sedrani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Sedrani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Sedrani">Richard Sedrani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juergen Maibaum</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juergen Maibaum</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juergen++Maibaum">Juergen Maibaum</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Christopher M. Adams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher M. Adams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+M.++Adams">Christopher M. Adams</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5246-884X" title="Orcid link">http://orcid.org/0000-0002-5246-884X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00279&amp;href=/doi/10.1021%2Facs.jmedchem.0c00279" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8088–8113</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 17, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 February 2020</li><li><span class="item_label"><b>Published</b> online</span>17 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00279" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00279</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8088%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEdwige%2BLorthiois%252C%2BJames%2BRoache%252C%2BDavid%2BBarnes-Seeman%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00279%26title%3DStructure-Based%2BDesign%2Band%2BPreclinical%2BCharacterization%2Bof%2BSelective%2Band%2BOrally%2BBioavailable%2BFactor%2BXIa%2BInhibitors%253A%2BDemonstrating%2Bthe%2BPower%2Bof%2Ban%2BIntegrated%2BS1%2BProtease%2BFamily%2BApproach%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8113%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00279"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2095</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00279" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Edwige&quot;,&quot;last_name&quot;:&quot;Lorthiois&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Roache&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Barnes-Seeman&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Altmann&quot;},{&quot;first_name&quot;:&quot;Ulrich&quot;,&quot;last_name&quot;:&quot;Hassiepen&quot;},{&quot;first_name&quot;:&quot;Gordon&quot;,&quot;last_name&quot;:&quot;Turner&quot;},{&quot;first_name&quot;:&quot;Rohit&quot;,&quot;last_name&quot;:&quot;Duvadie&quot;},{&quot;first_name&quot;:&quot;Viktor&quot;,&quot;last_name&quot;:&quot;Hornak&quot;},{&quot;first_name&quot;:&quot;Rajeshri&quot;,&quot;last_name&quot;:&quot;G. Karki&quot;},{&quot;first_name&quot;:&quot;Nikolaus&quot;,&quot;last_name&quot;:&quot;Schiering&quot;},{&quot;first_name&quot;:&quot;Wilhelm&quot;,&quot;last_name&quot;:&quot;A. Weihofen&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Perruccio&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Calhoun&quot;},{&quot;first_name&quot;:&quot;Tanzina&quot;,&quot;last_name&quot;:&quot;Fazal&quot;},{&quot;first_name&quot;:&quot;Darija&quot;,&quot;last_name&quot;:&quot;Dedic&quot;},{&quot;first_name&quot;:&quot;Corinne&quot;,&quot;last_name&quot;:&quot;Durand&quot;},{&quot;first_name&quot;:&quot;Solene&quot;,&quot;last_name&quot;:&quot;Dussauge&quot;},{&quot;first_name&quot;:&quot;Kamal&quot;,&quot;last_name&quot;:&quot;Fettis&quot;},{&quot;first_name&quot;:&quot;Fabien&quot;,&quot;last_name&quot;:&quot;Tritsch&quot;},{&quot;first_name&quot;:&quot;Celine&quot;,&quot;last_name&quot;:&quot;Dentel&quot;},{&quot;first_name&quot;:&quot;Adelaide&quot;,&quot;last_name&quot;:&quot;Druet&quot;},{&quot;first_name&quot;:&quot;Donglei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Louise&quot;,&quot;last_name&quot;:&quot;Kirman&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Lachal&quot;},{&quot;first_name&quot;:&quot;Kenji&quot;,&quot;last_name&quot;:&quot;Namoto&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;Bevan&quot;},{&quot;first_name&quot;:&quot;Rose&quot;,&quot;last_name&quot;:&quot;Mo&quot;},{&quot;first_name&quot;:&quot;Gabriela&quot;,&quot;last_name&quot;:&quot;Monnet&quot;},{&quot;first_name&quot;:&quot;Lionel&quot;,&quot;last_name&quot;:&quot;Muller&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Zessis&quot;},{&quot;first_name&quot;:&quot;Xueming&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Loren&quot;,&quot;last_name&quot;:&quot;Lindsley&quot;},{&quot;first_name&quot;:&quot;Treeve&quot;,&quot;last_name&quot;:&quot;Currie&quot;},{&quot;first_name&quot;:&quot;Yu-Hsin&quot;,&quot;last_name&quot;:&quot;Chiu&quot;},{&quot;first_name&quot;:&quot;Cary&quot;,&quot;last_name&quot;:&quot;Fridrich&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Delgado&quot;},{&quot;first_name&quot;:&quot;Shuangxi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Micah&quot;,&quot;last_name&quot;:&quot;Hollis-Symynkywicz&quot;},{&quot;first_name&quot;:&quot;Joerg&quot;,&quot;last_name&quot;:&quot;Berghausen&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Guiqing&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Hyungchul&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Hoffmann&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Hein&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Ramage&quot;},{&quot;first_name&quot;:&quot;Allan&quot;,&quot;last_name&quot;:&quot;D’Arcy&quot;},{&quot;first_name&quot;:&quot;Stefanie&quot;,&quot;last_name&quot;:&quot;Harlfinger&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Renatus&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Ruedisser&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Feldman&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Elliott&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Sedrani&quot;},{&quot;first_name&quot;:&quot;Juergen&quot;,&quot;last_name&quot;:&quot;Maibaum&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;M. Adams&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8088-8113&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00279&quot;},&quot;abstract&quot;:&quot;The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound 1, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1′ pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound 23 with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent w&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00279&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00279" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00279&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00279" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00279&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00279" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00279&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00279&amp;href=/doi/10.1021/acs.jmedchem.0c00279" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00279" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00279" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00279%26sid%3Dliteratum%253Aachs%26pmid%3D32551603%26genre%3Darticle%26aulast%3DLorthiois%26date%3D2020%26atitle%3DStructure-Based%2BDesign%2Band%2BPreclinical%2BCharacterization%2Bof%2BSelective%2Band%2BOrally%2BBioavailable%2BFactor%2BXIa%2BInhibitors%253A%2BDemonstrating%2Bthe%2BPower%2Bof%2Ban%2BIntegrated%2BS1%2BProtease%2BFamily%2BApproach%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8088%26epage%3D8113%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound <b>1</b>, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1′ pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound <b>23</b> with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31753" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31753" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of the anticoagulant properties of dicoumarol in 1940, and the subsequent development of warfarin, transformed the practice of medicine,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> offering patients at risk of thrombosis a prophylactic therapeutic option.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, warfarin’s clinical success is tempered by a narrow therapeutic index due to its mechanism of action (vitamin K antagonism), which poses a risk of major life-threatening bleeding.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> This is further compounded by drug–drug interactions (DDIs) and dietary interactions, which require dose titration and frequent laboratory monitoring.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The advent of non-vitamin K anticoagulants (NOACs) has offered patients an alternative to warfarin. Molecules selectively inhibiting the proteases factor Xa (FXa) (<i>e.g</i>., rivaroxaban<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and apixaban<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a>) or thrombin (factor II, FII) (<i>e.g</i>., dabigatran<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a>), which play a pivotal role in coagulation homeostasis, have gained clinical acceptance over the last decade, in part due to simpler dosing paradigms and a lower risk of bleeding.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> However, NOACs are still associated with substantial risk of major bleeding events, limiting their widespread use.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a></div><div class="NLM_p">More recently, the serine protease factor XI (FXI) has come to prominence as a drug target offering the potential of providing efficacious anticoagulation without an enhanced risk of major bleeds.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The activated form, FXIa, has a critical function in the amplification of thrombin generation in a low-tissue-factor environment by directly activating FIX without intrinsic cascade activation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This hypothesis is supported by human data, as individuals deficient in FXI activity have reduced risk of thromboembolic events without an increase in major bleeding events.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Furthermore, a recent clinical trial with an antisense oligonucleotide targeting FXI proved efficacious in preventing venous thrombosis in patients undergoing total knee arthroplasty.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Importantly, in this trial, there was also a trend toward a reduction in bleeding events versus enoxaparin, a heparin mimetic. In light of this strong clinical rationale, several efforts have been disclosed targeting FXIa with low-molecular-weight compounds and biologics.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16−19)</a> These efforts have afforded several linear and macrocyclic scaffolds targeting the enzyme catalytic site and most recently culminated in the discovery of first clinical candidates.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(20−23)</a></div><div class="NLM_p">Herein we disclose our efforts to identify potent and selective inhibitors of FXIa by leveraging the power of a platform drug discovery approach to target serine proteases.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> At the outset of this program, we decided to focus exclusively on demonstrating <i>in vitro</i> efficacy and selectivity in combination with high <i>in vivo</i> oral bioavailability for candidate FXIa inhibitors. These criteria included (1) sufficient potency and pharmacokinetic properties to maintain >85% inhibition of FXIa, in line with genetic evidence that correlates ≥85% FXI deficiency to thromboprotection,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and (2) having sufficient selectivity over other proteases of the coagulation cascade to mitigate the potential risk of bleeding.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> With regard to assessing FXI inhibition and selectivity, we chose to employ a combination of high-throughput enzymatic assays and clinically translatable human plasma coagulation assays. The activated partial thromboplastin time (aPTT) and prothrombin time (PT) assays provided the primary means of assessing the functional potency/efficacy and functional selectivity, respectively, of our FXIa inhibitors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These assays measure the time it takes for plasma to coagulate when the intrinsic (aPTT assay) or extrinsic (PT assay) pathway is stimulated by an exogenous trigger (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). We relied exclusively on the <i>in vitro</i> assessments of efficacy since the translatability of FXIa inhibition from preclinical models to the clinic has not been established. Herein we show the results of our lead optimization efforts leading to a selective and orally (p.o.) bioavailable FXIa inhibitor that prolonged aPTT without perturbation in the PT assay.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the coagulation cascade. The aPTT assay assesses inhibition of the intrinsic (blue) and progression (red) components of the pathway, while the PT assay assesses the extrinsic (orange) and progression components.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Endeavoring for an accelerated hit finding campaign to identify promising starting points with a high potential for oral bioavailability, we took advantage of a combination of high-throughput screening (HTS), virtual screening, and NMR-mediated fragment-based screening (FBS) approaches. We also embarked on a more focused screen of a knowledge-based diversity library (∼1750 compounds) of internal serine protease inhibitors and analogues thereof. This compound collection had been built as part of a protease drug discovery platform at Novartis.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> While the HTS and FBS efforts delivered several hits that were initially taken forward for structure–activity relationship (SAR) exploration, we eventually became most intrigued by the activity of compound <b>1</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which demonstrated an half maximal inhibitory concentration (IC<sub>50</sub>) of 0.63 μM against human FXIa and was structurally diverse from known FXIa inhibitors. This scaffold had originally been discovered as part of our efforts to identify inhibitors of complement factor D (FD),<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a> resulting from a dedicated structure-based design approach tackling a unique active-site architecture of an atypical trypsin-like S1 protease. Compound <b>1</b> appeared to be particularly attractive due to its structural simplicity, low molecular weight, and a balanced lipophilicity/polarity ratio (Log <i>D</i><sub>6.8</sub> = 1.91). These properties translated into encouraging absorption, distribution, metabolism, and excretion (ADME) properties and an excellent mouse pharmacokinetic profile.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Furthermore, the zwitterionic character of <b>1</b> provided a very low-affinity profile toward the human ether-à-go-go-related gene (hERG) ion-channel with IC<sub>50</sub> values >30 μM in both the dofetilide binding and the functional Q-patch assays. However, the potency of <b>1</b> against FD (IC<sub>50</sub>: 0.008 μM) and the relatively moderate selectivity against other trypsin-like S1 proteases of the coagulation cascade (<i>e.g</i>., plasma kallikrein (PKL), IC<sub>50</sub>: 3.1 μM; plasmin, IC<sub>50</sub>: 2.2 μM; FVIIa, IC<sub>50</sub>: 1.4 μM; and urokinase, IC<sub>50</sub>: 0.77 μM) needed to be addressed in addition to optimizing the potency against FXIa. Hence, the most prominent question raised was whether the design of a potent and highly selective FXIa inhibitor would be feasible at all by starting from a low-nanomolar FD inhibitor scaffold.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of early-stage S1-benzylamine-based FXIa inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the aim of developing a rational design concept toward improved FXIa selectivity, we resolved the cocrystal structure of a closely related analogue, <b>2</b> (FXIa IC<sub>50</sub>: 2.8 μM), bearing a carboxamide spacer instead of the ether linker in compound <b>1</b>. The overall binding mode of <b>2</b> in FXIa is similar to that observed in FD<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) in that it spans the S1 and S1′ pockets in a U-shaped conformation. The basic primary amine is within the H-bonding distance to the Ala<sub>190</sub> backbone carbonyl and forms a salt bridge with the side chain of Asp<sub>189</sub>. The biphenyl portion of the molecule is sandwiched between the Lys<sub>192</sub> side chain and the Trp<sub>215</sub> backbone, and the carboxylic acid moiety binds to the oxyanion hole making H-bonding interactions with the side chain of His<sub>57</sub> and the backbone NH of Gly<sub>193</sub>. The H-bonding interactions with Ser<sub>195</sub> are not visible in the X-ray structure as an FXIa active site mutant (S<sub>195</sub>A mutant; chymotrypsinogen numbering has been used throughout this paper) was used to obtain this cocrystal structure. The absence of the OH in the mutant protein does not have an influence on the position of the carboxylic acid based on comparison to related compounds in Ser<sub>195</sub> FXIa-containing crystals. The phenyl ring fits nicely in the S1′ pocket and forms an edge-to-face interaction with His<sub>57</sub>. Several X-ray structures of FXIa and inhibitor complexes, which were not available at the time of our work, have since been reported with a phenyl ring binding in a similar fashion in the S1′ pocket of the FXIa active site.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of compound <b>2</b>. (a) Crystal structure of <b>2</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS4">6TS4</a>) with FXIa S<sub>195</sub>A mutant (green). The surface of the protein is shown in gray, and oxygen atoms of crystallographic water molecules are shown as red spheres. (b) Comparison of the crystal structures of compound <b>2</b> with FXIa (yellow and green carbons) and FD (pale blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QMT">6QMT</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Only selected residues in the ligand binding pocket are shown. FXIa and FD residues are labeled in black and blue, respectively. H-bonding interactions are shown as black dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most importantly, the comparison between the FXIa<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and FD<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> inhibitor binding sites revealed several opportunities to concomitantly improve FXIa potency and FD selectivity by specifically targeting the deep S1 pocket, the S1β pocket, and/or the prime site of FXIa. With regard to the S1 pocket, trypsin-like proteases can be differentiated based on the nature of the amino acid 190 at the bottom of the S1 pocket, which dictates enzyme specificity. FXIa and thrombin display an alanine in position 190, while FD, urokinase, and FVIIa bear the larger, more polar, serine residue at this position. As a consequence, the latter enzymes show substrate specificity for the less sterically demanding P1 lysine residue, while FXIa prefers arginine.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This difference has been successfully exploited to enhance selectivity of various trypsin-like protease inhibitors.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Besides the S1 pocket, the small hydrophobic S1β pocket located on top of the Cys<sub>191</sub>–Cys<sub>219</sub> disulfide bridge was also considered to offer another opportunity for improving FXIa affinity and specificity, since the S1β pocket of FXIa is limited in size due to the side chain of Leu<sub>146</sub>. A literature survey of known inhibitors of serine proteases indicated that binding in this region could contribute to improved ligand binding affinity.<a onclick="showRef(event, 'ref27 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref27 ref34 ref35">(27,34,35)</a> Further extension into the S2′ site, for which significant structural differences are observed between FXIa and off-target serine proteases, offers another option to enhance selectivity. In particular, FXIa exhibits a comparatively more open S1′–S2′ binding region versus FD.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> However, accessing the S2′ pocket would require increasing the size of the molecule significantly, and therefore this strategy was initially deferred.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">A final key aspect defining our medicinal chemistry strategy related to the nature of the S1–S1′ linker. At the outset of our work, it was argued that the basic amine of <b>1</b>, positioned in S1, and the carboxylic acid are engaged in key interactions with Asp<sub>189</sub> and the canonical oxyanion hole (residues Gly<sub>193</sub> and Ser<sub>195</sub>), respectively, and therefore are unlikely to evoke differentiating binding interactions on their own for FXIa versus FD and other proteases.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> However, the appropriate spacing and alignment of these two motifs might offer an opportunity to enhance potency and selectivity and to modulate ADME properties. Of equal importance was the notion that the zwitterionic motif of this scaffold provided an advantageous <i>in vitro</i> and <i>in vivo</i> ADME profile, in particular, when retaining the less polar ether linker of compound <b>1</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">Our initial efforts focused on optimizing the binding interactions to the deep and solvent-shielded S1 specificity pocket, in particular, by growing toward Ala<sub>190</sub>, which was expected to enhance binding to FXIa and at the same time to be less well accommodated by the smaller S1 pocket of the Ser<sub>190</sub> S1 family serine proteases including FD. To probe the impact of the larger FXIa S1 pocket, compound <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was prepared, in which the benzylamine motif was replaced by the rigid bicyclic tetrahydroisoquinoline, thereby mimicking the FXIa-bound conformation of the flexible aminomethyl group in <b>2</b>. Compound <b>3</b> displayed similar potency against FXIa as compound <b>1</b>, and the inhibitory activity toward FD was reduced by 100-fold (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). To confirm our design rationale, the X-ray crystal structure of <b>3</b> bound to FXIa with the native catalytic triad was resolved (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The binding mode spanning S1 and S1′ and the oxyanion hole is very similar as observed for FXIa-bound <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The basic NH motif makes H-bonding interactions with the Ala<sub>190</sub> backbone carbonyl and the side chain of Asp<sub>189</sub> similar to that observed in the <b>2</b>–FXIa complex.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Crystal structure of compound <b>3</b> (yellow) complexed with FXIa (white, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS7">6TS7</a>). (b) Overlay of the crystal structure of compound <b>3</b> (yellow) complexed with FXIa (white) on compound <b>4</b> (cyan) complexed with PKL (pale blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T7P">6T7P</a>). Only selected residues in the ligand binding pocket are shown. H-bonding interactions are shown as black dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Encouraged by this result, we undertook a broad search of P1 moieties by close inspection of published and in-house cocrystal structures of S1-binding fragments and S1 protease inhibitors. Overlaying the FXIa–<b>2</b> and −<b>3</b> crystal structures with compound <b>4</b>, derived from our knowledge-based diversity library, bound to PKL,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> a related trypsin-like Ala<sub>190</sub> S1 protease, proved particularly fruitful. The aminodihydrobenzofuran of <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) overlapped with the S1-binding phenyl and basic amine motifs from both inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). Compound <b>4</b> was cocrystallized with PKL as a mixture of (<i>R</i>)- and (<i>S</i>)-2,3-dihydrobenzofuranyl-3-amine diastereoisomers. The electron density of the bound ligand was consistent with the absolute (<i>S</i>)-configuration of the 3-aminodihydrobenzofuran.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Racemic <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which combines the two key pharmacophores of <b>4</b> and <b>3</b>, was prepared and showed similar inhibitory affinity for both FXIa and FD as compared to <b>3</b>. Compound <b>5</b> was also found to be a weak inhibitor of PKL, albeit with a 5-fold lower IC<sub>50</sub> value of 1.3 μM versus FXIa (IC<sub>50</sub> of 0.2 μM). During our continued optimization efforts, we preferred both the tetrahydroisoquinoline and the 3-aminodihydrobenzofuran S1-binding motifs as more tractable replacements of the benzylamine moiety of the screening hit <b>1</b>, as these scaffolds offered the benefit of a lower risk for semicarbazide-sensitive amine oxidase (SSAO)-mediated metabolism<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and potential toxicity.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">Next, we focused our attention on targeting the S1β pocket in FXIa. SAR exploration of a representative selection of compound <b>1</b> analogues from the FD inhibitor program<a onclick="showRef(event, 'ref27 ref42'); return false;" href="javascript:void(0);" class="ref ref27 ref42">(27,42)</a> in the FXIa biochemical assay indicated a preference for small and branched aliphatic substituents. This finding was in line with the limited size of the FXIa S1β pocket due to the conformational fold of the Leu<sub>146</sub> side chain. Intriguingly, incorporation of an isopropyl substituent into the meta-position of the middle phenyl ring at the edge of the S1β site resulted in a significant 65-fold potency increase for compound <b>6</b> bearing the P1 (<i>S</i>)-2,3-dihydrobenzofuranyl-3-amine moiety as a single stereoisomer.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Inhibitor <b>6</b> displayed single-digit nanomolar potency toward FXIa with an IC<sub>50</sub> value of 0.003 μM in the biochemical assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>); however, a 40-fold drop in potency was observed for <b>6</b> when measured in the presence of 50% human plasma (catalytic domain (cd)-FXIa IC<sub>50</sub>: 0.12 μM; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The potency of <b>6</b> against FD was also increased, leading to a 10-fold selectivity for FXIa over FD. There was no improvement in PKL selectivity due to the high homology between FXIa and PKL. In previous reports,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> achieving selectivity toward PKL proved difficult and, to our knowledge, only the large FXIa inhibitor BMS-962212 lacking oral bioavailability demonstrated a significant selectivity against PKL (∼400-fold).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Among S1 proteases, PKL is an exceptionally close homolog of FXI, indicating a recent divergence from a common ancestor.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Selectivity over PKL was not considered a necessary attribute as human congenital deficiency in prekallikrein, the inactive precursor of PKL, or prekallikrein-deficient mice do not encounter an increase in clinically relevant bleeding.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> FXIa Potency (IC<sub>50</sub>), Selectivity Data versus FD and PKL, and <i>In Vitro</i> Profiles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char=".">FXIa IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cd-FXIa plasma IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">FD IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">PKL IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">Caco-2 <i>P</i><sub>app</sub>(AB)/(BA) × 10<sup>–6</sup> (cm/s) (ratio (BA)/(AB))</th><th class="colsep0 rowsep0" align="center">HT-eq solubility pH 6.8 (mM)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="left">7/17 (2.3)</td><td class="colsep0 rowsep0" align="left">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="left">1.4/41 (30)</td><td class="colsep0 rowsep0" align="left">0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="left">BLQ<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a>/19 (−)</td><td class="colsep0 rowsep0" align="left">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">0.067</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="left">BLQ<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a>/4 (−)</td><td class="colsep0 rowsep0" align="left">0.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.085</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="left">12/12 (1)</td><td class="colsep0 rowsep0" align="left"><0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Half-maximal inhibition of purified human FXIa.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Half-maximal inhibition of recombinant catalytic domain of human FXIa as determined in a fluorogenic rhodamine-110-based peptide cleavage assay.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Half-maximal inhibition of recombinant human complement FD as determined in a time-resolved fluorescence energy transfer (TR-FRET) assay.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Half-maximal inhibition of PKL as determined in a fluorogenic rhodamine-110-based peptide cleavage assay. Data represent geometric mean values of multiple measurements (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Equilibrium high-throughput solubility in an aqueous buffer (pH 6.8).</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">BLQ, below limit of quantitation.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">ND, not determined.</p></div></div></div><div class="NLM_p">The improvement in biochemical potency and selectivity against FD demonstrated by <b>6</b> warranted assessment in the aPTT and PT coagulation assays. In our hands, a 2-fold increase in the aPTT coagulation time correlated with ∼95% inhibition of FXIa activity in the plasma, surpassing our threshold of 85%.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Hence, we evaluated <b>6</b> and subsequent analogues on the concentration necessary to effect a doubling of coagulation time assessed by aPTT (2 × aPTT). For comparison, we also evaluated the inhibitor concentration required to double the prothrombin time (2 × PT) as a measure of selectivity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> We aimed for compounds that could achieve 2 × aPTT at total plasma concentrations ≤1.5 μM. These criteria were based on the assumption that identifying a compound with a pharmacokinetic profile enabling <i>C</i><sub>trough</sub> concentrations of >1.5 μM would be exceedingly difficult. For the PT selectivity assessment, we aimed for a ≥20-fold difference between aPTT and PT doubling concentrations with the assumption that such a margin should enable functional selectivity at both peak and trough plasma concentrations when paired with a suitable PK profile. Inhibitor <b>6</b> afforded a 2 × aPTT value of 2.2 μM and a 2 × PT value of 9.9 μM, resulting in a 2 × aPTT/PT ratio of only about 4-fold. Notably, the significant PT activity of this compound suggested that the off-target activity against other coagulation cascade proteases was likely influencing the aPTT assessment as well as resulting in an overestimation of FXIa-driven potency in the latter assay (<i>vide infra</i>; <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">Despite the suboptimal functional selectivity observed with <b>6</b>, we wanted to investigate how these structural changes relative to compound <b>1</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> impacted ADME and PK properties (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Gratifyingly, the favorable ADME properties of compound <b>1</b> were retained and translated to low clearance and excellent oral bioavailability in mice.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vivo</i> Mouse Pharmacokinetic Profiles for Compounds <b>1</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><b>6</b>–<b>8</b>, and <b>11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" char="±" /></col><col align="center" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>compounds</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>1</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>6</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>7</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>8</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>11</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/(min·kg))</td><td class="colsep0 rowsep0" align="center" char="±">14<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">55 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="center" char="±">0.7<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2term</sub> (h)</td><td class="colsep0 rowsep0" align="center" char="±">1.6<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC p.o. d.n. (nM·h)</td><td class="colsep0 rowsep0" align="char" char="±">3284 ± 138</td><td class="colsep0 rowsep0" align="center" char="±">48 927<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">171 ± 146</td><td class="colsep0 rowsep0" align="char" char="±">186 ± 26</td><td class="colsep0 rowsep0" align="char" char="±">6525 ± 1508</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">%<i>F</i></td><td class="colsep0 rowsep0" align="char" char="±">100 ± 17</td><td class="colsep0 rowsep0" align="center" char="±">100<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">25 ± 21</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">61 ± 14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> d.n. (nM)</td><td class="colsep0 rowsep0" align="char" char="±">2591 ± 36</td><td class="colsep0 rowsep0" align="center" char="±">5263<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">137 ± 111</td><td class="colsep0 rowsep0" align="char" char="±">99 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">1126 ± 320</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Discrete PK profiles, male mice (C57BL/6), dose intravenous (i.v.) 1.0 mg/kg, dose p.o. 3.0 mg/kg, except for compound <b>1</b> dosed p.o. at 10 mg/kg.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">No standard deviation (SD) calculated as one animal was excluded from the dosing group due to experimental issues.</p></div></div></div><div class="NLM_p">We next explored the interactions with the S1β pocket with the additional aim to improve solubility and to reduce the potency shift observed with compound <b>6</b> in the presence of plasma (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To that end, we investigated substitution of the P1β isopropyl group by various polar residues. Introduction of a nitrile (<b>7</b>), hydroxyl (<b>8</b>), or a primary carboxamide (<b>9</b>) retained the high biochemical potency for FXIa and PKL. For compound <b>7</b>, a slight improvement in potency in the 50% plasma assay was observed (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, biochemical selectivity against FD was also substantially improved for <b>8</b> (40-fold) and <b>9</b> (80-fold) but not for <b>7</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Introduction of S1β-binding residues to the P1 tetrahydroisoquinoline scaffold, as exemplified by compound <b>10</b>, afforded only a minor 4-fold improvement in potency for FXIa, while inhibitory activity toward FD was retained as compared to compound <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">The X-ray crystal structure of <b>7</b> in complex with FXIa (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a) revealed a binding pose very similar to that observed for compound <b>3</b> with a perfect overlap of the respective biphenyl scaffolds, the ether linkers, and the aryl acetic acid motifs of both inhibitors. The isopropyl nitrile moiety was nicely accommodated by the hydrophobic S1β pocket formed by the side chains of Leu<sub>146</sub>, Tyr<sub>143</sub>, and Lys<sub>192</sub>. The 2,3-dihydrobenzofuran-3(<i>S</i>)-amine moiety closely filled the S1 pocket, with the amine H-bonding with the side chain of Asp<sub>189</sub> and the backbone carbonyl of Ala<sub>190</sub> and Gly<sub>218</sub>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Crystal structure of compound <b>7</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS6">6TS6</a>) in complex with FXIa (white). The surface of the protein is shown in gray, and oxygen atoms of crystallographic water molecules are shown as red spheres. (b) Comparison of the cocrystal structure of compound <b>7</b> (yellow) complexed with FXIa (white) and compound <b>2</b> (pale blue) complexed with FD (pale blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QMT">6QMT</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Only selected residues in the ligand binding pocket are shown. H-bonding interactions are shown as black dotted lines. FXIa residues are labeled in black, and FD residues are labeled in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also noted that terminal polar P1β residues, as exemplified by compounds <b>7</b>–<b>9</b>, had a beneficial impact on solubility, but they also proved detrimental to cell permeability and induced efflux as measured by a Caco-2 assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, <i>in vivo</i> mouse PK profiles for compounds <b>7</b> and <b>8</b> indicated increased clearance and reduced oral bioavailability relative to compound <b>6</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This prompted us to explore the introduction of locally masked or shielded polarity as part of an additional heterocycle attached to the upper phenyl ring while keeping the beneficial hydrophobic van der Waals interactions to the S1β pocket. To this end, we synthesized the 3,3-dimethyl-dihydrobenzofuran analogue <b>11</b>, which exhibited similar low-nanomolar potency toward FXIa in both the biochemical and plasma assays and also showed a ∼17-fold selectivity over FD (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This compound demonstrated an improved mouse PK profile, as compared with <b>7</b> and <b>8</b>, characterized by low clearance and good bioavailability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). However, a 2 × PT value of 19.8 μM in relation to a 2 × aPTT value of 2.5 μM (aPTT/PT ratio of ∼8) needed further improvement (<i>vide infra</i>,<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). We then explored modifications of the aliphatic portion of the P1 pharmacophore, which is deeply buried at the bottom of the S1 recognition site upon binding to FXIa. We reasoned that filling more tightly the unoccupied space near Ala<sub>190</sub> could further improve selectivity versus FD and other Ser<sub>190</sub> proteases. As an example, enlargement of the (<i>S</i>)-2,3-dihydrobenzofuranyl-3-amine of <b>11</b> to the six-membered ring provided the sterically more demanding (<i>R</i>)-chromanyl amine <b>12</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Relative to compound <b>11</b>, compound <b>12</b> showed similar potency toward FXIa in the biochemical assay but with a 3-fold drop in potency in the FXIa plasma assay. Despite the insufficient FXIa plasma potency, <b>12</b> demonstrated exquisite 2500-fold selectivity against FD, which was attributed to a steric clash with Ser<sub>190</sub> present in FD.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> S1 Protease Selectivity Data for Selected FXIa Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="."><b>6</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11</b></th><th class="colsep0 rowsep0" align="center" char="."><b>12</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FVIIa IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">5.10</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FIXa IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FXa IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">0.84</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thrombin IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.090</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tPa IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.090</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasmin IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">2.60</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">urokinase IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">0.047</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Half-maximal inhibition of selected proteases as determined in biochemical activity assays using quenched fluorescent peptide substrates. Data represent mean values of duplicate measurements.</p></div></div></div><div class="NLM_p">To assess the selectivity profile of our emerging lead FXIa inhibitors, we tested them against a panel of serine proteases of the coagulation cascade and serine proteases, which play a role in fibrinolysis, <i>i.e</i>., in breaking down blood clots (<i>e.g</i>., tissue plasminogen activator (tPa), urokinase, plasmin). Inhibitors <b>6</b> and <b>11</b> exhibited acceptable selectivity over FVIIa and plasmin but also showed submicromolar affinities for FIXa, FXa, thrombin, tissue plasminogen activator (tPa), and urokinase (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>12</b> bearing a larger S1-binding motif demonstrated improved selectivity against Ser<sub>190</sub> proteases FVIIa, urokinase, FXa, and thrombin and also versus FIXa. However, we considered the moderate selectivity across the off-target protease panel for these three compounds still to be insufficient, as inhibition of either one specific enzyme, or the additive effect of partial inhibition of several of these proteases, may negatively affect the risk of bleeding, as evidenced by the poor 2 × aPTT/PT ratios for compounds <b>6</b> and <b>11</b>.</div><div class="NLM_p">FXIa inhibitor <b>6</b> comprising a very lean zwitterionic structure of low molecular weight and demonstrating a high inhibitory ligand efficiency for FXIa (binding efficiency index (BEI)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> of 20, lipophilic ligand efficiency (LLE)<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> of 5.4, Log <i>D</i><sub>7.4</sub> of 3.1) provided a better understanding of the foundational SAR as it relates to FXIa and FD activities. Compound <b>6</b> also demonstrated a low risk of DDI and hERG inhibition (CYPs 3A4, 2C9, 2D6: all IC<sub>50></sub>20 μM; hERG Qpatch IC<sub>50</sub>: 24 μM) and afforded good selectivity against a panel of 69 enzymes, receptors, and ion channels (all IC<sub>50</sub> values >30 μM, except Cox1 IC<sub>50</sub>: 3.3 μM; phosphodiesterase 4d (PDE4d) IC<sub>50</sub>: 7.2 μM; and vesicular monoamine transporter 2 (VMAT2) IC<sub>50</sub>: 5.2 μM). Furthermore, <b>6</b> afforded an excellent mouse pharmacokinetic profile (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Therefore, we chose compound <b>6</b> as a minimal pharmacophore, maintaining the key 3-amino-dihydrobenzofuran moiety at S1 and the <i>i</i>Pr group at S1β for further optimization.</div><div class="NLM_p">With our primary pharmacophore set, we turned our attention toward addressing protease selectivity. To this end, we explored optimizing the spacing between the 3-amino-dihydrobenzofuran and the carboxylic acid making the critical interaction in the oxyanion hole. We reasoned that rigidifying the structure to enforce a conformation that would better position the carboxylic acid in the oxyanion hole would improve both FXIa affinity and potentially enhance selectivity against other serine proteases. Molecular modeling suggested that a fused ring system would provide such an opportunity. A fused 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine, which essentially ties the aryl acetic acid back into the linker as in <b>13</b>, appeared particularly promising (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In addition, the added polarity of this linker offered the potential to reduce the plasma IC<sub>50</sub> shift associated with compound <b>6</b>. Synthesized as a mixture of diastereomers at the 2-position of the 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine and subsequently separated, the more potent (<i>R</i>)-isomer, <b>13</b>,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> exhibited exquisite potency that was at the limit of the biochemical assay (<0.7 nM). This increase in biochemical potency also translated to a 10-fold shift in potency relative to compound <b>6</b> in the presence of plasma (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In addition, the concentration necessary to elicit a doubling in aPTT time was only 0.4 μM (∼5-fold more potent than compound <b>6</b>). Unfortunately, the 2 × aPTT/PT ratio was low (5.1×), indicating very little selectivity between the intrinsic and extrinsic coagulation pathways and suggesting that the observed potency in the aPTT assay was not entirely due to FXIa inhibition.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure of the fused 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>13</b>) and benzoic acids (<b>14–19</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Potency and Selectivity Data: IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="."><b>6</b></th><th class="colsep0 rowsep0" align="center" char="."><b>13</b></th><th class="colsep0 rowsep0" align="center" char="."><b>14</b></th><th class="colsep0 rowsep0" align="center" char="."><b>15</b></th><th class="colsep0 rowsep0" align="center"><b>16</b></th><th class="colsep0 rowsep0" align="center" char="."><b>17</b></th><th class="colsep0 rowsep0" align="center" char="."><b>18</b></th><th class="colsep0 rowsep0" align="center" char="."><b>19</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><b>21</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><b>22</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><b>23</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FXIa</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char="."><0.0007</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="left">2.52</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.017</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char="."><0.0007</td><td class="colsep0 rowsep0" align="left">0.0004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cd-FXIa plasma</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">1.19</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">6.62</td><td class="colsep0 rowsep0" align="char" char=".">5.49</td><td class="colsep0 rowsep0" align="char" char=".">8.11</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.045</td><td class="colsep0 rowsep0" align="left">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FVIIa</td><td class="colsep0 rowsep0" align="char" char=".">5.10</td><td class="colsep0 rowsep0" align="char" char=".">2.00</td><td class="colsep0 rowsep0" align="char" char=".">3.27</td><td class="colsep0 rowsep0" align="char" char=".">28.3</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">6.23</td><td class="colsep0 rowsep0" align="char" char=".">45.1</td><td class="colsep0 rowsep0" align="char" char=".">20.5</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">8.75</td><td class="colsep0 rowsep0" align="char" char=".">16.7</td><td class="colsep0 rowsep0" align="left">3.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FIXa</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">3.30</td><td class="colsep0 rowsep0" align="char" char=".">11.3</td><td class="colsep0 rowsep0" align="char" char=".">9.60</td><td class="colsep0 rowsep0" align="char" char=".">15.5</td><td class="colsep0 rowsep0" align="char" char=".">7.86</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="left">1.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FXa</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">6.21</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">1.83</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">11.1</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="char" char=".">1.71</td><td class="colsep0 rowsep0" align="char" char=".">11.2</td><td class="colsep0 rowsep0" align="left">1.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thrombin</td><td class="colsep0 rowsep0" align="char" char=".">0.090</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">9.09</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">3.08</td><td class="colsep0 rowsep0" align="char" char=".">9.82</td><td class="colsep0 rowsep0" align="char" char=".">6.22</td><td class="colsep0 rowsep0" align="char" char=".">7.43</td><td class="colsep0 rowsep0" align="char" char=".">6.14</td><td class="colsep0 rowsep0" align="char" char=".">7.21</td><td class="colsep0 rowsep0" align="left">2.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKL</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.058</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tPA</td><td class="colsep0 rowsep0" align="char" char=".">0.090</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">2.20</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char=".">4.13</td><td class="colsep0 rowsep0" align="char" char=".">3.67</td><td class="colsep0 rowsep0" align="char" char=".">6.68</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasmin</td><td class="colsep0 rowsep0" align="char" char=".">2.60</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">30.8</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">2.56</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">34.0</td><td class="colsep0 rowsep0" align="char" char=".">46.2</td><td class="colsep0 rowsep0" align="char" char=".">9.58</td><td class="colsep0 rowsep0" align="char" char=".">17.4</td><td class="colsep0 rowsep0" align="left">1.89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">uPA</td><td class="colsep0 rowsep0" align="char" char=".">0.047</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.52</td><td class="colsep0 rowsep0" align="char" char=".">2.48</td><td class="colsep0 rowsep0" align="char" char=".">0.93</td><td class="colsep0 rowsep0" align="char" char=".">1.13</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">1.42</td><td class="colsep0 rowsep0" align="left">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FD</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">1.32</td><td class="colsep0 rowsep0" align="char" char=".">17.5</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">4.41</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">34.2</td><td class="colsep0 rowsep0" align="char" char=".">27.2</td><td class="colsep0 rowsep0" align="char" char=".">73.6</td><td class="colsep0 rowsep0" align="char" char=".">8.92</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All values are geometric means of ≥2 replicates.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Diastereomeric mixture.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">ND, not determined.</p></div></div></div><div class="NLM_p">With selectivity remaining a significant challenge, we next explored more substantial changes in the spacing between the 3-amino-dihydrobenzofuran and the carboxylic acid. Up to this point, we had focused on aryl acetic acids as a means of spanning the six-atom distance between the S1β moiety and the carboxylic acid of our pharmacophore. It was reasoned that pushing the P1′ phenyl ring further toward the oxyanion hole by converting the aryl acetic acid to a benzoic acid and by extending the linker by one atom to maintain the requisite spacing might offer new SAR to aid in addressing the selectivity challenge. To this end, an introductory set of benzoic acid compounds exemplified by <b>14</b>–<b>17</b> was synthesized (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The inclusion of indoline <b>17</b> was inspired by the exquisite potency offered by the fused ring system of <b>13</b>. The ether-linked benzoic acid, <b>14</b>, proved to be 5-fold less potent than <b>6</b> against FXIa and exhibited a larger plasma shift (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In addition, <b>14</b> did not demonstrate a significant improvement in selectivity over other serine proteases. Surprisingly, addition of an <i>m</i>-methoxy group to the benzoic acid, <b>15</b>, demonstrated a substantial increase in selectivity over most of the coagulation factors and fibrinolysis proteases, although FXIa potency, especially in the presence of plasma, did not improve compared to compound <b>6</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Exchanging the ether oxygen in the linker for a nitrogen, <b>16</b>, resulted in a significant loss of FXIa potency (IC<sub>50</sub> 2.52 μM). However, the indoline <b>17</b> provided biochemical potency on par with compound <b>6</b> and, like <b>15</b>, also afforded an increase in selectivity against the coagulation proteases (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In addition, indoline <b>17</b> demonstrated an encouraging <i>in vivo</i> mouse PK profile with a long <i>t</i><sub>1/2</sub> (9 h) and promising oral bioavailability (36%) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vivo</i> Mouse Pharmacokinetic Profiles of Indoline and Indole FXIa Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center"><b>17</b></th><th class="colsep0 rowsep0" align="center"><b>23</b></th><th class="colsep0 rowsep0" align="center"><b>23</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose [i.v./p.o.] (mg/kg)</td><td class="colsep0 rowsep0" align="left">0.4/3.0</td><td class="colsep0 rowsep0" align="left">1.0/3.0</td><td class="colsep0 rowsep0" align="left">100 (p.o.)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/(min·kg))</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">11.01</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2term</sub> (h)</td><td class="colsep0 rowsep0" align="left">9.2</td><td class="colsep0 rowsep0" align="left">3.73</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC i.v. d.n. (nM·h)</td><td class="colsep0 rowsep0" align="left">38 652</td><td class="colsep0 rowsep0" align="left">3264 ± 35</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC p.o. d.n. (nM·h)</td><td class="colsep0 rowsep0" align="left">14 041 ± 1090</td><td class="colsep0 rowsep0" align="left">1297 ± 112</td><td class="colsep0 rowsep0" align="left">260 215 ± 8503</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">%<i>F</i></td><td class="colsep0 rowsep0" align="left">36 ± 3</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">100%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> d.n. (nM)</td><td class="colsep0 rowsep0" align="left">1495 ± 158</td><td class="colsep0 rowsep0" align="left">494 ± 52</td><td class="colsep0 rowsep0" align="left">26 795 ± 144</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.7 ± 0.3</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4.0</td></tr></tbody></table></div></div><div class="NLM_p">From the introductory set of compounds, <b>15</b> and <b>17</b> emerged as frontrunners being equipotent with compound <b>6</b> but with improved selectivity in the coagulation pathway. However, further attempts to expand the SAR around <b>15</b> to improve FXIa potency, especially in the presence of 50% plasma, while maintaining selectivity proved nonproductive. The <i>m</i>-methyl and <i>m</i>-chloro derivatives, <b>18</b> and <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), were 5-fold less potent against FXIa than <b>15</b> and showed a greater than 300-fold IC<sub>50</sub> plasma shift (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_p">We then focused on the linker between the S1β and the prime site with an aim to enhance biochemical potency and reduce plasma IC<sub>50</sub> shift. We hypothesized that installation of a polar moiety could introduce additional conformational bias in the linker and lower the Log <i>D</i><sub>7.4</sub>. To this end, <b>20</b> and <b>21</b> were synthesized as diastereomeric mixtures with a hydroxyl group appended to the benzylic position of the linker (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). This modification lowered the calculated Log  <i>D</i><sub>7.4</sub> for each of these compounds compared to <b>15</b> and <b>17</b>. Unfortunately, this change was not productive in the context of <b>20</b>, which resulted in a 10-fold loss in potency against FXIa in the biochemical assay and a 200-fold plasma IC<sub>50</sub> shift (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Conversely, <b>21</b>, the hydroxyl analogue of <b>17</b>, maintained encouraging FXIa activity even as a mixture of diastereomers and appeared to improve selectivity on all relevant coagulation factors (FIXa, FXa, FVIIa, thrombin, and plasmin). In addition to the coagulation factors, an impressive improvement in FD selectivity from 700-fold for <b>17</b> to over 30 000-fold for <b>21</b> was observed (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). While the indoline afforded a promising selectivity and potency profile, it had a propensity to oxidize; thus, the corresponding indole, <b>22</b>, was synthesized as a diastereomeric mixture (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Interestingly, <b>22</b> increased FXIa potency 4-fold over the diastereomeric indoline and, despite an increase in cLog <i>D</i><sub>7.4</sub>, maintained a reasonable plasma IC<sub>50</sub> shift. Furthermore, the change to the indole appeared to suggest an improvement in selectivity versus all of the coagulation factors as well as the fibrinolysis proteases urokinase-type plasminogen activator (uPA) and tPA (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). When the diastereomeric mixture was separated, the (<i>S</i>)-isomer, <b>23</b>, proved to be the more active isomer<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> with subnanomolar activity against FXIa and an IC<sub>50</sub> of 10 nM in the presence of 50% plasma. Furthermore, the overall improvement in selectivity profile seen with <b>22</b> was maintained.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a><b>23</b> also preserved the high inhibitory ligand efficiency for FXIa of compound <b>6</b> (BEI<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> of 20) and demonstrated an improved LLE<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> of 7.2 (Log <i>D</i><sub>7.4</sub> of 2.2).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Exploration of addition of a hydroxyl to the linker between the S1β and S1′ sites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to better rationalize the enhanced FXIa potency and selectivity of <b>23</b>, we obtained a cocrystal structure of <b>23</b> with FXIa. Similar to earlier cocrystal structures, <b>23</b> binds to FXIa with the biphenyl portion of the inhibitor sitting in the S1 pocket and the basic amino group making H-bonding interactions with the backbone carbonyl from Ala<sub>190</sub> and the side chain of Asp<sub>189</sub> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). The carboxylic acid moiety binds in the oxyanion hole and has H-bonding contacts with the backbone NH of Gly<sub>193</sub> and the side chains of His<sub>57</sub> and Ser<sub>195</sub>. A water-mediated H-bonding interaction is also seen with the backbone carbonyl of Leu<sub>39</sub>. The binding interactions of <b>23</b> with FXIa gave no direct evidence to rationalize the increased selectivity. However, a superposition of the structures of compound <b>1</b> complexed with FD and <b>23</b> complexed with FXIa suggests that the carboxylic acid of <b>23</b> does not sit as deep in the oxyanion hole as for compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b). Interestingly, when a comparable overlay with one of the observed binding poses of the selective benzoic acid <b>15</b> is performed, a similar arrangement in the oxyanion hole is observed as with <b>23</b>. This weaker interaction in the oxyanion hole may be responsible for the increased selectivity of both <b>15</b> and <b>23</b> over the other coagulation factors.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Crystal structure of <b>23</b> (yellow) in complex with FXIa (white, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USY">6USY</a>). The surface of the protein is shown in gray, and oxygen atoms of crystallographic water molecules are shown as red spheres. Only selected residues in the ligand binding pocket are shown. H-bonding interactions are shown as black dotted lines. (b) Overlay of compound <b>1</b> (cyan) bound to FD, <b>15</b> bound to FXIa (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS5">6TS5</a>), and <b>23</b> (yellow) bound to FXIa.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The enhanced FXIa potency of <b>23</b> translated to requiring a concentration of 1.3 μM to effect a doubling in aPTT clotting time. More importantly, the enhancement in biochemical selectivity resulted in a PT value of 28.7 μM to afford a functional selectivity ratio (2 × aPTT/PT) of ∼21-fold; thus, <b>23</b> met our functional potency and selectivity requirements for advancement (<i>vide supra</i>). However, a low-dose mouse PK (3 mg/kg) study with <b>23</b> afforded only 16% bioavailability despite exhibiting relatively low clearance (11 mL/(min·Kg)) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_p">Assessment of <b>23</b> in an <i>in vitro</i> Madin–Darby canine kidney (MDCK)-multidrug-resistant gene 1 (MDR1) assay demonstrated low permeability (<i>P</i><sub>app</sub>(AB) 0.4 × 10<sup>–6</sup> cm/s) and a high efflux ratio (21.5). Speculating that transporter-mediated efflux might be contributing to the low oral bioavailability observed in mice, we examined the impact of higher oral doses to explore the possibility of saturating the efflux mechanism. When increasing the dose to 100 mg/kg, the oral bioavailability increased substantially to ∼100% (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). This phenomenon of overproportionality was also observed in PK studies conducted in both rats and dogs, albeit to a lesser extent, as increasing the dose to 100 mg/kg in rats afforded a bioavailability of ∼45% and in dogs it was 21% for a dose of 75 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). We postulate, based on preliminary mechanistic studies, that the nonlinear oral PK profile observed in rats and dogs is likely due to saturation of the intestinal metabolism and/or efflux transporters. While the precise cause of the observed dose overproportionality has not yet been identified, it was encouraging to see that across all preclinical species tested, improved bioavailability was observed at higher doses. Furthermore, as in the mouse, <b>23</b> demonstrated low clearance in both dogs and rats and a low volume of distribution providing additional confidence in the overall ADME profile in the context of an anticoagulant agent.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>In Vivo</i> rat and dog mean plasma pharmacokinetic parameters for <b>23</b>. D.N., dose normalized.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Combining the rat and dog PK profiles with our desire to maintain plasma <i>C</i><sub>trough</sub> concentrations of ∼1.3 μM (the 2 × aPTT value for <b>23</b> in human plasma) permitted preliminary physiologically based pharmacokinetic (PBPK) modeling (GastroPlus; version 9.5; Simulations Plus Inc., Lancaster, CA).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The modeling suggested that a 535–2000 mg dose administered bid should afford plasma concentrations above the 1.3 μM threshold at trough, with the low end of this range more likely. Furthermore, plasma exposure was predicted to stay below the 28.7 μM 2 × PT value for <b>23</b> (predicted human <i>C</i><sub>max</sub> = 7.9 μM). Compound <b>23</b> was then further profiled against a panel of ∼115 enzymes, receptors, and ion channels to assess potential safety liabilities, wherein all IC<sub>50</sub> values were ≥30 μM except for COX1 IC<sub>50</sub>: 4.3 μM; PDE4d IC<sub>50</sub>: 2.4 μM; bile salt export pump (BSEP) IC<sub>50</sub>: 28 μM; and peroxisome proliferator-activated receptor γ (PPARγ), 65% binding at 10 μM. The favorable aPTT and PT values, relatively clean <i>in vitro</i> safety profile, and a preclinical PK profile suggesting a high, but tractable, anticipated human dose led to the selection of <b>23</b> for advanced DMPK and preclinical safety profiling, which will be reported in due course.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The compounds described herein were generally constructed unless otherwise noted following the synthetic route depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> using either commercially available building blocks or readily synthesized building blocks as described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>. In the first step, a Mitsunobu reaction is performed between aliphatic alcohols (<b>24</b>–<b>29</b>) and phenols (<b>30</b>–<b>35</b>). The resulting aryl bromide intermediates (<b>36</b>–<b>44</b>) were then either transformed into the corresponding boronic ester and reacted with aryl bromide <b>49</b> or <b>45</b> or reacted with aryl bromides (<b>45</b> and <b>46</b>) using the two-step, one-pot palladium-catalyzed borylation/Suzuki cross-coupling reaction protocol developed by Molander<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> or reacted with the corresponding boronic acid/ester (<b>47</b>, <b>48</b>, <b>50</b>) using Suzuki coupling conditions. Finally, acidic deprotection of the Boc protected amine when necessary with concommitant <i>t</i>Bu ester deprotection, when present, or subsequent saponification of the methyl ester, when present, leads to the desired amino acid final compounds <b>3</b>, <b>5</b>–<b>12</b>, <b>15</b>, and <b>18</b>. For the synthesis of <b>14</b> and <b>19</b>, steps 1 and 2 were inverted, <i>i.e</i>., aryl bromide <b>28</b> was first engaged in the Suzuki reaction with the boronic acid <b>47</b>, followed by the Mitsunobu reaction with phenols <b>32</b> and <b>35</b>, respectively. For the synthesis of compounds <b>8</b> and <b>10</b>, modifications were made to the R<sub>1</sub> group of intermediate <b>40</b> (R<sub>1</sub> = CH<sub>2</sub>OH) to generate intermediate <b>41</b> (R<sub>1</sub> = C(CH<sub>3</sub>)<sub>2</sub>OH) prior to the Suzuki coupling and deprotection steps as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Compound <b>9</b> was obtained following the same sequence as for compound <b>7</b> except that after completion of the cross-coupling reaction the reaction mixture was heated with sodium hydroxide, water, and <i>tert-</i>butanol to hydrolyze the nitrile group into the corresponding amide (R<sub>1</sub> = CONH<sub>2</sub>).</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Aryl Acetic Acid and Benzoic Acid FXIa Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>20</b>–<b>22</b> containing a benzylic alcohol were prepared from either the appropriate α-bromo ketone or the epoxide intermediate and are described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> as are the synthesis of compounds <b>13</b>, <b>16</b>, and <b>17</b>. For the synthesis of compound <b>23</b>, the optically pure epoxide <b>54</b> was first synthesized in three steps. Asymmetric dihydroxylation of 1-bromo-3-isopropyl-5-vinylbenzene (<b>51</b>) using AD-mix-α afforded diol <b>52</b> in moderate yield, and activation of the primary alcohol with mesityl sulfonyl chloride followed by the intramolecular second-order nucleophilic substitution (S<sub>N</sub>2) reaction produced the desired chiral epoxide <b>54</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. (a) AD-mix-α, <i>t</i>-BuOH/H<sub>2</sub>O, −10 to 25 °C, 38%; (b) mesityl-Cl, pyridine, 4-dimethylaminopyridine (DMAP), CH<sub>2</sub>Cl<sub>2</sub>, 72%; (c) Cs<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 82%; (d) K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 86%; (e) KOH, EtOH, 0–100 °C, 100%; (f) PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 70 °C; (g) 3 N NaOH, MeOH, 60 °C, 32%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We then tried to open the epoxide with methyl 1<i>H</i>-indole-7-carboxylate, but this resulted in only a ∼10% yield of the desired hydroxyethyl indole (not shown). We reasoned that sterics might play a significant role in this reaction; thus, we explored a less hindered nucleophile. When 1<i>H</i>-indole-7-carbonitrile (<b>55</b>) was used instead, the desired product <b>56</b> was obtained in 86% yield. Hydrolysis of the nitrile to the corresponding carboxylic acid provided aryl bromide <b>57</b> in excellent yield. However, <b>57</b> proved troublesome to work with due to its tendency to lactonize both in the subsequent Suzuki reaction when boronic ester <b>48</b> was used and in the following Boc deprotection step. By switching to the trifluoroacetamide protected boronic ester <b>58</b>, a single basic hydrolysis step at the end of the synthesis deprotected the amine and hydrolyzed lactone <b>60</b> present in the reaction mixture, thereby affording compound <b>23</b>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Evaluating a knowledge-based small diversity library (∼1750 compounds) of internal serine protease inhibitors enabled the rapid identification of a micromolar FXIa inhibitor with a nonpeptidomimetic scaffold originating from a historical FD program. Compound <b>1</b> demonstrated good ADME and PK properties, and initial SAR demonstrated the possibility of increasing the potency for FXIa while improving selectivity against FD. Optimization of interactions in the S1 pocket led to the identification of compound <b>5</b> with a 3-amino-dihydrobenzofuran moiety conferring increased FXIa potency and reduced activity toward FD. Filling the small hydrophobic S1β pocket with an isopropyl group (compound <b>6</b>) further increased FXIa potency and FD selectivity. Finally, linker modifications and incorporation of a 6,5-fused indole moiety dramatically improved the selectivity over serine proteases from both the intrinsic and extrinsic coagulation pathways. Eventually, compound <b>23</b> emerged with subnanomolar potency on FXIa, excellent selectivity over coagulation proteases, and an acceptable pharmacokinetic profile in preclinical species. Based on the overall excellent <i>in vitro</i> and <i>in vivo</i> characteristics, <b>23</b> was selected for advanced preclinical evaluation.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76485" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76485" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Experimental Procedures and Compound Characterization for Novel Compounds (<b>3</b>, <b>5</b>–<b>23</b>)</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> General Chemistry Information</h4><div class="NLM_p last">Unless otherwise specified, all solvents and reagents were obtained from commercial suppliers and used without further drying or purification. KOAc and K<sub>2</sub>CO<sub>3</sub> were dried in an oven at 40 °C for 4 h; EtOH and aqueous K<sub>2</sub>CO<sub>3</sub> solution were thoroughly degassed by bubbling nitrogen prior to use in the two-step, one-pot palladium-catalyzed borylation/Suzuki cross-coupling reaction protocol. Phase separators were obtained from Biotage: isolute phase separator (part nr: 120-1908-F for 70 mL and part nr: 120-1909-J for 150 mL). Normal-phase flash chromatography was performed using Merck silica gel 60 (230–400 mesh), Merck Darmstadt, Germany. <i>R</i><sub><i>f</i></sub> values for thin-layer chromatography (TLC) were determined using 5 × 10 cm<sup>2</sup> TLC plates, silica gel F254, Merck, Darmstadt, Germany. <sup>1</sup>H NMR and <sup>13</sup>C spectra were recorded on a Bruker 600 MHz AVANCE III spectrometer equipped with a 5 mm broadband observe (BBO) probe with a <i>z</i>-gradient system and a Bruker 600 MHz AVANCE II spectrometer equipped with a 5 mm dual <sup>13</sup>C{<sup>1</sup>H} CryoProbe with a <i>z</i>-gradient system. High-resolution mass spectra (HRMS) measurements were made using electrospray ionization (ESI) in the positive ion mode after separation by liquid chromatography (Vanquish, Thermo). The elemental composition was derived from the mass spectra acquired at the high resolution of about 240 000 on an Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific). The high mass accuracy below <1 ppm was obtained using an Internal Calibrant (IC). Liquid chromatography–mass spectra (LC–MS) were determined using electrospray ionization in positive and negative ion modes using a Waters Acquity UPLC instrument. Purity was determined by analytical HPLC using an Agilent 1100 series instrument and by integration of the area under the UV absorption curve at λ = 254 or 214 nm and <sup>1</sup>H NMR; all final compounds reported were ≥95% pure unless otherwise stated. <i>t</i><sub>R</sub> refers to retention time. The following conditions (a–k) were used for analytical HPLC, UPLC, or preparative HPLC, if not indicated otherwise. HPLC conditions: (a) Waters X-Bridge C18; particle size: 2.5 μm; column size: 3 × 30 mm<sup>2</sup>; eluent/gradient: 10–98% CH<sub>3</sub>CN/H<sub>2</sub>O/3 min, 98% CH<sub>3</sub>CN/0.5 min (CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% trifluoroacetic acid (TFA)); flow rate: 1.4 mL/min; column temperature: 40 °C. (b) Waters X-Bridge C18; particle size: 2.5 μm; column size: 3 × 50 mm<sup>2</sup>; eluent/gradient: 10–98% CH<sub>3</sub>CN/H<sub>2</sub>O/8.6 min, 98% CH<sub>3</sub>CN/1.4 min (CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% TFA); flow rate: 1.4 mL/min; column temperature: 40 °C. UPLC/MS conditions: (c) Acquity HSS T3; particle size: 1.8 μm; column size: 2.1 × 50 mm<sup>2</sup>; eluent A: H<sub>2</sub>O + 0.05% HCOOH + 3.75 mM ammonium acetate; eluent B: CH<sub>3</sub>CN + 0.04% HCOOH; gradient: 10–95% B in 1.5 min; flow rate: 1 mL/min; column temperature: 60 °C. (d) Acquity HSS T3; particle size: 1.8 μm; column size: 2.1 × 50 mm<sup>2</sup>; eluent A: H<sub>2</sub>O + 0.05% HCOOH + 3.75 mM ammonium acetate; eluent B: CH<sub>3</sub>CN + 0.04% HCOOH; gradient: 5–98% B in 9.4 min; flow rate: 1 mL/min; column temperature: 60 °C. (e) Acquity UPLC BEH C18; particle size: 1.7 μm; column size: 2.1 × 50 mm<sup>2</sup>; eluent A: H<sub>2</sub>O with 0.1% formic acid; eluent B: acetonitrile with 0.1% formic acid; gradient: 2–98% B in 4.40 min, 98% B for 0.75 min; flow rate: 1 mL/min; column temperature: 50 °C. (f) Acquity UPLC BEH C18; particle size: 1.7 μm; column size: 2.1 × 50 mm<sup>2</sup>; eluent A: H<sub>2</sub>O with 5 mM NH<sub>4</sub>OH; eluent B: acetonitrile with 5 mM NH<sub>4</sub>OH; gradient: 2–98% B in 4.40 min, 98% B for 0.75 min; flow rate: 1 mL/min; column temperature: 50 °C. Preparative HPLC conditions: (g) Waters X-Bridge C18 OBD; particle size: 5 μm; column size: 30 × 100 mm<sup>2</sup>; eluent A: H<sub>2</sub>O with 7.3 mM NH<sub>4</sub>OH; eluent B: CH<sub>3</sub>CN with 7.3 mM NH<sub>4</sub>OH; gradient: 10–99% B in 12.5 min, 99% B for 2.5 min; flow rate: 45 mL/min; column temperature: room temperature (RT). (h) HPLC-MS Waters X-Bridge C18 OBD; particle size: 5 μm; column size: 30 × 100 mm<sup>2</sup>; eluent A: H<sub>2</sub>O with 7.3 mM NH<sub>4</sub>OH; eluent B: CH<sub>3</sub>CN with 7.3 mM NH<sub>4</sub>OH; gradient: 5–99% B in 12.5 min, 99% B for 2.5 min; flow rate: 45 mL/min; column temperature: RT. (i) Waters X-Bridge BEH C18 OBD Prep; particle size: 5 μm; column size: 30 × 50 mm<sup>2</sup>; eluent A: H<sub>2</sub>O containing 10 mM NH<sub>4</sub>OH; eluent B: acetonitrile containing 10 mM NH<sub>4</sub>OH; gradient: variable; flow rate: 75 mL/min. (j) Shimadzu preparative liquid chromatograph LC-Phenomenex Gemini-NX C18; particle size: 5 μm; column size: 30 × 100 mm<sup>2</sup>; eluent A: H<sub>2</sub>O containing 0.1% NH<sub>4</sub>OH; eluent B: acetonitrile; gradient variable; flow rate: 40 mL/min. (k) Shimadzu preparative liquid chromatograph LC-8A Sunfire Prep C18; particle size: 5 μm; column size: 30 × 100 mm<sup>2</sup>; eluent A: H<sub>2</sub>O containing 0.1% TFA; eluent B: acetonitrile; gradient variable; flow rate: 42 mL/min.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Experimental Section</h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> 2-(2-((3-(1,2,3,4-Tetrahydroisoquinolin-7-yl)benzyl)oxy)phenyl)acetic Acid (<b>3</b>)</h5><div class="NLM_p">In a microwave vial with a stir bar were placed methyl 2-(2-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)acetate (125 mg, 0.33 mmol) and 7-bromo-1,2,3,4-tetrahydroisoquinoline (<b>49</b>) (83 mg, 0.39 mmol) in DMF (2.94 mL) and H<sub>2</sub>O (0.33 mL). Then, K<sub>3</sub>PO<sub>4</sub> (aqueous 2 M, 654 μL, 1.31 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (13.35 mg, 0.016 mmol) were added. The vial was sealed, and the reaction was heated at 110 °C for 60 min to complete the reaction. NaOH (2 N, 818 μL, 1.64 mmol) was added, and the mixture was heated at 55 °C overnight. The reaction mixture was concentrated, filtered, and purified by preparative HPLC (Gemini-NX 5 μm C18 110A; column size 100 × 30 mm<sup>2</sup>; gradient: MeCN/water containing 0.1% (ammonium hydroxide 28%) to give, after lyophilization of the product-containing fractions, the title compound (42 mg, 34% yield)). HPLC (Acquity BEH C18; particle size: 1.7 μm; column size: 2.1 × 50 mm<sup>2</sup>; eluent/gradient: 0.2–98% CH<sub>3</sub>CN/H<sub>2</sub>O/7.5 min (CH<sub>3</sub>CN containing 0.04% formic acid and 3.75 mM ammonium acetate); flow rate: 1.0 mL/min; temperature 50 °C), <i>t</i><sub>R</sub>: 2.68 min, purity 100%; <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub>) δ ppm 7.83–7.72 (m, 1H), 7.55 (m, 1H), 7.48–7.33 (m, 4H), 7.22–7.10 (m, 2H), 7.07–6.99 (m, 1H), 6.94–6.88 (m, 1H), 6.80 (td, <i>J</i> = 7.3, 0.85 Hz, 1H), 5.12 (d, <i>J</i> = 6.85 Hz, 2H), 4.50 (s, 1H), 3.91 (s, 1H), 3.50 (t, <i>J</i> = 5.4 Hz, 1H), 3.26 (s, 1H), 3.20 (s, 1H), 2.96 (t, <i>J</i> = 5.7 Hz, 1H), 2.73–2.63 (m, 2H).</div><div class="NLM_p last">Methyl 2-(2-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)acetate: A degassed mixture of methyl 2-(2-((3-bromobenzyl)oxy)phenyl)acetate (<b>36</b>) (0.8 g, 2.39 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.51 g, 5.97 mmol), potassium acetate (586 mg, 5.97 mmol), and PdCl<sub>2</sub>(dppf) (0.11 g, 0.14 mmol) in dichloroethane (12 mL) was heated at 80 °C for 2.5 h. The reaction mixture was cooled to room temperature, directly loaded onto a silica column, and purified by flash chromatography (eluent: 0–50% EtOAc in heptane) to give the title compound (866 mg, 78% yield, purity 80%). HPLC (Acquity HSS T3; particle size: 1.8 μm; column size: 2.1 × 50 mm<sup>2</sup>; eluent A: H<sub>2</sub>O + 0.05% HCOOH + 3.75 mM ammonium acetate; eluent B: CH<sub>3</sub>CN + 0.04% HCOOH; gradient: 5–95% B in 1.4 min; flow rate: 1.2 mL/min; column temperature: 80 °C), <i>t</i><sub>R</sub>: 1.33 min, purity 80%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75–7.69 (m, 1H), 7.63 (dt, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.54 (dt, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.45–7.37 (m, 1H), 7.29–7.18 (m, 2H), 7.05 (dd, <i>J</i> = 8.2, 1.1 Hz, 1H), 6.91 (td, <i>J</i> = 7.4, 1.1 Hz, 1H), 5.11 (s, 2H), 3.62 (s, 2H), 3.57 (s, 3H), 1.30 (s, 12H).</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-((3-bromobenzyl)oxy)phenyl)acetate (<b>36</b>): To a solution of (3-bromophenyl)methanol (<b>24</b>) (3 g, 16.0 mmol) in anhydrous tetrahydrofuran (THF) (50 mL) under an argon atmosphere was added PPh<sub>3</sub> (5.05 g, 19.25 mmol) followed by methyl 2-(2-hydroxyphenyl)acetate (<b>30</b>) (3.20 g, 19.25 mmol). The mixture was cooled to 0 °C, and diisopropyl azodicarboxylate (DIAD) (3.74 mL, 19.25 mmol) was added dropwise. The reaction mixture was allowed to reach RT. After completion of the reaction, the mixture was diluted with EtOAc and washed with a saturated solution of NaHCO<sub>3</sub>. The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to dryness. The crude residue was purified by flash chromatography (Isolera Four system, column: 100 g, eluent: EtOAc in <i>c</i>-hexane from 0 to 55% in 55 min) to give the title compound as a yellow oil (4.58 g, 82% yield). UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 1.29 min, purity 96%; 352.0/354.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.63 (br s, 1H), 7.53 (br d, <i>J</i> = 7.8 Hz, 1H), 7.53 (br d, <i>J</i> = 7.8 Hz, 1H), 7.37 (t, <i>J</i> = 7.7 Hz, 1H), 7.28–7.24 (m, 2H), 7.04 (d, <i>J</i> = 8.2 Hz, 1H), 6.93 (t, <i>J</i> = 7.4 Hz, 1H), 5.13 (s, 2H), 3.67 (s, 2H), 3.60 (s, 3H).</div></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-hydroxyphenyl)acetate (<b>30</b>): To an ice-cooled, yellow solution of 2-(2-hydroxyphenyl)acetic acid (10 g, 65.7 mmol) in MeOH (143 mL) was added dropwise under a nitrogen atmosphere thionyl chloride (9.59 mL, 131 mmol). The reaction mixture was stirred at RT for 1 h. The reaction mixture was evaporated to dryness to give the title compound as a brown solid (10.9 g, 95%), which was used without purification in the next step. TLC, <i>R</i><sub><i>f</i></sub> (EtOAc) = 0.43; UPLC/MS (ESI)<sup>+</sup><i>m</i>/<i>z</i> 167.0 (M + 1); HPLC (conditions b), <i>t</i><sub>R</sub>: 1.93 min, purity 100%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.50 (s, 1H), 7.12–7.06 (m, 2H), 6.80 (d, <i>J</i> = 8.1 Hz, 1H), 6.74 (t, <i>J</i> = 7.4 Hz, 1H), 3.59 (s, 3H), 3.5 (s, 2H).</div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> 2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)benzyl)oxy)phenyl)acetic Acid (<b>5</b>)</h5><div class="NLM_p last">To a yellow solution of <i>tert</i>-butyl 2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)benzyl)oxy)phenyl)acetate (purity ∼85%, 113 mg, 0.22 mmol) in dioxane (3.1 mL) was added HCl (4 N in dioxane, 1.67 mL, 6.68 mmol), and the solution was stirred at RT for 2.5 days. The reaction mixture was concentrated, and the crude residue was purified by preparative HPLC-MS (conditions h) to give, after lyophilization of the compound-containing fractions, the title compound as a beige solid (47 mg, 55%). HPLC (conditions a), <i>t</i><sub>R</sub>: 1.66 min, purity 98%; HPLC (conditions b), <i>t</i><sub>R</sub>: 3.14 min, purity 98%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 376.2 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.91 (s, 1H), 7.80 (s, 1H), 7.55 (d, <i>J</i> = 7.7 Hz, 2H), 7.42 (t, <i>J</i> = 7.6 Hz, 1H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.21–7.16 (m, 2H), 7.00 (d, <i>J</i> = 8.2 Hz, 1H), 6.88 (m, 2H), 5.22 (s, 2H), 4.79 (m, 1H), 4.71 (t, <i>J</i> = 8.8 Hz, 1H), 4.23 (dd, <i>J</i> = 9.7, 5.2 Hz, 1H), 3.59 (d, <i>J</i> = 15.8 Hz, 1H), 3.52 (d, <i>J</i> = 15.8 Hz, 1H).</div></div><div id="sec5_1_2_6" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl 2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)benzyl)oxy)phenyl)acetate: A microwave vial was charged with <i>tert</i>-butyl 2-(2-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)acetate (120 mg, 0.27 mmol), 5-bromo-2,3-dihydro-benzofuran-3-ylamine (HCl salt, 82 mg, 0.33 mmol), K<sub>3</sub>PO<sub>4</sub> (2 N in water, 543 μL, 1.09 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (11.1 mg, 0.014 mmol) in acetonitrile (4 mL). The reaction mixture was purged with nitrogen and heated under microwave irradiations at 120 °C for 40 min. The reaction mixture was allowed to cool to RT and filtered through a pad of celite. The solvents were evaporated, the residue was taken up in THF (3 mL), and SiliaMetSThiol (particle size: 40–63 μm; loading 1.39 mmol/g; 0.054 mmol, 39 mg) was added. The mixture was swirled for 1 h at 40 °C, filtered, rinsed with THF, and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (ISCO Companion; column: 12 g, eluent: CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/MeOH 97:3 in 9 min, then held for 5 min) to give the title compound (115 mg, 83%, purity 85%). TLC, <i>R</i><sub><i>f</i></sub> (EtOAc) = 0.2; HPLC (conditions a), <i>t</i><sub>R</sub>: 2.11 min, purity 85%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 432.3 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.68 (br s, 2H), 7.55 (d, <i>J</i> = 7.7 Hz, 2H), 7.48–7.43 (m, 2H), 7.39 (d, <i>J</i> = 7.6 Hz, 1H), 7.29–7.20 (m, 2H), 7.06 (d, <i>J</i> = 8.2 Hz, 1H), 6.91 (t, <i>J</i> = 7.4 Hz, 1H), 6.86 (d, <i>J</i> = 8.6 Hz, 1H), 5.18 (s, 2H), 4.67–4.60 (m, 2H), 4.09 (m, 1H), 3.57 (s, 2H), 2.19 (m, 2H), 1.30 (s, 9H).</div></div><div id="sec5_1_2_7" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl 2-(2-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)acetate: To <i>tert</i>-butyl 2-(2-((3-bromobenzyl)oxy)phenyl)acetate (<b>37</b>) (1.50 g, 3.98 mmol) in dioxane (45 mL) were added bis(pinacolato)diboron (1.41 g, 5.57 mmol), potassium acetate (1.17 g, 11.9 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (162 mg, 0.20 mmol). The reaction mixture was evacuated under vacuum, nitrogen was added (this operation was repeated three times), and the mixture was stirred at 100 °C overnight. The reaction mixture was diluted with EtOAc, water was added, and the layers were separated. The aqueous layer was back-extracted with EtOAc, and the combined organic extracts were dried (phase separator) and concentrated. The crude residue was purified by flash chromatography (<i>c</i>-hexane to <i>c</i>-hexane/EtOAc 9:1 in 50 min) to give the title compound as a colorless oil (836 mg, 48%). TLC, <i>R</i><sub><i>f</i></sub> (<i>c</i>-hexane/EtOAc 9:1): 0.23; HPLC (conditions a), <i>t</i><sub>R</sub>: 3.02 min, purity 96%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 442.3 (M + 18); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.76 (s, 1H), 7.64 (d, <i>J</i> = 7.3 Hz, 1H), 7.60 (d, <i>J</i> = 7.7 Hz, 1H), 7.41 (t, <i>J</i> = 7.5 Hz, 1H), 7.25 (t, <i>J</i> = 7.8 Hz, 1H), 7.20 (d, <i>J</i> = 7.4 Hz, 1H), 7.05 (d, <i>J</i> = 8.1 Hz, 1H), 6.91 (t, <i>J</i> = 7.4 Hz, 1H), 5.12 (s, 2H), 3.53 (s, 2H), 1.32 (s, 21H).</div></div><div id="sec5_1_2_8" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl 2-(2-((3-bromobenzyl)oxy)phenyl)acetate (<b>37</b>): To a solution of <i>tert</i>-butyl 2-(2-hydroxyphenyl)acetate (<b>31</b>) (3.28 g, 15.75 mmol) in THF (90 mL) were successively added under a nitrogen atmosphere triphenylphosphine (4.54 g, 17.3 mmol) and 3-bromobenzyl alcohol (<b>24</b>) (3.24 g, 17.3 mmol). The solution was cooled at 0 °C, and diisopropyl azodicarboxylate (3.37 mL, 17.3 mmol) was added dropwise. The yellow solution was stirred at 0 °C and slowly allowed to reach RT. The reaction mixture was poured into a saturated aqueous solution of NaHCO<sub>3</sub> and extracted with EtOAc (2×). The combined organic layers were dried (phase separator) and concentrated. The crude residue was purified by flash chromatography (<i>c</i>-hexane to <i>c</i>-hexane/EtOAc 7:3 in 45 min) to give the tile compound as a pale-yellow solid (5.16 g, 87%). TLC, <i>R</i><sub><i>f</i></sub> (<i>c</i>-hexane/EtOAc 7:3): 0.82; HPLC (conditions a), <i>t</i><sub>R</sub>: 2.87 min, purity 100%; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 377.1/379.1 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.66 (s, 1H), 7.54 (br d, <i>J</i> = 7.9 Hz, 1H), 7.46 (d, <i>J</i> = 7.9 Hz, 1H), 7.37 (t, <i>J</i> = 7.8 Hz, 1H), 7.25 (td, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.22 (dd, <i>J</i> = 7.4, 1.7 Hz, 1H), 7.02 (d, <i>J</i> = 8.3 Hz, 1H), 6.9 (td, <i>J</i> = 7.4, 1.1 Hz, 1H), 5.13 (s, 2H), 3.56 (s, 2H), 1.34 (s, 9H).</div></div><div id="sec5_1_2_9" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl 2-(2-hydroxyphenyl)acetate (<b>31</b>): The title compound was prepared as described in WO15009977. To a suspension of (2-hydroxybenzyl)-triphenylphosphonium bromide (10.1 g, 22.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (75 mL) was added Et<sub>3</sub>N (9.35 mL, 67.4 mmol) followed by slow addition of Boc<sub>2</sub>O (5.22 mL, 22.5 mmol). The reaction mixture was stirred at 40 °C for 7 days. A saturated aqueous solution of NaHCO<sub>3</sub> was added, the layers were separated, and the aqueous one was back-extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (phase separator) and concentrated. The crude residue was purified by flash column chromatography (<i>c</i>-hexane to <i>c</i>-hexane/EtOAc 8:2 in 50 min) to give the title compound as a pale-yellow oil (3.28 g, 70%). TLC, <i>R</i><sub><i>f</i></sub> (<i>c</i>-hexane/EtOAc 1:1): 0.85; HPLC (conditions a), <i>t</i><sub>R</sub>: 1.94 min, purity 100%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 209.1 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.43 (s, 1H), 7.09–7.04 (m, 2H), 7.79 (d, <i>J</i> = 7.4 Hz, 1H), 7.73 (td, <i>J</i> = 7.4, 1.2 Hz, 1H), 3.44 (s, 2H), 1.41 (s, 9H).</div></div><div id="sec5_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> (<i>S</i>)-2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylbenzyl)oxy)phenyl)acetic Acid (<b>6</b>)</h5><div class="NLM_p last">To a solution of (<i>S</i>)-<i>tert</i>-butyl 2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylbenzyl)oxy)phenyl)acetate (154 mg, 0.29 mmol, purity 90%) in dioxane (3 mL) was added a 4 N solution of HCl in dioxane (1.46 mL, 5.85 mmol). The reaction mixture was stirred at RT until completion and then was concentrated under reduced pressure. The crude residue was purified by preparative HPLC (conditions g), and the combined purified fractions were lyophilized to give the title compound (60 mg, 45%). UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 418.2 (M + 1); HPLC (conditions a), <i>t</i><sub>R</sub>: 1.94 min, purity 100%; HPLC (conditions b), <i>t</i><sub>R</sub>: 3.94 min, purity 100%; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (s, 1H), 7.59 (s, 1H), 7.54 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.40 (s, 1H), 7.22 (s, 1H), 7.20–7.16 (m, 2H), 7.00 (d, <i>J</i> = 8.1 Hz, 1H), 6.87 (m, 2H), 5.17 (s, 2H), 4.79 (dd, <i>J</i> = 8.4, 5.4 Hz, 1H), 4.70 (t, <i>J</i> = 9.0 Hz, 1H), 4.23 (dd, <i>J</i> = 9.6, 5.4 Hz, 1H), 3.58 (d, <i>J</i> = 15.9 Hz, 1H), 3.50 (d, <i>J</i> = 15.9 Hz, 1H), 2.96 (hept., <i>J</i> = 6.9 Hz, 1H), 1.27 (d, <i>J</i> = 6.9 Hz, 6H); HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>27</sub>NO<sub>4</sub> [M + H]<sup>+</sup> 418.20129; found, 418.20120.</div></div><div id="sec5_1_2_11" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-<i>tert</i>-Butyl 2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylbenzyl)oxy)phenyl)acetate: To an oven-dried glass vial charged with a stirring bar were subsequently added <i>tert</i>-butyl 2-(2-((3-bromo-5-isopropylbenzyl)oxy)phenyl)acetate (<b>38</b>) (170 mg, 0.32 mmol), X-Phos-Pd-G2 (2.55 mg, 3.24 μmol), X-Phos (3.09 mg, 6.49 μmol), tetrahydroxydiboron (87 mg, 0.97 mmol), and KOAc (95 mg, 0.97 mmol). The vessel was sealed, then evacuated, and back-filled with argon (4×). EtOH (2.1 mL) was added <i>via</i> a syringe, and the reaction mixture was heated at 80 °C for 1 h. After completion of the formation of the boronic intermediate, 1.8 M aqueous K<sub>2</sub>CO<sub>3</sub> (0.72 mL, 1.30 mmol) was added, followed by the addition of (<i>S</i>)-5-bromo-2,3-dihydro-benzofuran-3-ylamine hydrochloride (<b>45</b>) (J&W Pharmlab, 81 mg, 0.32 mmol) dissolved in EtOH (2.1 mL). The reaction mixture was heated at 80 °C until completion of the reaction. After cooling to RT, the mixture was diluted with EtOAc, water was added, and the layers were separated. The aqueous phase was extracted with EtOAc (2×), and the combined organics were dried (phase separator) and concentrated in vacuo. SiliaMetSThiol (particle size: 40–63 μm; loading 1.39 mmol/g; 0.026 mmol, 19 mg) was added to the residue in THF (3 mL), and the mixture was swirled for 1 h at 40 °C, filtered, rinsed with THF and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1 in 35 min) to give the title compound (154 mg, 90%). TLC, <i>R</i><sub><i>f</i></sub> (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1): 0.50; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 474.3 (M + 1); HPLC (conditions a), <i>t</i><sub>R</sub>: 2.37 min, purity 90%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.66 (d, <i>J</i> = 2.0 Hz, 1H), 7.48 (s, 1H), 7.46 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.40 (s, 1H), 7.27 (s, 1H), 7.25 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.20 (dd, <i>J</i> = 7.4, 1.7 Hz, 1H), 7.06 (d, <i>J</i> = 8.2 Hz, 1H), 6.91 (t, <i>J</i> = 7.9 Hz, 1H), 6.85 (d, <i>J</i> = 8.3 Hz, 1H), 5.14 (s, 2H), 4.67–4.60 (m, 2H), 4.09 (dd, <i>J</i> = 7.5, 4.3 Hz, 1H), 3.56 (s, 2H), 2.97 (m, 1H), 2.28 (s, 9H), 1.27 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_12" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl 2-(2-((3-bromo-5-isopropylbenzyl)oxy)phenyl)acetate (<b>38</b>): To a solution of <i>tert</i>-butyl 2-(2-hydroxyphenyl)acetate (<b>31</b>) (0.91 g, 4.36 mmol) in dry THF (35 mL) under a nitrogen atmosphere were subsequently added triphenylphosphine (1.37 g, 5.24 mmol) and (3-bromo-5-isopropylphenyl)methanol (<b>25</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (1.00 g, 4.36 mmol). The solution was cooled to 0 °C, and DIAD (1.02 mL, 5.24 mmol) was added dropwise. The yellow solution was allowed to slowly warm up to RT, and stirring was continued overnight. The reaction mixture was poured into a saturated aqueous NaHCO<sub>3</sub> solution and was extracted with EtOAc (2×). The combined organics were dried (phase separator) and concentrated in vacuo, and the residue was purified by flash column chromatography (<i>c</i>-hexane to <i>c</i>-hexane/EtOAc 9:1) to give the title compound (1.40 g, 61%, purity 80%). TLC, <i>R</i><sub><i>f</i></sub> (<i>c</i>-hexane/EtOAc 9:1): 0.75; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 419.1/421.1 (M + 1); HPLC (conditions a), <i>t</i><sub>R</sub>: 3.16 min, purity 80%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.46 (s, 1H), 7.40 (s, 1H), 7.34 (s, 1H), 7.28–7.20 (m, 2H), 7.02 (d, <i>J</i> = 8.3 Hz, 1H), 6.92 (t, <i>J</i> = 7.3 Hz, 1H), 5.10 (s, 2H), 3.56 (s, 2H), 2.91 (m, 1H), 1.33 (s, 9H), 1.21 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> (<i>S</i>)-2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-(2-cyanopropan-2-yl)benzyl)oxy)phenyl)acetic Acid (<b>7</b>)</h5><div class="NLM_p last">A round-bottomed flask was charged with methyl 2-(2-((3-bromo-5-(2-cyanopropan-2-yl)benzyl)oxy)phenyl)acetate (<b>39</b>) (300 mg, 0.75 mmol), X-Phos-Pd-G2 (5.87 mg, 7.46 μmol), X-Phos (7.11 mg, 0.02 mmol), tetrahydroxydiboron (201 mg, 2.24 mmol), and KOAc (220 mg, 2.24 mmol). The flask was evacuated and back-filled with argon (3×). Then, EtOH (6 mL) was added <i>via</i> a syringe, and the reaction mixture was heated at 80 °C for 1 h. After completion of the formation of the boronic intermediate, a 1.8 M aqueous solution of K<sub>2</sub>CO<sub>3</sub> (2.07 mL, 3.73 mmol) was added <i>via</i> a syringe, followed by the addition of (<i>S</i>)-5-bromo-2,3-dihydrobenzofuran-3-amine hydrochloride (<b>45</b>) (187 mg, 0.75 mmol). The reaction mixture was stirred at 80 °C until completion (17 h). Volatiles were removed under reduced pressure, and the residue was dissolved in THF (6 mL), MeOH (2 mL), and water (0.6 mL), followed by addition of 1 M aqueous NaOH (6.24 mL, 6.24 mmol), and the mixture was stirred at RT for 16 h. Volatiles were removed under reduced pressure, and the aqueous layer was acidified by the addition of 1 N aqueous HCl, followed by lyophilization. To the residue dissolved in THF (2 mL) was added SiliaMetSThiol (30 μmol, 21 mg); the mixture was swirled for 1 h at 40 °C, filtered, and washed with THF, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (conditions g). The fractions containing the product were combined and lyophilized to give the title compound as a white powder (121 mg, 37%). UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 0.82 min, purity 99.5%; UPLC/MS (conditions d), <i>t</i><sub>R</sub>: 3.07 min, purity 100%, UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 443.2 (M + 1); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (s, 1H), 7.77 (s, 1H), 7.65 (s, 1H), 7.60 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.50 (s, 1H), 7.21–7.17 (m, 2H), 7.01 (d, <i>J</i> = 8.1 Hz, 1H), 6.91 (d, <i>J</i> = 8.3 Hz, 1H), 6.88 (t, <i>J</i> = 7.3 Hz, 1H), 5.24 (s, 2H), 4.81 (m, 1H), 4.72 (t, <i>J</i> = 9.0 Hz, 1H), 4.25 (dd, <i>J</i> = 9.6, 5.3 Hz, 1H), 3.59 (d, <i>J</i> = 15.8 Hz, 1H), 3.50 (d, <i>J</i> = 15.8 Hz, 1H), 1.77 (s, 3H), 1.76 (s, 3H); HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 443.19653; found, 443.19635.</div></div><div id="sec5_1_2_14" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-((3-bromo-5-(2-cyanopropan-2-yl)benzyl)oxy)phenyl)acetate (<b>39</b>): To a solution of methyl 2-(2-hydroxyphenyl)acetate (<b>30</b>) (301 mg, 1.81 mmol), triphenylphosphine (570 mg, 2.17 mmol), and 2-(3-bromo-5-(hydroxylmethyl)phenyl)-2-methylpropanenitrile (<b>26</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (460 mg, 1.81 mmol) in dry THF (18 mL) under a nitrogen atmosphere, cooled to 0 °C, was added DIAD (422 μL, 2.17 mmol). The ice bath was removed, and the mixture was stirred at RT for 3 h. The reaction mixture was poured into a saturated aqueous solution of NaHCO<sub>3</sub> and extracted with EtOAc (2×). The combined organic extracts were dried (phase separator) and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (<i>c</i>-hexane to <i>c</i>-hexane/EtOAc 7:3) to give the title compound as a colorless oil (428 mg, 59%). TLC <i>R</i><sub><i>f</i></sub> (<i>c</i>-hexane/EtOAc 7:3) = 0.57; UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 1.37 min, purity 100%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 402.1/404.1 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.66 (br s, 1H), 7.61 (br s, 2H), 7.30–7.24 (m, 2H), 7.06 (d, <i>J</i> = 8.1 Hz, 1H), 6.95 (t, <i>J</i> = 7.5 Hz, 1H), 5.17 (s, 2H), 3.68 (s, 2H), 3.59 (s, 3H), 1.72 (s, 6H).</div></div><div id="sec5_1_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> (<i>S</i>)-2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-(2-hydroxypropan-2-yl)benzyl)oxy)phenyl)acetic Acid (<b>8</b>)</h5><div class="NLM_p last">To a solution of (<i>S</i>)-<i>tert</i>-butyl 2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-(2-hydroxypropan-2-yl)benzyl)oxy)phenyl)acetate (55 mg, 0.11 mmol) in dioxane (1 mL) was added HCl (4 N in dioxane, 0.56 mL, 2.25 mmol), and the reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated, and the residue was purified by preparative HPLC (conditions g) to give, after lyophilization of the compound-containing fractions, the title compound (19 mg, 39%). UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 434.3 (M + 1); HPLC (conditions a) <i>t</i><sub>R</sub>: 1.59 min, purity 100%; HPLC (conditions b) <i>t</i><sub>R</sub>: 2.96 min, purity 100%; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (s, 1H), 7.65 (s, 1H), 7.62 (s, H), 7.53 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.42 (s, 1H), 7.20–7.16 (m, 2H), 7.00 (d, <i>J</i> = 8.1 Hz, 1H), 6.89–6.86 (m, 2H), 5.18 (s, 2H), 4.80 (dd, <i>J</i> = 8.4, 5.5 Hz, 1H), 4.70 (t, <i>J</i> = 9.0 Hz, 1H), 4.23 (dd, <i>J</i> = 9.6, 5.3 Hz, 1H), 3.58 (d, <i>J</i> = 15.8 Hz, 1H), 3.50 (d, <i>J</i> = 15.8 Hz, 1H), 1.49 (s, 3H), 1.48 (s, 3H); HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>27</sub>NO<sub>5</sub> [M + H]<sup>+</sup> 434.1962; found, 434.19611.</div></div><div id="sec5_1_2_16" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-<i>tert</i>-Butyl 2-(2-(3-(3-amino-2,3-dihydrobenzofuran-5-yl)))-5-(2-hydroxypropan-2-yl): In an oven-dried glass vessel were added <i>tert</i>-butyl 2-(2-((3-bromo-5-(2-hydroxypropan-2-yl)benzyl)oxy)phenyl)acetate (<b>41</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (85 mg, 0.18 mmol), X-Phos-Pd-G2 (1.41 mg, 1.79 μmol), X-Phos (1.71 mg, 3.59 μmol), tetrahydroxydiboron (48.3 mg, 0.54 mmol), and KOAc (52.9 mg, 0.54 mmol). The vessel was sealed and then evacuated and back-filled with argon (4×). EtOH 1.2 mL (degassed during 10 min) was added <i>via</i> a syringe. The reaction mixture was then heated to 80 °C for 1 h. UPLC indicates formation of the boronic intermediate. Then, degassed K<sub>2</sub>CO<sub>3</sub> (1.8 M aqueous, 0.40 mL, 0.72 mmol) was added followed by the addition of (<i>S</i>)-5-bromo-2,3-dihydro-benzofuran-3-ylamine hydrochloride (<b>45</b>) (45.0 mg, 0.18 mmol) in a solution in degassed EtOH (1.2 mL). The reaction mixture was heated at 80 °C for 60 h. The reaction mixture was filtered through a pad of celite, and the solvents were evaporated. The residue was taken up in THF (3 mL) and SiliaMetSThiol (particle size: 40–63 μm, loading 1.39 mmol/g, 0.007 mmol, 5 mg) was added; the mixture was swirled at 40 °C for 1 h and then filtered, and the filtrate was concentrated. The crude residue was purified by flash chromatography (eluent: CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1 in 35 min) to give the title compound as a pale-beige oil (55 mg, 63%). TLC, <i>R</i><sub><i>f</i></sub> (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1): 0.50; HPLC (conditions a), <i>t</i><sub>R</sub>: 2.03 min; purity 100%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 490.3 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.66 (br s, 2H), 7.50–7.44 (m, 3H), 7.25 (td, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.20 (dd, <i>J</i> = 7.4, 1.7 Hz, 1H), 7.07 (d, <i>J</i> = 8.1 Hz, 1H), 6.91 (t, <i>J</i> = 7.3 Hz, 1H), 6.85 (d, <i>J</i> = 8.3 Hz, 1H), 5.16 (s, 2H), 5.09 (s, 1H), 4.67–4.60 (m, 2H), 4.09 (dd, <i>J</i> = 7.5, 4.2 Hz, 1H), 3.56 (s, 2H), 1.49 (s, 6H), 1.27 (s, 9H).</div></div><div id="sec5_1_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> (<i>S</i>)-2-(2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-(1-amino-2-methyl-1-oxopropan-2-yl)benzyl)oxy)phenyl)acetic Acid Trifluoroacetate (<b>9</b>)</h5><div class="NLM_p last">A round-bottomed flask was charged with methyl 2-(2-((3-bromo-5-(2-cyanopropan-2-yl)benzyl)oxy)phenyl)acetate (<b>39</b>) (178 mg, 0.44 mmol), X-Phos-Pd-G2 (3.48 mg, 4.42 μmol), X-Phos (4.22 mg, 8.85 μmol), tetrahydroxydiboron (119 mg, 1.33 mmol), and KOAc (130 mg, 1.33 mmol). The flask was evacuated under vacuum and back-filled with argon (3×). EtOH (4.5 mL) was added <i>via</i> a syringe, and the reaction mixture was heated at 80 °C for 1.5 h. After conversion of the starting material into the corresponding boronic acid, K<sub>2</sub>CO<sub>3</sub> (1.8 M in water; 0.98 mL, 1.77 mmol) and (<i>S</i>)-5-bromo-2,3-dihydrobenzofuran-3-amine hydrochloride (<b>45</b>) (111 mg, 0.44 mmol) were added and the reaction mixture was stirred at 80 °C for 18 h. Volatiles were removed under reduced pressure, the residue was dissolved in <i>t</i>-BuOH (2 mL) and water (0.1 mL), and a 1 M aqueous NaOH solution (4.42 mL, 4.42 mmol) was added. The mixture was stirred at 120 °C for 5 h and subsequently at 80 °C for 17 h. The reaction mixture was concentrated under reduced pressure; the residual aqueous layer was acidified by addition of 4 M aqueous HCl and then lyophilized. The residue was taken up in THF (5 mL), and SiliaMetSThiol (18 μmol, 4.5 mg (particle size: 40–63 μm; loading 1.39 mmol/g)) was added; the mixture was swirled at 40 °C for 1 h, filtered, and washed with THF, and the filtrate was concentrated. The residue was purified by preparative HPLC (condition j) to give after lyophilization the title compound as a TFA salt as a white solid (68 mg, 27%); the corresponding nitrile precursor was also isolated (45 mg, 18%). UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 0.70 min, purity 100%; UPLC/MS (conditions d), <i>t</i><sub>R</sub>: 2.55 min, purity 100%, UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 461.3 (M + 1); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.2 (br s, 1H), 8.43 (br s, 3H), 7.83 (s, 1H), 7.64 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.54 (s, 1H), 7.46 (s, 1H), 7.44 (s, 1H), 7.27–7.23 (m, 2H), 7.09 (d, <i>J</i> = 8.2 Hz, 1H), 7.05 (d, <i>J</i> = 8.4 Hz, 1H), 6.98 (br s, 1H), 6.94–9.91 (m, 2H), 5.17 (s, 2H), 5.13 (dd, <i>J</i> = 8.2, 3.5 Hz, 1H), 4.77 (dd, <i>J</i> = 10.9, 8.2 Hz, 1H), 4.54 (dd, <i>J</i> = 10.9, 3.5 Hz, 1H), 3.60 (s, 2H), 1.52 (s, 3H), 1.51 (s, 3H); HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 461.20710; found, 461.20700.</div></div><div id="sec5_1_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 2-(2-((3-(2-Hydroxypropan-2-yl)-5-(1,2,3,4-tetrahydroisoquinolin-7-yl)benzyl)oxy)phenyl)acetic Acid (<b>10</b>)</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl 7-(3-((2-(2-(<i>tert</i>-butoxy)-2-oxoethyl)phenoxy)methyl)-5-(2-hydroxypropan-2-yl)phenyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (35 mg, 0.06 mmol) in dioxane (0.8 mL) was added HCl (4 N in dioxane, 447 μL, 1.79 mmol). The solution was stirred at RT for 15 h. HCl (4 N in dioxane, 149 μL, 0.60 mmol) was again added, and the reaction mixture was further stirred at RT for 3 h and then heated at 60 °C for 1 h. The reaction mixture was concentrated, and the crude residue was purified by preparative HPLC (conditions h) to give the title compound as a white solid (3 mg, 20%). HPLC (conditions a), <i>t</i><sub>R</sub>: 1.60 min, purity 97%; HPLC (conditions b), <i>t</i><sub>R</sub>: 3.0 min, purity 97%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 432.3 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.69 (br s, 1H), 7.66 (br s, 1H), 7.50 (br s, 1H), 7.45 (dd, <i>J</i> = 7.9, 2.0 Hz, 1H), 7.37 (br s, 1H), 7.27–7.22 (m, 2H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.92 (t, <i>J</i> = 7.3 Hz, 1H), 5.17 (s, 2H), 3.99 (s, 2H), 3.60 (s, 2H), 3.04 (t, <i>J</i> = 5.8 Hz, 1H), 2.77 (t, <i>J</i> = 5.9 Hz, 1H), 4.47 (m, 2H), 1.49 (s, 6H).</div></div><div id="sec5_1_2_19" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl 7-(3-((2-(2-(<i>tert</i>-butoxy)-2-oxoethyl)phenoxy)methyl)-5-(2-hydroxypropan-2-yl)phenyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate: A microwave vial was charged with <i>tert</i>-butyl 2-(2-((3-bromo-5-(2-hydroxypropan-2-yl)benzyl)oxy)phenyl)acetate (<b>41</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (62 mg, 0.14 mmol), 2-boc-1,2,3,4-tetrahydroisoquinolin-7-ylboronic acid (<b>50</b>) (43.2 mg, 0.16 mmol), K<sub>3</sub>PO<sub>4</sub> (2 N in water, 0.21 mL, 0.43 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (5.8 mg, 7.09 μmol) in acetonitrile (1.9 mL). The reaction mixture was heated at 120 °C for 40 min under microwave irradiations. The reaction mixture was filtrated through a pad of celite, the solvents were evaporated, and the residue was taken up in THF (2 mL). SiliaMetSThiol (particle size: 40–63 μm, loading 1.39 mmol/g, 0.028 mmol, 20 mg) was added, the mixture was swirled at 40 °C for 1 h, filtered, and washed with THF, and the filtrate was concentrated. The crude residue was purified by flash chromatography (ISCO Companion, column 12 g, flow: 25 mL/min, eluent: <i>c</i>-hexane to <i>c</i>-hexane/EtOAc 4:1 in 25 min, then held 10 min) to give the title compound as a white foam (36 mg, 43%). HPLC (conditions a), <i>t</i><sub>R</sub>: 2.99 min, purity 100%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 588.3 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.70 (br s, 1H), 7.57 (br s, 1H), 7.51–7.48 (m, 3H), 7.27–7.20 (m, 3H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 6.91 (t, <i>J</i> = 7.6 Hz, 1H), 5.17 (s, 2H), 5.11 (s, 1H), 4.59 (m, 2H), 3.59 (m, 2H), 3.56 (s, 2H), 2.82 (m, 2H), 1.52 (s, 6H), 1.45 (s, 9H).</div></div><div id="sec5_1_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> (<i>S</i>)-2-(2-((3′-Amino-3,3-dimethyl-2,2′,3,3′-tetrahydro-[5,5′-bibenzofuran]-7-yl)methoxy)phenyl)acetic Acid (<b>11</b>)</h5><div class="NLM_p last">The title compound (592 mg, 53%) was prepared from methyl 2-(2-((5-bromo-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)acetate (<b>42</b>) (1.00 g, 2.47 mmol) and (<i>S</i>)-5-bromo-2,3-dihydro-benzofuran-3-ylamine hydrochloride (<b>45</b>) (618 mg, 2.47 mmol) in a similar manner as described for the preparation of (<i>S</i>)-2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-(2-cyanopropan-2-yl)benzyl)oxy)phenyl)acetic acid (<b>7</b>). The title compound was purified by preparative HPLC (conditions h). UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 0.90 min, purity 100%; UPLC/MS (conditions d), <i>t</i><sub>R</sub>: 3.47 min, purity 100%, UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 446.3 (M + 1); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88 (s, 1H), 7.57 (s, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.41 (s, 1H), 7.19–7.14 (m, 2H), 6.97 (d, <i>J</i> = 8.1 Hz, 1H), 6.87–6.84 (m, 2H), 5.13 (d, <i>J</i> = 13.1 Hz, 1H), 5.09 (d, <i>J</i> = 13.1 Hz, 1H), 4.81 (m, 1H), 4.70 (t, <i>J</i> = 9.0 Hz, 1H), 4.33 (s, 2H), 4.24 (dd, <i>J</i> = 9.8, 5.2 Hz, 1H), 3.57 (d, <i>J</i> = 15.7 Hz, 1H), 3.46 (d, <i>J</i> = 15.7 Hz, 1H), 1.37 (s, 3H), 1.35 (s, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>27</sub>NO<sub>5</sub> [M + H]<sup>+</sup> 446.1962; found, 446.19614.</div></div><div id="sec5_1_2_21" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-((5-bromo-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)acetate (<b>42</b>): The title compound (1.42 g, 67%) was prepared from (5-bromo-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)methanol (<b>29</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (1.34 g, 5.21 mmol) and methyl 2-(2-hydroxyphenyl)acetate (<b>30</b>) (0.87 g, 5.21 mmol) in a similar manner as described for the preparation of <i>tert</i>-butyl 2-(2-((3-bromo-5-isopropylbenzyl)oxy)phenyl)acetate (<b>38</b>). TLC, <i>R</i><sub><i>f</i></sub> (<i>c</i>-hexane/EtOAc 9:1): 0.50; UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 1.51 min, purity 98%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 405.1/407.1 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.41 (d, <i>J</i> = 2.1 Hz, 1H), 7.33 (d, <i>J</i> = 2.1 Hz, 1H), 7.29–7.22 (m, 2H), 7.06 (d, <i>J</i> = 8.3 Hz, 1H), 6.94 (t, <i>J</i> = 7.4 Hz, 1H), 5.01 (s, 2H), 4.31 (s, 2H), 3.64 (s, 2H), 3.59 (s, 3H), 1.32 (s, 6H).</div></div><div id="sec5_1_2_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> (<i>R</i>)-2-(2-((5-(4-Aminochroman-6-yl)-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)acetic Acid Trifluoroacetate (<b>12</b>)</h5><div class="NLM_p last">The title compound (14.5 mg, 21%) was prepared from methyl 2-(2-((5-bromo-3,3-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)acetate (<b>42</b>) (50 mg, 0.12 mmol) and (<i>R</i>)-6-bromochroman-4-amine hydrochloride (<b>46</b>) (32.6 mg, 0.12 mmol) in a similar manner as described for the preparation of (<i>S</i>)-2-(2-((3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-(2-cyanopropan-2-yl)benzyl)oxy)phenyl)acetic acid (<b>7</b>). The title compound was purified by preparative HPLC (conditions g) and then again by preparative HPLC (column: Waters Sunfire C18 OBD; particle size: 5 μm; column size: 30 × 100 mm<sup>2</sup>; eluent: 5–100% CH<sub>3</sub>CN/H<sub>2</sub>O in 20 min, 100% CH<sub>3</sub>CN/3 min (CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% TFA); flow rate: 40 mL/min; column temperature: RT), and the compound-containing fractions were lyophilized to give the title compound as a trifluoroacetate salt. UPLC/MS (conditions c), <i>t</i><sub>R</sub>: 0.96 min, purity 100%; UPLC/MS (conditions d), <i>t</i><sub>R</sub>: 3.71 min, purity 100%; UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 460.3 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (br s, 1H), 7.56 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.51 (br s, 1H), 7.43 (d, <i>J</i> = 2.0 Hz, 1H), 7.26–7.20 (m, 2H), 7.07 (d, <i>J</i> = 8.1 Hz, 1H), 6.92 (d, <i>J</i> = 8.3 Hz, 1H), 6.91 (t, <i>J</i> = 7.3 Hz, 1H), 5.09 (s, 2H), 4.58 (m, 1H), 4.35 (s, 2H), 4.28 (m, 2H), 3.58 (s, 2H), 2.29 (m, 1H), 2.10 (m, 1H), 1.38 (s, 6H).</div></div><div id="sec5_1_2_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 2-((<i>R</i>)-2-(3-((<i>S</i>)-3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetic Acid (<b>13</b>)</h5><div class="NLM_p last">To a solution of 2-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetic acid (84 mg, 0.15 mmol) in dioxane (0.8 mL) was added 4 N HCl in dioxane (0.77 mL, 3.08 mmol). The reaction mixture was shaken at RT for 18 h. The volatiles were removed under reduced pressure, the residue was taken up in CH<sub>3</sub>CN, the solvent was removed under reduced pressure, and the residue was purified by reversed-phase column chromatography (RediSep <i>R</i><sub><i>f</i></sub> GOLD 50 g C18 column; eluent A: H<sub>2</sub>O + 0.1% TFA, B: CH<sub>3</sub>CN, gradient: 10–100% B in 13 min, flow 40 mL/min) to afford 2-(2-(3-((<i>S</i>)-3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetic acid as a trifluoroacetate salt (55 mg, 63%). UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 445 (M + 1), <i>t</i><sub>R</sub>: 3.33 min, purity 99% (conditions d). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 3H), 7.86 (s, 1H), 7.69 (d, <i>J</i> = 8.7 Hz, 1H), 7.47 (s, 1H), 7.41 (s, 1H), 7.34 (s, 1H), 7.05 (d, <i>J</i> = 8.4 Hz, 1H), 6.67 (t, <i>J</i> = 7.6 Hz, 1H), 6.61–6.55 (m, 1H), 6.48 (d, <i>J</i> = 6.9 Hz, 1H), 5.98 (m, 1H), 5.13 (m, 1H), 5.06 (d, <i>J</i> = 8.3 Hz, 1H), 4.78 (t, <i>J</i> = 10.1 Hz, 1H), 4.55 (dd, <i>J</i> = 10.9, 3.5 Hz, 1H), 3.59 (d, <i>J</i> = 10.9 Hz, 1H), 3.50 (s, 1H), 3.22–3.13 (m, 1H), 3.03–2.95 (m, 2H), 1.29 (d, <i>J</i> = 6.9 Hz, 6H). The diastereomers (50 mg, 0.11 mmol) were separated by preparative HPLC (Sepiatec ASAP HPLC system; column: Chiralpak ID 250 × 20 mm<sup>2</sup> 5 μm; eluent: <i>n</i>-heptane/CH<sub>2</sub>Cl<sub>2</sub>/MeOH 85:7.5:7.5 (v/v/v + 0.05% Et<sub>2</sub>NH); flow: 10 mL/min; temperature: RT; detection at 270 nm). The title compound eluted as the first peak from the column (<i>t</i><sub>R</sub> = 55 min) (5.7 mg, 11%, >99% chiral purity). UPLC/MS (conditions d), <i>t</i><sub>R</sub>: 3.33 min, purity 100%; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 445 (M + 1). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91 (s, 1H), 7.57 (s, 1H), 7.51 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.39 (s, 1H), 7.22 (s, 1H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 6.58 (t, <i>J</i> = 7.6 Hz, 1H), 6.51–6.44 (m, 2H), 5.78 (s, 1H), 5.17 (dd, <i>J</i> = 7.7, 2.7 Hz, 1H), 4.77 (dd, <i>J</i> = 8.3, 5.2 Hz, 1H), 4.69 (t, <i>J</i> = 8.9 Hz, 1H), 4.21 (dd, <i>J</i> = 9.5, 5.2 Hz, 1H), 3.58–3.51 (m, 3H), 3.05 (dd, <i>J</i> = 11.8, 8.0 Hz, 1H), 3.00–2.91 (m, 1H), 1.26 (dd, <i>J</i> = 7.0, 1.7 Hz, 6H).</div></div><div id="sec5_1_2_24" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetic acid: To a solution of ethyl 2-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetate (95 mg, 0.154 mmol) in THF/water/MeOH (1:0.1:0.5, 3.2 mL) was added 1 M NaOH aqueous solution (1.54 mL, 1.54 mmol). The reaction mixture was stirred at RT for 18 h. The volatiles were removed under reduced pressure, and the residual aqueous layer was acidified with 1 N hydrochloric acid followed by extraction with CH<sub>2</sub>Cl<sub>2</sub> (2×). The combined organic layers were dried (phase separator) and evaporated to afford the title compound, which was used without purification (108 mg, quant.). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 545 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.79–7.73 (m, 1H), 7.63–7.61 (m, 1H), 7.52 (t, <i>J</i> = 7.1 Hz, 1H), 7.46 (s, 1H), 7.36 (s, 1H), 7.27 (s, 1H), 6.88 (d, <i>J</i> = 6.9 Hz, 1H), 6.53 (dd, <i>J</i> = 8.3, 6.8 Hz, 1H), 6.49–6.44 (m, 1H), 6.40 (d, <i>J</i> = 7.7 Hz, 1H), 5.69 (s, 1H), 5.34–5.25 (m, 1H), 5.03–4.95 (m, 1H), 4.76–4.66 (m, 1H), 4.27–4.21 (m, 1H), 3.50 (m, 1H), 3.18–3.11 (m, 2H), 3.01–2.92 (m, 1H), 2.56–2.54 (m, 1H), 1.41 (s, 9H), 1.26 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_25" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Ethyl 2-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetate: To a solution of ethyl 2-(2-(3-bromo-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetate (95 mg, 0.23 mmol) in CH<sub>3</sub>CN (4.5 mL) were added (<i>S</i>)-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)boronic acid (<b>47</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (63.4 mg, 0.23 mmol) and 2 M K<sub>3</sub>PO<sub>4</sub> aqueous solution (0.34 mL, 0.68 mmol). The reaction was degassed with argon for 2 min, and then PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (9.27 mg, 0.011 mmol) was added. The reaction was stirred at 125 °C for 30 min under microwave irradiation. The reaction mixture was diluted with EtOAc and washed with water and brine. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (100% <i>c</i>-hexane to <i>c</i>-hexane/EtOAc (7:3) in 15 min) to afford the title compound (95 mg, 68%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 573 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.57 (m, 2H), 7.50 (d, <i>J</i> = 8.4 Hz, 1H), 7.40 (s, 1H), 7.37 (s, 1H), 7.23 (s, 1H), 6.89 (d, <i>J</i> = 8.1 Hz, 1H), 6.65 (t, <i>J</i> = 7.6 Hz, 1H), 6.57 (d, <i>J</i> = 8.2 Hz, 1H), 6.45 (d, <i>J</i> = 7.3 Hz, 1H), 5.98 (s, 1H), 5.31 (m, 1H), 5.02–4.95 (m, 1H), 4.70 (t, <i>J</i> = 9.1 Hz, 1H), 4.26 (m, 1H), 3.95 (m, 2H), 3.56 (m, 1H), 3.52 (s, 2H), 3.15 (t, <i>J</i> = 10.3 Hz, 1H), 2.95 (m, 1H), 1.40 (s, 9H), 1.25 (d, <i>J</i> = 6.9 Hz, 6H), 1.01 (td, <i>J</i> = 7.0, 2.3 Hz, 3H).</div></div><div id="sec5_1_2_26" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Ethyl 2-(2-(3-bromo-5-isopropylphenyl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetate: To a solution of 2-(2-(3-bromo-5-isopropylphenyl)-3-oxo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetate (138 mg, 0.319 mmol) in THF (3 mL) at 0 °C was added BH<sub>3</sub>·Me<sub>2</sub>S (61 μL, 0.638 mmol). The reaction mixture was stirred at RT for 4 h, cooled to 0 °C, quenched with water, and extracted with EtOAc (2×). The combined organic layer was washed with brine and dried (phase separator), the solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography (eluent: 100% <i>c</i>-hexane to <i>c</i>-hexane/EtOAc (1:1) in 20 min) to afford the title compound (95.7 mg, 72% yield). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 418/420 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.42–7.37 (m, 2H), 7.31 (s, 1H), 6.65 (t, <i>J</i> = 7.6 Hz, 1H), 6.56 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 6.45 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 5.98 (d, <i>J</i> = 3.5 Hz, 1H), 4.98 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 4.03 (q, <i>J</i> = 7.1 Hz, 2H), 3.57–3.46 (m, 3H), 3.07 (dd, <i>J</i> = 11.4, 8.0 Hz, 1H), 2.90 (p, <i>J</i> = 6.8 Hz, 1H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H), 1.09 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_1_2_27" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Ethyl 2-(2-(3-bromo-5-isopropylphenyl)-3-oxo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)acetate: To a flask charged with NaH (60% in mineral oil, 79 mg, 1.97 mmol) was added a solution of ethyl 2-(3-amino-2-hydroxyphenyl)acetate (240 mg, 0.98 mmol) in DMF (4 mL). The solution was stirred at RT for 10 min; then, methyl 2-bromo-2-(3-bromo-5-isopropylphenyl)acetate (174 mg, 0.49 mmol) in DMF (6 mL) was added dropwise, and the reaction mixture was stirred at RT for 2 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organic layer was washed with brine and dried (phase separator), the solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography (100% <i>c</i>-hexane to <i>c</i>-hexane/EtOAc (1:1) in 15 min) to afford the title compound (139 mg, 65%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 432/434 (M + 1); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.98 (s, 1H), 7.46 (m, 1H), 7.32 (t, <i>J</i> = 1.7 Hz, 1H), 7.25 (m, 1H), 6.99–6.85 (m, 3H), 5.73 (s, 1H), 4.04–3.95 (m, 2H), 3.63 (d, <i>J</i> = 4.0 Hz, 2H), 2.96–2.85 (m, 1H), 1.17 (d, <i>J</i> = 6.9 Hz, 6H), 1.09 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_1_2_28" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-bromo-2-(3-bromo-5-isopropylphenyl)acetate: To a solution of methyl 2-(3-bromo-5-isopropylphenyl)acetate (500 mg, 1.75 mmol) in THF (9 mL) at −78 °C was added dropwise LiHMDS (1 M solution in THF, 1.93 mL, 1.93 mmol) under an inert atmosphere. The reaction mixture was stirred at −78 °C for 15 min. Then, trimethylsilyl chloride (TMSCl) (0.425 mL, 3.33 mmol) was added and stirring continued at −78 °C for 15 min. Then, <i>N</i>-bromosuccinimide (327 mg, 1.84 mmol) was added to the reaction mixture, which was subsequently warmed to RT and stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with EtOAc (2×). The combined organic layer was washed with brine and dried (phase separator), the solvent was evaporated under reduced pressure, and the residue was purified by reversed-phase column chromatography (RediSep <i>R</i><sub><i>f</i></sub> GOLD 50 g C18 column, eluent A: H<sub>2</sub>O + 0.1% TFA, B: CH<sub>3</sub>CN, gradient: 10–100% B in 13 min, flow 40 mL/min) to afford the title compound (174 mg, 28%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 368/370 (M + 18); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.56 (t, <i>J</i> = 1.7 Hz, 1H), 7.46 (t, <i>J</i> = 1.7 Hz, 1H), 7.43 (t, <i>J</i> = 1.5 Hz, 1H), 5.93 (s, 1H), 3.73 (s, 3H), 2.91 (hept, <i>J</i> = 7.3 Hz, 1H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_29" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(3-bromo-5-isopropylphenyl)acetate: To a solution of 2-(3-bromo-5-isopropylphenyl)acetic acid (1.48 g, 5.4 mmol) in THF/MeOH (1:1, 44 mL) was added dropwise over 30 min trimethylsilyldiazomethane (2 M solution in Et<sub>2</sub>O, 5.41 mL, 10.82 mmol), and the reaction mixture was stirred at RT for 4 h. The volatiles were evaporated under reduced pressure, and the residue was purified by flash column chromatography (100% <i>c</i>-hexane to <i>c</i>-hexane/EtOAc (1:1) in 20 min) to afford the title compound (1.25 g, 81%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 288/290 (M + 18); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.33 (t, <i>J</i> = 1.7 Hz, 1H), 7.30 (t, <i>J</i> = 1.6 Hz, 1H), 7.15 (t, <i>J</i> = 1.5 Hz, 1H), 3.69 (s, 2H), 3.62 (s, 3H), 2.87 (hept, <i>J</i> = 6.9 Hz, 1H), 1.18 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_30" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-(3-Bromo-5-isopropylphenyl)acetic acid: To a solution of 2-(3-bromo-5-isopropylphenyl)acetonitrile (1.40 g, 5.84 mmol) in EtOH/H<sub>2</sub>O (1:1, 22 mL) was added KOH (1.64 g, 29 mmol). The reaction mixture was stirred at 85 °C for 18 h and cooled to RT, and the volatiles were evaporated under reduced pressure. The residue was taken up in 1 N aqueous HCl and extracted with EtOAc (2×). The combined organic layers were washed with brine and dried (phase separator), and the solvent was evaporated under reduced pressure to provide the title compound, which was used without further purification (1.48 g, 93%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 274/276 (M + 18); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.40 (s, 1H), 7.31 (t, <i>J</i> = 1.7 Hz, 1H), 7.28 (t, <i>J</i> = 1.7 Hz, 1H), 7.14 (t, <i>J</i> = 1.6 Hz, 1H), 3.57 (s, 2H), 2.87 (hept, <i>J</i> = 6.9 Hz, 1H), 1.18 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_31" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-(3-Bromo-5-isopropylphenyl)acetonitrile: A solution of (3-bromo-5-isopropylphenyl)methanol (<b>25</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (1.85 g, 7.9 mmol), Et<sub>3</sub>N (1.64 mL, 11.9 mmol), and MsCl (0.74 mL, 9.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was stirred at 0 °C for 30 min. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with H<sub>2</sub>O (2×). The organic layer was dried (phase separator), the solvent was evaporated under reduced pressure, the crude intermediate was dissolved in dry DMF (30 mL), and sodium cyanide (0.76 g, 15.8 mmol) was added. The reaction mixture was stirred at RT for 56 h. The reaction mixture was diluted with water and extracted with EtOAc (2×). The organic layer was washed with brine and dried (phase separator), the solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography (100% <i>c</i>-hexane to <i>c</i>-hexane/EtOAc (4:1) in 15 min) to afford the title compound (1.39 g, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.42 (t, <i>J</i> = 1.7 Hz, 1H), 7.38 (t, <i>J</i> = 1.7 Hz, 1H), 7.24 (t, <i>J</i> = 1.4 Hz, 1H), 4.03 (s, 2H), 2.90 (hept, <i>J</i> = 7.0 Hz, 1H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> (<i>S</i>)-2-(3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoic Acid Trifluoroacetate (<b>14</b>)</h5><div class="NLM_p last">To a solution of (<i>S</i>)-2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoic acid (35 mg, 0.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added TFA (156 μL, 2.03 mmol). The reaction mixture was stirred at RT for 18 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and MeOH, and then volatiles were evaporated. The reaction mixture was taken up in MeOH and then evaporated. This operation was done twice. The crude mixture was purified by preparative HPLC (column: Sunfire C18-ODB 5 μm, 30 × 100 mm<sup>2</sup>, flow: 40 mL/min, eluent: 5–100% CH<sub>3</sub>CN/H<sub>2</sub>O/20 min, 100% CH<sub>3</sub>CN/2 min, CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% TFA). The desired fractions were combined, and CH<sub>3</sub>CN was evaporated, followed by freeze-drying overnight to obtain the TFA salt of the title compound as a white solid (17 mg, 46%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 418.2 (M + 1); HPLC <i>t</i><sub>R</sub>: 4.05 min, purity 99% (conditions b); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.56 (bs, 1H), 8.43 (s, 3H), 7.83 (d, <i>J</i> = 1.9 Hz, 1H), 7.68–7.62 (m, 2H), 7.51–7.44 (m, 1H), 7.38 (d, <i>J</i> = 1.8 Hz, 1H), 7.28 (d, <i>J</i> = 1.8 Hz, 1H), 7.24 (d, <i>J</i> = 1.7 Hz, 1H), 7.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.04–6.95 (m, 2H), 5.16–5.06 (m, 1H), 4.76 (dd, <i>J</i> = 11.0, 8.2 Hz, 1H), 4.53 (dd, <i>J</i> = 11.0, 3.5 Hz, 1H), 4.27 (t, <i>J</i> = 6.7 Hz, 2H), 3.08 (t, <i>J</i> = 6.6 Hz, 2H), 2.98–2.89 (m, 1H), 1.29–1.20 (m, 6H).</div></div><div id="sec5_1_2_33" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-2-(3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoic acid: To a solution of (<i>S</i>)-methyl 2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoate (30 mg, 0.06 mmol) in THF (0.5 mL) and water (0.5 mL) was added LiOH·H<sub>2</sub>O (4.74 mg, 0.11 mmol). The reaction mixture was stirred at 60 °C for 18 h. The reaction mixture was acidified to pH = 1 with HCl (6 N) and was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2×). The combined organic layers were dried (phase separator) and evaporated under vacuum to afford the title compound (35 mg, quantitative) as a colorless oil. MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 518.2 (M + 1).</div></div><div id="sec5_1_2_34" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-Methyl 2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl))-5-isopropylphenethyl 2-hydroxybenzoate: To an ice-cooled solution of (<i>S</i>)-<i>tert</i>-butyl (5-(3-(2-hydroxyethyl)-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate (90 mg, 0.23 mmol) in THF (1.5 mL) were added methyl 2-hydroxybenzoate (<b>32</b>) (34.4 mg, 0.23 mmol), PPh<sub>3</sub> (71.3 mg, 0.27 mmol), and DIAD (0.05 mL, 0.27 mmol). The reaction mixture was allowed to warm to RT and stirred for 18 h. Volatiles were evaporated, and the residue was taken up in EtOAc and then washed with a saturated aqueous NH<sub>4</sub>Cl solution (5 mL). The organic phase was dried (phase separator) and evaporated under vacuum. The crude mixture was purified by preparative HPLC (column: Sunfire, C18-ODB 5 μm, 30 × 100 mm<sup>2</sup>, flow: 40 mL/min, 40–100% CH<sub>3</sub>CN/H<sub>2</sub>O/20 min, 100% CH<sub>3</sub>CN/2 min, CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% TFA). The desired fractions were combined, and CH<sub>3</sub>CN was evaporated, followed by freeze-drying overnight to obtain the title compound (30 mg, 24%) as a white solid. MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 532.2 (M + 1).</div></div><div id="sec5_1_2_35" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-<i>tert</i>-Butyl (5-(3-(2-hydroxyethyl)-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate: In a 10–20 mL microwave reaction vessel, to a solution of 2-(3-bromo-5-isopropylphenyl)ethanol (<b>28</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (100 mg, 0.41 mmol) in CH<sub>3</sub>CN (3 mL) were added (<i>S</i>)-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)boronic acid (<b>47</b>,<a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (135 mg, 0.41 mmol) and 2 M K<sub>3</sub>PO<sub>4</sub> (0.62 mL, 1.24 mmol). The reaction mixture was degassed under argon for 2 min, and then PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (16.8 mg, 0.02 mmol) was added. The reaction mixture was stirred at 120 °C for 40 min under microwave irradiations (with a Biotage Initiator<sup>+</sup> apparatus). The reaction mixture was diluted with AcOEt and then washed with water (10 mL). The organic phase was dried (phase separator) and evaporated under vacuum to afford the title compound (158 mg, 93%) as a brown oil, which was used without further purification. MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 415.2 (M + 18).</div></div><div id="sec5_1_2_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> (<i>S</i>)-2-(3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methoxybenzoic Acid Trifluoroacetate (<b>15</b>)</h5><div class="NLM_p last">The TFA salt of the title compound (22 mg, 42%) was prepared from (<i>S</i>)-2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methoxybenzoic acid (50 mg, 0.091 mmol) in a similar manner as described for (<i>S</i>)-2-(3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoic acid trifluoroacetate (<b>14</b>). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 432.3 (M + 1); HPLC <i>t</i><sub>R</sub>: 4.12 min, purity 100% (conditions b); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.84 (s, 1H), 8.41 (s, 3H), 7.83 (d, <i>J</i> = 2.0 Hz, 1H), 7.64 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.33–7.27 (m, 2H), 7.22–7.08 (m, 4H), 7.02 (d, <i>J</i> = 8.4 Hz, 1H), 5.16–5.07 (m, 1H), 4.76 (dd, <i>J</i> = 11.0, 8.2 Hz, 1H), 4.53 (dd, <i>J</i> = 11.0, 3.5 Hz, 1H), 4.21 (t, <i>J</i> = 7.2 Hz, 2H), 3.77 (s, 3H), 3.06 (t, <i>J</i> = 7.2 Hz, 2H), 2.97–2.89 (m, 1H), 1.28–1.21 (m, 6H).</div></div><div id="sec5_1_2_37" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-2-(3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methoxybenzoic acid: The title compound (50 mg, 64%) was prepared from (<i>S</i>)-methyl 2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methoxybenzoate in a similar manner as described for (<i>S</i>)-methyl 2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoic acid (described in the synthesis of compound <b>14</b>). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 548.3 (M + 1).</div></div><div id="sec5_1_2_38" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-Methyl 2-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methoxybenzoate: The title compound was prepared from methyl 2-(3-bromo-5-isopropylphenethoxy)-3-methoxybenzoate (<b>43</b>) (80 mg, 0.20 mmol) and (<i>S</i>)-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)boronic acid (<b>47</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (64.5 mg, 0.20 mmol) in a similar manner as described for (<i>S</i>)-<i>tert</i>-butyl (5-(3-(2-hydroxyethyl)-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate (described in the synthesis of compound <b>14</b>). The crude mixture was purified by preparative HPLC (column: Sunfire, C18-ODB 5 μm, 30 × 100 mm<sup>2</sup>; flow: 40 mL/min; gradient: 20–100% CH<sub>3</sub>CN/H<sub>2</sub>O/20 min, 100% CH<sub>3</sub>CN/2 min, CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% TFA). The desired fractions were combined, and CH<sub>3</sub>CN was evaporated, followed by freeze-drying overnight to obtain the title compound as a colorless oil (60 mg, 43%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 562.3 (M + 1).</div></div><div id="sec5_1_2_39" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(3-bromo-5-isopropylphenethoxy)-3-methoxybenzoate (<b>43</b>): The title compound (80 mg, 65%) was prepared from 2-(3-bromo-5-isopropylphenyl)ethanol (<b>28</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (70 mg, 0.29 mmol) and methyl 2-hydroxy-3-methoxybenzoate (<b>33</b>) (52.4 mg, 0.29 mmol) in a similar manner as described for (<i>S</i>)-3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl 2-hydroxybenzoate (described in the synthesis of compound <b>14</b>). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 409.5 (M + 1).</div></div><div id="sec5_1_2_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> (<i>S</i>)-2-((3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)amino)benzoic Acid Hydrochloride (<b>16</b>)</h5><div class="NLM_p last">To a solution of (<i>S</i>)-2-((3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)amino)benzoic acid (62.2 mg, 60% pure, 0.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added TFA (1.56 mmol). The reaction was stirred at RT for 3 h. The reaction was concentrated to a brown film. The crude residue was purified by preparative HPLC (column: Sunfire C18 5 μM 100 × 30 mm<sup>2</sup>; flow: 42 mL/min; 10–80% CH<sub>3</sub>CN/H<sub>2</sub>O/20 min, 80% CH<sub>3</sub>CN/2 min, CH<sub>3</sub>CN and H<sub>2</sub>O containing 0.1% TFA). The combined product fractions were lyophilized to afford the TFA salt of the title compound. The TFA salt was converted to HCl salt by dissolution in 1:1 CH<sub>3</sub>CN/H<sub>2</sub>O and addition of 1 N HCl (0.05 mL, 0.05 mmol, 2 equiv) followed by lyophilization. This procedure was repeated three times to give the hydrochloride salt of the title compound (9.60 mg, 26%). UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 417.3 (M + 1), <i>t</i><sub>R</sub>: 2.03 min, purity 95% (conditions e); <sup>1</sup>H NMR (400 MHz, deuterium oxide, MeCN-<i>d</i><sub><i>3</i></sub> added to solubilize) δ 7.86 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.76 (d, <i>J</i> = 1.9 Hz, 1H), 7.63 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.47–7.37 (m, 1H), 7.30 (d, <i>J</i> = 18.7 Hz, 2H), 7.12 (s, 1H), 7.04 (d, <i>J</i> = 8.5 Hz, 1H), 6.91 (d, <i>J</i> = 8.4 Hz, 1H), 6.75 (t, <i>J</i> = 7.5 Hz, 1H), 5.13 (dd, <i>J</i> = 7.5, 2.9 Hz, 1H), 4.81–4.65 (m, 2H), 3.55 (t, <i>J</i> = 6.5 Hz, 2H), 2.98 (t, <i>J</i> = 6.6 Hz, 2H), 2.96–2.87 (m, 1H), 1.22 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_41" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-2-((3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)amino)benzoic acid: A microwave vial was charged with 2-((3-bromo-5-isopropylphenethyl)amino)benzoic acid (30.8 mg, 0.077 mmol) and (<i>S</i>)-<i>tert</i>-butyl (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (<b>48</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (35.0 mg, 0.097 mmol) in 1,4-dioxane (1.5 mL). PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (3.6 mg, 4.41 μmol) and Na<sub>2</sub>CO<sub>3</sub> (2 M aqueous, 0.12 mL, 0.24 mmol) were added to the vial. N<sub>2</sub> was bubbled through the reaction mixture for 5 min, and the vial was sealed. The reaction was heated at 120 °C under microwave irradiations for 90 min. The reaction mixture was diluted with a pH = 7.0 buffer and extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was taken up in THF (5 mL), and SiliaMetSThiol (SiliCycle; 50 mg, 1.25 mmol/g) was added to scavenge residual palladium. The resulting suspension was stirred for 1 h at 40 °C. The scavenger was filtered and washed with THF (2×). The filtrate was concentrated to afford the title compound as a brown film (62.2 mg, 94%, 60% pure). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 517.1 (M + 1).</div></div><div id="sec5_1_2_42" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-((3-Bromo-5-isopropylphenethyl)amino)benzoic acid: To a suspension of 2-((3-bromo-5-isopropylphenethyl)amino)benzonitrile (47.9 mg, 0.14 mmol) in ethylene glycol (1.5 mL) was added KOH (70 mg, 1.25 mmol). The reaction mixture was heated to 185 °C and stirred for 16 h. The reaction mixture was cooled to RT, diluted with H<sub>2</sub>O, and extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by flash column chromatography (ISCO RediSep 12 g silica cartridge; gradient: 0–30% EtOAc in <i>n</i>-heptane) to afford the title compound (30.8 mg, 55%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 363.9 (M + 1).</div></div><div id="sec5_1_2_43" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-((3-Bromo-5-isopropylphenethyl)amino)benzonitrile: To a suspension of 2-(3-bromo-5-isopropylphenyl)ethanamine (115 mg, 0.475 mmol) and K<sub>2</sub>CO<sub>3</sub> (130 mg, 0.94 mmol) in anhydrous DMF (2 mL) was added 2-fluorobenzonitrile (0.10 mL, 0.94 mmol). The reaction mixture was stirred at 80 °C for 21 h, then at 120 °C for 5 h, and finally cooled to 100 °C and stirred for 16 h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with H<sub>2</sub>O. The aqueous layer was extracted with EtOAc (2×), and the combined organic layers were washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to a yellow oil. This crude residue was purified by flash column chromatography (ISCO RediSep 24 g silica cartridge; gradient 0–15% EtOAc in <i>n</i>-heptane) to afford the title compound (169 mg, 72%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 344.9 (M + 1).</div></div><div id="sec5_1_2_44" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-(3-Bromo-5-isopropylphenyl)ethanamine: To a solution of 2-(3-bromo-5-isopropylphenyl)acetonitrile (described in the synthesis of compound <b>13</b>) (968 mg, 4.07 mmol) in anhydrous THF (12 mL) cooled to 0 °C was slowly added BH<sub>3</sub>·THF (1.0 M in THF, 12.0 mL, 12.0 mmol). Upon completion of addition, the ice bath was removed and the reaction mixture warmed to RT while stirring was maintained for 3.5 h. The reaction mixture was cooled to 10 °C, and MeOH (1.6 mL) was slowly added to quench the excess borane (gas evolved). The reaction mixture was allowed to warm to RT and stirred for 30 min. The resulting solution was concentrated, taken up in MeOH, and concentrated to a viscous oil, which was taken up in EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub>. The aqueous layer was extracted with EtOAc (2×), and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by flash column chromatography (ISCO RediSep 12 g silica cartridge; gradient 0–20% (10% triethylamine (TEA)/MeOH) in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound (115 mg, 12%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 243.8 (M + 1).</div></div><div id="sec5_1_2_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (<i>S</i>)-1-(3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)indoline-7-carboxylic Acid Trifluoroacetate (<b>17</b>)</h5><div class="NLM_p last">Methyl (<i>S</i>)-1-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)indoline-7-carboxylate (14 mg, 0.025 mmol) was dissolved in THF/MeOH/H<sub>2</sub>O (0.9 mL, 4:2:1), LiOH·H<sub>2</sub>O (5.28 mg, 0.126 mmol) was added, and the mixture was stirred at 50 °C until consumption of the starting material. The mixture was concentrated under reduced pressure. The residue was coevaporated with toluene (2×) and dried under high vacuum overnight. The crude residue, (<i>S</i>)-1-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)indoline-7-carboxylic acid (10.9 mg), was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL), TFA (0.04 mL, 0.50 mmol) was added, and the reaction mixture was stirred at RT. After completion, the reaction mixture was concentrated and the crude residue was purified by reverse-phase preparative HPLC (prep HPLC conditions k, gradient: 10–80% CH<sub>3</sub>CN) to afford the title compound (6 mg, 34%). UPLC/MS (ESI<sup>–</sup>) <i>m</i>/<i>z</i> 440.9 (M-1), <i>t</i><sub>R</sub>: 1.64 min, purity 100% (condition e); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (bs, 3H), 7.83 (d, <i>J</i> = 2.0 Hz, 1H), 7.65–7.60 (m, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 7.28–7.21 (m, 2H), 7.16 (d, <i>J</i> = 7.0 Hz, 1H), 7.05–7.00 (m, 2H), 6.62 (t, <i>J</i> = 7.4 Hz, 1H), 5.14–5.07 (m, 1H), 4.79–4.72 (m, 1H), 4.57–4.51 (m, 1H), 2.98–2.87 (m, 3H), 2.83–2.75 (m, 2H), 1.25 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_1_2_46" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl (<i>S</i>)-1-(3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)indoline-7-carboxylate: The title compound was prepared in a similar manner as described for (<i>S</i>)-2-((3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)amino)benzoic acid (described in the synthesis of compound <b>16</b>) using methyl 1-(3-bromo-5-isopropylphenethyl)indoline-7-carboxylate (24 mg, 0.06 mmol) and <i>tert</i>-butyl (S)-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (<b>48</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (0.213 mmol). The crude residue was purified by flash column chromatography (ISCO RediSep 12 g silica cartridge; gradient: 0–15% EtOAc in <i>n</i>-heptane) to afford the title compound (14 mg, 42%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 557.1 (M + 1).</div></div><div id="sec5_1_2_47" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 1-(3-bromo-5-isopropylphenethyl)indoline-7-carboxylate: To a solution of 2-(3-bromo-5-isopropylphenyl)acetaldehyde (180 mg, 0.75 mmol) in EtOH (5 mL) was added methyl indoline-7-carboxylate (304 mg, 1.72 mmol) followed by a catalytic amount of AcOH and powdered 4 Å molecular sieves. The resulting mixture was stirred at 70 °C for 12 h, cooled to RT, and concentrated under reduced pressure. The resulting residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), AcOH (0.064 mL, 1.10 mmol) and NaBH(OAc)<sub>3</sub> (633 mg, 3.00 mmol) were added, and the reaction mixture was stirred at RT overnight. Then, the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with a saturated aqueous solution of NaHCO<sub>3</sub>, with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by preparative reverse-phase HPLC (prep. HPLC conditions k; gradient: 10–80% CH<sub>3</sub>CN) to afford the title compound (54 mg, 14%) as a TFA salt. MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 402.0 (M + 1).</div></div><div id="sec5_1_2_48" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-(3-Bromo-5-isopropylphenyl)acetaldehyde: To a mixture of lead tetraacetate (591 mg, 1.30 mmol) in TFA (1.10 mL) at 0 °C was added 1-bromo-3-isopropyl-5-vinylbenzene (<b>51</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (250 mg, 1.10 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.1 mL) dropwise, and the resulting mixture was allowed to warm to RT and stirred at RT for 2 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and poured into water. The mixture was vigorously stirred and filtered through a plug of Celite. The filter cake was washed with CH<sub>2</sub>Cl<sub>2</sub> and water. The filtrate was collected, and the organic phase was separated. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic layers were washed with water and a saturated aqueous solution of NaHCO<sub>3</sub>, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (gradient: 0–10% EtOAc in <i>n</i>-heptane) to give the title compound (80 mg, 30%). MS (ESI<sup>–</sup>) <i>m</i>/<i>z</i> 238.8 (M-1).</div></div><div id="sec5_1_2_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (<i>S</i>)-2-(3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methylbenzoic Acid Trifluoroacetate (<b>18</b>)</h5><div class="NLM_p last">The title compound (32 mg, 61%) was prepared in a similar manner as described for (<i>S</i>)-2-(3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-methoxybenzoic acid trifluoroacetate (<b>15</b>) using methyl 2-hydroxy-3-methylbenzoate (<b>34</b>) (47.8 mg, 0.29 mmol) instead of methyl 2-hydroxy-3-methoxybenzoate (<b>33</b>). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 432.3 (M + 1); HPLC <i>t</i><sub>R</sub>: 4.35 min, purity 99% (conditions b); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.87 (bs, 1H), 8.43 (bs, 3H), 7.84 (d, <i>J</i> = 2.0 Hz, 1H), 7.64 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.51 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.38–7.27 (m, 3H), 7.17 (d, <i>J</i> = 1.8 Hz, 1H), 7.06 (t, <i>J</i> = 7.6 Hz, 1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 5.15–5.06 (m, 1H), 4.76 (dd, <i>J</i> = 11.0, 8.2 Hz, 1H), 4.53 (dd, <i>J</i> = 11.0, 3.6 Hz, 1H), 4.14 (t, <i>J</i> = 6.9 Hz, 2H), 3.08 (t, <i>J</i> = 6.9 Hz, 2H), 2.98–2.89 (m, 1H), 2.08 (s, 3H), 1.29–1.21 (m, 6H).</div></div><div id="sec5_1_2_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (<i>S</i>)-2-(3-(3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)-3-chlorobenzoic Acid Trifluoroacetate (<b>19</b>)</h5><div class="NLM_p last">The title compound (32 mg, 68%) was prepared in a similar manner as described for (<i>S</i>)-2-(3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethoxy)benzoic acid trifluoroacetate (<b>14</b>) using methyl 3-chloro-2-hydroxybenzoate (<b>35</b>) (32.9 mg, 0.18 mmol) instead of methyl 2-hydroxybenzoate (<b>32</b>). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 452.2 (M + 1); HPLC <i>t</i><sub>R</sub>: 4.50 min, purity 100% (conditions b); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (s, 3H), 7.83 (d, <i>J</i> = 2.0 Hz, 1H), 7.69–7.61 (m, 3H), 7.32 (s, 1H), 7.29 (s, 1H), 7.22 (t, <i>J</i> = 7.9 Hz, 1H), 7.17 (s, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 1H), 5.15–5.06 (m, 1H), 4.76 (dd, <i>J</i> = 11.0, 8.2 Hz, 1H), 4.53 (dd, <i>J</i> = 11.0, 3.6 Hz, 1H), 4.26 (t, <i>J</i> = 7.0 Hz, 2H), 3.13 (t, <i>J</i> = 7.1 Hz, 2H), 2.98–2.89 (m, 1H), 1.25 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 2-(2-(3-((<i>S</i>)-3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoic Acid (<b>20</b>)</h5><div class="NLM_p last">To a solution of methyl 2-(2-(3-((<i>S</i>)-3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoate (45 mg, 0.094 mmol) in THF/MeOH/H<sub>2</sub>O (7:2:1, 2.5 mL) cooled to 0 °C was slowly added a solution of LiOH·H<sub>2</sub>O (0.28 mmol) in THF/MeOH/H<sub>2</sub>O (7:2:1, 2.5 mL). The reaction mixture was stirred at RT for 6 h. The reaction mixture was acidified with 1 N HCl and partitioned between water and EtOAc. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford the title compound (13 mg, 30%). MS (ESI<sup>–</sup>) <i>m</i>/<i>z</i> 462.05 (M – 1); HPLC (ZORBAX Eclipse C18 5 μm, 4.6 × 150 mm<sup>2</sup>; gradient: 5% (1:1 CH<sub>3</sub>CN/MeOH) in H<sub>2</sub>O (containing 0.1% TFA)/1 min, 5–100% (1:1 CH<sub>3</sub>CN/MeOH) in H<sub>2</sub>O (containing 0.1% TFA)/5 min, 100% (1:1 CH<sub>3</sub>CN/MeOH)/2 min; flow rate: 1.0 mL/min; column temperature: 40 °C); <i>t</i><sub>R</sub>: 6.68 min, purity 99%; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 7.93 (s, 1H), 7.73 (s, 1H), 7.64 (m, 2H), 7.33 (s, 1H), 7.20 (m, 1H), 7.01 (m, 3H), 5.10 (m, 1H), 4.90 (m,1H), 4.80 (m, 1H), 4.60 (m, 1H), 4.38 (m, 1H), 4.22 (m, 1H), 4.12 (m, 1H), 3.82 (d, <i>J</i> = 2.1 Hz, 3H), 2.96 (m, 1H), 1.28 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_1_2_52" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-(3-((<i>S</i>)-3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoate: To a solution of methyl 2-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoate (65 mg, 0.11 mmol) in 1,4-dioxane (0.5 mL) was added HCl (4 N in 1,4-dioxane, 3.0 mL, 12.0 mmol). The reaction mixture was stirred at RT for 6 h; then, it was concentrated under reduced pressure to give the title compound as a HCl salt (45 mg, 64%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.48 (bs, 3H), 7.87 (s, 1H), 7.64 (m, 1H), 7.45 (m, 1H), 7.35 (m, 1H), 7.2 (m, 4H), 7.03 (m, 1H), 5.57 (d, <i>J</i> = 3.9 Hz, 1H), 5.1 (m, 1H), 4.9 (m, 1H), 4.79 (m, 1H), 4.55 (m, 1H), 4.2 (m, 2H), 3.8 (s, 3H), 3.75 (s, 3H), 2.96 (m, 1H), 1.25 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_53" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoate: To a solution of methyl 2-(2-(3-bromo-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoate (75 mg, 0.18 mmol) and <i>tert</i>-butyl (<i>S</i>)-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (<b>48</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (76.1 mg, 0.21 mmol) in 1,4-dioxane (4.0 mL) was added Na<sub>2</sub>CO<sub>3</sub> (2 N aqueous, 0.4 mL, 0.40 mmol). The suspension was degassed with argon for 10 min, and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (7.8 mg, 0.008 mmol) was added. The reaction mixture was further degassed with argon for 5 min and then heated to 80 °C and stirred for 16 h. The reaction mixture was partitioned between water and EtOAc. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (gradient: 0–20% EtOAc in hexane) to give the title compound (65 mg, 64%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 7.56 (s, 1H), 7.46 (m, 3H), 7.3 (m, 2H), 7.10 (m, 2H), 6.88 (m, 1H), 5.51(m, 1H), 5.38 (m, 1H), 5.13 (m, 1H), 4.92 (m, 1H), 4.69 (m, 2H), 3.92 (s, 3H), 3.86 (s, 3H), 2.96 (m, 1H), 1.46 (s, 9H), 1.28 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_54" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-(3-bromo-5-isopropylphenyl)-2-hydroxyethoxy)-3-methoxybenzoate: To a solution of methyl 2-(2-(3-bromo-5-isopropylphenyl)-2-oxoethoxy)-3-methoxybenzoate (100 mg, 0.24 mmol) in THF/MeOH (1:1, 5.0 mL) cooled to 0 °C was added NaBH<sub>4</sub> (18.1 mg, 0.48 mmol) under an inert atmosphere. The reaction mixture was stirred at RT for 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (gradient: 0–15% EtOAc in hexane) to give the title compound (75 mg, 78%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 7.43 (m, 2H), 7.25 (m, 2H), 7.10 (d, <i>J</i> = 5.4 Hz, 2H), 5.52 (s, 1H), 5.03 (d, <i>J</i> = 9.3 Hz, 1H), 4.6 (d, <i>J</i> = 9.4 Hz, 1H), 3.93 (s, 3H), 3.87 (s, 3H), 3.81 (m, 1H), 2.87 (m, 1H), 1.23 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_55" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 2-(2-(3-bromo-5-isopropylphenyl)-2-oxoethoxy)-3-methoxybenzoate: To a solution of methyl 2-hydroxy-3-methoxybenzoate (<b>33</b>) (100 mg, 0.55 mmol) in anhydrous acetone (5 mL) cooled to 0 °C was added 2-bromo-1-(3-bromo-5-isopropylphenyl)ethan-1-one (226 mg, 0.71 mmol) followed by Cs<sub>2</sub>CO<sub>3</sub> (267 mg, 0.82 mmol). The reaction mixture was stirred at 0 °C for 2 h. Then, it was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (gradient: 0–10% EtOAc in hexane) to give the title compound (50 mg, 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 7.99 (m, 1H), 7.81 (m, 1H), 7.57 (m, 1H), 7.36 (m, 1H), 7.12 (m, 2H), 5.25 (s, 2H), 3.80 (s, 6H), 2.95 (m, 1H), 1.26 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 1-(2-(3-((<i>S</i>)-3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)indoline-7-carboxylic Acid Trifluoroacetate (<b>21</b>)</h5><div class="NLM_p last">The title compound (5 mg, 16%) was prepared as a mixture of diastereomers in a similar manner as described for (<i>S</i>)-1-(3-(3-amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)indoline-7-carboxylic acid trifluoroacetate (<b>17</b>) from methyl 1-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)indoline-7-carboxylate (25 mg, 0.44 mmol). UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 459.3 (M + 1), <i>t</i><sub>R</sub>: 1.60 min, purity 96% (conditions e); <sup>1</sup>H NMR (400 MHz, acetonitrile-<i>d</i><sub>3</sub>) δ 7.82 (bs, 1H), 7.57 (br d, <i>J =</i> 8.31 Hz, 1H), 7.48–7.35 (m, 2H), 7.27 (br s, 1H), 7.20–7.14 (m, 2H), 6.89 (m, 1H), 6.82–6.72 (m, 1H), 5.13–5.09 (m, 1H), 5.02–4.94 (m, 1H), 4.69–4.57 (m, 2H), 3.79–3.65 (m, 2H), 3.39–3.31 (m, 1H), 3.06–2.85 (m, 4H), 1.19 (m, 6H).</div></div><div id="sec5_1_2_57" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">Methyl 1-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)indoline-7-carboxylate: A solution of <i>tert</i>-butyl ((3<i>S</i>)-5-(3-isopropyl-5-(oxiran-2-yl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate (62 mg, 0.16 mmol) and methyl indoline-7-carboxylate (30.6 mg, 0.17 mmol) in <i>t</i>-BuOH (0.3 mL) was stirred at 90 °C for 3 days. The reaction mixture was cooled to RT and purified directly by flash column chromatography (gradient: 0–20% EtOAc in <i>n</i>-heptane) to give the title compound as a mixture of diastereomers (40 mg, 45%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 573.4 (M + 1).</div></div><div id="sec5_1_2_58" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl ((3<i>S</i>)-5-(3-isopropyl-5-(oxiran-2-yl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate: Saturated aqueous NaHCO<sub>3</sub> (2 mL) was added to a solution of <i>tert</i>-butyl (<i>S</i>)-(5-(3-isopropyl-5-vinylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate (65 mg, 0.17 mmol) in CH<sub>3</sub>CN/acetone (2:1, 3 mL), followed by oxone (316 mg, 0.51 mmol). The reaction mixture was stirred at RT for 2 h and then diluted with H<sub>2</sub>O and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the title compound (65 mg, 96%), which was used in the next step without purification. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.59–7.56 (m, 1H), 7.51–7.46 (m, 1H), 7.35–7.32 (m, 1H), 7.27–7.26 (m, 1H), 7.13 (s, 1H), 6.92 (d, <i>J =</i> 8.3 Hz, 1H), 5.43 (s, 1H), 4.79–4.71 (m, 1H), 4.46–4.40 (m, 1H), 3.96–3.91 (m, 1H), 3.19 (dd, <i>J =</i> 5.5, 4.1 Hz, 1H), 3.03–2.94 (m, 1H), 2.89–2.85 (m, 1H), 1.50 (s, 9H), 1.32 (d, <i>J =</i> 6.9 Hz, 6H).</div></div><div id="sec5_1_2_59" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl (<i>S</i>)-(5-(3-isopropyl-5-vinylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate: A mixture of (<i>S</i>)-3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl trifluoromethanesulfonate (200 mg, 0.40 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (76 mg, 0.47 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (0.60 mL, 1.20 mmol) in DME (4 mL) was sparged with nitrogen for 5 min. Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15 mg, 0.02 mmol) was then added, and the resulting mixture was stirred at 70 °C for 16 h. The reaction mixture was cooled to RT, diluted with H<sub>2</sub>O, and extracted with EtOAc. The aqueous layer was back-extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was dissolved in THF (5 mL), and SiliaMetSThiol (SiliCycle; 100 mg, 1.25 mmol/g) was added. The resulting suspension was stirred at 40 °C for 1 h and then filtered. The filter cake was washed with THF. The filtrate was concentrated, and the crude residue was purified by flash column chromatography (gradient: 0–15% EtOAc in <i>n</i>-heptane) to give the title compound (145 mg, 96%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 380.5 (M + 1).</div></div><div id="sec5_1_2_60" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-3-(3-((<i>tert</i>-Butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl trifluoromethanesulfonate: To a solution of <i>tert</i>-butyl (<i>S</i>)-(5-(3-hydroxy-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate (100 mg, 0.22 mmol) and pyridine (254 mg, 0.62 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) cooled to 0 °C was slowly added Tf<sub>2</sub>O (100 mg, 0.30 mmol). Upon completion of the addition, the reaction mixture was stirred at RT for 1 h, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and poured into ice-cold sat. aq. NaHCO<sub>3</sub>. The layers were separated, and the aqueous layer was back-extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography (gradient: 0–30% EtOAc in <i>n</i>-heptane) to afford the title compound (126 mg, 93%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.55 (d, <i>J</i> = 1.9 Hz, 1H), 7.45 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.40 (t, <i>J</i> = 1.3 Hz, 1H), 7.25–7.21 (m, 1H), 7.09–7.05 (m, 1H), 6.94 (d, <i>J</i> = 8.4 Hz, 1H), 5.45 (s, 1H), 4.93 (d, <i>J</i> = 6.6 Hz, 1H), 4.77 (dd, <i>J</i> = 10.0, 8.0 Hz, 1H), 4.44 (dd, <i>J</i> = 10.1, 4.1 Hz, 1H), 3.02 (m, 1H), 1.50 (s, 9H), 1.33 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_61" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl (<i>S</i>)-(5-(3-hydroxy-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate: Tetra-<i>n</i>-butylammonium fluoride (TBAF) (1.0 M in THF, 1.40 mL, 1.40 mmol) was added to a solution of <i>tert</i>-butyl (<i>S</i>)-(5-(3-((<i>tert</i>-butyldimethylsilyl)oxy)-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate (534 mg, 1.10 mmol) in THF (10 mL). The resulting mixture was stirred at RT for 2 h and then was diluted with H<sub>2</sub>O and extracted with EtOAc. The aqueous layer was back-extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by flash column chromatography (gradient: 0–50% EtOAc in <i>n</i>-heptane) to afford the title compound (259 mg, 63%). MS (ESI<sup>–</sup>) <i>m</i>/<i>z</i> 367.9 (M-1).</div></div><div id="sec5_1_2_62" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl (<i>S</i>)-(5-(3-((<i>tert</i>-butyldimethylsilyl)oxy)-5-isopropylphenyl)-2,3-dihydrobenzofuran-3-yl)carbamate: The title compound was prepared in a similar manner as described for (<i>S</i>)-2-((3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)amino)benzoic acid (described in the synthesis of compound <b>16</b>) using <i>tert</i>-butyl (3-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)dimethylsilane (473 mg, 1.26 mmol) and (<i>S</i>)-<i>tert</i>-butyl (5-bromo-2,3-dihydrobenzofuran-3-yl)carbamate (425 mg, 1.35 mmol). The crude residue was purified by flash column chromatography (gradient: 0–30% EtOAc in <i>n</i>-heptane) to afford the title compound (534 mg, 88%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 484.0 (M + 1).</div></div><div id="sec5_1_2_63" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl (3-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)dimethylsilane: Nitrogen gas was bubbled through a solution of <i>tert</i>-butyl (3-isopropylphenoxy)dimethylsilane (50 mg, 0.20 mmol) in <i>c</i>-hexane (2.0 mL) for ∼5 min. The solution was then added to a microwave vial containing bis(pinacoloto)diboron (55 mg, 0.22 mmol), [Ir(cod)(OMe)]<sub>2</sub> (5.0 mg, 7.5 μmol), and 4,4′-di-<i>tert</i>-butyl-2,2′-dipyridyl (4.3 mg, 0.02 mmol). The resulting mixture was heated at 80 °C for 8 h under microwave irradiations and then cooled to RT and concentrated. The crude residue was purified by flash column chromatography (gradient: 0–100% CH<sub>2</sub>Cl<sub>2</sub> in <i>n</i>-heptane) to afford the title compound (25 mg, 33%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.26 (s, 1H), 7.09 (dd, <i>J</i> = 2.4, 0.8 Hz, 1H), 6.79 (t, <i>J</i> = 2.0 Hz, 1H), 2.97–2.75 (m, 1H), 1.33 (s, 12H), 1.23 (d, <i>J</i> = 6.9 Hz, 6H), 0.99 (s, 9H), 0.19 (s, 6H).</div></div><div id="sec5_1_2_64" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last"><i>tert</i>-Butyl (3-isopropylphenoxy)dimethylsilane: To a solution of 3-isopropylphenol (5.0 g, 36.7 mmol) in DMF (100 mL) was added imidazole (5.0 g, 73.4 mmol) followed by TBSCl (8.5 g, 56.4 mmol). The reaction mixture was stirred at RT for 2.5 days, diluted with 1:1 EtOAc/heptane, and washed with saturated aqueous NaHCO<sub>3</sub>. After separation of the organic layer, the aqueous layer was back-extracted with 1:1 EtOAc/heptane. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by flash column chromatography (gradient: 0–10% EtOAc in heptane) to afford the title compound (9.27 g, quantitative). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.13 (t, <i>J =</i> 7.8 Hz, 1H), 6.85–6.77 (m, 1H), 6.73–6.68 (m, 1H), 6.65 (m, 1H), 2.84 (m, 1H), 1.22 (d, <i>J =</i> 6.9 Hz, 6H), 0.98 (s, 9H), 0.19 (s, 6H).</div></div><div id="sec5_1_2_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(2-(3-((<i>S</i>)-3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic Acid (<b>22</b>)</h5><div class="NLM_p last">TFA (0.09 mL, 1.2 mmol) was added to a solution of 1-(2-(3-((<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic acid (25 mg, 0.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL). The reaction mixture was stirred at RT for 2 h and concentrated under reduced pressure. The resulting residue was dissolved in THF (1.0 mL), and 2 M aqueous LiOH (0.6 mL, 1.2 mmol) was added. The reaction mixture was stirred at 50 °C for 1 h, cooled to RT, and purified directly by reverse-phase HPLC (prep HPLC conditions i; gradient: 15–40% CH<sub>3</sub>CN) to afford the title compound as a mixture of diastereomers (3.0 mg, 13%). UPLC/MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 457.1 (M + 1), <i>t</i><sub>R</sub>: 1.29 min, purity 92% (conditions f); <sup>1</sup>H NMR (400 MHz, acetonitrile-<i>d</i><sub>3</sub>) δ 8.54–8.45 (m, 1H), 8.19–8.14 (m, 2H), 8.14–8.05 (m, 1H), 7.95–7.91 (m, 1H), 7.88–7.82 (m, 1H), 7.76 (d, <i>J</i> = 1.7 Hz, 1H), 7.73 (dd, <i>J</i> = 5.7, 3.2 Hz, 1H), 7.59–7.52 (m, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 1H), 7.05–7.00 (m, 1H), 5.67–5.59 (m, 1H), 5.52–5.44 (m, 1H), 5.33–5.22 (m, 1H), 5.13–5.02 (m, 3H), 3.56–3.45 (m, 1H), 1.84–1.79 (m, 6H).</div></div><div id="sec5_1_2_66" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">1-(2-(3-((<i>S</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic acid: The title compound was prepared in a similar manner as described for (<i>S</i>)-2-((3-(3-((<i>tert</i>-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenethyl)amino)benzoic acid (described in the synthesis of compound <b>16</b>) using 1-(2-(3-bromo-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic acid (20 mg, 0.05 mmol) and <i>tert</i>-butyl (<i>S</i>)-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (<b>48</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (20 mg, 0.06 mmol). The crude residue was used in the next step without purification. MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 557.3 (M + 1).</div></div><div id="sec5_1_2_67" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">1-(2-(3-Bromo-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic acid: Methyl 1<i>H</i>-indole-7-carboxylate (425 mg, 2.43 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (790 mg, 2.43 mmol) were added to a solution of 2-(3-bromo-5-isopropylphenyl)oxirane (195 mg, 0.81 mmol) in DMF (8.0 mL), and the resulting mixture was stirred at 90 °C for 17 h. The reaction mixture was then cooled to RT, filtered, and purified directly by preparative reverse-phase HPLC (prep HPLC conditions j; gradient: 10–30% CH<sub>3</sub>CN) to give the title compound (33 mg, 10%, 70% pure). <sup>1</sup>H NMR (600 MHz, chloroform-<i>d</i>) δ 7.95–7.91 (m, 1H), 7.88–7.85 (m, 1H), 7.39–7.38 (m, 1H), 7.16 (t, <i>J</i> = 7.7 Hz, 1H), 7.11–7.08 (m, 2H), 7.05 (d, <i>J</i> = 1.6 Hz, 1H), 6.60 (d, <i>J</i> = 3.2 Hz, 1H), 5.07–5.02 (m, 1H), 4.80–4.74 (m, 1H), 4.60–4.53 (m, 1H), 2.86–2.76 (m, 1H), 1.18–1.15 (m, 6H).</div></div><div id="sec5_1_2_68" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">2-(3-Bromo-5-isopropylphenyl)oxirane: <i>meta</i>-Chloroperoxybenzoic acid (<i>m</i>CPBA) (1.20 g, 5.33 mmol) was added to a solution of 1-bromo-3-isopropyl-5-vinylbenzene (<b>51</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (1.0 g, 4.40 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C. The reaction mixture was stirred at RT for 16 h, washed with sat. aq. NaHCO<sub>3</sub> and brine, and then concentrated. The crude residue was purified by flash column chromatography (gradient: 0–10% EtOAc in <i>n</i>-heptane) to afford the title compound as a racemate (420 mg, 39%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.31–7.29 (m, 1H), 7.24–7.22 (m, 1H), 7.07–7.05 (m, 1H), 3.83–3.78 (m, 1H), 3.13 (dd, <i>J</i> = 5.5, 4.0 Hz, 1H), 2.92–2.82 (m, 1H), 2.76 (dd, <i>J</i> = 5.5, 2.5 Hz, 1H), 1.23 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 1-((<i>S</i>)-2-(3-((<i>S</i>)-3-Amino-2,3-dihydrobenzofuran-5-yl)-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic Acid (<b>23</b>)</h5><div class="NLM_p last">A mixture of 1-((<i>S</i>)-2-hydroxy-2-(3-isopropyl-5-((<i>S</i>)-3-(2,2,2-trifluoroacetamido)-2,3-dihydrobenzofuran-5-yl)phenyl)ethyl)-1<i>H</i>-indole-7-carboxylic acid (<b>59</b>) and 2,2,2-trifluoro-<i>N</i>-((<i>S</i>)-5-(3-isopropyl-5-((<i>S</i>)-1-oxo-3,4-dihydro-1<i>H</i>-[1,4]oxazepino[6,5,4-<i>hi</i>]indol-3-yl)phenyl)-2,3-dihydrobenzofuran-3-yl)acetamide (<b>60</b>) (2.00 g, 3.62 mmol) was dissolved in MeOH (24.1 mL), and 2 M aqueous NaOH (7.24 mL, 18.1 mmol) was added. The reaction mixture was heated at 60 °C for 90 min, and then MeOH was removed under reduced pressure. The resulting aqueous residue was dissolved by the addition of CH<sub>3</sub>CN and DMSO. The solution was partially purified by reverse-phase flash column chromatography (gradient: 10–60% CH<sub>3</sub>CN (containing 0.1% NH<sub>4</sub>OH) in water (containing 0.1% NH<sub>4</sub>OH)). The resulting residue was further purified by SFC (Chiralpak IG 4.6 × 100 mm<sup>2</sup> 5 μm, 5–55% MeOH w/ 10 mM NH<sub>4</sub>OH/CO<sub>2</sub>) to give the title compound (562 mg, 32%). UPLC/MS (ESI<sup>–</sup>) <i>m</i>/<i>z</i> 455.0 (M – 1), <i>t</i><sub>R</sub>: 1.63 min, purity 100% (conditions e); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.83 (d, <i>J =</i> 2.0 Hz, 1H), 7.56–7.61 (m, 2H), 7.52 (dd, <i>J =</i> 8.3, 2.0 Hz, 1H), 7.30–7.40 (m, 3H), 7.19 (s, 1H), 6.99 (t, <i>J =</i> 7.6 Hz, 1H), 6.91 (d, <i>J =</i> 8.8 Hz, 1H), 6.47 (d, <i>J =</i> 3.4 Hz, 1H), 4.76–4.83 (m, 2H), 4.69 (dd, <i>J =</i> 14.2, 3.4 Hz, 1H), 4.59–4.66 (m, 1H), 4.44 (dd, <i>J =</i> 14.2, 9.3 Hz, 1H), 4.29 (dd, <i>J =</i> 10.3, 4.9 Hz, 1H), 2.89–2.96 (m, 1H), 1.34 (d, <i>J</i> = 6.9 Hz, 3H), 1.25 (d, <i>J =</i> 6.9 Hz, 3H); HRMS <i>m</i>/<i>z</i> (ESI<sup>+</sup>) calcd for C<sub>28</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub> (2M + 1) 913.4176; found, 913.4174.</div></div><div id="sec5_1_2_70" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">1-((<i>S</i>)-2-Hydroxy-2-(3-isopropyl-5-((<i>S</i>)-3-(2,2,2-trifluoroacetamido)-2,3-dihydrobenzofuran-5-yl)phenyl)ethyl)-1<i>H</i>-indole-7-carboxylic acid (<b>59</b>) and 2,2,2-trifluoro-<i>N</i>-((<i>S</i>)-5-(3-isopropyl-5-((<i>S</i>)-1-oxo-3,4-dihydro-1<i>H</i>-[1,4]oxazepino[6,5,4-<i>hi</i>]indol-3-yl)phenyl)-2,3-dihydrobenzofuran-3-yl)acetamide (<b>60</b>): To a mixture of (<i>S</i>)-1-(2-(3-bromo-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic acid (<b>57</b>) (365 mg, 1.02 mmol), (<i>S</i>)-2,2,2-trifluoro-<i>N</i>-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzofuran-3-yl)acetamide (<b>58</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (337 mg, 0.84 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (82 mg, 0.10 mmol) in 1,4-dioxane (8 mL) was added 2 M aq. Na<sub>2</sub>CO<sub>3</sub> (1.26 mL 2.52 mmol), and the resulting mixture was sparged with N<sub>2</sub> gas for 5 min. The reaction mixture was then stirred at 70 °C for 4.25 h, cooled to RT, and diluted with EtOAc. The mixture was further diluted with pH 7 buffer, and the layers were separated. The aqueous layer was back-extracted twice with EtOAc, and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was passed through a plug of silica gel eluting with EtOAc to afford a mixture of the title compounds <b>59</b> (MS (ESI<sup>–</sup>) <i>m</i>/<i>z</i> 551.3 (M – 1)) and the corresponding lactone <b>60</b> (MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 534.2 (M + 1)), which was carried on to the next step without further purification.</div></div><div id="sec5_1_2_71" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-1-(2-(3-Bromo-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carboxylic acid (<b>57</b>): To (<i>S</i>)-1-(2-(3-bromo-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carbonitrile (<b>56</b>) (785 mg, 2.05 mmol) dissolved in EtOH (12 mL) and cooled to 0 °C was added KOH (8.2 mL, 20.5 mmol), and the resulting mixture was heated under microwave irradiations at 100 °C for 8 h. The reaction mixture was then diluted with 1 M aq. HCl and EtOAc and extracted with EtOAc. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to afford the title compound (867 mg, 100%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 402.2 (M + 1).</div></div><div id="sec5_1_2_72" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-1-(2-(3-Bromo-5-isopropylphenyl)-2-hydroxyethyl)-1<i>H</i>-indole-7-carbonitrile (<b>56</b>): To a solution of 1<i>H</i>-indole-7-carbonitrile (<b>55</b>) (295 mg, 2.07 mmol) in DMF (10 mL) at RT was added K<sub>2</sub>CO<sub>3</sub> (574 mg, 4.15 mmol), and the resulting mixture was stirred for 5 min. (<i>S</i>)-2-(3-Bromo-5-isopropylphenyl)oxirane (<b>54</b>) (550 mg, 2.28 mmol) in DMF (10 mL) was then added, and the reaction mixture was heated to 80 °C and stirred for 16 h. The reaction mixture was then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The crude residue was purified by flash column chromatography (gradient: 0–50% EtOAc in <i>n</i>-heptane) to give the title compound (685 mg, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.84–8.00 (m, 1H), 7.57 (dd, <i>J =</i> 7.4, 1.1 Hz, 1H), 7.52 (d, <i>J =</i> 3.0 Hz, 1H), 7.43 (t, <i>J =</i> 1.7 Hz, 1H), 7.30 (t, <i>J =</i> 1.9 Hz, 1H), 7.20–7.27 (m, 1H), 7.09–7.18 (m, 1H), 6.63 (d, <i>J =</i> 2.9 Hz, 1H), 5.76 (d, <i>J =</i> 4.4 Hz, 1H), 4.97 (dt, <i>J =</i> 8.7, 4.3 Hz, 1H), 4.65 (dd, <i>J =</i> 14.5, 4.1 Hz, 1H), 4.51 (dd, <i>J =</i> 14.6, 8.8 Hz, 1H), 2.81 (hept, <i>J =</i> 6.9 Hz, 1H), 1.13 (d, <i>J =</i> 7.3 Hz, 6H).</div></div><div id="sec5_1_2_73" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-2-(3-Bromo-5-isopropylphenyl)oxirane (<b>54</b>): To a solution of (<i>S</i>)-2-(3-bromo-5-isopropylphenyl)-2-hydroxyethyl 2,4,6-trimethylbenzenesulfonate (<b>53</b>) (1.86 g, 4.21 mmol) in toluene (64 mL) cooled to 0 °C was added 10% NaOH (aq.) (32 mL, 4.21 mmol). The reaction was then warmed to RT and stirred for 16 h. The reaction mixture was diluted with water and extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The crude residue was purified by flash column chromatography (gradient: 0–50% EtOAc in <i>n</i>-heptane) to give the title compound (265 mg, 26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.38 (t, <i>J</i> = 1.7 Hz, 1H), 7.27 (t, <i>J</i> = 1.7 Hz, 1H), 7.20 (t, <i>J</i> = 1.6 Hz, 1H), 3.93 (dd, <i>J</i> = 4.0, 2.5 Hz, 1H), 3.10 (dd, <i>J</i> = 5.4, 4.0 Hz, 1H), 2.95–2.83 (m, 2H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_74" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-2-(3-Bromo-5-isopropylphenyl)-2-hydroxyethyl 2,4,6-trimethylbenzenesulfonate (<b>53</b>): 2,4,6-Trimethylbenzene-1-sulfonyl chloride (1.92 g, 8.80 mmol) was added to a solution of (<i>S</i>)-1-(3-bromo-5-isopropylphenyl)ethane-1,2-diol (<b>52</b>) (1.52 g, 5.87 mmol), pyridine (0.95 mL, 11.7 mmol), and DMAP (0.05 g, 0.411 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The reaction mixture was stirred at RT for about 60 h. The reaction mixture was then concentrated, and the residue was purified by flash column chromatography (gradient: 0–60% EtOAc in <i>n</i>-heptane) to give the title compound (1.86 g, 72%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.30 (t, <i>J</i> = 1.6 Hz, 1H), 7.27–7.24 (m, 1H), 7.10 (s, 1H), 6.98–6.96 (m, 2H), 4.95 (dd, <i>J</i> = 8.2, 3.4 Hz, 1H), 4.09 (dd, <i>J</i> = 10.5, 3.4 Hz, 1H), 3.98 (dd, <i>J</i> = 10.5, 8.2 Hz, 1H), 2.85 (hept, <i>J</i> = 6.7 Hz, 1H), 2.59 (s, 6H), 2.32 (s, 3H), 1.21 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_1_2_75" class="NLM_sec NLM_sec_level_4"><div class="NLM_p first last">(<i>S</i>)-1-(3-Bromo-5-isopropylphenyl)ethane-1,2-diol (<b>52</b>): AD-mix-α (23.0 g, 15.5 mmol) was added to a mixture of <i>t</i>-BuOH (100 mL) and H<sub>2</sub>O (100 mL), and the reaction mixture was stirred at RT until both phases were clear. The reaction mixture was then cooled to −10 °C, and 1-bromo-3-isopropyl-5-vinylbenzene (<b>51</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>) (3.50 g, 15.5 mmol) was added. The resulting slurry was stirred vigorously at 0 °C for 1 h and then warmed to RT for 16 h. Sodium sulfite (9.80 g, 78 mmol) was added, and the mixture was stirred at RT for 30 min, diluted with water, and extracted with EtOAc. The organic layer was concentrated, and the residue was purified by flash column chromatography (gradient: 0–60% EtOAc in <i>n</i>-heptane) to provide the title compound (1.52 g, 38%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.36 (t, <i>J</i> = 1.4 Hz, 1H), 7.32 (t, <i>J</i> = 1.5 Hz, 1H), 7.16 (s, 1H), 4.79 (dd, <i>J</i> = 8.1, 3.5 Hz, 1H), 3.78 (dd, <i>J</i> = 11.3, 3.5 Hz, 1H), 3.65 (dd, <i>J</i> = 11.3, 7.9 Hz, 1H), 2.89 (h, <i>J</i> = 7.0 Hz, 1H), 1.26 (d, <i>J</i> = 6.9 Hz, 6H).</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Biological and <i>In Vivo</i> Experiments</h3><div class="NLM_p">Protocols, handling, and care of animals were in accordance with the policy of the NIBR Cambridge Animal Care and Use Committee.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Human FXIa Assay</h4><div class="NLM_p">The activity of human FXIa (Kordia Life Science NL, catalog number HFXIa 1111a) was determined by monitoring the cleavage of a fluorescently labeled peptide with the sequence <span class="smallcaps smallerCapital">d</span>-Leu-Pro-Arg*Rh110-<span class="smallcaps smallerCapital">d</span>-Pro (product number BS-2494.P2; Biosyntan GmbH, Berlin, Germany), where * indicates the scissile bond; <span class="smallcaps smallerCapital">d</span>-Leu, <span class="smallcaps smallerCapital">d</span>-leucine; Pro, proline; Arg, arginine; Rh110, rhodamine 110; <span class="smallcaps smallerCapital">d</span>-Pro, <span class="smallcaps smallerCapital">d</span>-proline. FXIa-mediated cleavage of the scissile bond of the peptide substrate leads to an increase of fluorescence intensity of the rhodamine 110 when using excitation and emission wavelengths of 485 and 535 nm, respectively. Fluorescence intensity 1 h after addition of the substrate was measured using the Synergy Neo2 (BioTek, Winooski, VT) 384-well microtiter plate reader at room temperature. The assay buffer contained 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) at pH 7.4, 125 mM NaCl, 5 mM CaCl<sub>2</sub>, and 0.05% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS). Human FXIa was used at a final concentration of 0.1–0.4 nM (depending on enzyme batch activity), and the substrate BS-2494 concentration was 0.5 μM, which was much below its measured <i>K</i><sub>m</sub> of 171 ± 14 μM. Under these conditions, the increase of fluorescence intensity over time is linear for at least 60 min.</div><div class="NLM_p last">For testing the inhibitory activity of molecules, serial dilutions of compounds were prepared in 100% DMSO and then diluted into 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer pH 7.4 with 125 mM NaCl and 0.05% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS), with final DMSO concentrations not exceeding 1%. One microliter of the compound solution was preincubated with 11.5 μL of the FXIa solution in an assay buffer (50 mM HEPES buffer pH 7.4 with 125 mM NaCl, 5 mM CaCl<sub>2</sub>, and 0.05% (w/v) CHAPS) for 60 min at room temperature. After the preincubation step, 12.5 μL of substrate BS-2494.P2 (diluted in assay buffer) was added and the enzymatic reaction was allowed to proceed for 60 min before measuring the fluorescence intensity.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Human FXIa Assay in Plasma</h4><div class="NLM_p">To measure the activity of human FXIa in the presence of plasma, the catalytic domain fragment of the enzyme was used to prevent activation of the entire coagulation pathway (the catalytic domain fragment is incapable of activating factor IX). A catalytic domain fragment containing a C500S mutation was added to 50% normal human plasma control obtained as a lyophilized powder “Coagulation Control N” (reference no. 5020050) purchased from Technoclone GmbH (Vienna, Austria). It was pooled from citrated plasma of selected healthy donors. The lyophilized plasma was stored at 4 °C. Prior to its use, the plasma was resuspended in 1 mL of distilled water by carefully rotating the vial and then keeping it for 10 min at room temperature.</div><div class="NLM_p">The catalytic domain fragment of FXIa (FXIa_cd_C500s) was produced in <i>Escherichia</i><i>coli</i> strain BL21(DE3) using the following synthetic DNA fragment:<ul class="NLM_list-list_type-label"><li><p class="inline"><u class="uu">MGSS</u><b><u class="uu">DDDDK</u></b>IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPISLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV</p></li></ul></div><div class="NLM_p">The underlined N-terminal extension was removed following enterokinase cleavage (recognition sequence in bold).</div><div class="NLM_p last">To measure the inhibitory activity of molecules in this system, serial dilutions of compounds were prepared in 100% DMSO and then diluted into 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer pH 7.4 with 125 mM NaCl and 0.05% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS), with final DMSO concentrations not exceeding 1%. One microliter of the compound solution was preincubated with 11.5 μL of FXIa_cd_C500S in 100% normal human control plasma for 60 min at room temperature. After the preincubation step, 12.5 μL of substrate BS-2494.P2 in the assay buffer (50 mM HEPES buffer pH 7.4 with 125 mM NaCl, 5 mM CaCl<sub>2</sub>, and 0.05% (w/v) CHAPS) was added, and the enzymatic reaction was allowed to proceed for 60 min before measuring the fluorescence intensity as described above for the biochemical assay without plasma. The final enzyme concentration in this system was 30 nM FXIa_cd_C500S, and the final substrate concentration was 0.5 μM.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Protease Panel: FXIa</h4><div class="NLM_p last">To determine the biochemical selectivity, a panel of related protease activities was profiled using a similar assay setup to that described above for human FXIa. Factor D was assessed using a TR-FRET-based assay as described in ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>. The relevant conditions for each of the protease selectivity assays delineated in the text, including the enzyme source, the fluorogenic peptide sequence, and buffer modifications, are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Plasma Coagulation Assays</h4><div class="NLM_p">The antithrombotic activities of compounds were tested using the activated partial thromboplastin time (aPTT) assay performed using an Amelung ball coagulometer model KC4A (purchased through SYCOmed, Lemgo, Germany) or MC-10 (Merlin Medical, Lemgo, Germany). Compounds were diluted to 4× final concentration into a dilution buffer containing 80 mM Tris/HCl at pH 7.5 (Invitrogen, 15567-027) and 0.05% (w/v) CHAPS (Calbiochem, 220201). Assay reagents were added into a special cuvette containing a stainless steel ball (Merlin medical, Germany, Z05100) at the 12 o’clock position. Then, 50 μL of 4× compound solution was added to 50 μL of prewarmed (37 °C) normal human plasma (“Coagulation Control N” reference no. 5020050) and 50 μL of the prewarmed aPTT-s reagent (reference no. TE0350 purchased from SYCOmed Lemgo, Germany) and incubated for 3 min at 37 °C under rotation. The coagulation reaction was triggered by addition of 50 μL of 25 mM calcium chloride with an automatic handystep pipette supplied with the coagulometer to start recording automatically upon reagent addition. Time until clotting was measured and plotted as a function of compound concentration to determine the potency of intrinsic pathway inhibition (reported as the concentration required to double the clotting time measured without the compound present).</div><div class="NLM_p last">To measure any off-target coagulation activity, compounds were profiled in the prothrombin time (PT) assay to assess extrinsic coagulation cascade activity. Theoretically, compounds that selectively inhibit FXIa alone in the coagulation cascade should not modulate the prothrombin time assay. For measurement of the prothrombin time, compounds were tested at 1:3 serial dilutions starting from 100 μM top concentration. Compounds were prepared as a 5× concentrate in a dilution buffer containing 80 mM Tris/HCl at pH 7.5 (Invitrogen, 15567-027) and 0.05% (w/v) CHAPS (Calbiochem, 220201). Next, 60 μL of the compound (5× the final concentration) was placed into the coagulometer cuvette containing a stainless steel ball (Merlin medical, Germany, Z05100) at the 12 o’clock position, and 40 μL of prewarmed (37 °C) normal human plasma was placed at the 9 o’clock position. The reaction was started by addition of 200 μL of the Thromboplastin-DS reagent using the automatic handystep pipette supplied with the coagulometer to start recording automatically upon reagent addition. Time until clotting was measured and plotted as a function of compound concentration to determine the potency of extrinsic pathway inhibition.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Plasma Pharmacokinetic Studies in Mice</h4><div class="NLM_p">The pharmacokinetics of compounds <b>1</b>, <b>6</b>–<b>8</b>, <b>11</b>, and <b>17</b> were determined in C57BL/6 mice, and pharmacokinetics of compound <b>23</b> were determined in CD1 mice. Blood concentration versus time profiles were obtained from two groups of three male mice except for compound <b>17</b>, where two male mice were used for the intravenous PK study. In the intravenous PK group, the compound was administered intravenously (i.v.) by bolus injection (5 mL/kg) at a dose of 1 mg/kg (compounds <b>1</b>, <b>6</b>–<b>8</b>, <b>11</b>, <b>23</b>) or 0.4 mg/kg (compound <b>17</b>), solubilized in <i>N</i>-methyl-2-pyrrolidone (10%) and blank plasma (90%) (compounds <b>6</b>, <b>7</b>, <b>11</b>) or 10% propyleneglycol and 25% Solutol (20%), dissolved in phosphate-buffered saline (PBS) (compounds <b>1</b> and <b>8</b>) or 20% captisol in water (compound <b>17</b>) or 10% propyleneglycol and 10% Solutol, dissolved in PBS (compound <b>23</b>).</div><div class="NLM_p">For oral PK, in another group of three male mice, a dose of 3 mg/kg (additional dose of 100 mg/kg for compound <b>23</b>) was orally applied (dosing volume of 10 mL/kg) as a homogenous suspension of water (99%), Tween 80 (0.5%), and methylcellulose (0.5%) (compounds <b>1</b>, <b>6</b>–<b>8</b>, <b>11</b>, and <b>17</b>) or 20% captisol in water (compound <b>23</b>).</div><div class="NLM_p">For compounds <b>6</b>, <b>7</b>, <b>11</b>, <b>17</b>, and <b>23</b>, blood (10 μL/time point, without anticoagulant) was collected by puncture of the lateral saphenous vein at different time points from the same animal (<i>n</i> = 3 mice per route). The awake mice were restrained in a plastic tube for blood sampling. At the last time point, the animals were sacrificed. Analyses of parent compound concentrations were carried out in blood using LC–MS/MS. An aliquot of 10 μL was taken, and 200 μL of acetonitrile (including Glyburide (<i>c</i> = 50 ng/mL) as the internal standard) was added for protein precipitation. Sample analysis was performed on an LC–MS/MS system.</div><div class="NLM_p last">In the cases of compounds <b>1</b> and <b>8</b>, approximately 50 μL of whole blood was collected from the tails at 5 min (IV dose only) and 15 min (p.o. dose only) and 0.5, 1, 2, 4, and 7 h postdose and was transferred to ethylenediaminetetraacetic acid (EDTA) tubes. Blood was centrifuged at 3000 rpm, and the resultant plasma was transferred to a capped PCR 96-well plate and frozen at −20 °C until subsequent analysis by high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Similarly, the relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA). Other relevant calculations were performed in Microsoft Excel.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Plasma Pharmacokinetic Studies in Rats</h4><div class="NLM_p last">The pharmacokinetics of compound <b>23</b> was determined in Sprague Dawley rats. The compound was dosed intravenously (i.v., <i>via</i> injection into the jugular vein catheter; 1 mg/kg, <i>n</i> = 3 animals) and orally (p.o., <i>via</i> oral gavage; at 3, 30, and 100 mg/kg, <i>n</i> = 3 animals). The IV solution was prepared as a 1 mg/mL formulation of 10% hydroxypropyl-β-cyclodextrin (HP-β-CD) and 20% poly(ethylene glycol) 300 in water. The p.o. solution formulations were prepared at concentrations of 0.3, 3, and 10 mg/mL for the 3, 30, and 100 mg/kg doses, respectively, and were prepared with 10% hydroxypropyl-β-cyclodextrin (HP-β-CD) and 20% poly(ethylene glycol) 300 in water. Approximately 200 μL of whole blood was collected from the tails at 5 min (i.v. dose only), 15 min and 0.5, 1, 2, 4, 7, and 24 h postdose and was transferred to EDTA tubes. Blood was centrifuged at 3000 rpm, and the resultant plasma was transferred to a capped PCR 96-well plate and frozen at −20 °C until subsequent analysis by HPLC-MS/MS. The relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA).</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Plasma Pharmacokinetic Studies in Dogs</h4><div class="NLM_p last">The pharmacokinetics of compound <b>23</b> was determined in beagle dogs. The compound was dosed intravenously (i.v., <i>via</i> slow bolus injection <i>via</i> the cephalic vein; 1 mg/kg, <i>n</i> = 3 animals) and orally (p.o.; 10 mg/kg and 75 mg/kg <i>n</i> = 3 animals/compound) by gavage. The i.v. formulation was a 1 mg/mL solution consisting of 10% hydroxypropyl-β-cyclodextrin (HP-β-CD) and 20% poly(ethylene glycol) 300 in water. The p.o. solution formulations were prepared at concentrations of 1 and 15 mg/mL for the 10 and 75 mg/kg doses, respectively, and were prepared with 10% hydroxypropyl-β-cyclodextrin (HP-β-CD) and 20% poly(ethylene glycol) 300 in water. Blood was collected at 5 min (i.v. dose only), 15 min and 0.5, 1, 2, 4, 7, and 24 h postdose for the 1 mg/kg IV dose and the 10 mg/kg p.o. dose. For the 75 mg/kg dose, blood was collected at 0.5, 1, 3, 7, and 24 h postdose. Blood was centrifuged at 3000 rpm, and the resultant plasma was transferred for subsequent analysis by HPLC-MS/MS. Similarly, the relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA). Other relevant calculations were performed in Microsoft Excel.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00279" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61111" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61111" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00279?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00279</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis and characterization of compounds <b>4</b>, <b>25</b>, <b>26</b>, <b>28</b>, <b>29</b>, <b>40</b>, <b>41</b>, <b>47</b>, <b>48</b>, <b>51</b>, and <b>58</b>; crystallographic structure determination of PKL in complex with <b>4</b> and of fXIa in complex with compounds <b>2</b>, <b>3</b>, <b>7</b>, <b>15</b>, and <b>23</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula string (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf">jm0c00279_si_001.pdf (421.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_002.csv">jm0c00279_si_002.csv (1.87 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and structure factors for the crystal structures of PKL with compound <b>4</b> and of FXIa with compounds <b>2</b>, <b>3</b>, <b>7</b>, <b>15</b>, and <b>23</b> can be accessed using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T7P">6T7P</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS4">6TS4</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS7">6TS7</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS6">6TS6</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS5">6TS5</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USY">6USY</a>, respectively.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00279" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23867" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23867" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edwige Lorthiois</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6147-9321" title="Orcid link">http://orcid.org/0000-0002-6147-9321</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ec89889b858b89c280839e98848583859fac82839a8d9e98859fc28f8381"><span class="__cf_email__" data-cfemail="2a4f4e5d434d4f044645585e42434543596a44455c4b585e435904494547">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Roache</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9515-2394" title="Orcid link">http://orcid.org/0000-0002-9515-2394</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#442e252921376a362b25272c21042a2b322536302d376a272b29"><span class="__cf_email__" data-cfemail="4f252e222a3c613d202e2c272a0f2120392e3d3b263c612c2022">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Barnes-Seeman</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Altmann</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2749-6347" title="Orcid link">http://orcid.org/0000-0002-2749-6347</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ulrich Hassiepen</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gordon Turner</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rohit Duvadie</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Viktor Hornak</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajeshri G. Karki</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2210-5789" title="Orcid link">http://orcid.org/0000-0003-2210-5789</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nikolaus Schiering</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wilhelm A. Weihofen</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Perruccio</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Calhoun</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tanzina Fazal</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darija Dedic</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Corinne Durand</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Solene Dussauge</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kamal Fettis</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        K.F.: Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabien Tritsch</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celine Dentel</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adelaide Druet</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglei Liu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louise Kirman</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        L.K.: Cedilla Therapeutics, 38 Sidney Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Lachal</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenji Namoto</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas Bevan</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rose Mo</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriela Monnet</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lionel Muller</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Zessis</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xueming Huang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loren Lindsley</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Treeve Currie</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Hsin Chiu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cary Fridrich</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        C.F.: Department of Medicinal Chemistry, Relay Therapeutics, 399 Binney Street, Cambridge, Massachusetts 02138, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Delgado</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuangxi Wang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Micah Hollis-Symynkywicz</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joerg Berghausen</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Williams</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        E.W.: Molecular Templates, Inc., 9301 Amberglen Boulevard, Suite 100, Austin, Texas 78729, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Liu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiqing Liang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyungchul Kim</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Hoffmann</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Hein</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Ramage</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allan D’Arcy</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefanie Harlfinger</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        S.H.: DMPK Modelling & Simulation, AstraZeneca, Oncology R&D, DMPK, Hodgkin Building (B900), Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Renatus</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Ruedisser</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        S.R.: Biomolecular NMR platform, ETH Zurich, HPP L 25.2, Hönggerbergring 64, 8093 Zürich, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Feldman</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, East Hanover, New Jersey 07396, United States</span>; 
    <span>Present Address:
                        D.F.: National Kidney Foundation, 30 East 33rd Street, New York, New York 10016, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Elliott</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Sedrani</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juergen Maibaum</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher M. Adams</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5246-884X" title="Orcid link">http://orcid.org/0000-0002-5246-884X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>The authors declare no competing financial interest beyond their employment by Novartis Institutes for BioMedical Research Inc., which funded all work described in the manuscript.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors declare no competing financial interest beyond their employment by Novartis Institutes for BioMedical Research Inc. which funded all work described in the manuscript.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8891-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Prasad Appukuttan, Sangamesh Badiger, Ramalinga Vara Prasad, and their team at Aurigene Discovery Technologies Limited (<a href="http://www.aurigene.com" class="extLink">www.aurigene.com</a>) and James Powers for the synthesis of select compounds for this project. Arnaud Decock is acknowledged for the crystallization of compound <b>4</b> with PKL.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">aPTT</td><td class="NLM_def"><p class="first last">activated partial thromboplastin time</p></td></tr><tr><td class="NLM_term">BEI</td><td class="NLM_def"><p class="first last">binding efficiency index</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export pump</p></td></tr><tr><td class="NLM_term">cd</td><td class="NLM_def"><p class="first last">catalytic domain</p></td></tr><tr><td class="NLM_term">cLog <i>D</i></td><td class="NLM_def"><p class="first last">calculated Log <i>D</i></p></td></tr><tr><td class="NLM_term">COX1</td><td class="NLM_def"><p class="first last">cyclooxygenase-1</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">D.N.</td><td class="NLM_def"><p class="first last">dose normalized</p></td></tr><tr><td class="NLM_term">FII</td><td class="NLM_def"><p class="first last">factor II</p></td></tr><tr><td class="NLM_term">FVIIa</td><td class="NLM_def"><p class="first last">factor VIIa</p></td></tr><tr><td class="NLM_term">FIX</td><td class="NLM_def"><p class="first last">factor IX</p></td></tr><tr><td class="NLM_term">FXa</td><td class="NLM_def"><p class="first last">factor Xa</p></td></tr><tr><td class="NLM_term">FXI</td><td class="NLM_def"><p class="first last">factor XI</p></td></tr><tr><td class="NLM_term">FXIa</td><td class="NLM_def"><p class="first last">factor XIa</p></td></tr><tr><td class="NLM_term">FD</td><td class="NLM_def"><p class="first last">factor D</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fragment-based screening</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug-resistant gene 1</p></td></tr><tr><td class="NLM_term">NOACs</td><td class="NLM_def"><p class="first last">non-vitamin K anticoagulants</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiologically based pharmacokinetic</p></td></tr><tr><td class="NLM_term">PDE4d</td><td class="NLM_def"><p class="first last">phosphodiesterase 4d</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">prekallikrein</p></td></tr><tr><td class="NLM_term">PKL</td><td class="NLM_def"><p class="first last">plasma kallikrein</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptors</p></td></tr><tr><td class="NLM_term">PT</td><td class="NLM_def"><p class="first last">prothrombin time</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SSAO</td><td class="NLM_def"><p class="first last">semicarbazide-sensitive amine oxidase</p></td></tr><tr><td class="NLM_term">tPa</td><td class="NLM_def"><p class="first last">tissue plasminogen activator</p></td></tr><tr><td class="NLM_term">uPA</td><td class="NLM_def"><p class="first last">urokinase-type plasminogen activator</p></td></tr><tr><td class="NLM_term">VMAT2</td><td class="NLM_def"><p class="first last">vesicular monoamine transporter 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 56 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardrop, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, D.</span></span> <span> </span><span class="NLM_article-title">The story of the discovery of heparin and warfarin</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2008.07119.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fj.1365-2141.2008.07119.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=18355382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD1czjtV2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2008&pages=757-763&author=D.+Wardropauthor=D.+Keeling&title=The+story+of+the+discovery+of+heparin+and+warfarin&doi=10.1111%2Fj.1365-2141.2008.07119.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The story of the discovery of heparin and warfarin</span></div><div class="casAuthors">Wardrop Douglas; Keeling David</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">757-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Heparin and coumarins have been the mainstay of anticoagulant therapy throughout our working lives.  As we stand on the threshold of a new era of anticoagulants it is timely to look back upon their discovery and development.  Both have fascinating stories to tell.  Jay McLean claimed to have discovered heparin whilst a medical student, although this is disputed.  The story of warfarin leads us from a mysterious haemorrhagic disease of cattle to the development of a rat poison which became one of the most commonly prescribed drugs in history.  Many people were involved in both stories and we owe them all a debt of gratitude.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrf7pNvbhOB-xsqfvU0ziafW6udTcc2eachg51FsNsDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjtV2rsQ%253D%253D&md5=9ffdb66a5c68edbc5bf4ce37828ed9fc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2008.07119.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2008.07119.x%26sid%3Dliteratum%253Aachs%26aulast%3DWardrop%26aufirst%3DD.%26aulast%3DKeeling%26aufirst%3DD.%26atitle%3DThe%2520story%2520of%2520the%2520discovery%2520of%2520heparin%2520and%2520warfarin%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2008%26volume%3D141%26spage%3D757%26epage%3D763%26doi%3D10.1111%2Fj.1365-2141.2008.07119.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qato, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, G. C.</span></span> <span> </span><span class="NLM_article-title">National trends in oral anticoagulant use in the United States 2007-2011</span>. <i>Circ. Cardiovasc. Qual. Outcomes</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1161/CIRCOUTCOMES.112.967299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2FCIRCOUTCOMES.112.967299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=22949490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC38bktFyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=615-621&author=K.+Kirleyauthor=D.+M.+Qatoauthor=R.+Kornfieldauthor=R.+S.+Staffordauthor=G.+C.+Alexander&title=National+trends+in+oral+anticoagulant+use+in+the+United+States+2007-2011&doi=10.1161%2FCIRCOUTCOMES.112.967299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">National trends in oral anticoagulant use in the United States, 2007 to 2011</span></div><div class="casAuthors">Kirley Kate; Qato Dima M; Kornfield Rachel; Stafford Randall S; Alexander G Caleb</div><div class="citationInfo"><span class="NLM_cas:title">Circulation. Cardiovascular quality and outcomes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">615-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Little is known regarding the adoption of direct thrombin inhibitors in clinical practice.  We examine trends in oral anticoagulation for the prevention of thromboembolism in the United States.  METHODS AND RESULTS:  We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of office-based providers, to quantify patterns of oral anticoagulant use among all subjects and stratified by clinical indication.  We quantified oral anticoagulant expenditures using the IMS Health National Prescription Audit.  Between 2007 and 2011, warfarin treatment visits declined from ≈2.1 million (M) quarterly visits to ≈1.6M visits.  Dabigatran use increased from 0.062M quarterly visits (2010Q4) to 0.363M visits (2011Q4), reflecting its increasing share of oral anticoagulant visits from 3.1% to 18.9%.  In contrast to warfarin, the majority of dabigatran visits have been for atrial fibrillation, though this proportion decreased from 92% (2010Q4) to 63% (2011Q4), with concomitant increases in dabigatran's off-label use.  Among atrial fibrillation visits, warfarin use decreased from 55.8% visits (2010Q4) to 44.4% (2011Q4), whereas dabigatran use increased from 4.0% to 16.9%.  Of atrial fibrillation visits, the fraction not treated with any oral anticoagulants has remained unchanged at ≈40%.  Expenditures related to dabigatran increased rapidly from $16M in 2010Q4 to $166M in 2011Q4, exceeding expenditures on warfarin ($144M) in 2011Q4.  CONCLUSIONS:  Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications.  We did not find evidence that it has increased overall atrial fibrillation treatment rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbGob37j0dCae0F5ixvZgXfW6udTcc2eachg51FsNsDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bktFyqsw%253D%253D&md5=c08907f0ff94e3b21d692adbdc722eec</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2FCIRCOUTCOMES.112.967299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCOUTCOMES.112.967299%26sid%3Dliteratum%253Aachs%26aulast%3DKirley%26aufirst%3DK.%26aulast%3DQato%26aufirst%3DD.%2BM.%26aulast%3DKornfield%26aufirst%3DR.%26aulast%3DStafford%26aufirst%3DR.%2BS.%26aulast%3DAlexander%26aufirst%3DG.%2BC.%26atitle%3DNational%2520trends%2520in%2520oral%2520anticoagulant%2520use%2520in%2520the%2520United%2520States%25202007-2011%26jtitle%3DCirc.%2520Cardiovasc.%2520Qual.%2520Outcomes%26date%3D2012%26volume%3D5%26spage%3D615%26epage%3D621%26doi%3D10.1161%2FCIRCOUTCOMES.112.967299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ageno, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittkowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palareti, G.</span></span> <span> </span><span class="NLM_article-title">Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence Based-Based Clinical Practice Guidelines</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">e44S</span>– <span class="NLM_lpage">e88S</span>, <span class="refDoi"> DOI: 10.1378/chest.11-2292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1378%2Fchest.11-2292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=22315269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2012&pages=e44S-e88S&author=W.+Agenoauthor=A.+S.+Gallusauthor=A.+Wittkowskyauthor=M.+Crowtherauthor=E.+M.+Hylekauthor=G.+Palareti&title=Oral+anticoagulant+therapy%3A+antithrombotic+therapy+and+prevention+of+thrombosis%2C+9th+ed%3A+American+College+of+Chest+Physicians+Evidence+Based-Based+Clinical+Practice+Guidelines&doi=10.1378%2Fchest.11-2292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-2292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-2292%26sid%3Dliteratum%253Aachs%26aulast%3DAgeno%26aufirst%3DW.%26aulast%3DGallus%26aufirst%3DA.%2BS.%26aulast%3DWittkowsky%26aufirst%3DA.%26aulast%3DCrowther%26aufirst%3DM.%26aulast%3DHylek%26aufirst%3DE.%2BM.%26aulast%3DPalareti%26aufirst%3DG.%26atitle%3DOral%2520anticoagulant%2520therapy%253A%2520antithrombotic%2520therapy%2520and%2520prevention%2520of%2520thrombosis%252C%25209th%2520ed%253A%2520American%2520College%2520of%2520Chest%2520Physicians%2520Evidence%2520Based-Based%2520Clinical%2520Practice%2520Guidelines%26jtitle%3DChest%26date%3D2012%26volume%3D141%26spage%3De44S%26epage%3De88S%26doi%3D10.1378%2Fchest.11-2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meurer, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, B.</span></span> <span> </span><span class="NLM_article-title">What is the interval for monitoring warfarin therapy once therapeutic levels are achieved?</span>. <i>J. Fam. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15689292" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=156-178&author=L.+N.+Meurerauthor=B.+Jamieson&title=What+is+the+interval+for+monitoring+warfarin+therapy+once+therapeutic+levels+are+achieved%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeurer%26aufirst%3DL.%2BN.%26aulast%3DJamieson%26aufirst%3DB.%26atitle%3DWhat%2520is%2520the%2520interval%2520for%2520monitoring%2520warfarin%2520therapy%2520once%2520therapeutic%2520levels%2520are%2520achieved%253F%26jtitle%3DJ.%2520Fam.%2520Pract.%26date%3D2005%26volume%3D54%26spage%3D156%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roehrig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pernerstorfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinemer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perzborn, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5900</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1021/jm050101d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050101d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFShsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5900-5908&author=S.+Roehrigauthor=A.+Straubauthor=J.+Pohlmannauthor=T.+Lampeauthor=J.+Pernerstorferauthor=K.-H.+Schlemmerauthor=P.+Reinemerauthor=E.+Perzborn&title=Discovery+of+the+novel+antithrombotic+agent+5-chloro-N-%28%7B%285S%29-2-oxo-3-%5B4-%283-oxomorpholin-4-yl%29phenyl%5D-1%2C3-oxazolidin-5-yl%7Dmethyl%29thiophene-2-carboxamide+%28BAY+59-7939%29%3A+an+oral%2C+direct+factor+Xa+inhibitor&doi=10.1021%2Fjm050101d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor</span></div><div class="casAuthors">Roehrig, Susanne; Straub, Alexander; Pohlmann, Jens; Lampe, Thomas; Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Reinemer, Peter; Perzborn, Elisabeth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5900-5908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants.  The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-mol. inhibitors with good oral bioavailability.  We identified oxazolidinone derivs. as a new class of potent FXa inhibitors.  Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity.  The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity.  The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5.  Compd. 5 is currently under clin. development for the prevention and treatment of thromboembolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoreRYH8j2AErVg90H21EOLACvtfcHk0lhhOsvcBFAqmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFShsL0%253D&md5=034bd4efd9c8fbfeae95c230ac1c28a8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm050101d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050101d%26sid%3Dliteratum%253Aachs%26aulast%3DRoehrig%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DLampe%26aufirst%3DT.%26aulast%3DPernerstorfer%26aufirst%3DJ.%26aulast%3DSchlemmer%26aufirst%3DK.-H.%26aulast%3DReinemer%26aufirst%3DP.%26aulast%3DPerzborn%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520the%2520novel%2520antithrombotic%2520agent%25205-chloro-N-%2528%257B%25285S%2529-2-oxo-3-%255B4-%25283-oxomorpholin-4-yl%2529phenyl%255D-1%252C3-oxazolidin-5-yl%257Dmethyl%2529thiophene-2-carboxamide%2520%2528BAY%252059-7939%2529%253A%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5900%26epage%3D5908%26doi%3D10.1021%2Fjm050101d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwat, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallwood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5339</span>– <span class="NLM_lpage">5356</span>, <span class="refDoi"> DOI: 10.1021/jm070245n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070245n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5339-5356&author=D.+J.+P.+Pintoauthor=M.+J.+Orwatauthor=S.+Kochauthor=K.+A.+Rossiauthor=R.+A.+Alexanderauthor=A.+Smallwoodauthor=P.+C.+Wongauthor=A.+R.+Rendinaauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=K.+Heauthor=B.+Xinauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Discovery+of+1-%284-methoxyphenyl%29-7-oxo-6-%284-%282-oxopiperidin-1-yl%29phenyl%29-4%2C5%2C6%2C7-tetrahydro-1H-pyrazolo%5B3%2C4-c%5Dpyridine-3-carboxamide+%28Apixaban%2C+BMS-562247%29%2C+a+highly+potent%2C+selective%2C+efficacious%2C+and+orally+bioavailable+inhibitor+of+blood+coagulation+factor+Xa&doi=10.1021%2Fjm070245n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa</span></div><div class="casAuthors">Pinto, Donald J. P.; Orwat, Michael J.; Koch, Stephanie; Rossi, Karen A.; Alexander, Richard S.; Smallwood, Angela; Wong, Pancras C.; Rendina, Alan R.; Luettgen, Joseph M.; Knabb, Robert M.; He, Kan; Xin, Baomin; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5339-5356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efforts to identify a suitable follow-up compd. to razaxaban [i.e., 1-(3-amino-1,2-benzisoxazol-5-yl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide] focused on modification of a carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline.  Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained the potent factor Xa binding activity.  Exceptional potency of the series prompted an investigation of the neutral P1 moieties that resulted in the identification of the p-methoxyphenyl P1, which retained factor Xa binding affinity and good oral bioavailability.  Further optimization of the C-3 pyrazole position and replacement of the terminal P4 ring with a neutral heterocycle culminated in the discovery of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban).  Apixaban [i.e., 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide] exhibits a high degree of factor Xa potency, selectivity, and efficacy and has an improved pharmacokinetic profile relative to razaxaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbx6Ke9VLiirVg90H21EOLACvtfcHk0lhhOsvcBFAqmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF&md5=6620ac3af9109ab38bda8268d0ec446a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm070245n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070245n%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%2BA.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DDiscovery%2520of%25201-%25284-methoxyphenyl%2529-7-oxo-6-%25284-%25282-oxopiperidin-1-yl%2529phenyl%2529-4%252C5%252C6%252C7-tetrahydro-1H-pyrazolo%255B3%252C4-c%255Dpyridine-3-carboxamide%2520%2528Apixaban%252C%2520BMS-562247%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520efficacious%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520blood%2520coagulation%2520factor%2520Xa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5339%26epage%3D5356%26doi%3D10.1021%2Fjm070245n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauel, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priepke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassen, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienen, W.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of novel potent nonpeptide thrombin inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1021/jm0109513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0109513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1OgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1757-1766&author=N.+H.+Hauelauthor=H.+Narauthor=H.+Priepkeauthor=U.+Riesauthor=J.-M.+Stassenauthor=W.+Wienen&title=Structure-based+design+of+novel+potent+nonpeptide+thrombin+inhibitors&doi=10.1021%2Fjm0109513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of novel potent nonpeptide thrombin inhibitors</span></div><div class="casAuthors">Hauel, Norbert H.; Nar, Herbert; Priepke, Henning; Ries, Uwe; Stassen, Jean-Marie; Wienen, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1757-1766</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. syndromes of thromboembolism are evoked by an excessive stimulation of the coagulation cascade.  In this context, the serine protease thrombin plays a key role.  Considerable efforts have therefore been devoted to the discovery of safe, orally active inhibitors of this enzyme.  On the basis of the X-ray crystal structure of the peptidelike thrombin inhibitor NAPAP complexed with bovine thrombin, we have designed a new structural class of nonpeptidic inhibitors employing a 1,2,5-trisubstituted benzimidazole as the central scaffold.  Supported by a series of X-ray structure analyses, we optimized the activity of these compds.  Thrombin inhibition in the lower nanomolar range could be achieved although the binding energy mainly results from nonpolar, hydrophobic interactions.  To improve in vivo potency, we increased the overall hydrophilicity of the mols. by introducing carboxylate groups.  The very polar compd. BIBR 953 exhibited the most favorable activity profile in vivo.  This zwitterionic mol. was converted into the double-prodrug BIBR 1048, which showed strong oral activity in different animal species.  On the basis of these results, BIBR 1048 was chosen for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxoMVJTKRisLVg90H21EOLACvtfcHk0liYWGasz6sqBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1OgsLs%253D&md5=d69204226d1d74aab2995a3465505eac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm0109513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0109513%26sid%3Dliteratum%253Aachs%26aulast%3DHauel%26aufirst%3DN.%2BH.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DPriepke%26aufirst%3DH.%26aulast%3DRies%26aufirst%3DU.%26aulast%3DStassen%26aufirst%3DJ.-M.%26aulast%3DWienen%26aufirst%3DW.%26atitle%3DStructure-based%2520design%2520of%2520novel%2520potent%2520nonpeptide%2520thrombin%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1757%26epage%3D1766%26doi%3D10.1021%2Fjm0109513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Briere, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauchier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taieb, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, O.</span></span> <span> </span><span class="NLM_article-title">Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review</span>. <i>Expert Rev. Pharmacoecon. Outcomes Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1080/14737167.2018.1518134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1080%2F14737167.2018.1518134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=30169975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BB3c3ktlSjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=27-36&author=J.+B.+Briereauthor=K.+Bowrinauthor=C.+Colemanauthor=L.+Fauchierauthor=P.+Levyauthor=K.+Folkertsauthor=M.+Toumiauthor=V.+Taiebauthor=A.+Millierauthor=O.+Wu&title=Real-world+clinical+evidence+on+rivaroxaban%2C+dabigatran%2C+and+apixaban+compared+with+vitamin+K+antagonists+in+patients+with+nonvalvular+atrial+fibrillation%3A+a+systematic+literature+review&doi=10.1080%2F14737167.2018.1518134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review</span></div><div class="casAuthors">Briere Jean-Baptiste; Bowrin Kevin; Coleman Craig; Fauchier Laurent; Levy Pierre; Folkerts Kerstin; Toumi Mondher; Taieb Vanessa; Millier Aurelie; Wu Olivia</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of pharmacoeconomics & outcomes research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Several comparative real-world effectiveness studies on direct oral anticoagulants (DOACs) have been conducted, but an overview of the available evidence remains to be developed, which could provide a better understanding of the value of DOACs relative to vitamin K antagonists (VKAs).  AREAS COVERED:  A systematic literature review was conducted on the available real-world evidence (RWE) of three DOACs (rivaroxaban, dabigatran, and apixaban) compared with VKAs (e.g. warfarin), in patients with nonvalvular atrial fibrillation (NVAF).This systematic literature review included RWE published up to December 2016.  Studies with > 50 patients reporting on incident and prevalent NVAF cases were included.  The following databases were searched: Medline, Embase, and the Cochrane Library.  Outcomes of interest included thromboembolic events, all-cause mortality, bleeding events, and nonpersistence.  Of the 562 RWE DOACs articles retrieved, 49 presented results for rivaroxaban versus VKAs, 79 for dabigatran versus VKAs, and 18 for apixaban versus VKAs.  Substantial heterogeneity was found across patient population, outcome definition, and follow-up period.  Major bleeding, ischemic stroke, and intracranial hemorrhage were the most frequent outcomes analyzed.  EXPERT COMMENTARY:  Overall, the RWE studies were aligned with the Phase 3 trials.  However, conflicting results were reported for several outcomes of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTb3fTuXcbWBJZoeNcnHOQ9fW6udTcc2ebZMf0TLuxej7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3ktlSjug%253D%253D&md5=018cba54845b88cdc80489b1b64d105d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1080%2F14737167.2018.1518134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737167.2018.1518134%26sid%3Dliteratum%253Aachs%26aulast%3DBriere%26aufirst%3DJ.%2BB.%26aulast%3DBowrin%26aufirst%3DK.%26aulast%3DColeman%26aufirst%3DC.%26aulast%3DFauchier%26aufirst%3DL.%26aulast%3DLevy%26aufirst%3DP.%26aulast%3DFolkerts%26aufirst%3DK.%26aulast%3DToumi%26aufirst%3DM.%26aulast%3DTaieb%26aufirst%3DV.%26aulast%3DMillier%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DO.%26atitle%3DReal-world%2520clinical%2520evidence%2520on%2520rivaroxaban%252C%2520dabigatran%252C%2520and%2520apixaban%2520compared%2520with%2520vitamin%2520K%2520antagonists%2520in%2520patients%2520with%2520nonvalvular%2520atrial%2520fibrillation%253A%2520a%2520systematic%2520literature%2520review%26jtitle%3DExpert%2520Rev.%2520Pharmacoecon.%2520Outcomes%2520Res.%26date%3D2019%26volume%3D19%26spage%3D27%26epage%3D36%26doi%3D10.1080%2F14737167.2018.1518134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangaralingham, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellolio, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBane, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noseworthy, P. A.</span></span> <span> </span><span class="NLM_article-title">Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation</span>. <i>J. Am. Heart Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e003725</span> <span class="refDoi"> DOI: 10.1161/JAHA.116.003725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2FJAHA.116.003725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=27412905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVWmsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=X.+Yaoauthor=N.+S.+Abrahamauthor=L.+R.+Sangaralinghamauthor=M.+F.+Bellolioauthor=R.+D.+McBaneauthor=N.+D.+Shahauthor=P.+A.+Noseworthy&title=Effectiveness+and+safety+of+dabigatran%2C+rivaroxaban%2C+and+apixaban+versus+warfarin+in+nonvalvular+atrial+fibrillation&doi=10.1161%2FJAHA.116.003725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation</span></div><div class="casAuthors">Yao, Xiaoxi; Abraham, Neena S.; Sangaralingham, Lindsey R.; Bellolio, Fernanda; McBane, Robert D.; Shah, Nilay D.; Noseworthy, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Heart Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e003725/1-e003725/18</span>CODEN:
                <span class="NLM_cas:coden">JAHABZ</span>;
        ISSN:<span class="NLM_cas:issn">2047-9980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background-The introduction of non-vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clin. trials may not translate to routine practice.  We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin.  Methods and Results-Using a large US insurance database, we identified privately insured and Medicare Advantage patients with nonvalvular atrial fibrillation who were users of apixaban, dabigatran, rivaroxaban, or warfarin between Oct. 1, 2010, and June 30, 2015.  We created 3 matched cohorts using 1:1 propensity score matching: apixaban vs. warfarin (n=15 390), dabigatran vs. warfarin (n=28 614), and rivaroxaban vs. warfarin (n=32 350).  Using Cox proportional hazards regression, we found that for stroke or systemic embolism, apixaban was assocd. with lower risk (hazard ratio [HR] 0.67, 95% CI 0.46-0.98, P=0.04), but dabigatran and rivaroxaban were assocd. with a similar risk (dabigatran: HR 0.98, 95% CI 0.76-1.26, P=0.98; rivaroxaban: HR 0.93, 95% CI 0.72-1.19, P=0.56).  For major bleeding, apixaban and dabigatran were assocd. with lower risk (apixaban: HR 0.45, 95% CI 0.34-0.59, P<0.001; dabigatran: HR 0.79, 95% CI 0.67-0.94, P<0.01), and rivaroxaban was assocd. with a similar risk (HR 1.04, 95% CI 0.90-1.20, P=0.60).  All non-vitamin K antagonist oral anticoagulants were assocd. with a lower risk of intracranial bleeding.  Conclusions-In patients with nonvalvular atrial fibrillation, apixaban was assocd. with lower risks of both stroke and major bleeding, dabigatran was assocd. with similar risk of stroke but lower risk of major bleeding, and rivaroxaban was assocd. with similar risks of both stroke and major bleeding in comparison to warfarin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYl1FAgjs16bVg90H21EOLACvtfcHk0liYWGasz6sqBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVWmsrg%253D&md5=5088d522d513f981fa93d2b8935aef36</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1161%2FJAHA.116.003725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FJAHA.116.003725%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DX.%26aulast%3DAbraham%26aufirst%3DN.%2BS.%26aulast%3DSangaralingham%26aufirst%3DL.%2BR.%26aulast%3DBellolio%26aufirst%3DM.%2BF.%26aulast%3DMcBane%26aufirst%3DR.%2BD.%26aulast%3DShah%26aufirst%3DN.%2BD.%26aulast%3DNoseworthy%26aufirst%3DP.%2BA.%26atitle%3DEffectiveness%2520and%2520safety%2520of%2520dabigatran%252C%2520rivaroxaban%252C%2520and%2520apixaban%2520versus%2520warfarin%2520in%2520nonvalvular%2520atrial%2520fibrillation%26jtitle%3DJ.%2520Am.%2520Heart%2520Assoc.%26date%3D2016%26volume%3D5%26doi%3D10.1161%2FJAHA.116.003725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y.</span></span> <span> </span><span class="NLM_article-title">Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2298</span>– <span class="NLM_lpage">2307</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.055079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2FCIRCULATIONAHA.111.055079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=22514252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1arsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2298-2307&author=L.+Fribergauthor=M.+Rosenqvistauthor=G.+Y.+Lip&title=Net+clinical+benefit+of+warfarin+in+patients+with+atrial+fibrillation%3A+a+report+from+the+Swedish+atrial+fibrillation+cohort+study&doi=10.1161%2FCIRCULATIONAHA.111.055079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study</span></div><div class="casAuthors">Friberg, Leif; Rosenqvist, Marten; Lip, Gregory Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2298-2307</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: Known risk factors for bleeding during anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF).  Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding.  METHODS AND RESULTS: All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were studied for an av. of 1.5 years (260 000 patient-years at risk).  Patients were stratified according to risk scores with the use of historic International Classification of Disease diagnostic codes in the register.  Information about medication was obtained from the Swedish Drug Registry.  Our primary end point was net benefit defined as no. of avoided ischemic strokes with anticoagulation minus the no. of excess intracranial bleedings with a wt. of 1.5 to compensate for the generally more severe outcome with intracranial bleedings.  The adjusted net clin. benefit favored anticoagulation for almost all atrial fibrillation patients.  The exceptions were patients at very low risk of ischemic stroke with a CHA2DS2-VASc score of 0 and moderately elevated bleeding risk (-1.7%/y).  The results were broadly similar with CHADS2, except for patients with very low embolic risk; the CHA2DS2-VASc was able to identify those patients (n=6205, 3.9% of all patients) who had no net clin. benefit or even some disadvantage from anticoagulant treatment.  CONCLUSIONS: In almost all patients with atrial fibrillation, the risk of ischemic stroke without anticoagulant treatment is higher than the risk of intracranial bleeding with anticoagulant treatment.  Anal. of the net benefit indicates that more patients may benefit from anticoagulant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnotOpxLaJRbVg90H21EOLACvtfcHk0lhc6gcLJvUDEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1arsr0%253D&md5=0622db049f66b613fc8f1101956996e2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.055079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.055079%26sid%3Dliteratum%253Aachs%26aulast%3DFriberg%26aufirst%3DL.%26aulast%3DRosenqvist%26aufirst%3DM.%26aulast%3DLip%26aufirst%3DG.%2BY.%26atitle%3DNet%2520clinical%2520benefit%2520of%2520warfarin%2520in%2520patients%2520with%2520atrial%2520fibrillation%253A%2520a%2520report%2520from%2520the%2520Swedish%2520atrial%2520fibrillation%2520cohort%2520study%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D2298%26epage%3D2307%26doi%3D10.1161%2FCIRCULATIONAHA.111.055079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bassand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Accetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzmaurice, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhaber, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misselwitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Cate, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheugt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkar, A. K.</span></span> <span> </span><span class="NLM_article-title">Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2882</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehw233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1093%2Feurheartj%2Fehw233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=27357359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltVSktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=2882-2889&author=J.+P.+Bassandauthor=G.+Accettaauthor=A.+J.+Cammauthor=F.+Coolsauthor=D.+A.+Fitzmauriceauthor=K.+A.+Foxauthor=S.+Z.+Goldhaberauthor=S.+Gotoauthor=S.+Haasauthor=W.+Hackeauthor=G.+Kayaniauthor=L.+G.+Mantovaniauthor=F.+Misselwitzauthor=H.+Ten+Cateauthor=A.+G.+Turpieauthor=F.+W.+Verheugtauthor=A.+K.+Kakkar&title=Two-year+outcomes+of+patients+with+newly+diagnosed+atrial+fibrillation%3A+results+from+GARFIELD-AF&doi=10.1093%2Feurheartj%2Fehw233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF</span></div><div class="casAuthors">Bassand Jean-Pierre; Bassand Jean-Pierre; Accetta Gabriele; Kayani Gloria; Kakkar Ajay K; Camm Alan John; Cools Frank; Fitzmaurice David A; Fox Keith A A; Goldhaber Samuel Z; Goto Shinya; Haas Sylvia; Hacke Werner; Mantovani Lorenzo G; Misselwitz Frank; Ten Cate Hugo; Turpie Alexander G G; Verheugt Freek W A; Verheugt Freek W A; Kakkar Ajay K</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">2882-2889</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year.  METHODS AND RESULTS:  GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF.  Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy.  The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy.  At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively.  Rates for all three major events were highest during the first 4 months.  Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%.  Anticoagulant treatment was associated with a 35% lower risk of death.  CONCLUSION:  The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation.  This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome.  This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death.  CLINICAL TRIAL REGISTRATION:  http://www.clinicaltrials.gov.  Unique identifier: NCT01090362.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqozCPMEXdb3O4gDb7JggCfW6udTcc2eZoAkRwcJ2fVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltVSktw%253D%253D&md5=4a9eeb250adfc4ea4d20fb446b4e4750</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehw233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehw233%26sid%3Dliteratum%253Aachs%26aulast%3DBassand%26aufirst%3DJ.%2BP.%26aulast%3DAccetta%26aufirst%3DG.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DCools%26aufirst%3DF.%26aulast%3DFitzmaurice%26aufirst%3DD.%2BA.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DGoldhaber%26aufirst%3DS.%2BZ.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DHaas%26aufirst%3DS.%26aulast%3DHacke%26aufirst%3DW.%26aulast%3DKayani%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DL.%2BG.%26aulast%3DMisselwitz%26aufirst%3DF.%26aulast%3DTen%2BCate%26aufirst%3DH.%26aulast%3DTurpie%26aufirst%3DA.%2BG.%26aulast%3DVerheugt%26aufirst%3DF.%2BW.%26aulast%3DKakkar%26aufirst%3DA.%2BK.%26atitle%3DTwo-year%2520outcomes%2520of%2520patients%2520with%2520newly%2520diagnosed%2520atrial%2520fibrillation%253A%2520results%2520from%2520GARFIELD-AF%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D2882%26epage%3D2889%26doi%3D10.1093%2Feurheartj%2Fehw233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bane, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruberm, A.</span></span> <span> </span><span class="NLM_article-title">Factor XI and contact activation as targets for antithrombotic therapy</span>. <i>J. Thromb. Haemost.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1111/jth.13005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fjth.13005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=25976012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC2MfktVCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1383-1395&author=D.+Gailaniauthor=C.+E.+Baneauthor=A.+Gruberm&title=Factor+XI+and+contact+activation+as+targets+for+antithrombotic+therapy&doi=10.1111%2Fjth.13005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XI and contact activation as targets for antithrombotic therapy</span></div><div class="casAuthors">Gailani D; Bane C E; Gruber A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thrombosis and haemostasis : JTH</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1383-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The most commonly used anticoagulants produce therapeutic antithrombotic effects either by inhibiting thrombin or factor Xa (FXa) or by lowering the plasma levels of the precursors of these key enzymes, prothrombin and FX.  These drugs do not distinguish between thrombin generation contributing to thrombosis from thrombin generation required for hemostasis.  Thus, anticoagulants increase bleeding risk, and many patients who would benefit from therapy go untreated because of comorbidities that place them at unacceptable risk for hemorrhage.  Studies in animals demonstrate that components of the plasma contact activation system contribute to experimentally induced thrombosis, despite playing little or no role in hemostasis.  Attention has focused on FXII, the zymogen of a protease (FXIIa) that initiates contact activation when blood is exposed to foreign surfaces, and FXI, the zymogen of the protease FXIa, which links contact activation to the thrombin generation mechanism.  In the case of FXI, epidemiologic data indicate this protein contributes to stroke and venous thromboembolism, and perhaps myocardial infarction, in humans.  A phase 2 trial showing that reduction of FXI may be more effective than low molecular weight heparin at preventing venous thrombosis during knee replacement surgery provides proof of concept for the premise that an antithrombotic effect can be uncoupled from an anticoagulant effect in humans by targeting components of contact activation.  Here, we review data on the role of FXI and FXII in thrombosis and results of preclinical and human trials for therapies targeting these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFpzo98DHKlKx48Rj5GnGofW6udTcc2eZoAkRwcJ2fVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfktVCmtw%253D%253D&md5=3a17ac6f58b2ab941bccbc6080a9ea27</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fjth.13005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13005%26sid%3Dliteratum%253Aachs%26aulast%3DGailani%26aufirst%3DD.%26aulast%3DBane%26aufirst%3DC.%2BE.%26aulast%3DGruberm%26aufirst%3DA.%26atitle%3DFactor%2520XI%2520and%2520contact%2520activation%2520as%2520targets%2520for%2520antithrombotic%2520therapy%26jtitle%3DJ.%2520Thromb.%2520Haemost.%26date%3D2015%26volume%3D13%26spage%3D1383%26epage%3D1395%26doi%3D10.1111%2Fjth.13005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of factor XI activity as a promising antithrombotic strategy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1435</span>– <span class="NLM_lpage">1439</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.drudis.2014.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=24794465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFerurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1435-1439&author=Z.+Chenauthor=D.+Seiffertauthor=B.+Hawes&title=Inhibition+of+factor+XI+activity+as+a+promising+antithrombotic+strategy&doi=10.1016%2Fj.drudis.2014.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Factor XI activity as a promising antithrombotic strategy</span></div><div class="casAuthors">Chen, Zhu; Seiffert, Dietmar; Hawes, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1435-1439</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Prevention and treatment of thromboembolic disorders with minimal bleeding risk remains a significant unmet medical need.  Studies in Factor XI (FXI)-deficient humans and exptl. animal models suggest that targeting FXI in humans provides antithrombotic benefits with reduced bleeding liability compared with current std. of care.  In this review, we describe an exciting era in the discovery and development of antithrombotic agents as multiple therapeutic modalities for FXI(a) inhibition progress through preclin. and clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUC5zfGWcW6LVg90H21EOLACvtfcHk0liRuo_mQODAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFerurg%253D&md5=2c492b2af52bc361025f028e3521b271</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSeiffert%26aufirst%3DD.%26aulast%3DHawes%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520factor%2520XI%2520activity%2520as%2520a%2520promising%2520antithrombotic%2520strategy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1435%26epage%3D1439%26doi%3D10.1016%2Fj.drudis.2014.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bane, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span> <span> </span><span class="NLM_article-title">Factor XI as a target for antithrombotic therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.drudis.2014.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=24886766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCitb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1454-1458&author=C.+E.+Baneauthor=D.+Gailani&title=Factor+XI+as+a+target+for+antithrombotic+therapy&doi=10.1016%2Fj.drudis.2014.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XI as a target for antithrombotic therapy</span></div><div class="casAuthors">Bane, Charles E., Jr.; Gailani, David</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1454-1458</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anticoagulants currently used in clin. practice to treat thromboembolic disorders are effective but increase the risk of severe bleeding because they target proteins that are essential for normal coagulation (hemostasis).  Drugs with better safety profiles are required for prevention and treatment of thromboembolic disease.  Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzzQ4yWZR1R7Vg90H21EOLACvtfcHk0liRuo_mQODAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCitb%252FE&md5=92c657d769a88603800bb29ca9340886</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DBane%26aufirst%3DC.%2BE.%26aulast%3DGailani%26aufirst%3DD.%26atitle%3DFactor%2520XI%2520as%2520a%2520target%2520for%2520antithrombotic%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1454%26epage%3D1458%26doi%3D10.1016%2Fj.drudis.2014.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, O.</span></span> <span> </span><span class="NLM_article-title">Congenital factor XI deficiency: an update</span>. <i>Semin. Thromb. Hemostasis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1353420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1055%2Fs-0033-1353420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=23929304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=621-631&author=S.+Dugaauthor=O.+Salomon&title=Congenital+factor+XI+deficiency%3A+an+update&doi=10.1055%2Fs-0033-1353420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Congenital factor XI deficiency: an update</span></div><div class="casAuthors">Duga, Stefano; Salomon, Ophira</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-631</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Severe factor XI (FXI) deficiency is an injury-related bleeding disorder, common in Ashkenazi Jews (with two mutations prevailing), but rare worldwide (with heterogeneous mutations).  In the past two decades, more than 220 mutations in the FXI gene have been reported in patients with FXI deficiency, of which 7 showed a founder effect.  Inhibitors to FXI were described in patients with null-allele mutations, following exposure to plasma, FXI concs., or anti-RhD Ig.  Treatment of patients with severe FXI deficiency remains challenging because factors influencing bleeding risks are still unknown.  The use of lower doses of recombinant activated factor VII in comparison with the doses commonly applied in hemophilia A or B seems promising also when assessed in vitro by thrombin generation test.  Recently, FXI has been shown to have a sep. role in hemostasis and in thrombosis.  In animal models, targeting FXI by knocking out the gene or by using FXI-neutralizing antibodies, antisense oligonucleotides, and peptidomimetic inhibitors, prevents arterial and vein thrombosis.  The homol. between human and murine FXI and the significant antithrombotic effect of FXI deficiency in animal models resulted in the development of a novel approach of targeting FXI for prevention of thrombosis without impairing hemostasis in high-risk patients.  The acceptance of FXI as a risk factor for thrombosis is a new concept, and patients with severe FXI deficiency might gain profit during life course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9p2sCb_-8EbVg90H21EOLACvtfcHk0liRuo_mQODAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLnN&md5=7bad95a2c1a4f6e30f7bdae6b1149cb4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1353420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1353420%26sid%3Dliteratum%253Aachs%26aulast%3DDuga%26aufirst%3DS.%26aulast%3DSalomon%26aufirst%3DO.%26atitle%3DCongenital%2520factor%2520XI%2520deficiency%253A%2520an%2520update%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2013%26volume%3D39%26spage%3D621%26epage%3D631%26doi%3D10.1055%2Fs-0033-1353420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Büller, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethune, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raskob, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhamme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Factor XI antisense oligonucleotide for prevention of venous thrombosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1405760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1056%2FNEJMoa1405760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=25482425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFSrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=232-240&author=H.+R.+B%C3%BCllerauthor=C.+Bethuneauthor=S.+Bhanotauthor=D.+Gailaniauthor=B.+P.+Moniaauthor=G.+E.+Raskobauthor=A.+Segersauthor=P.+Verhammeauthor=J.+I.+Weitz&title=Factor+XI+antisense+oligonucleotide+for+prevention+of+venous+thrombosis&doi=10.1056%2FNEJMoa1405760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XI antisense oligonucleotide for prevention of venous thrombosis</span></div><div class="casAuthors">Bueller, Harry R.; Bethune, Claudette; Bhanot, Sanjay; Gailani, David; Monia, Brett P.; Raskob, Gary E.; Segers, Annelise; Verhamme, Peter; Weitz, Jeffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-240/1-232-240/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Exptl. data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown.  FXI-ASO (ISIS 416858) is a second generation antisense oligonucleotide that specifically reduces factor XI levels.  We compared the efficacy and safety of FXI-ASO with those of enoxaparin in patients undergoing total knee arthroplasty.  Methods In this open-label, parallel-group study, we randomly assigned 300 patients who were undergoing elective primary unilateral total knee arthroplasty to receive one of two doses of FXI-ASO (200 mg or 300 mg) or 40 mg of enoxaparin once daily.  The primary efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral venog. or report of symptomatic events).  The principal safety outcome was major or clin. relevant nonmajor bleeding.  Results Around the time of surgery, the mean (±SE) factor XI levels were 0.38±0.01 units per mL in the 200-mg FXI-ASO group, 0.20±0.01 units per mL in the 300-mg FXI-ASO group, and 0.93±0.02 units per mL in the enoxaparin group.  The primary efficacy outcome occurred in 36 of 134 patients (27%) who received the 200-mg dose of FXI-ASO and in 3 of 71 patients (4%) who received the 300-mg dose of FXI-ASO, as compared with 21 of 69 patients (30 %) who received enoxaparin.  The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to enoxaparin (P<0.001).  Bleeding occurred in 3 %, 3 %, and 8 % of the patients in the three study groups, resp.  Conclusions This study showed that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients undergoing elective primary unilateral total knee arthroplasty was an effective method for its prevention and appeared to be safe with respect to the risk of bleeding. (Funded by Isis Pharmaceuticals; FXI-ASO TKA ClinicalTrials.gov no., NCT01713361.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIN16Q4zBOZLVg90H21EOLACvtfcHk0liRuo_mQODAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFSrsb4%253D&md5=dca68c696383ef3fdbf25b16f27e2989</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1405760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1405760%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCller%26aufirst%3DH.%2BR.%26aulast%3DBethune%26aufirst%3DC.%26aulast%3DBhanot%26aufirst%3DS.%26aulast%3DGailani%26aufirst%3DD.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DRaskob%26aufirst%3DG.%2BE.%26aulast%3DSegers%26aufirst%3DA.%26aulast%3DVerhamme%26aufirst%3DP.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DFactor%2520XI%2520antisense%2520oligonucleotide%2520for%2520prevention%2520of%2520venous%2520thrombosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D232%26epage%3D240%26doi%3D10.1056%2FNEJMoa1405760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallheer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span> <span> </span><span class="NLM_article-title">Factor XIa inhibitors as new anticoagulants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7425</span>– <span class="NLM_lpage">7447</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00173</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00173" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1yitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7425-7447&author=M.+L.+Quanauthor=D.+J.+P.+Pintoauthor=J.+M.+Smallheerauthor=W.+R.+Ewingauthor=K.+A.+Rossiauthor=J.+M.+Luettgenauthor=D.+A.+Seiffertauthor=R.+R.+Wexler&title=Factor+XIa+inhibitors+as+new+anticoagulants&doi=10.1021%2Facs.jmedchem.8b00173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XIa Inhibitors as New Anticoagulants</span></div><div class="casAuthors">Quan, Mimi L.; Pinto, Donald J. P.; Smallheer, Joanne M.; Ewing, William R.; Rossi, Karen A.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7425-7447</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved.  Early clin. and preclin. data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications.  This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrri7-BSbXNpLVg90H21EOLACvtfcHk0liVFkotH-Mnyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1yitL0%253D&md5=192aec0b37c394ffb790b874e34e79cf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00173%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DSmallheer%26aufirst%3DJ.%2BM.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DFactor%2520XIa%2520inhibitors%2520as%2520new%2520anticoagulants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7425%26epage%3D7447%26doi%3D10.1021%2Facs.jmedchem.8b00173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Horani, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, U. R.</span></span> <span> </span><span class="NLM_article-title">Factor XIa inhibitors: a review of patent literature</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1154045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1517%2F13543776.2016.1154045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=26881476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1Chtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=323-345&author=R.+A.+Al-Horaniauthor=U.+R.+Desai&title=Factor+XIa+inhibitors%3A+a+review+of+patent+literature&doi=10.1517%2F13543776.2016.1154045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XIa inhibitors: A review of the patent literature</span></div><div class="casAuthors">Al-Horani, Rami A.; Desai, Umesh R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-345</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Anticoagulants are the mainstay for prevention and/or treatment of thrombotic disorders.  Each clin. used anticoagulant is assocd. with significant adverse consequences, esp. bleeding.  Factor XIa (FXIa), a key factor involved in the amplification of procoagulation signal, has been suggested as a major target for anticoagulant drug discovery because of reduced risk of bleeding.: Our literature search uncovered dozens of industrial and academic patents on the discovery of novel FXIa/FXI inhibitors.  Small peptidomimetics, sulfated glycosaminoglycan mimetics, polypeptides, antisense oligonucleotides, and monoclonal antibodies have been developed as inhibitors of FXIa.  Although many agents are in early discovery/development phases, the activity and safety of a few have been evaluated in various animal models and in humans.: FXIa is a promising drug target for development of effective anticoagulants with limited bleeding complications.  Literature reveals a major trend in the no. of patent applications over the last three years.  These inhibitors exploit different approaches for target inhibition.  Allosteric modulation of FXIa and biosynthetic inhibition of FXI are mechanistically unique.  Despite initial results in patients undergoing knee anthroplasty as with antisense oligonucleotides, major advances should be realized, particularly with respect to pharmacokinetics, for FXI/FXIa inhibitors to enter the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcAvCXF1PYbVg90H21EOLACvtfcHk0liVFkotH-Mnyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1Chtbw%253D&md5=647cc7fcd90903cf5fbacce6c733d280</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1154045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1154045%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Horani%26aufirst%3DR.%2BA.%26aulast%3DDesai%26aufirst%3DU.%2BR.%26atitle%3DFactor%2520XIa%2520inhibitors%253A%2520a%2520review%2520of%2520patent%2520literature%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D323%26epage%3D345%26doi%3D10.1517%2F13543776.2016.1154045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Mey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heubach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yassen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxnick, S.</span></span> <span> </span><span class="NLM_article-title">First evaluation of the safety, pharmacokinetics and pharmacodynamics of BAY1213790, a full human IgG1 antibody targeting coagulation factor XIa, in healthy young men</span>. <i>Res. Pract. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=392&author=D.+Thomasauthor=K.+Thelenauthor=D.+van+der%0AMeyauthor=S.+Schwersauthor=S.+Schifferauthor=J.+Ungerauthor=A.+Heubachauthor=A.+Yassenauthor=S.+Boxnick&title=First+evaluation+of+the+safety%2C+pharmacokinetics+and+pharmacodynamics+of+BAY1213790%2C+a+full+human+IgG1+antibody+targeting+coagulation+factor+XIa%2C+in+healthy+young+men"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DThelen%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BMey%26aufirst%3DD.%26aulast%3DSchwers%26aufirst%3DS.%26aulast%3DSchiffer%26aufirst%3DS.%26aulast%3DUnger%26aufirst%3DJ.%26aulast%3DHeubach%26aufirst%3DA.%26aulast%3DYassen%26aufirst%3DA.%26aulast%3DBoxnick%26aufirst%3DS.%26atitle%3DFirst%2520evaluation%2520of%2520the%2520safety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520BAY1213790%252C%2520a%2520full%2520human%2520IgG1%2520antibody%2520targeting%2520coagulation%2520factor%2520XIa%252C%2520in%2520healthy%2520young%2520men%26jtitle%3DRes.%2520Pract.%2520Thromb.%2520Haemostasis%26date%3D2017%26volume%3D1%26spage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">(Abstract PB 834)</p></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melkko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horny, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPetrillo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGagne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulmatycki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basson, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, R. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khder, Y.</span></span> <span> </span><span class="NLM_article-title">MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1516</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-10-880849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1182%2Fblood-2018-10-880849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=30692123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2019&pages=1507-1516&author=A.+W.+Kochauthor=N.+Schieringauthor=S.+Melkkoauthor=S.+Ewertauthor=J.+Salterauthor=Y.+Zhangauthor=P.+McCormackauthor=J.+Yuauthor=X.+Huangauthor=Y.+H.+Chiuauthor=Z.+Chenauthor=S.+Schleegerauthor=G.+Hornyauthor=K.+DiPetrilloauthor=L.+Mullerauthor=A.+Heinauthor=F.+Villardauthor=M.+Scharenbergauthor=P.+Ramageauthor=U.+Hassiepenauthor=S.+C%C3%B4t%C3%A9author=J.+DeGagneauthor=C.+Krantzauthor=J.+Ederauthor=B.+Stollauthor=K.+Kulmatyckiauthor=D.+L.+Feldmanauthor=P.+Hoffmannauthor=C.+T.+Bassonauthor=R.+J.+A.+Frostauthor=Y.+Khder&title=MAA868%2C+a+novel+FXI+antibody+with+a+unique+binding+mode%2C+shows+durable+effects+on+markers+of+anticoagulation+in+humans&doi=10.1182%2Fblood-2018-10-880849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans</span></div><div class="casAuthors">Koch, Alexander W.; Schiering, Nikolaus; Melkko, Samu; Ewert, Stefan; Salter, Janeen; Zhang, Yiming; McCormack, Peter; Yu, Jianying; Huang, Xueming; Chiu, Yu-Hsin; Chen, Zhiping; Schleeger, Simone; Horny, Geraldine; Dipetrillo, Keith; Muller, Lionel; Hein, Andreas; Villard, Frederic; Scharenberg, Meike; Ramage, Paul; Hassiepen, Ulrich; Cote, Serge; Degagne, Julie; Krantz, Carsten; Eder, Joerg; Stoll, Brian; Kulmatycki, Kenneth; Feldman, David L.; Hoffmann, Peter; Basson, Craig T.; Frost, Robert J. A.; Khder, Yasser</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1507-1516</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A large unmet medical need exists for safer antithrombotic drugs because all currently approved anticoagulant agents interfere with hemostasis, leading to an increased risk of bleeding.  Genetic and pharmacol. evidence in humans and animals suggests that reducing factor XI (FXI) levels has the potential to effectively prevent and treat thrombosis with a minimal risk of bleeding.  We generated a fully human antibody (MAA868) that binds the catalytic domain of both FXI (zymogen) and activated FXI.  Our structural studies show that MAA868 traps FXI and activated FXI in an inactive, zymogen-like conformation, explaining its equally high binding affinity for both forms of the enzyme.  This binding mode allows the enzyme to be neutralized before entering the coagulation process, revealing a particularly attractive anticoagulant profile of the antibody.  MAA868 exhibited favorable anticoagulant activity in mice with a dose-dependent protection from carotid occlusion in a ferric chloride-induced thrombosis model.  MAA868 also caused robust and sustained anticoagulant activity in cynomolgus monkeys as assessed by activated partial thromboplastin time without any evidence of bleeding.  Based on these preclin. findings, we conducted a first-in-human study in healthy subjects and showed that single s.c. doses of MAA868 were safe and well tolerated.  MAA868 resulted in dose- and time-dependent robust and sustained prolongation of activated partial thromboplastin time and FXI suppression for up to 4 wk or longer, supporting further clin. investigation as a potential once-monthly s.c. anticoagulant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEg6DvzFGi7Vg90H21EOLACvtfcHk0lhSx3nNK7VgkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlSrtL8%253D&md5=69bf3a18273147a4b32c96be252c2d2c</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-10-880849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-10-880849%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BW.%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DMelkko%26aufirst%3DS.%26aulast%3DEwert%26aufirst%3DS.%26aulast%3DSalter%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMcCormack%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChiu%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSchleeger%26aufirst%3DS.%26aulast%3DHorny%26aufirst%3DG.%26aulast%3DDiPetrillo%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DHein%26aufirst%3DA.%26aulast%3DVillard%26aufirst%3DF.%26aulast%3DScharenberg%26aufirst%3DM.%26aulast%3DRamage%26aufirst%3DP.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DS.%26aulast%3DDeGagne%26aufirst%3DJ.%26aulast%3DKrantz%26aufirst%3DC.%26aulast%3DEder%26aufirst%3DJ.%26aulast%3DStoll%26aufirst%3DB.%26aulast%3DKulmatycki%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DD.%2BL.%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DBasson%26aufirst%3DC.%2BT.%26aulast%3DFrost%26aufirst%3DR.%2BJ.%2BA.%26aulast%3DKhder%26aufirst%3DY.%26atitle%3DMAA868%252C%2520a%2520novel%2520FXI%2520antibody%2520with%2520a%2520unique%2520binding%2520mode%252C%2520shows%2520durable%2520effects%2520on%2520markers%2520of%2520anticoagulation%2520in%2520humans%26jtitle%3DBlood%26date%3D2019%26volume%3D133%26spage%3D1507%26epage%3D1516%26doi%3D10.1182%2Fblood-2018-10-880849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corte, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspady, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neithnadka, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span> <span> </span><span class="NLM_article-title">Potent, orally bioavailable, and efficacious macrocyclic inhibitors of factor XIa. Discovery of pyridine-based macrocycles possessing phenylazole carboxamide P1 groups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=784-803&author=J.+R.+Corteauthor=D.+J.+P.+Pintoauthor=T.+Fangauthor=H.+Osunaauthor=W.+Yangauthor=Y.+Wangauthor=A.+Laiauthor=C.+G.+Clarkauthor=J.-H.+Sunauthor=R.+Rampullaauthor=A.+Mathurauthor=M.+Kaspadyauthor=P.+R.+Neithnadkaauthor=Y.-X.+C.+Liauthor=K.+A.+Rossiauthor=J.+E.+Myersauthor=S.+Sheriffauthor=Z.+Louauthor=T.+W.+Harperauthor=C.+Huangauthor=J.+J.+Zhengauthor=J.+M.+Bozarthauthor=Y.+Wuauthor=P.+C.+Wongauthor=E.+J.+Crainauthor=D.+A.+Seiffertauthor=J.+M.+Luettgenauthor=P.+Y.+S.+Lamauthor=R.+R.+Wexlerauthor=W.+R.+Ewing&title=Potent%2C+orally+bioavailable%2C+and+efficacious+macrocyclic+inhibitors+of+factor+XIa.+Discovery+of+pyridine-based+macrocycles+possessing+phenylazole+carboxamide+P1+groups&doi=10.1021%2Facs.jmedchem.9b01768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups</span></div><div class="casAuthors">Corte, James R.; Pinto, Donald J. P.; Fang, Tianan; Osuna, Honey; Yang, Wu; Wang, Yufeng; Lai, Amy; Clark, Charles G.; Sun, Jung-Hui; Rampulla, Richard; Mathur, Arvind; Kaspady, Mahammed; Neithnadka, Premsai Rai; Li, Yi-Xin Cindy; Rossi, Karen A.; Myers, Joseph E.; Sheriff, Steven; Lou, Zhen; Harper, Timothy W.; Huang, Christine; Zheng, Joanna J.; Bozarth, Jeffrey M.; Wu, Yiming; Wong, Pancras C.; Crain, Earl J.; Seiffert, Dietmar A.; Luettgen, Joseph M.; Lam, Patrick Y. S.; Wexler, Ruth R.; Ewing, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Factor XIa (FXIa) inhibitors are promising novel anticoagulants, which show excellent efficacy in preclin. thrombosis models with minimal effects on hemostasis.  The discovery of potent and selective FXIa inhibitors which are also orally bioavailable has been a challenge.  Here, we describe optimization of the imidazole-based macrocyclic series and our initial progress toward meeting this challenge.  A two-pronged strategy, which focused on replacement of the imidazole scaffold and the design of new P1 groups, led to the discovery of potent, orally bioavailable pyridine-based macrocyclic FXIa inhibitors.  Moreover, pyridine-based macrocycle 19, possessing the phenylimidazole carboxamide P1, exhibited excellent selectivity against relevant blood coagulation enzymes and displayed antithrombotic efficacy in a rabbit thrombosis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDJ6B4dsypXrVg90H21EOLACvtfcHk0lhSx3nNK7VgkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrO&md5=c6443b52ba7e7c21ffe915d3f34ec736</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01768%26sid%3Dliteratum%253Aachs%26aulast%3DCorte%26aufirst%3DJ.%2BR.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DFang%26aufirst%3DT.%26aulast%3DOsuna%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DC.%2BG.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DKaspady%26aufirst%3DM.%26aulast%3DNeithnadka%26aufirst%3DP.%2BR.%26aulast%3DLi%26aufirst%3DY.-X.%2BC.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DHarper%26aufirst%3DT.%2BW.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DBozarth%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DCrain%26aufirst%3DE.%2BJ.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DPotent%252C%2520orally%2520bioavailable%252C%2520and%2520efficacious%2520macrocyclic%2520inhibitors%2520of%2520factor%2520XIa.%2520Discovery%2520of%2520pyridine-based%2520macrocycles%2520possessing%2520phenylazole%2520carboxamide%2520P1%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D784%26epage%3D803%26doi%3D10.1021%2Facs.jmedchem.9b01768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwat, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apedo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toussaint, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetsko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudmundsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a parenteral small molecule coagulation factor XIa inhibitor clinical candidate (BMS-962212)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9703</span>– <span class="NLM_lpage">9723</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01171</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01171" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslent7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9703-9723&author=D.+J.+P.+Pintoauthor=M.+J.+Orwatauthor=L.+M.+Smithauthor=M.+L.+Quanauthor=P.+Y.+S.+Lamauthor=K.+A.+Rossiauthor=A.+Apedoauthor=J.+M.+Bozarthauthor=Y.+Wuauthor=J.+J.+Zhengauthor=B.+Xinauthor=N.+Toussaintauthor=P.+Stetskoauthor=O.+Gudmundssonauthor=B.+Maxwellauthor=E.+J.+Crainauthor=P.+C.+Wongauthor=Z.+Louauthor=T.+W.+Harperauthor=S.+A.+Chackoauthor=J.+E.+Myersauthor=S.+Sheriffauthor=H.+Zhangauthor=X.+Houauthor=A.+Mathurauthor=D.+A.+Seiffertauthor=R.+R.+Wexlerauthor=J.+M.+Luettgenauthor=W.+R.+Ewing&title=Discovery+of+a+parenteral+small+molecule+coagulation+factor+XIa+inhibitor+clinical+candidate+%28BMS-962212%29&doi=10.1021%2Facs.jmedchem.7b01171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)</span></div><div class="casAuthors">Pinto, Donald J. P.; Orwat, Michael J.; Smith, Leon M.; Quan, Mimi L.; Lam, Patrick Y. S.; Rossi, Karen A.; Apedo, Atsu; Bozarth, Jeffrey M.; Wu, Yiming; Zheng, Joanna J.; Xin, Baomin; Toussaint, Nathalie; Stetsko, Paul; Gudmundsson, Olafur; Maxwell, Brad; Crain, Earl J.; Wong, Pancras C.; Lou, Zhen; Harper, Timothy W.; Chacko, Silvi A.; Myers, Joseph E.; Sheriff, Steven; Zhang, Huiping; Hou, Xiaoping; Mathur, Arvind; Seiffert, Dietmar A.; Wexler, Ruth R.; Luettgen, Joseph M.; Ewing, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9703-9723</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Factor XIa (FXIa) is a blood coagulation enzyme that is involved in the amplification of thrombin generation.  Mounting evidence suggests that direct inhibition of FXIa can block pathol. thrombus formation while preserving normal hemostasis.  Preclin. studies using a variety of approaches to reduce FXIa activity, including direct inhibitors of FXIa, have demonstrated good antithrombotic efficacy without increasing bleeding.  Based on this potential, the authors targeted the efforts at identifying potent inhibitors of FXIa with a focus on discovering an acute antithrombotic agent for use in a hospital setting.  Herein the authors describe the discovery of a potent FXIa clin. candidate, I (FXIa Ki = 0.7 nM), with excellent preclin. efficacy in thrombosis models and aq. soly. suitable for i.v. administration.  BMS-962212 is a reversible, direct, and highly selective small mol. inhibitor of FXIa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDjxJ_bitf6rVg90H21EOLACvtfcHk0lgVNd_Ny8SthQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslent7bE&md5=8873c054b79778fe7c45daa2eda64084</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01171%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DApedo%26aufirst%3DA.%26aulast%3DBozarth%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DToussaint%26aufirst%3DN.%26aulast%3DStetsko%26aufirst%3DP.%26aulast%3DGudmundsson%26aufirst%3DO.%26aulast%3DMaxwell%26aufirst%3DB.%26aulast%3DCrain%26aufirst%3DE.%2BJ.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DHarper%26aufirst%3DT.%2BW.%26aulast%3DChacko%26aufirst%3DS.%2BA.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DDiscovery%2520of%2520a%2520parenteral%2520small%2520molecule%2520coagulation%2520factor%2520XIa%2520inhibitor%2520clinical%2520candidate%2520%2528BMS-962212%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9703%26epage%3D9723%26doi%3D10.1021%2Facs.jmedchem.7b01171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCreta, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSouza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirincione, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, R. J. A.</span></span> <span> </span><span class="NLM_article-title">First in human study to assess safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">876</span>, <span class="refDoi"> DOI: 10.1111/bcp.13520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fbcp.13520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=29346838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=876&author=V.+Pereraauthor=J.+M.+Luettgenauthor=Z.+Wangauthor=C.+E.+Frostauthor=C.+Yonesauthor=C.+Russoauthor=J.+Leeauthor=Y.+Zhaoauthor=F.+P.+LaCretaauthor=X.+Maauthor=R.+M.+Knabbauthor=D.+Seiffertauthor=M.+DeSouzaauthor=P.+Mugnierauthor=B.+Cirincioneauthor=T.+Uenoauthor=R.+J.+A.+Frost&title=First+in+human+study+to+assess+safety%2C+pharmacokinetics+and+pharmacodynamics+of+BMS-962212%2C+a+direct%2C+reversible%2C+small+molecule+factor+XIa+inhibitor+in+non-Japanese+and+Japanese+healthy+subjects&doi=10.1111%2Fbcp.13520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects</span></div><div class="casAuthors">Perera, Vidya; Luettgen, Joseph M.; Wang, Zhaoqing; Frost, Charles E.; Yones, Cynthia; Russo, Cesare; Lee, John; Zhao, Yue; La Creta, Frank P.; Ma, Xuewen; Knabb, Robert M.; Seiffert, Dietmar; De Souza, Mary; Mugnier, Pierre; Cirincione, Brenda; Ueno, Takayo; Frost, Robert J. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">876-887</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-962212, a first-in-class factor XIa inhibitor, in Japanese and non-Japanese healthy subjects.  Methods : This was a randomized, placebo-controlled, double-blind, sequential, ascending-dose study of 2-h (part A) and 5-day (part B) i.v. (IV) infusions of BMS-962212.  Part A used four doses (1.5, 4, 10 and 25 mg h-1) of BMS-962212 or placebo in a 6:2 ratio per dose.  Part B used four doses (1, 3, 9 and 20 mg h-1) enrolling Japanese (n = 4 active, n = 1 placebo) and non-Japanese (n = 4 active, n = 1 placebo) subjects per dose.  The PK, PD, safety and tolerability were assessed throughout the study.  Results : BMS-962212 was well tolerated; there were no signs of bleeding, and adverse events were mild.  In parts A and B, BMS-962212 demonstrated dose proportionality.  The mean half-life in parts A and B ranged from 2.04 to 4.94 h and 6.22 to 8.65 h, resp.  Exposure-dependent changes were obsd. in the PD parameters, activated partial thromboplastin time (aPTT) and factor XI clotting activity (FXI:C).  The max. mean aPTT and FXI:C change from baseline at 20 mg h-1 in part B was 92% and 90%, resp.  No difference was obsd. in wt.-cor. steady-state concns., aPTT or FXI:C between Japanese and non-Japanese subjects (P > 0.05).  Conclusion : BMS-962212 has tolerability, PK and PD properties suitable for investigational use as an acute antithrombotic agent in Japanese or non-Japanese subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9bWTBwIh5OLVg90H21EOLACvtfcHk0lgVNd_Ny8SthQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGlsLY%253D&md5=30badec3a1c297fe1c85d37e22b821d3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13520%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DV.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DYones%26aufirst%3DC.%26aulast%3DRusso%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLaCreta%26aufirst%3DF.%2BP.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DSeiffert%26aufirst%3DD.%26aulast%3DDeSouza%26aufirst%3DM.%26aulast%3DMugnier%26aufirst%3DP.%26aulast%3DCirincione%26aufirst%3DB.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DFrost%26aufirst%3DR.%2BJ.%2BA.%26atitle%3DFirst%2520in%2520human%2520study%2520to%2520assess%2520safety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520BMS-962212%252C%2520a%2520direct%252C%2520reversible%252C%2520small%2520molecule%2520factor%2520XIa%2520inhibitor%2520in%2520non-Japanese%2520and%2520Japanese%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D876%26doi%3D10.1111%2Fbcp.13520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span>Oral factor XIa inhibitor for
the prevention of new ischemic stroke in patients receiving aspirin
and clopidogrel following acute ischemic stroke or transient ischemic
attack (TIA). <a href="https://clinicaltrials.gov/ct2/show/NCT03766581" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03766581</a> (accessed April 26, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+factor+XIa+inhibitor+for%0Athe+prevention+of+new+ischemic+stroke+in+patients+receiving+aspirin%0Aand+clopidogrel+following+acute+ischemic+stroke+or+transient+ischemic%0Aattack+%28TIA%29.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03766581+%28accessed+April+26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokesch, P. M.</span></span> <span> </span><span class="NLM_article-title">Abstract 13747: Phase 1a/1b study of EP-7041: a novel, potent, selective, small molecule FXIa inhibitor</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>, <span class="NLM_elocation-id">A13747</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&author=N.+J.+Haywardauthor=D.+I.+Goldbergauthor=E.+M.+Morrelauthor=P.+M.+Fridenauthor=P.+M.+Bokesch&title=Abstract+13747%3A+Phase+1a%2F1b+study+of+EP-7041%3A+a+novel%2C+potent%2C+selective%2C+small+molecule+FXIa+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DN.%2BJ.%26aulast%3DGoldberg%26aufirst%3DD.%2BI.%26aulast%3DMorrel%26aufirst%3DE.%2BM.%26aulast%3DFriden%26aufirst%3DP.%2BM.%26aulast%3DBokesch%26aufirst%3DP.%2BM.%26atitle%3DAbstract%252013747%253A%2520Phase%25201a%252F1b%2520study%2520of%2520EP-7041%253A%2520a%2520novel%252C%2520potent%252C%2520selective%252C%2520small%2520molecule%2520FXIa%2520inhibitor%26jtitle%3DCirculation%26date%3D2017%26volume%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sedrani, R.</span>; <span class="NLM_string-name">Hommel, U.</span>; <span class="NLM_string-name">Eder, J.</span></span> <span> </span><span class="NLM_article-title">Protease-Directed Drug Discovery</span>. In  <i>Gene Family Targeted Molecular Design</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>, Ed.; <span class="NLM_publisher-name">John Wiley and Sons</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2008</span>; Chapter 6, pp  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">197</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1002%2F9780470423936.ch6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=159-197&author=R.+Sedrani&author=U.+Hommel&author=J.+Ederauthor=K.+E.+Lackey&title=Gene+Family+Targeted+Molecular+Design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2F9780470423936.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470423936.ch6%26sid%3Dliteratum%253Aachs%26aulast%3DSedrani%26aufirst%3DR.%26atitle%3DProtease-Directed%2520Drug%2520Discovery%26btitle%3DGene%2520Family%2520Targeted%2520Molecular%2520Design%26aulast%3DLackey%26aufirst%3DK.%2BE.%26pub%3DJohn%2520Wiley%2520and%2520Sons%26date%3D2008%26spage%3D159%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renné, T.</span></span> <span> </span><span class="NLM_article-title">Human deficiencies in intrinsic cascade proteases FXII and plasma kallikrein (PKL) have not been strongly associated with antithrombotic protection or enhanced bleeding risk, see: Contact system revisited: an interface between inflammation, coagulation, and innate immunity</span>. <i>J. Thromb. Haemost.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1111/jth.13235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fjth.13235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=26707513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC28rltVSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=427-437&author=A.+T.+Longauthor=E.+Kenneauthor=R.+Jungauthor=T.+A.+Fuchsauthor=T.+Renn%C3%A9&title=Human+deficiencies+in+intrinsic+cascade+proteases+FXII+and+plasma+kallikrein+%28PKL%29+have+not+been+strongly+associated+with+antithrombotic+protection+or+enhanced+bleeding+risk%2C+see%3A+Contact+system+revisited%3A+an+interface+between+inflammation%2C+coagulation%2C+and+innate+immunity&doi=10.1111%2Fjth.13235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Contact system revisited: an interface between inflammation, coagulation, and innate immunity</span></div><div class="casAuthors">Long A T; Jung R; Fuchs T A; Renne T; Kenne E; Fuchs T A; Renne T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thrombosis and haemostasis : JTH</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The contact system is a plasma protease cascade initiated by factor XII (FXII) that activates the proinflammatory kallikrein-kinin system and the procoagulant intrinsic coagulation pathway.  Anionic surfaces induce FXII zymogen activation to form proteolytically active FXIIa.  Bacterial surfaces also have the ability to activate contact system proteins, indicating an important role for host defense using the cooperation of the inflammatory and coagulation pathways.  Recent research has shown that inorganic polyphosphate found in platelets activates FXII in vivo and can induce coagulation in pathological thrombus formation.  Experimental studies have shown that interference with FXII provides thromboprotection without a therapy-associated increase in bleeding, renewing interest in the FXIIa-driven intrinsic pathway of coagulation as a therapeutic target.  This review summarizes how the contact system acts as the cross-road of inflammation, coagulation, and innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQjjvqKO9Cintlzo9xastyfW6udTcc2eaP-CKRhPQv5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rltVSntA%253D%253D&md5=7ef45350f96bacbde9109bd153bcccba</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fjth.13235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13235%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DA.%2BT.%26aulast%3DKenne%26aufirst%3DE.%26aulast%3DJung%26aufirst%3DR.%26aulast%3DFuchs%26aufirst%3DT.%2BA.%26aulast%3DRenn%25C3%25A9%26aufirst%3DT.%26atitle%3DHuman%2520deficiencies%2520in%2520intrinsic%2520cascade%2520proteases%2520FXII%2520and%2520plasma%2520kallikrein%2520%2528PKL%2529%2520have%2520not%2520been%2520strongly%2520associated%2520with%2520antithrombotic%2520protection%2520or%2520enhanced%2520bleeding%2520risk%252C%2520see%253A%2520Contact%2520system%2520revisited%253A%2520an%2520interface%2520between%2520inflammation%252C%2520coagulation%252C%2520and%2520innate%2520immunity%26jtitle%3DJ.%2520Thromb.%2520Haemost.%26date%3D2016%26volume%3D14%26spage%3D427%26epage%3D437%26doi%3D10.1111%2Fjth.13235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Coagulation Assays</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">e53</span>– <span class="NLM_lpage">e60</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.104.478222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2Fcirculationaha.104.478222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=16043649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD2MzosFShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2005&pages=e53-e60&author=S.+M.+Batesauthor=J.+I.+Weitz&title=Coagulation+Assays&doi=10.1161%2FCIRCULATIONAHA.104.478222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Coagulation assays</span></div><div class="casAuthors">Bates Shannon M; Weitz Jeffrey I</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e53-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6m8OL_uszrDjk2McQZ6XmfW6udTcc2eaP-CKRhPQv5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzosFShsA%253D%253D&md5=0a8f0f84d91fc2005b6d5f38b714ad3c</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1161%2Fcirculationaha.104.478222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fcirculationaha.104.478222%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DS.%2BM.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DCoagulation%2520Assays%26jtitle%3DCirculation%26date%3D2005%26volume%3D112%26spage%3De53%26epage%3De60%26doi%3D10.1161%2FCIRCULATIONAHA.104.478222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, S.</span>; <span class="NLM_string-name">McCraw, A.</span>; <span class="NLM_string-name">Echenagucia, M.</span></span> <i>Diagnosis of Hemophilia and Other Bleeding Disorders</i>, A Laboratory Manual, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">World Federation of Hemophilia</span>, <span class="NLM_year">2010</span>. <a href="http://www1.wfh.org/publication/files/pdf-1283.pdf" class="extLink">http://www1.wfh.org/publication/files/pdf-1283.pdf</a> (accessed April 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Kitchen&author=A.+McCraw&author=M.+Echenagucia&title=Diagnosis+of+Hemophilia+and+Other+Bleeding+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKitchen%26aufirst%3DS.%26btitle%3DDiagnosis%2520of%2520Hemophilia%2520and%2520Other%2520Bleeding%2520Disorders%26pub%3DWorld%2520Federation%2520of%2520Hemophilia%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prentiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradoux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Erkenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and preclinical characterization of selective factor D inhibitors targeting the alternative complement pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4656</span>– <span class="NLM_lpage">4668</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4656-4668&author=R.+G.+Karkiauthor=J.+Powersauthor=N.+Mainolfiauthor=K.+Andersonauthor=D.+B.+Belangerauthor=D.+Liuauthor=N.+Jiauthor=K.+Jendzaauthor=C.+F.+Gelinauthor=A.+Mac+Sweeneyauthor=C.+Solovayauthor=O.+Delgadoauthor=M.+Crowleyauthor=S.-M.+Liaoauthor=U.+A.+Argikarauthor=S.+Flohrauthor=L.+R.+La+Bonteauthor=E.+Lorthioisauthor=A.+Vulpettiauthor=A.+Brownauthor=D.+Longauthor=M.+Prentissauthor=N.+Gradouxauthor=A.+de+Erkenezauthor=F.+Cuminauthor=C.+Adamsauthor=B.+Jaffeeauthor=M.+Mogi&title=Design%2C+synthesis%2C+and+preclinical+characterization+of+selective+factor+D+inhibitors+targeting+the+alternative+complement+pathway&doi=10.1021%2Facs.jmedchem.9b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway</span></div><div class="casAuthors">Karki, Rajeshri G.; Powers, James; Mainolfi, Nello; Anderson, Karen; Belanger, David B.; Liu, Donglei; Ji, Nan; Jendza, Keith; Gelin, Christine F.; Mac Sweeney, Aengus; Solovay, Catherine; Delgado, Omar; Crowley, Maura; Liao, Sha-Mei; Argikar, Upendra A.; Flohr, Stefanie; La Bonte, Laura R.; Lorthiois, Edwige L.; Vulpetti, Anna; Brown, Ann; Long, Debby; Prentiss, Melissa; Gradoux, Nathalie; de Erkenez, Andrea; Cumin, Frederic; Adams, Christopher; Jaffee, Bruce; Mogi, Muneto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4656-4668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system.  Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria.  Previously, the authors have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (I and II) binding to the open active conformation of FD.  In continuation of the authors' drug discovery program, the authors designed compds. applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases.  The authors report herein the design, synthesis, and medicinal chem. optimization of the benzylamine series culminating in the discovery of (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid, an orally bioavailable and selective FD inhibitor.  (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5uolWfBzK7Vg90H21EOLACvtfcHk0liy41xkfvtYPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D&md5=a4a56886a758093516952737306a5d8a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00271%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DBelanger%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DN.%26aulast%3DJendza%26aufirst%3DK.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DSolovay%26aufirst%3DC.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DCrowley%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DLong%26aufirst%3DD.%26aulast%3DPrentiss%26aufirst%3DM.%26aulast%3DGradoux%26aufirst%3DN.%26aulast%3Dde%2BErkenez%26aufirst%3DA.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520preclinical%2520characterization%2520of%2520selective%2520factor%2520D%2520inhibitors%2520targeting%2520the%2520alternative%2520complement%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4656%26epage%3D4668%26doi%3D10.1021%2Facs.jmedchem.9b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Structure-based library design and fragment screening for the identification of reversible complement factor D protease inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1946-1958&author=A.+Vulpettiauthor=R.+Randlauthor=S.+R%C3%BCdisserauthor=N.+Ostermannauthor=P.+Erbelauthor=A.+Mac+Sweeneyauthor=T.+Zollerauthor=B.+Salemauthor=B.+Gerhartzauthor=F.+Cuminauthor=U.+Hommelauthor=C.+Dalvitauthor=E.+Lorthioisauthor=J.+Maibaum&title=Structure-based+library+design+and+fragment+screening+for+the+identification+of+reversible+complement+factor+D+protease+inhibitors&doi=10.1021%2Facs.jmedchem.6b01684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span></div><div class="casAuthors">Vulpetti, Anna; Randl, Stefan; Rudisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic dysregulation of alternative complement pathway activation has been assocd. with diverse clin. disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.  Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymic reaction of the amplification loop of the alternative pathway.  In this paper, the authors describe two hit finding approaches leading to the discovery of new chem. matter for this pivotal protease of the complement system: in silico active site mapping for hot spots identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries.  The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different sub-pockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPFgFvVDvCyrVg90H21EOLACvtfcHk0libGGiQZxY1kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D&md5=179ea6dc5fb9ccb60931da60f23e6381</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01684%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DRandl%26aufirst%3DR.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DStructure-based%2520library%2520design%2520and%2520fragment%2520screening%2520for%2520the%2520identification%2520of%2520reversible%2520complement%2520factor%2520D%2520protease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1946%26epage%3D1958%26doi%3D10.1021%2Facs.jmedchem.6b01684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and design of first benzylamine-based ligands binding to an unlocked conformation of the complement factor D</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00104</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00104" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1Cjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=490-495&author=A.+Vulpettiauthor=N.+Ostermannauthor=S.+Randlauthor=T.+Yoonauthor=A.+Mac+Sweeneyauthor=F.+Cuminauthor=E.+Lorthioisauthor=S.+R%C3%BCdisserauthor=P.+Erbelauthor=J.+Maibaum&title=Discovery+and+design+of+first+benzylamine-based+ligands+binding+to+an+unlocked+conformation+of+the+complement+factor+D&doi=10.1021%2Facsmedchemlett.8b00104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D</span></div><div class="casAuthors">Vulpetti, Anna; Ostermann, Nils; Randl, Stefan; Yoon, Taeyoung; MacSweeney, Aengus; Cumin, Frederic; Lorthiois, Edwige; Rudisser, Simon; Erbel, Paul; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">490-495</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Complement Factor D, a serine protease of the S1 family and key component of the alternative pathway amplification loop, represents a promising target for the treatment of several prevalent and rare diseases linked to the innate immune system.  Previously reported FD inhibitors have been shown to bind to the FD active site in its self-inhibited conformation characterized by the presence of a salt bridge at the bottom of the S1 pocket between Asp189 and Arg218.  We report herein a new set of small-mol. FD ligands that harbor a basic S1 binding moiety directly binding to the carboxylate of Asp189, thereby displacing the Asp189-Arg218 ionic interaction and significantly changing the conformation of the self-inhibitory loop.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRdpNj9LCQYrVg90H21EOLACvtfcHk0libGGiQZxY1kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1Cjs74%253D&md5=c24dccac197253f882e3a38a86a597ed</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00104%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DT.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520design%2520of%2520first%2520benzylamine-based%2520ligands%2520binding%2520to%2520an%2520unlocked%2520conformation%2520of%2520the%2520complement%2520factor%2520D%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D490%26epage%3D495%26doi%3D10.1021%2Facsmedchemlett.8b00104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, S. V.</span></span> <span> </span><span class="NLM_article-title">Complement factor D, a novel serine protease</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1002/pro.5560050401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1002%2Fpro.5560050401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=8845746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADyaK28XitFShu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1996&pages=553-564&author=J.+E.+Volanakisauthor=S.+V.+Narayana&title=Complement+factor+D%2C+a+novel+serine+protease&doi=10.1002%2Fpro.5560050401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Complement factor D, a novel serine protease</span></div><div class="casAuthors">Volanakis, John E.; Narayana, Sthanam V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-64</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review with many refs.  Factor D is unique among serine proteases in that it requires neither enzymic cleavage for expression of proteolytic activity nor inactivation by a serpin for its control.  Regulation of factor D activity is instead attained by a novel mechanism that depends on reversible conformational changes for expression and control of catalytic activity.  These conformational changes are believed to be induced by the single natural substrate, C3bB, and to result in realignment of the catalytic triad, the specificity pocket, and the nonspecific substrate binding site, all of which have atypical conformations.  Mutational studies have defined structural determinants responsible for these unique structural features of factor D and for the resultant low reactivity with synthetic esters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR-WO4fTyq7LVg90H21EOLACvtfcHk0libGGiQZxY1kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitFShu7g%253D&md5=d55e7afa5c827b02023dd94994690eaa</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560050401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560050401%26sid%3Dliteratum%253Aachs%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26aulast%3DNarayana%26aufirst%3DS.%2BV.%26atitle%3DComplement%2520factor%2520D%252C%2520a%2520novel%2520serine%2520protease%26jtitle%3DProtein%2520Sci.%26date%3D1996%26volume%3D5%26spage%3D553%26epage%3D564%26doi%3D10.1002%2Fpro.5560050401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Design of small-molecule active-site inhibitors of the S1A family proteases as procoagulant and anticoagulant drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3799</span>– <span class="NLM_lpage">3822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00772</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00772" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3799-3822&author=P.+M.+Fischer&title=Design+of+small-molecule+active-site+inhibitors+of+the+S1A+family+proteases+as+procoagulant+and+anticoagulant+drugs&doi=10.1021%2Facs.jmedchem.7b00772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs</span></div><div class="casAuthors">Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3799-3822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Vitamin K antagonists (VKA) have long been the default drugs for anticoagulant management in venous thrombosis.  While efficacious, they are difficult to use due to interpatient dose-response variability and the risks of bleeding.  The approval of fondaparinux, a heparin-derived factor Xa (fXa) inhibitor, provided validation for the development of direct oral anticoagulants (DOAC), and currently such inhibitors of thrombin and fXa are in clin. use.  These agents can be used without regular coagulation monitoring, but the inherent risk of bleeding complications assocd. with blocking the common coagulation pathway remains.  Efforts are now underway to develop DOACs that inhibit components of the intrinsic and extrinsic coagulation cascades upstream of thrombin and fX.  Evidence from humans and from transgenic animal models suggests that this strategy may provide a better therapeutic margin between antithrombotic and antihemostatic effects.  Here the design of active-site inhibitors of S1A proteases involved in coagulation and fibrinolysis is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWkNuyZdaKyrVg90H21EOLACvtfcHk0liuM3FnPQmiJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7bF&md5=9f213939b2bd2ef1a2d3c779096b5981</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00772%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDesign%2520of%2520small-molecule%2520active-site%2520inhibitors%2520of%2520the%2520S1A%2520family%2520proteases%2520as%2520procoagulant%2520and%2520anticoagulant%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3799%26epage%3D3822%26doi%3D10.1021%2Facs.jmedchem.7b00772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallheer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corte, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamurthy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1635</span>– <span class="NLM_lpage">1642</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2015.01.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=25728130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1635-1642&author=D.+J.+Pintoauthor=J.+M.+Smallheerauthor=J.+R.+Corteauthor=E.+J.+Austinauthor=C.+Wangauthor=T.+Fangauthor=L.+M.+Smithauthor=K.+A.+Rossiauthor=A.+R.+Rendinaauthor=J.+M.+Bozarthauthor=G.+Zhangauthor=A.+Weiauthor=V.+Ramamurthyauthor=S.+Sheriffauthor=J.+E.+Myersauthor=P.+E.+Morinauthor=J.+M.+Luettgenauthor=D.+A.+Seiffertauthor=M.+L.+Quanauthor=R.+R.+Wexler&title=Structure-based+design+of+inhibitors+of+coagulation+factor+XIa+with+novel+P1+moieties&doi=10.1016%2Fj.bmcl.2015.01.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties</span></div><div class="casAuthors">Pinto, Donald J. P.; Smallheer, Joanne M.; Corte, James R.; Austin, Erin J. D.; Wang, Cailan; Fang, Tianan; Smith, Leon M.; Rossi, Karen A.; Rendina, Alan R.; Bozarth, Jeffrey M.; Zhang, Ge; Wei, Anzhi; Ramamurthy, Vidhyashankar; Sheriff, Steven; Myers, Joseph E.; Morin, Paul E.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Quan, Mimi L.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1635-1642</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. 2 was previously identified as a potent inhibitor of factor XIa lacking oral bioavailability.  A structure-based approach was used to design analogs of 2 with novel P1 moieties with good selectivity profiles and oral bioavailability.  Further optimization of the P1 group led to the identification of a 4-chlorophenyltetrazole P1 analog, which when combined with further modifications to the linker and P2' group provided compd. 32 with FXIa Ki = 6.7 nM and modest oral exposure in dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTasnhdatPMrVg90H21EOLACvtfcHk0liuM3FnPQmiJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7g%253D&md5=c1d175da55f89b425610bcb2a1d0caa2</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DSmallheer%26aufirst%3DJ.%2BM.%26aulast%3DCorte%26aufirst%3DJ.%2BR.%26aulast%3DAustin%26aufirst%3DE.%2BJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DBozarth%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DRamamurthy%26aufirst%3DV.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DStructure-based%2520design%2520of%2520inhibitors%2520of%2520coagulation%2520factor%2520XIa%2520with%2520novel%2520P1%2520moieties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1635%26epage%3D1642%26doi%3D10.1016%2Fj.bmcl.2015.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleha, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (Razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1021/jm0497949</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0497949" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1729-1744&author=M.+L.+Quanauthor=P.+Y.+S.+Lamauthor=Q.+Hanauthor=D.+J.+P.+Pintoauthor=M.+Y.+Heauthor=R.+Liauthor=C.+D.+Ellisauthor=C.+G.+Clarkauthor=C.+A.+Telehaauthor=J.+H.+Sunauthor=R.+S.+Alexanderauthor=S.+Baiauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=P.+C.+Wongauthor=R.+R.+Wexler&title=Discovery+of+1-%283%E2%80%B2-aminobenzisoxazol-5%E2%80%B2-yl%29-3-trifluoromethyl-N-%5B2-fluoro-4-%5B%282%E2%80%B2-dimethylaminomethyl%29imidazol-1-yl%5Dphenyl%5D-1H-pyrazole-5-carboxyamide+hydrochloride+%28Razaxaban%29%2C+a+highly+potent%2C+selective%2C+and+orally+bioavailable+factor+Xa+inhibitor&doi=10.1021%2Fjm0497949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</span></div><div class="casAuthors">Quan, Mimi L.; Lam, Patrick Y. S.; Han, Qi; Pinto, Donald J. P.; He, Ming Y.; Li, Renhua; Ellis, Christopher D.; Clark, Charles G.; Teleha, Christopher A.; Sun, Jung-Hui; Alexander, Richard S.; Bai, Steve; Luettgen, Joseph M.; Knabb, Robert M.; Wong, Pancras C.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1729-1744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compds. with improved selectivity for factor Xa relative to trypsin and plasma kallikrein.  Further optimization of the P4 moiety led to compds. with enhanced permeability and reduced protein binding.  The SAR and pharmacokinetic profile of this series of compds. is described.  These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide (I), a potent, selective, and orally bioavailable inhibitor of factor Xa.  On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compd. was selected for clin. development as razaxaban (DPC 906, BMS-561389).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSs9m3fldmGbVg90H21EOLACvtfcHk0liuM3FnPQmiJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D&md5=c16a8d1ca98191a873f2e53cb0c5678c</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Fjm0497949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0497949%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DHe%26aufirst%3DM.%2BY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DC.%2BD.%26aulast%3DClark%26aufirst%3DC.%2BG.%26aulast%3DTeleha%26aufirst%3DC.%2BA.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DDiscovery%2520of%25201-%25283%25E2%2580%25B2-aminobenzisoxazol-5%25E2%2580%25B2-yl%2529-3-trifluoromethyl-N-%255B2-fluoro-4-%255B%25282%25E2%2580%25B2-dimethylaminomethyl%2529imidazol-1-yl%255Dphenyl%255D-1H-pyrazole-5-carboxyamide%2520hydrochloride%2520%2528Razaxaban%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520factor%2520Xa%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1729%26epage%3D1744%26doi%3D10.1021%2Fjm0497949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elrod, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirtley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span> <span> </span><span class="NLM_article-title">Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(01)00084-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS1074-5521%2801%2900084-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=11731301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1KmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=1107-1121&author=B.+A.+Katzauthor=P.+A.+Sprengelerauthor=C.+Luongauthor=E.+Vernerauthor=K.+Elrodauthor=M.+Kirtleyauthor=J.+Jancauthor=J.+R.+Spencerauthor=J.+G.+Breitenbucherauthor=H.+Huiauthor=D.+McGeeauthor=D.+Allenauthor=A.+Martelliauthor=R.+L.+Mackman&title=Engineering+inhibitors+highly+selective+for+the+S1+sites+of+Ser190+trypsin-like+serine+protease+drug+targets&doi=10.1016%2FS1074-5521%2801%2900084-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets</span></div><div class="casAuthors">Katz, Bradley A.; Sprengeler, Paul A.; Luong, Christine; Verner, Erik; Elrod, Kyle; Kirtley, Matt; Janc, James; Spencer, Jeffrey R.; Breitenbucher, J. Guy; Hui, Hon; McGee, Danny; Allen, Darin; Martelli, Arnold; Mackman, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Background: Involved or implicated in a wide spectrum of diseases, trypsin-like serine proteases comprise well studied drug targets and anti-targets that can be subdivided into two major classes.  In one class there is a serine at position 190 at the S1 site, as in urokinase type plasminogen activator (urokinase or uPA) and factor VIIa, and in the other there is an alanine at 190, as in tissue type plasminogen activator (tPA) and factor Xa.  A hydrogen bond unique to Ser190 protease-arylamidine complexes between OγSer190 and the inhibitor amidine confers an intrinsic preference for such inhibitors toward Ser190 proteases over Ala190 counterparts.  Results: Based on the structural differences between the S1 sites of Ser190 and Ala190 protease-arylamidine complexes, we amplified the selectivity of amidine inhibitors toward uPA and against tPA, by factors as high as 220-fold, by incorporating a halo group ortho to the amidine of a lead inhibitor scaffold.  Comparison of Ki values of such halo-substituted and parent inhibitors toward a panel of Ser190 and Ala190 proteases demonstrates pronounced selectivity of the halo analogs for Ser190 proteases over Ala190 counterparts.  Crystal structures of Ser190 proteases, uPA and trypsin, and of an Ala190 counterpart, thrombin, bound by a set of ortho (halo, amidino) aryl inhibitors and of non-halo parents reveal the structural basis of the exquisite selectivity and validate the design principle.  Conclusions: Remarkable selectivity enhancements of exceptionally small inhibitors are achieved toward the uPA target over the highly similar tPA anti-target through a single atom substitution on an otherwise relatively non-selective scaffold.  Overall selectivities for uPA over tPA as high as 980-fold at physiol. pH were realized.  The increase in selectivity results from the displacement of a single bound water mol. common to the S1 site of both the uPA target and the tPA anti-target because of the ensuing deficit in hydrogen bonding of the arylamidine inhibitor when bound in the Ala190 protease anti-target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjSa9M4EVJVrVg90H21EOLACvtfcHk0lgJ5bPY5qh6NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1KmtLc%253D&md5=2c9f68fc584ac016ca320d0cfdf51027</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2801%2900084-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252801%252900084-9%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DElrod%26aufirst%3DK.%26aulast%3DKirtley%26aufirst%3DM.%26aulast%3DJanc%26aufirst%3DJ.%26aulast%3DSpencer%26aufirst%3DJ.%2BR.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DMcGee%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DD.%26aulast%3DMartelli%26aufirst%3DA.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26atitle%3DEngineering%2520inhibitors%2520highly%2520selective%2520for%2520the%2520S1%2520sites%2520of%2520Ser190%2520trypsin-like%2520serine%2520protease%2520drug%2520targets%26jtitle%3DChem.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D1107%26epage%3D1121%26doi%3D10.1016%2FS1074-5521%2801%2900084-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3063</span>– <span class="NLM_lpage">3068</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(04)00530-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS0960-894X%2804%2900530-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15149645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktVektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3063-3068&author=M.+D.+Wendtauthor=A.+Geyerauthor=W.+J.+McClellanauthor=T.+W.+Rockwayauthor=M.+Weitzbergauthor=X.+Zhaoauthor=R.+Manteiauthor=K.+Stewartauthor=V.+Nienaberauthor=V.+Klinghoferauthor=V.+L.+Giranda&title=Interaction+with+the+S1+beta-pocket+of+urokinase%3A+8-heterocycle+substituted+and+6%2C8-disubstituted+2-naphthamidine+urokinase+inhibitors&doi=10.1016%2FS0960-894X%2804%2900530-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction with the S1β-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors</span></div><div class="casAuthors">Wendt, Michael D.; Geyer, Andrew; McClellan, William J.; Rockway, Todd W.; Weitzberg, Moshe; Zhao, Xumiao; Mantei, Robert; Stewart, Kent; Nienaber, Vicki; Klinghofer, Vered; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3063-3068</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Several 8-substituted 2-naphthamidine-based inhibitors of the serine protease urokinase plasminogen activator (uPA) are described.  Direct attachment of five-membered satd. or unsatd. rings improved inhibitor performance; substitution with sulfones further improved binding profiles.  Combination of these substituents or of previously described NH-linked heteroarom. rings with 6-Ph amide substituents provided further enhancements to potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOGuP9062FOrVg90H21EOLACvtfcHk0lgJ5bPY5qh6NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktVektb4%253D&md5=d680f577a48c809e875d5fe46cabbb8e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2804%2900530-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252804%252900530-X%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DInteraction%2520with%2520the%2520S1%2520beta-pocket%2520of%2520urokinase%253A%25208-heterocycle%2520substituted%2520and%25206%252C8-disubstituted%25202-naphthamidine%2520urokinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D3063%26epage%3D3068%26doi%3D10.1016%2FS0960-894X%2804%2900530-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span> <span> </span><span class="NLM_article-title">Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3856</span>– <span class="NLM_lpage">3871</span>, <span class="refDoi"> DOI: 10.1021/jm010244+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010244%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlWrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3856-3871&author=R.+L.+Mackmanauthor=B.+A.+Katzauthor=J.+G.+Breitenbucherauthor=H.+C.+Huiauthor=E.+Vernerauthor=C.+Luongauthor=L.+Liuauthor=P.+A.+Sprengeler&title=Exploiting+subsite+S1+of+trypsin-like+serine+proteases+for+selectivity%3A+potent+and+selective+inhibitors+of+urokinase-type+plasminogen+activator&doi=10.1021%2Fjm010244%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting Subsite S1 of Trypsin-Like Serine Proteases for Selectivity: Potent and Selective Inhibitors of Urokinase-Type Plasminogen Activator</span></div><div class="casAuthors">Mackman, Richard L.; Katz, Bradley A.; Breitenbucher, J. Guy; Hui, Hon C.; Verner, Erik; Luong, Christine; Liu, Liang; Sprengeler, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3856-3871</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A nonselective inhibitor of trypsin-like serine proteases, 2-(2-hydroxybiphenyl-3-yl)-1H-indole-5-carboxamidine (I) (Verner, E.; Katz, B. A.; Spencer, J.; Allen, D.; Hataye, J.; Hruzewicz, W.; Hui, H. C.; Kolesnikov, A.; Li, Y.; Luong, C.; Martelli, A.; Radika. K.; Rai, R.; She, M.; Shrader, W.; Sprengeler, P. A.; Trapp, S.; Wang, J.; Young, W. B.; Mackman, R. L. J. Med. Chem. 2001, 44, 2753-2771) has been optimized through minor structural changes on the S1 binding group to afford remarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA).  The trypsin-like serine proteases1 that comprise drug targets can be broadly categorized into two subfamilies, those with Ser190 and those with Ala190.  A single-atom modification, for example, replacement of hydrogen for chlorine at the 6-position of the 5-amidinoindole P1 group on I, generated ≤6700-fold selectivity toward the Ser190 enzymes and against the Ala190 enzymes.  The larger chlorine atom displaces a water mol. (H2O1S1) that binds near residue 190 in all the complexes of I, and related inhibitors, in uPA, thrombin, and trypsin.  The water mol., H2O1S1, in both the Ser190 or Ala190 enzymes, hydrogen bonds with the amidine N1 nitrogen of the inhibitor.  When it is displaced, a redn. in affinity toward the Ala190 enzymes is obsd. due to the amidine N1 nitrogen of the bound inhibitor being deprived of a key hydrogen-bonding partner.  In the Ser190 enzymes the affinity is maintained since the serine hydroxyl oxygen OγSer190 compensates for the displaced water mol.  High-resoln. crystallog. provided evidence for the displacement of the water mol. and validated the design rationale.  In summation, a novel and powerful method for engineering selectivity toward Ser190 proteases and against Ala190 proteases without substantially increasing mol. wt. is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxZsTVtV-cArVg90H21EOLACvtfcHk0lgJ5bPY5qh6NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlWrt7Y%253D&md5=d431091b463a9168c4e7223b7f96f460</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm010244%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010244%252B%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26atitle%3DExploiting%2520subsite%2520S1%2520of%2520trypsin-like%2520serine%2520proteases%2520for%2520selectivity%253A%2520potent%2520and%2520selective%2520inhibitors%2520of%2520urokinase-type%2520plasminogen%2520activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3856%26epage%3D3871%26doi%3D10.1021%2Fjm010244%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="note"><p class="first last">Our subsequent efforts to target the S2′ pocket will be reported in due course.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">For examples of S1 serine protease inhibitors with acid-like motif interacting in the oxyanion hole:</p></div><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Huis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willardsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapundalo, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiya-Cork, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witlow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">mcKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaiz, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">light, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span> <span> </span><span class="NLM_article-title">The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4752</span>– <span class="NLM_lpage">4756</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.07.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2005.07.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=16125385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVanu7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4752-4756&author=J.+T.+Kohrtauthor=K.+J.+Filipskiauthor=W.+L.+Codyauthor=C.+Caiauthor=D.+A.+Dudleyauthor=C.+A.+Van+Huisauthor=A.+Willardsenauthor=S.+T.+Rapundaloauthor=K.+Saiya-Corkauthor=R.+J.+Leadleyauthor=L.+Narasimhanauthor=E.+Zhangauthor=M.+Witlowauthor=M.+Adlerauthor=K.+McLeanauthor=Y.-L.+Chouauthor=C.+mcKnightauthor=D.+O.+Arnaizauthor=K.+J.+Shawauthor=D.+R.+lightauthor=J.+J.+Edmunds&title=The+discovery+of+fluoropyridine-based+inhibitors+of+the+factor+VIIa%2FTF+complex&doi=10.1016%2Fj.bmcl.2005.07.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex</span></div><div class="casAuthors">Kohrt, Jeffrey T.; Filipski, Kevin J.; Cody, Wayne L.; Cai, Cuiman; Dudley, Danette A.; Van Huis, Chad A.; Willardsen, J. Adam; Rapundalo, Stephen T.; Saiya-Cork, Kamlai; Leadley, Robert J.; Narasimhan, Lakshmi; Zhang, Erli; Whitlow, Marc; Adler, Marc; McLean, Kirk; Chou, Yuo-Ling; McKnight, Cecile; Arnaiz, Damian O.; Shaw, Kenneth J.; Light, David R.; Edmunds, Jeremy J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4752-4756</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The activated Factor VII/tissue factor complex (FVIIa/TF) plays a key role in the formation of blood clots.  Inhibition of this complex may lead to new antithrombotic drugs.  An X-ray crystal structure of a fluoropyridine-based FVIIa/TF inhibitor bound in the active site of the enzyme complex suggested that incorporation of substitution at the 5-position of the hydroxybenzoic acid side chain could lead to the formation of more potent inhibitors through interactions with the S1'/S2' pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPXXiEgbcYurVg90H21EOLACvtfcHk0liL6wtjfhVsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVanu7zM&md5=e50b3a1dfc4f93a22f1f970a13907e0a</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.07.059%26sid%3Dliteratum%253Aachs%26aulast%3DKohrt%26aufirst%3DJ.%2BT.%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DCody%26aufirst%3DW.%2BL.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DVan%2BHuis%26aufirst%3DC.%2BA.%26aulast%3DWillardsen%26aufirst%3DA.%26aulast%3DRapundalo%26aufirst%3DS.%2BT.%26aulast%3DSaiya-Cork%26aufirst%3DK.%26aulast%3DLeadley%26aufirst%3DR.%2BJ.%26aulast%3DNarasimhan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DWitlow%26aufirst%3DM.%26aulast%3DAdler%26aufirst%3DM.%26aulast%3DMcLean%26aufirst%3DK.%26aulast%3DChou%26aufirst%3DY.-L.%26aulast%3DmcKnight%26aufirst%3DC.%26aulast%3DArnaiz%26aufirst%3DD.%2BO.%26aulast%3DShaw%26aufirst%3DK.%2BJ.%26aulast%3Dlight%26aufirst%3DD.%2BR.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520discovery%2520of%2520fluoropyridine-based%2520inhibitors%2520of%2520the%2520factor%2520VIIa%252FTF%2520complex%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4752%26epage%3D4756%26doi%3D10.1016%2Fj.bmcl.2005.07.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">West, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaiz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualtieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukovich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltlow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span> <span> </span><span class="NLM_article-title">Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5712</span>– <span class="NLM_lpage">5715</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2009.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=19703768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFakur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5712-5715&author=C.+W.+Westauthor=M.+Adlerauthor=D.+Arnaizauthor=D.+Chenauthor=K.+Chuauthor=G.+Gualtieriauthor=E.+Hoauthor=C.+Huweauthor=D.+Lightauthor=G.+Phillipsauthor=R.+Pulkauthor=D.+Sukovichauthor=M.+Wiltlowauthor=S.+Yuanauthor=J.+Bryant&title=Identification+of+orally+bioavailable%2C+non-amidine+inhibitors+of+urokinase+plasminogen+activator+%28uPA%29&doi=10.1016%2Fj.bmcl.2009.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA)</span></div><div class="casAuthors">West, Christopher W.; Adler, Marc; Arnaiz, Danny; Chen, Deborah; Chu, Kieu; Gualtieri, Giovanna; Ho, Elena; Huwe, Christoph; Light, David; Phillips, Gary; Pulk, Rebecca; Sukovich, Drew; Whitlow, Marc; Yuan, Shendong; Bryant, Judi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5712-5715</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter the synthesis and evaluation of a series of non-amidine inhibitors of Urokinase Plasminogen Activator (uPA) are reported.  Starting from compd. I, a significant change provided compds. in which the amidine, binding in the S1 pocket, was replaced with a primary amine.  Further modifications led to the identification of potent, selective, and orally bioavailable uPA inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZYJuZGz1EJLVg90H21EOLACvtfcHk0liL6wtjfhVsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFakur3P&md5=ca3529dc06e384edeea54b6b62b25252</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DC.%2BW.%26aulast%3DAdler%26aufirst%3DM.%26aulast%3DArnaiz%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DK.%26aulast%3DGualtieri%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DE.%26aulast%3DHuwe%26aufirst%3DC.%26aulast%3DLight%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DSukovich%26aufirst%3DD.%26aulast%3DWiltlow%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DBryant%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520orally%2520bioavailable%252C%2520non-amidine%2520inhibitors%2520of%2520urokinase%2520plasminogen%2520activator%2520%2528uPA%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5712%26epage%3D5715%26doi%3D10.1016%2Fj.bmcl.2009.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almond, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Garavilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savvides, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1727</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/jm0700619</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0700619" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivF2isb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1727-1730&author=M.+N.+Grecoauthor=M.+J.+Hawkinsauthor=E.+T.+Powellauthor=H.+R.+Almondauthor=L.+de+Garavillaauthor=J.+Hallauthor=L.+K.+Minorauthor=Y.+P.+Wangauthor=T.+W.+Corcoranauthor=E.+Di+Ceraauthor=A.+M.+Cantwellauthor=S.+N.+Savvidesauthor=B.+P.+Damianoauthor=B.+E.+Maryanoff&title=Discovery+of+potent%2C+selective%2C+orally+active%2C+nonpeptide+inhibitors+of+human+mast+cell+chymase&doi=10.1021%2Fjm0700619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37cR"><div class="casContent"><span class="casTitleNuber">37c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Selective, Orally Active, Nonpeptide Inhibitors of Human Mast Cell Chymase</span></div><div class="casAuthors">Greco, Michael N.; Hawkins, Michael J.; Powell, Eugene T.; Almond, Harold R., Jr.; De Garavilla, Lawrence; Hall, Jeffrey; Minor, Lisa K.; Wang, Yuanping; Corcoran, Thomas W.; Di Cera, Enrico; Cantwell, Angelene M.; Savvides, Savvas N.; Damiano, Bruce P.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1727-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of β-carboxamido-phosphon(in)ic acids, e.g., I, II, and III, was identified as a new structural motif for obtaining potent inhibitors of human mast cell chymase.  For example, 1-naphthyl deriv. I had an IC50 value of 29 nM and (E)-styryl deriv. II had an IC50 value of 3.5 nM.  An X-ray structure for I·chymase revealed key interactions within the enzyme active site.  I was selective for inhibiting chymase vs. eight serine proteases.  III was orally bioavailable in rats (F = 39%), and orally efficacious in a hamster model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcqGFCHhLjK7Vg90H21EOLACvtfcHk0liL6wtjfhVsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivF2isb0%253D&md5=f81cddf73934642d0ffad18cfe389c39</span></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=10.1021%2Fjm0700619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0700619%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DM.%2BN.%26aulast%3DHawkins%26aufirst%3DM.%2BJ.%26aulast%3DPowell%26aufirst%3DE.%2BT.%26aulast%3DAlmond%26aufirst%3DH.%2BR.%26aulast%3Dde%2BGaravilla%26aufirst%3DL.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DMinor%26aufirst%3DL.%2BK.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DCorcoran%26aufirst%3DT.%2BW.%26aulast%3DDi%2BCera%26aufirst%3DE.%26aulast%3DCantwell%26aufirst%3DA.%2BM.%26aulast%3DSavvides%26aufirst%3DS.%2BN.%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520orally%2520active%252C%2520nonpeptide%2520inhibitors%2520of%2520human%2520mast%2520cell%2520chymase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1727%26epage%3D1730%26doi%3D10.1021%2Fjm0700619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decock, A.</span>; <span class="NLM_string-name">Renatus, M.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Decock%2C+A.%3B+Renatus%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDecock%26aufirst%3DA." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span>The
assignment of the (S)-configured
absolute stereochemistry was not entirely unambiguous.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The%0Aassignment+of+the+%28S%29-configured%0Aabsolute+stereochemistry+was+not+entirely+unambiguous."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi-Sledeski, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minnich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sides, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, R. J.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and profiling of a β-tryptase inhibitor with a spiro-piperidineamide scaffold, benzylamnine P1 group, and a substituted indole P4 group</span>. <i>Med. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">794</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1039/c1md00104c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1039%2Fc1md00104c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=794-798&author=G.+Liangauthor=Y.+M.+Choi-Sledeskiauthor=G.+B.+Poliauthor=X.+Chenauthor=A.+Minnichauthor=Q.+Wangauthor=J.+Tsayauthor=K.+Sidesauthor=R.+J.+Vaz&title=Structure-based+design%2C+synthesis+and+profiling+of+a+%CE%B2-tryptase+inhibitor+with+a+spiro-piperidineamide+scaffold%2C+benzylamnine+P1+group%2C+and+a+substituted+indole+P4+group&doi=10.1039%2Fc1md00104c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1039%2Fc1md00104c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00104c%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DChoi-Sledeski%26aufirst%3DY.%2BM.%26aulast%3DPoli%26aufirst%3DG.%2BB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMinnich%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DTsay%26aufirst%3DJ.%26aulast%3DSides%26aufirst%3DK.%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520profiling%2520of%2520a%2520%25CE%25B2-tryptase%2520inhibitor%2520with%2520a%2520spiro-piperidineamide%2520scaffold%252C%2520benzylamnine%2520P1%2520group%252C%2520and%2520a%2520substituted%2520indole%2520P4%2520group%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D794%26epage%3D798%26doi%3D10.1039%2Fc1md00104c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espina, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.-S.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of benzylamine to reactive intermediates in rodents: formation of glutathione, glutamate, and peptide conjugates</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.1021/tx020063q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx020063q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt1Skur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=1190-1207&author=A.+E.+Mutlibauthor=P.+Dickensonauthor=S.-Y.+Chenauthor=R.+J.+Espinaauthor=J.+S.+Danielsauthor=L.-S.+Gan&title=Bioactivation+of+benzylamine+to+reactive+intermediates+in+rodents%3A+formation+of+glutathione%2C+glutamate%2C+and+peptide+conjugates&doi=10.1021%2Ftx020063q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of Benzylamine to Reactive Intermediates in Rodents: Formation of Glutathione, Glutamate, and Peptide Conjugates</span></div><div class="casAuthors">Mutlib, Abdul E.; Dickenson, Patricia; Chen, Shiang-Yuan; Espina, Robert J.; Daniels, J. Scott; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1190-1207</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vivo and in vitro disposition of benzylamine was investigated in rats.  Benzylamine was metabolized to only a small extent by rat liver subcellular fractions.  In contrast, it was extensively metabolized in vivo in rats.  In vivo studies performed with stable isotope-labeled benzylamine enabled rapid mass spectrometric identification of metabolites present in rat bile and urine.  The major metabolite of benzylamine was the hippuric acid formed by glycine conjugation of benzoic acid. LC/MS anal. of bile and urine obtained from rats dosed with 1:1 equimolar mixt. of either d0:d7- or d0:d2-benzylamine showed the presence of several glutathione adducts in addn. to the hippuric acid metabolite.  The presence of various glutathione adducts indicated that benzylamine was metabolized to a no. of reactive intermediates.  Various metabolic pathways, including those independent of P 450, were found to produce these intermediates.  A previously undocumented pathway included the formation of a new carbon-nitrogen bond that led to a potentially reactive intermediate, Ar-CH2-NH(CO)-X, capable of interacting with various nucleophiles.  The origin of this reactive intermediate is postulated to occur via the formation of either a formamide or carbamic acid metabolites.  Metabolites which were produced by the reaction of this intermediate, Ar-CH2-NH(CO)-X with nucleophiles included S-[benzylcarbamoyl]glutathione, N-acetyl-S-[benzylcarbamoyl]cysteine, S-[benzylcarbamoyl]cysteinylglycine, S-[benzylcarbamoyl]cysteinylglutamate, N-[benzylcarbamoyl]glutamate, and an oxidized glutathione adduct.  Bioactivation of amines via this pathway has not been previously described.  The oxidative deamination of benzylamine yielding the benzaldehyde was demonstrated to be a precursor to the hippuric acid metabolite and S-benzyl-L-glutathione.  The formation of the S-benzyl-L-glutathione conjugate showed that a net displacement of amine from benzylamine had taken place with a subsequent addn. of glutathione at the benzylic position.  In addn. to these novel pathways, a no. of other glutathione-derived adducts formed as a result of epoxide formation was characterized.  It was demonstrated that benzylamine was converted by rat P 450 2A1 and 2E1 to benzamide that was rapidly metabolized to an epoxide.  Mechanisms are proposed for the formation of various GSH adducts of benzylamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVVaqbZJzp9LVg90H21EOLACvtfcHk0lhFiyqADLNYeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt1Skur0%253D&md5=338150cc6889accab3cf580cc76b8e9a</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1021%2Ftx020063q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx020063q%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDickenson%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DS.-Y.%26aulast%3DEspina%26aufirst%3DR.%2BJ.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DBioactivation%2520of%2520benzylamine%2520to%2520reactive%2520intermediates%2520in%2520rodents%253A%2520formation%2520of%2520glutathione%252C%2520glutamate%252C%2520and%2520peptide%2520conjugates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D1190%26epage%3D1207%26doi%3D10.1021%2Ftx020063q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espina, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shockcor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.-S.</span></span> <span> </span><span class="NLM_article-title">P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogues to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1021/tx0101189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0101189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVWitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=63-75&author=A.+E.+Mutlibauthor=S.-Y.+Chenauthor=R.+J.+Espinaauthor=J.+Shockcorauthor=S.+R.+Prakashauthor=L.-S.+Gan&title=P450-mediated+metabolism+of+1-%5B3-%28aminomethyl%29phenyl%5D-N-%5B3-fluoro-2%E2%80%B2-%28methylsulfonyl%29-%5B1%2C1%E2%80%B2-biphenyl%5D-4-yl%5D-3-%28trifluoromethyl%29-1H-pyrazole-+5-carboxamide+%28DPC+423%29+and+its+analogues+to+aldoximes.+Characterization+of+glutathione+conjugates+of+postulated+intermediates+derived+from+aldoximes&doi=10.1021%2Ftx0101189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)- [1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogs to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes</span></div><div class="casAuthors">Mutlib, Abdul E.; Chen, Shiang-Yuan; Espina, Robert J.; Shockcor, John; Prakash, Shimoga R.; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-75</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vivo and in vitro disposition of DPC 423, a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa, has recently been described.  Several metabolites, some of which were considered potentially reactive, were identified in rats.  A novel GSH adduct, the structure of which was not detd. conclusively, was isolated from bile of rats dosed with DPC 423.  Herein, we describe the complete structural elucidation of this unique GSH conjugate employing LC/MS and high-field NMR.  Similar GSH adducts of DPC 602, [13CD2]DPC 602, and SX 737, all structural analogs of DPC 423, were isolated, characterized spectroscopically, and shown to have identical mass fragmentation pathways.  The structures of these conjugates were initially suspected to be either an amide with N-S bond or a nitrogen-oxygen juxtaposed amide with a C-S bond.  Studies conducted with [13CD2]DPC 602 indicated an aldoxime structure.  The concluding evidence came from HMBC NMR spectrum of the conjugate, which showed strong correlation of the cysteine methylene protons with the imino carbon.  Further spectroscopic studies with chem. prepd. GSH adduct from benzaldehyde oxime confirmed this pattern of correlation.  In vivo and in vitro studies with the synthetic oxime intermediate from DPC 423 showed an adduct identical to the one isolated from the bile of rats dosed with DPC 423.  This supported the intermediacy of an aldoxime as a precursor to the GSH adducts.  It is postulated that the benzylamine moiety of DPC 423 (and its analogs) is oxidized to a hydroxylamine, which is subsequently converted to a nitroso intermediate.  Subsequent rearrangement of the nitroso leads to an aldoxime which in turn is metabolized by P 450 to a reactive intermediate.  The formation of oxime from DPC 423 (and its analogs) was found to be mediated by rat CYP 3A1/2, which were also responsible for converting the oxime to the GSH trappable reactive intermediate.  It is postulated that the aldoxime produces a radical or a nitrile oxide intermediate that reacts with GSH and hence produces this unusual GSH adduct.  On the basis of synthetic analogy, it is more likely that the nitrile oxide resulting from two-electron oxidn. of the aldoxime is the reactive intermediate.  Intramol. kinetic isotope effects were studied with [13CD2]DPC 602 to assess the importance of the metabolic cleavage of the aminomethyl carbon-hydrogen bond in forming this GSH adduct.  The lack of isotope effect in forming the aldoxime from [13CD2]DPC 602 suggests its formation does not occur through the imine intermediate.  Instead the data supports the postulated mechanism of hydroxylamine and nitroso intermediates as precursors to the aldoxime.  However, the formation of the GSH adduct from [13CD2]DPC 602 did show a significant intramol. kinetic isotope effect (kH/kD = 2.3) since a carbon-deuterium bond had to be broken on the aldoxime prior to the formation of the adduct.  A stable nitrile oxide derived from DPC 602 was postulated as the reactive intermediate responsible for forming this unique GSH adduct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosaKWZWKi61rVg90H21EOLACvtfcHk0lhFiyqADLNYeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVWitLg%253D&md5=dc073373f899d4189bfafba24e4fea8e</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1021%2Ftx0101189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0101189%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DChen%26aufirst%3DS.-Y.%26aulast%3DEspina%26aufirst%3DR.%2BJ.%26aulast%3DShockcor%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DS.%2BR.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DP450-mediated%2520metabolism%2520of%25201-%255B3-%2528aminomethyl%2529phenyl%255D-N-%255B3-fluoro-2%25E2%2580%25B2-%2528methylsulfonyl%2529-%255B1%252C1%25E2%2580%25B2-biphenyl%255D-4-yl%255D-3-%2528trifluoromethyl%2529-1H-pyrazole-%25205-carboxamide%2520%2528DPC%2520423%2529%2520and%2520its%2520analogues%2520to%2520aldoximes.%2520Characterization%2520of%2520glutathione%2520conjugates%2520of%2520postulated%2520intermediates%2520derived%2520from%2520aldoximes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D63%26epage%3D75%26doi%3D10.1021%2Ftx0101189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, D.</span>; <span class="NLM_string-name">Flohr, S.</span>; <span class="NLM_string-name">Gelin, C. F.</span>; <span class="NLM_string-name">Jendza, K.</span>; <span class="NLM_string-name">Ji, N.</span>; <span class="NLM_string-name">Karki, R. G.</span>; <span class="NLM_string-name">Liu, D.</span>; <span class="NLM_string-name">Lorthiois, E.</span>; <span class="NLM_string-name">Mainolfi, N.</span>; <span class="NLM_string-name">Powers, J. J.</span>; <span class="NLM_string-name">Vulpetti, A.</span></span> <span> </span><span class="NLM_article-title">Amidomethyl-biaryl Derivatives Complement Factor D Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO2016/088082</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Belanger&author=S.+Flohr&author=C.+F.+Gelin&author=K.+Jendza&author=N.+Ji&author=R.+G.+Karki&author=D.+Liu&author=E.+Lorthiois&author=N.+Mainolfi&author=J.+J.+Powers&author=A.+Vulpetti&title=Amidomethyl-biaryl+Derivatives+Complement+Factor+D+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBelanger%26aufirst%3DD.%26atitle%3DAmidomethyl-biaryl%2520Derivatives%2520Complement%2520Factor%2520D%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="note"><p class="first last">The enantiomer of <b>6</b> with (<i>R</i>)-2,3-dihydrobenzofuranyl-3-amine P1 moiety was found significantly less potent with an IC<sub>50</sub> of 1.90 μM against FXIa.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span>Of note, for the
assessment of
FXIa inhibition in human plasma we chose to use only the catalytic
domain of FXIa to prevent FXIa activation of endogenous substrates
present in the plasma (e.g FIX) which could lead to unintended activation
of the fluorescent peptide substrates used in the assay. Based on
crystallographic data of the delineated inhibitors in this manuscript
we do not expect substantial differences in potency would arise due
to differences between full length and catalytic domain variants.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Of+note%2C+for+the%0Aassessment+of%0AFXIa+inhibition+in+human+plasma+we+chose+to+use+only+the+catalytic%0Adomain+of+FXIa+to+prevent+FXIa+activation+of+endogenous+substrates%0Apresent+in+the+plasma+%28e.g+FIX%29+which+could+lead+to+unintended+activation%0Aof+the+fluorescent+peptide+substrates+used+in+the+assay.+Based+on%0Acrystallographic+data+of+the+delineated+inhibitors+in+this+manuscript%0Awe+do+not+expect+substantial+differences+in+potency+would+arise+due%0Ato+differences+between+full+length+and+catalytic+domain+variants."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veloso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shilling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitch, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colman, R. W.</span></span> <span> </span><span class="NLM_article-title">Recent evolutionary divergence of plasma prekallikrein and factor XI</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/0049-3848(86)90056-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2F0049-3848%2886%2990056-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=3638032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADyaL28XltFWjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1986&pages=153-160&author=D.+Velosoauthor=J.+Shillingauthor=J.+Shineauthor=W.+M.+Fitchauthor=R.+W.+Colman&title=Recent+evolutionary+divergence+of+plasma+prekallikrein+and+factor+XI&doi=10.1016%2F0049-3848%2886%2990056-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Recent evolutionary divergence of plasma prekallikrein and factor XI</span></div><div class="casAuthors">Veloso, D.; Shilling, J.; Shine, J.; Fitch, W. M.; Colman, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-60</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    </div><div class="casAbstract">The evolution in mammals of the zymogens of the contact activation system of coagulation (prekallikrein and blood-coagulation factors XI and XII) was investigated.  The N-terminal sequences of human blood plasma prekallikrein and the heavy and light chain of kallikrein were detd. and compared with those of bovine prekallikrein and of human and bovine factors XI and XII.  The human and bovine N-terminal sequences of the light chains (catalytic polypeptide) showed striking similarities both among themselves and with those of the catalytic polypeptide chains of other coagulation and digestive proteases, indicating a common origin.  Comparison of the N-terminal sequences of human prekallikrein with those of the bovine prekallikrein and human and bovine factors XIa and XIIa indicated a common origin of the heavy chain of kallikrein and factor XIa, different from that of either factor XIIa or other known amino acid sequences.  Ancestral sequences for human and bovine prekallikrein and factor XI, deduced by genetic anal. of the min. no. of base changes indicated that the N-terminus of prekallikrein and factor XI evolved at about the same rate.  The estd. time for the gene duplication was ∼124 million years ago, a value consistent with the age of the mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokCak9CrFNw7Vg90H21EOLACvtfcHk0livEM7FA0Q-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XltFWjsL0%253D&md5=a2efc5a4cdbeec168a18339af8a1a2b1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2F0049-3848%2886%2990056-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0049-3848%252886%252990056-3%26sid%3Dliteratum%253Aachs%26aulast%3DVeloso%26aufirst%3DD.%26aulast%3DShilling%26aufirst%3DJ.%26aulast%3DShine%26aufirst%3DJ.%26aulast%3DFitch%26aufirst%3DW.%2BM.%26aulast%3DColman%26aufirst%3DR.%2BW.%26atitle%3DRecent%2520evolutionary%2520divergence%2520of%2520plasma%2520prekallikrein%2520and%2520factor%2520XI%26jtitle%3DThromb.%2520Res.%26date%3D1986%26volume%3D43%26spage%3D153%26epage%3D160%26doi%3D10.1016%2F0049-3848%2886%2990056-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girolami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarparo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candeo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, A. M.</span></span> <span> </span><span class="NLM_article-title">Congenital prekallikrein deficiency</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">695</span>, <span class="refDoi"> DOI: 10.1586/ehm.10.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1586%2Fehm.10.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=21091145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGktr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=685-695&author=A.+Girolamiauthor=P.+Scarparoauthor=N.+Candeoauthor=A.+M.+Lombardi&title=Congenital+prekallikrein+deficiency&doi=10.1586%2Fehm.10.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Congenital prekallikrein deficiency</span></div><div class="casAuthors">Girolami, Antonio; Scarparo, Pamela; Candeo, Nicole; Lombardi, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-695</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4086</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The congenital deficiency of prekallikrein (PK) is a rare condition in which there is a peculiar discrepancy between a severe in vitro defect and absence of bleeding.  The gene controlling PK synthesis is located on chromosome 4 and consists of 14 exons and 15 introns.  Only approx. 80 cases of PK deficiency have been described in the literature.  Owing to the lack of bleeding, most cases go undetected or, if detected, go unreported.  Occasional bleeding or thrombosis have been reported in a few patients but this was only due to the presence of assocd. risk factors.  It is certain that the defect does not protect from thrombosis.  Diagnosis is based on the presence of a great prolongation of partial thromboplastin time and normal prothrombin time and thrombin time.  The long partial thromboplastin time is fully cor. by the addn. of normal plasma or normal serum and presents the unusual feature of shortening on long incubation times.  Platelet and vascular tests are normal.  Immunol. studies allow differentiation into two types, namely cases of true deficiency, which are approx. 70% of the total, and cases with abnormal forms.  PK is a glycoprotein synthesized in the liver as a single-chain peptide of 88000 Da.  It mostly circulates (∼75%) as a complex with high-mol.-wt. kininogen.  It is cleaved by FXIIa into a heavy chain and a light chain (catalytic domain), held together by disulfide bonds.  Mol. biol. techniques have so far only been applied to eleven families, and these studies do not yet allow definite phenotype/genotype conclusions.  The exons involved are 5, 8, 11, 14 and 15.  The noncoagulative effects of PK, mainly based on the effect of kallikrein, have been studied less, since they appear to be the result of the involvement of other components of the contact phase.  Kallikrein can mainly affect the formation of bradykinin from high-mol.-wt. kininogen and the activation of pro-urokinase to urokinase.  Bradykinin causes inflammation, vasodilatation and an increase in vessel permeability.  The activation of pro-urokinase results in enhanced fibrinolysis.  However, fibrinolysis has been reported to be normal or defective in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOHzI3XZCgnLVg90H21EOLACvtfcHk0livEM7FA0Q-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGktr3K&md5=9ba709f3bd31daa3935f853bb855c95d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1586%2Fehm.10.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fehm.10.69%26sid%3Dliteratum%253Aachs%26aulast%3DGirolami%26aufirst%3DA.%26aulast%3DScarparo%26aufirst%3DP.%26aulast%3DCandeo%26aufirst%3DN.%26aulast%3DLombardi%26aufirst%3DA.%2BM.%26atitle%3DCongenital%2520prekallikrein%2520deficiency%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2010%26volume%3D3%26spage%3D685%26epage%3D695%26doi%3D10.1586%2Fehm.10.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="note"><p class="first last">The correlation of FXI activity to 2xaPTT was determined via a calibration curve using FXI depleted plasma. Please see the supporting information for details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span>One advantage of employing the
PT assay is that it provides a more comprehensive assessment of off-target
coagulation modulation by compounds, in particular those which may
inhibit more than one proteases in the cascade, which would be challenging
to asses by individual biochemical selectivity values alone.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=One+advantage+of+employing+the%0APT+assay+is+that+it+provides+a+more+comprehensive+assessment+of+off-target%0Acoagulation+modulation+by+compounds%2C+in+particular+those+which+may%0Ainhibit+more+than+one+proteases+in+the+cascade%2C+which+would+be+challenging%0Ato+asses+by+individual+biochemical+selectivity+values+alone."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, P. A.</span></span> <span> </span><span class="NLM_article-title">The maximal affinity of ligands</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">9997</span>– <span class="NLM_lpage">10002</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.18.9997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1073%2Fpnas.96.18.9997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10468550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=9997-10002&author=I.+D.+Kuntzauthor=K.+Chenauthor=K.+A.+Sharpauthor=P.+A.+Kollman&title=The+maximal+affinity+of+ligands&doi=10.1073%2Fpnas.96.18.9997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49aR"><div class="casContent"><span class="casTitleNuber">49a</span><div class="casTitle"><span class="NLM_cas:atitle">The maximal affinity of ligands</span></div><div class="casAuthors">Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9997-10002</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We explore the question of what are the best ligands for macromol. targets.  A survey of exptl. data on a large no. of the strongest-binding ligands indicates that the free energy of binding increases with the no. of nonhydrogen atoms with an initial slope of ≈-1.5 kcal/mol (1 cal = 4.18 J) per atom.  For ligands that contain more than 15 nonhydrogen atoms, the free energy of binding increases very little with relative mol. mass.  This nonlinearity is largely ascribed to nonthermodynamic factors.  An anal. of the dominant interactions suggests that van der Waals interactions and hydrophobic effects provide a reasonable basis for understanding binding affinities across the entire set of ligands.  Interesting outliers that bind unusually strongly on a per atom basis include metal ions, covalently attached ligands, and a few well known complexes such as biotin-avidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0L6KZhR0TxbVg90H21EOLACvtfcHk0livEM7FA0Q-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D&md5=46fe894b016f3041831a2f0b71f812b1</span></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.9997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.9997%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DI.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DK.%2BA.%26aulast%3DKollman%26aufirst%3DP.%2BA.%26atitle%3DThe%2520maximal%2520affinity%2520of%2520ligands%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D9997%26epage%3D10002%26doi%3D10.1073%2Fpnas.96.18.9997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit49b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eY7YYmZJnGCM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit49c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency indices as guideposts for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03386-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+efficiency+indices+as+guideposts+for+drug+discovery&doi=10.1016%2FS1359-6446%2805%2903386-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49cR"><div class="casContent"><span class="casTitleNuber">49c</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2eY7YYmZJnGCM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit49c&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520efficiency%2520indices%2520as%2520guideposts%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469%26doi%3D10.1016%2FS1359-6446%2805%2903386-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit49d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bembenek, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tounge, B. A.</span></span> <span> </span><span class="NLM_article-title">The role of molecular size in ligand efficiency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4258</span>– <span class="NLM_lpage">4261</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.05.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2007.05.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=17532632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVKntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4258-4261&author=C.+H.+Reynoldsauthor=S.+D.+Bembenekauthor=B.+A.+Tounge&title=The+role+of+molecular+size+in+ligand+efficiency&doi=10.1016%2Fj.bmcl.2007.05.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49dR"><div class="casContent"><span class="casTitleNuber">49d</span><div class="casTitle"><span class="NLM_cas:atitle">The role of molecular size in ligand efficiency</span></div><div class="casAuthors">Reynolds, Charles H.; Bembenek, Scott D.; Tounge, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4258-4261</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ligand efficiency is a simple metric for assessing whether a ligand derives its potency from optimal fit with the protein target or simply by virtue of making many contacts.  Comparison of protein-ligand binding affinities for over 8000 ligands with 28 protein targets shows conclusively that the av. ligand binding affinities are not linear with mol. size.  It is therefore important to scale ligand efficiencies by the size of the ligand, particularly where small ligands (e.g., fragments) are involved.  The authors propose a simple 'fit quality' metric that removes this dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnIaZs8-gK1rVg90H21EOLACvtfcHk0ljBKyWtZ84PwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVKntbo%253D&md5=2f95a0b64b1da0755d7f624dad18b2bc</span></div><a href="/servlet/linkout?suffix=cit49d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.05.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.05.038%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26aulast%3DBembenek%26aufirst%3DS.%2BD.%26aulast%3DTounge%26aufirst%3DB.%2BA.%26atitle%3DThe%2520role%2520of%2520molecular%2520size%2520in%2520ligand%2520efficiency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4258%26epage%3D4261%26doi%3D10.1016%2Fj.bmcl.2007.05.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug+like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50aR"><div class="casContent"><span class="casTitleNuber">50a</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljm_4kCDog6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug%2520like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Perola, E.</span></span> <span> </span><span class="NLM_article-title">An analysis of binding efficiencies of drugs and their leads in successful drug discovery programs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2986</span>– <span class="NLM_lpage">2997</span>, <span class="refDoi"> DOI: 10.1021/jm100118x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100118x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2986-2997&author=E.+Perola&title=An+analysis+of+binding+efficiencies+of+drugs+and+their+leads+in+successful+drug+discovery+programs&doi=10.1021%2Fjm100118x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">An Analysis of the Binding Efficiencies of Drugs and their Leads in Successful Drug Discovery Programs</span></div><div class="casAuthors">Perola, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2986-2997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the evolution of binding efficiency in successful drug discovery programs, a data set of 60 lead/drug pairs with known binding affinities has been compiled and analyzed.  Low-end thresholds for the binding efficiencies of viable leads and drugs have been derived.  On av., the drugs in the set are significantly larger and more potent but have similar lipophilicity relative to their originating leads, suggesting that the ability to maintain low levels of lipophilicity while increasing mol. wt. is one of the keys to a successful drug discovery program.  A no. of examples demonstrate that large increases in binding efficiency from leads to more elaborate drugs sharing the same scaffold can be achieved.  The importance of dissecting a lead structure to identify the most efficient fragments and the option of sacrificing binding efficiency to optimize other properties are discussed, and relevant examples are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRqzYFBuX2Q7Vg90H21EOLACvtfcHk0ljm_4kCDog6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D&md5=a7eaad792f1518d093588951df64d22f</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1021%2Fjm100118x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100118x%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26atitle%3DAn%2520analysis%2520of%2520binding%2520efficiencies%2520of%2520drugs%2520and%2520their%2520leads%2520in%2520successful%2520drug%2520discovery%2520programs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2986%26epage%3D2997%26doi%3D10.1021%2Fjm100118x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4406</span>– <span class="NLM_lpage">4409</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB2+agonists+using+parallel+synthesis+protocols%3A+a+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50cR"><div class="casContent"><span class="casTitleNuber">50c</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0ljm_4kCDog6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit50c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB2%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520a%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The thermodynamic basis for the use of lipophilic efficiency in enthalpic optimization</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+thermodynamic+basis+for+the+use+of+lipophilic+efficiency+in+enthalpic+optimization&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50dR"><div class="casContent"><span class="casTitleNuber">50d</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0liXdL0QI1_THw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit50d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520thermodynamic%2520basis%2520for%2520the%2520use%2520of%2520lipophilic%2520efficiency%2520in%2520enthalpic%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Practical application of ligand efficiency metrics in lead optimisation</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3015</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmc.2018.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=29655612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVent7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3006-3015&author=J.+S.+Scottauthor=M.+J.+Waring&title=Practical+application+of+ligand+efficiency+metrics+in+lead+optimisation&doi=10.1016%2Fj.bmc.2018.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50eR"><div class="casContent"><span class="casTitleNuber">50e</span><div class="casTitle"><span class="NLM_cas:atitle">Practical application of ligand efficiency metrics in lead optimisation</span></div><div class="casAuthors">Scott, James S.; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3006-3015</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of composite metrics that normalize biol. potency values in relation to markers of physicochem. properties, such as size or lipophilicity, has gained a significant amt. of traction with many medicinal chemists in recent years.  However, there is no consensus on best practice in the area and their application has attracted some criticism.  Here we present our approach to their application in lead optimization projects, provide an objective discussion of the principles we consider important and illustrate how our use of lipophilic ligand efficiency enabled the progression of a no. of our successful drug discovery projects.  We derive, from this and some recent literature highlights, a set of heuristic guidelines for lipophilicity based optimization that we believe are generally applicable across chem. series and protein targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrcXUmwxG8rVg90H21EOLACvtfcHk0liXdL0QI1_THw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVent7g%253D&md5=50bba76316f6f2ec3c89e06f6717c388</span></div><a href="/servlet/linkout?suffix=cit50e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DPractical%2520application%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520lead%2520optimisation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3006%26epage%3D3015%26doi%3D10.1016%2Fj.bmc.2018.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span>The absolute
stereochemistry
was confirmed by chemical correlation via asymmetric synthesis and
via X-ray co-crystal structure of <b>13</b> and FXIa (not shown).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+absolute%0Astereochemistry%0Awas+confirmed+by+chemical+correlation+via+asymmetric+synthesis+and%0Avia+X-ray+co-crystal+structure+of+13+and+FXIa+%28not+shown%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span>The (R)-isomer, proved
to be
the less active isomer with a FXIa IC<sub>50</sub> of 0.005 μM
and IC<sub>50</sub> in the presence of plasma of 0.42 μM.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+%28R%29-isomer%2C+proved%0Ato+be%0Athe+less+active+isomer+with+a+FXIa+IC50+of+0.005+%CE%BCM%0Aand+IC50+in+the+presence+of+plasma+of+0.42+%CE%BCM."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span>Structurally, the activity
of
the (S)-isomer correlated well with the active (R) conformation of
the fused 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine <b>13</b>, described earlier with the S benzylic
hydroxyl group of <b>23</b> lying in the same trajectory as
the C3 carbon of the 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Structurally%2C+the+activity%0Aof%0Athe+%28S%29-isomer+correlated+well+with+the+active+%28R%29+conformation+of%0Athe+fused+3%2C4-dihydro-2H-benzo%5Bb%5D%5B1%2C4%5Doxazine+13%2C+described+earlier+with+the+S+benzylic%0Ahydroxyl+group+of+23+lying+in+the+same+trajectory+as%0Athe+C3+carbon+of+the+3%2C4-dihydro-2H-benzo%5Bb%5D%5B1%2C4%5Doxazine."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwat, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallwood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5339</span>– <span class="NLM_lpage">5356</span>, <span class="refDoi"> DOI: 10.1021/jm070245n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070245n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5339-5356&author=D.+J.+P.+Pintoauthor=M.+J.+Orwatauthor=S.+Kochauthor=K.+A.+Rossiauthor=R.+S.+Alexanderauthor=A.+Smallwoodauthor=P.+C.+Wongauthor=A.+R.+Rendinaauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=K.+Heauthor=B.+Xinauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Discovery+of+1-%284-methoxyphenyl%29-7-oxo-6-%284-%282-oxopiperidin-1-yl%29phenyl%29-4%2C5%2C6%2C7-tetrahydro-1H-pyrazolo%5B3%2C4-c%5Dpyridine-3-carboxamide+%28apixaban%2C+BMS-562247%29%2C+a+highly+potent%2C+selective%2C+efficacious%2C+and+orally+bioavailable+inhibitor+of+blood+coagulation+factor+Xa&doi=10.1021%2Fjm070245n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa</span></div><div class="casAuthors">Pinto, Donald J. P.; Orwat, Michael J.; Koch, Stephanie; Rossi, Karen A.; Alexander, Richard S.; Smallwood, Angela; Wong, Pancras C.; Rendina, Alan R.; Luettgen, Joseph M.; Knabb, Robert M.; He, Kan; Xin, Baomin; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5339-5356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efforts to identify a suitable follow-up compd. to razaxaban [i.e., 1-(3-amino-1,2-benzisoxazol-5-yl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide] focused on modification of a carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline.  Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained the potent factor Xa binding activity.  Exceptional potency of the series prompted an investigation of the neutral P1 moieties that resulted in the identification of the p-methoxyphenyl P1, which retained factor Xa binding affinity and good oral bioavailability.  Further optimization of the C-3 pyrazole position and replacement of the terminal P4 ring with a neutral heterocycle culminated in the discovery of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban).  Apixaban [i.e., 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide] exhibits a high degree of factor Xa potency, selectivity, and efficacy and has an improved pharmacokinetic profile relative to razaxaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbx6Ke9VLiirVg90H21EOLACvtfcHk0lgcevN6gAvuEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF&md5=6620ac3af9109ab38bda8268d0ec446a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm070245n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070245n%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DDiscovery%2520of%25201-%25284-methoxyphenyl%2529-7-oxo-6-%25284-%25282-oxopiperidin-1-yl%2529phenyl%2529-4%252C5%252C6%252C7-tetrahydro-1H-pyrazolo%255B3%252C4-c%255Dpyridine-3-carboxamide%2520%2528apixaban%252C%2520BMS-562247%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520efficacious%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520blood%2520coagulation%2520factor%2520Xa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5339%26epage%3D5356%26doi%3D10.1021%2Fjm070245n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Buck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the GastroPlus Advanced Compartmental and Transit (ACAT) model in early discovery</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1007/s11095-016-1951-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1007%2Fs11095-016-1951-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=27278908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOrsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=2126-2139&author=N.+Gobeauauthor=R.+Stringerauthor=S.+De+Buckauthor=B.+Faller&title=Evaluation+of+the+GastroPlus+Advanced+Compartmental+and+Transit+%28ACAT%29+model+in+early+discovery&doi=10.1007%2Fs11095-016-1951-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the GastroPlus Advanced Compartmental and Transit (ACAT) Model in Early Discovery</span></div><div class="casAuthors">Gobeau, N.; Stringer, R.; De Buck, S.; Tuntland, T.; Faller, B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2126-2139</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The aim of this study was to evaluate the oral exposure predictions obtained early in drug discovery with a generic GastroPlus Advanced Compartmental And Transit (ACAT) model based on the in vivo i.v. blood concn.-time profile, in silico properties (lipophilicity, pKa) and in vitro high-throughput absorption-distribution-metab.-excretion (ADME) data (as detd. by PAMPA, soly., liver microsomal stability assays).  Methods: The model was applied to a total of 623 discovery mols. and their oral exposure was predicted in rats and/or dogs.  The predictions of Cmax, AUClast and Tmax were compared against the observations.  Results: The generic model proved to make predictions of oral Cmax, AUClast and Tmax within 3-fold of the observations for rats in resp. 65%, 68% and 57% of the 537 cases.  For dogs, it was resp. 77%, 79% and 85% of the 124 cases.  Statistically, the model was most successful at predicting oral exposure of Biopharmaceutical Classification System (BCS) class 1 compds. compared to classes 2 and 3, and was worst at predicting class 4 compds. oral exposure.  Conclusion: The generic GastroPlus ACAT model provided reasonable predictions esp. for BCS class 1 compds.  For compds. of other classes, the model may be refined by obtaining more information on soly. and permeability in secondary assays.  This increases confidence that such a model can be used in discovery projects to understand the parameters limiting absorption and extrapolate predictions across species.  Also, when predictions disagree with the observations, the model can be updated to test hypotheses and understand oral absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI6kj-cQp2LLVg90H21EOLACvtfcHk0lgcevN6gAvuEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOrsrk%253D&md5=7314c07ecba5be0c58b48f45d3b9d781</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs11095-016-1951-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-016-1951-z%26sid%3Dliteratum%253Aachs%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DStringer%26aufirst%3DR.%26aulast%3DDe%2BBuck%26aufirst%3DS.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DEvaluation%2520of%2520the%2520GastroPlus%2520Advanced%2520Compartmental%2520and%2520Transit%2520%2528ACAT%2529%2520model%2520in%2520early%2520discovery%26jtitle%3DPharm.%2520Res.%26date%3D2016%26volume%3D33%26spage%3D2126%26epage%3D2139%26doi%3D10.1007%2Fs11095-016-1951-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molander, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trice, S. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S. M.</span></span> <span> </span><span class="NLM_article-title">Scope of the two-step, one-pot palladium-catalyzed borylation/Suzuki cross-coupling reaction utilizing bis-boronic acid</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">8678</span>– <span class="NLM_lpage">8688</span>, <span class="refDoi"> DOI: 10.1021/jo301642v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo301642v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=8678-8688&author=G.+A.+Molanderauthor=S.+L.+J.+Triceauthor=S.+M.+Kennedy&title=Scope+of+the+two-step%2C+one-pot+palladium-catalyzed+borylation%2FSuzuki+cross-coupling+reaction+utilizing+bis-boronic+acid&doi=10.1021%2Fjo301642v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Scope of the Two-Step, One-Pot Palladium-Catalyzed Borylation/Suzuki Cross-Coupling Reaction Utilizing Bis-Boronic Acid</span></div><div class="casAuthors">Molander, Gary A.; Trice, Sarah L. J.; Kennedy, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8678-8688</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of bis-boronic acid for the direct synthesis of boronic acids has greatly facilitated the two-step, one-pot borylation/Suzuki cross-coupling reaction between aryl and heteroaryl halides.  With use of Buchwald's second-generation XPhos preformed catalyst, high yields of cross-coupled products were obtained for most substrates.  The method also allows an efficient two-step, one-pot synthesis, providing access to three distinct cross-coupled products after column chromatog.  The method also provides a rapid and convenient route to teraryl compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDMxPPa0A15rVg90H21EOLACvtfcHk0lgcevN6gAvuEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO&md5=80b369825dd060e4e3d243d3c85a9354</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjo301642v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo301642v%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DTrice%26aufirst%3DS.%2BL.%2BJ.%26aulast%3DKennedy%26aufirst%3DS.%2BM.%26atitle%3DScope%2520of%2520the%2520two-step%252C%2520one-pot%2520palladium-catalyzed%2520borylation%252FSuzuki%2520cross-coupling%2520reaction%2520utilizing%2520bis-boronic%2520acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D8678%26epage%3D8688%26doi%3D10.1021%2Fjo301642v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':[],'ref37':['cit37a','cit37b','cit37c'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41a','cit41b'],'ref42':['cit42'],'ref43':[],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':[],'ref48':['cit48'],'ref49':['cit49a','cit49b','cit49c','cit49d'],'ref50':['cit50a','cit50b','cit50c','cit50d','cit50e'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Juraj Velcicky, Rainer Wilcken, Simona Cotesta, Philipp Janser, Achim Schlapbach, Trixie Wagner, Philippe Piechon, Frederic Villard, Rochdi Bouhelal, Fabian Piller, Stephanie Harlfinger, Rowan Stringer, Dominique Fehlmann, Klemens Kaupmann, Amanda Littlewood-Evans, Matthias Haffke, <span class="NLM_string-name hlFld-ContribAuthor">Nina Gommermann</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9856-9875. <a href="https://doi.org/10.1021/acs.jmedchem.0c01020" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01020%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BNovel%252BSUCNR1%252BInhibitors%25253A%252BDesign%252Bof%252BZwitterionic%252BDerivatives%252Bwith%252Ba%252BSalt%252BBridge%252Bfor%252Bthe%252BImprovement%252Bof%252BOral%252BExposure%26aulast%3DVelcicky%26aufirst%3DJuraj%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D28082020%26volume%3D63%26issue%3D17%26spage%3D9856%26epage%3D9875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Lei</span>, <span class="hlFld-ContribAuthor ">Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiwen  Dai</span>, <span class="hlFld-ContribAuthor ">Yulin  Duan</span>, <span class="hlFld-ContribAuthor ">Qing  Mao</span>, <span class="hlFld-ContribAuthor ">Jun  Gao</span>, <span class="hlFld-ContribAuthor ">Yuwei  Yang</span>, <span class="hlFld-ContribAuthor ">Ziyang  Bao</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Fu</span>, <span class="hlFld-ContribAuthor ">Kunqi  Ping</span>, <span class="hlFld-ContribAuthor ">Chengda  Yan</span>, <span class="hlFld-ContribAuthor ">Yanhua  Mou</span>, <span class="hlFld-ContribAuthor ">Shaojie  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113437. <a href="https://doi.org/10.1016/j.ejmech.2021.113437" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113437%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BFXIa%252Binhibitors%252Bwith%252B2-phenyl-1H-imidazole-5-carboxamide%252Bmoiety%252Bas%252BP1%252Bfragment%26aulast%3DLei%26aufirst%3DYu%26date%3D2021%26volume%3D220%26spage%3D113437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bastien  Champciaux</span>, <span class="hlFld-ContribAuthor ">Clément  Raynaud</span>, <span class="hlFld-ContribAuthor ">Albertus  Viljoen</span>, <span class="hlFld-ContribAuthor ">Loïc  Chene</span>, <span class="hlFld-ContribAuthor ">Jérôme  Thibonnet</span>, <span class="hlFld-ContribAuthor ">Stéphane P.  Vincent</span>, <span class="hlFld-ContribAuthor ">Laurent  Kremer</span>, <span class="hlFld-ContribAuthor ">Emilie  Thiery</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 3,4-dihydro-1H-[1,4] oxazepino [6,5,4-hi] indol-1-ones and 4,6-dihydrooxepino [5,4,3-cd] indol-1(3H)-ones as Mycobacterium tuberculosis inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>43 </em>, 116248. <a href="https://doi.org/10.1016/j.bmc.2021.116248" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116248%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3%25252C4-dihydro-1H-%25255B1%25252C4%25255D%252Boxazepino%252B%25255B6%25252C5%25252C4-hi%25255D%252Bindol-1-ones%252Band%252B4%25252C6-dihydrooxepino%252B%25255B5%25252C4%25252C3-cd%25255D%252Bindol-1%2525283H%252529-ones%252Bas%252BMycobacterium%252Btuberculosis%252Binhibitors%26aulast%3DChampciaux%26aufirst%3DBastien%26date%3D2021%26volume%3D43%26spage%3D116248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the coagulation cascade. The aPTT assay assesses inhibition of the intrinsic (blue) and progression (red) components of the pathway, while the PT assay assesses the extrinsic (orange) and progression components.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of early-stage S1-benzylamine-based FXIa inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of compound <b>2</b>. (a) Crystal structure of <b>2</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS4">6TS4</a>) with FXIa S<sub>195</sub>A mutant (green). The surface of the protein is shown in gray, and oxygen atoms of crystallographic water molecules are shown as red spheres. (b) Comparison of the crystal structures of compound <b>2</b> with FXIa (yellow and green carbons) and FD (pale blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QMT">6QMT</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Only selected residues in the ligand binding pocket are shown. FXIa and FD residues are labeled in black and blue, respectively. H-bonding interactions are shown as black dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Crystal structure of compound <b>3</b> (yellow) complexed with FXIa (white, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS7">6TS7</a>). (b) Overlay of the crystal structure of compound <b>3</b> (yellow) complexed with FXIa (white) on compound <b>4</b> (cyan) complexed with PKL (pale blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T7P">6T7P</a>). Only selected residues in the ligand binding pocket are shown. H-bonding interactions are shown as black dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Crystal structure of compound <b>7</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS6">6TS6</a>) in complex with FXIa (white). The surface of the protein is shown in gray, and oxygen atoms of crystallographic water molecules are shown as red spheres. (b) Comparison of the cocrystal structure of compound <b>7</b> (yellow) complexed with FXIa (white) and compound <b>2</b> (pale blue) complexed with FD (pale blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QMT">6QMT</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Only selected residues in the ligand binding pocket are shown. H-bonding interactions are shown as black dotted lines. FXIa residues are labeled in black, and FD residues are labeled in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure of the fused 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>13</b>) and benzoic acids (<b>14–19</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Exploration of addition of a hydroxyl to the linker between the S1β and S1′ sites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Crystal structure of <b>23</b> (yellow) in complex with FXIa (white, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USY">6USY</a>). The surface of the protein is shown in gray, and oxygen atoms of crystallographic water molecules are shown as red spheres. Only selected residues in the ligand binding pocket are shown. H-bonding interactions are shown as black dotted lines. (b) Overlay of compound <b>1</b> (cyan) bound to FD, <b>15</b> bound to FXIa (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS5">6TS5</a>), and <b>23</b> (yellow) bound to FXIa.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>In Vivo</i> rat and dog mean plasma pharmacokinetic parameters for <b>23</b>. D.N., dose normalized.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route to Aryl Acetic Acid and Benzoic Acid FXIa Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/medium/jm0c00279_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. (a) AD-mix-α, <i>t</i>-BuOH/H<sub>2</sub>O, −10 to 25 °C, 38%; (b) mesityl-Cl, pyridine, 4-dimethylaminopyridine (DMAP), CH<sub>2</sub>Cl<sub>2</sub>, 72%; (c) Cs<sub>2</sub>CO<sub>3</sub>, dimethylformamide (DMF), 82%; (d) K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 86%; (e) KOH, EtOH, 0–100 °C, 100%; (f) PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 70 °C; (g) 3 N NaOH, MeOH, 60 °C, 32%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00279/20200806/images/large/jm0c00279_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00279&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 56 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardrop, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, D.</span></span> <span> </span><span class="NLM_article-title">The story of the discovery of heparin and warfarin</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2008.07119.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fj.1365-2141.2008.07119.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=18355382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD1czjtV2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2008&pages=757-763&author=D.+Wardropauthor=D.+Keeling&title=The+story+of+the+discovery+of+heparin+and+warfarin&doi=10.1111%2Fj.1365-2141.2008.07119.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The story of the discovery of heparin and warfarin</span></div><div class="casAuthors">Wardrop Douglas; Keeling David</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">757-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Heparin and coumarins have been the mainstay of anticoagulant therapy throughout our working lives.  As we stand on the threshold of a new era of anticoagulants it is timely to look back upon their discovery and development.  Both have fascinating stories to tell.  Jay McLean claimed to have discovered heparin whilst a medical student, although this is disputed.  The story of warfarin leads us from a mysterious haemorrhagic disease of cattle to the development of a rat poison which became one of the most commonly prescribed drugs in history.  Many people were involved in both stories and we owe them all a debt of gratitude.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrf7pNvbhOB-xsqfvU0ziafW6udTcc2eZLgaOnRl05BLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjtV2rsQ%253D%253D&md5=9ffdb66a5c68edbc5bf4ce37828ed9fc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2008.07119.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2008.07119.x%26sid%3Dliteratum%253Aachs%26aulast%3DWardrop%26aufirst%3DD.%26aulast%3DKeeling%26aufirst%3DD.%26atitle%3DThe%2520story%2520of%2520the%2520discovery%2520of%2520heparin%2520and%2520warfarin%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2008%26volume%3D141%26spage%3D757%26epage%3D763%26doi%3D10.1111%2Fj.1365-2141.2008.07119.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qato, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, G. C.</span></span> <span> </span><span class="NLM_article-title">National trends in oral anticoagulant use in the United States 2007-2011</span>. <i>Circ. Cardiovasc. Qual. Outcomes</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1161/CIRCOUTCOMES.112.967299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2FCIRCOUTCOMES.112.967299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=22949490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC38bktFyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=615-621&author=K.+Kirleyauthor=D.+M.+Qatoauthor=R.+Kornfieldauthor=R.+S.+Staffordauthor=G.+C.+Alexander&title=National+trends+in+oral+anticoagulant+use+in+the+United+States+2007-2011&doi=10.1161%2FCIRCOUTCOMES.112.967299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">National trends in oral anticoagulant use in the United States, 2007 to 2011</span></div><div class="casAuthors">Kirley Kate; Qato Dima M; Kornfield Rachel; Stafford Randall S; Alexander G Caleb</div><div class="citationInfo"><span class="NLM_cas:title">Circulation. Cardiovascular quality and outcomes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">615-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Little is known regarding the adoption of direct thrombin inhibitors in clinical practice.  We examine trends in oral anticoagulation for the prevention of thromboembolism in the United States.  METHODS AND RESULTS:  We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of office-based providers, to quantify patterns of oral anticoagulant use among all subjects and stratified by clinical indication.  We quantified oral anticoagulant expenditures using the IMS Health National Prescription Audit.  Between 2007 and 2011, warfarin treatment visits declined from ≈2.1 million (M) quarterly visits to ≈1.6M visits.  Dabigatran use increased from 0.062M quarterly visits (2010Q4) to 0.363M visits (2011Q4), reflecting its increasing share of oral anticoagulant visits from 3.1% to 18.9%.  In contrast to warfarin, the majority of dabigatran visits have been for atrial fibrillation, though this proportion decreased from 92% (2010Q4) to 63% (2011Q4), with concomitant increases in dabigatran's off-label use.  Among atrial fibrillation visits, warfarin use decreased from 55.8% visits (2010Q4) to 44.4% (2011Q4), whereas dabigatran use increased from 4.0% to 16.9%.  Of atrial fibrillation visits, the fraction not treated with any oral anticoagulants has remained unchanged at ≈40%.  Expenditures related to dabigatran increased rapidly from $16M in 2010Q4 to $166M in 2011Q4, exceeding expenditures on warfarin ($144M) in 2011Q4.  CONCLUSIONS:  Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications.  We did not find evidence that it has increased overall atrial fibrillation treatment rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbGob37j0dCae0F5ixvZgXfW6udTcc2eZLgaOnRl05BLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bktFyqsw%253D%253D&md5=c08907f0ff94e3b21d692adbdc722eec</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2FCIRCOUTCOMES.112.967299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCOUTCOMES.112.967299%26sid%3Dliteratum%253Aachs%26aulast%3DKirley%26aufirst%3DK.%26aulast%3DQato%26aufirst%3DD.%2BM.%26aulast%3DKornfield%26aufirst%3DR.%26aulast%3DStafford%26aufirst%3DR.%2BS.%26aulast%3DAlexander%26aufirst%3DG.%2BC.%26atitle%3DNational%2520trends%2520in%2520oral%2520anticoagulant%2520use%2520in%2520the%2520United%2520States%25202007-2011%26jtitle%3DCirc.%2520Cardiovasc.%2520Qual.%2520Outcomes%26date%3D2012%26volume%3D5%26spage%3D615%26epage%3D621%26doi%3D10.1161%2FCIRCOUTCOMES.112.967299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ageno, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittkowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palareti, G.</span></span> <span> </span><span class="NLM_article-title">Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence Based-Based Clinical Practice Guidelines</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">e44S</span>– <span class="NLM_lpage">e88S</span>, <span class="refDoi"> DOI: 10.1378/chest.11-2292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1378%2Fchest.11-2292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=22315269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2012&pages=e44S-e88S&author=W.+Agenoauthor=A.+S.+Gallusauthor=A.+Wittkowskyauthor=M.+Crowtherauthor=E.+M.+Hylekauthor=G.+Palareti&title=Oral+anticoagulant+therapy%3A+antithrombotic+therapy+and+prevention+of+thrombosis%2C+9th+ed%3A+American+College+of+Chest+Physicians+Evidence+Based-Based+Clinical+Practice+Guidelines&doi=10.1378%2Fchest.11-2292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-2292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-2292%26sid%3Dliteratum%253Aachs%26aulast%3DAgeno%26aufirst%3DW.%26aulast%3DGallus%26aufirst%3DA.%2BS.%26aulast%3DWittkowsky%26aufirst%3DA.%26aulast%3DCrowther%26aufirst%3DM.%26aulast%3DHylek%26aufirst%3DE.%2BM.%26aulast%3DPalareti%26aufirst%3DG.%26atitle%3DOral%2520anticoagulant%2520therapy%253A%2520antithrombotic%2520therapy%2520and%2520prevention%2520of%2520thrombosis%252C%25209th%2520ed%253A%2520American%2520College%2520of%2520Chest%2520Physicians%2520Evidence%2520Based-Based%2520Clinical%2520Practice%2520Guidelines%26jtitle%3DChest%26date%3D2012%26volume%3D141%26spage%3De44S%26epage%3De88S%26doi%3D10.1378%2Fchest.11-2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meurer, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, B.</span></span> <span> </span><span class="NLM_article-title">What is the interval for monitoring warfarin therapy once therapeutic levels are achieved?</span>. <i>J. Fam. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15689292" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=156-178&author=L.+N.+Meurerauthor=B.+Jamieson&title=What+is+the+interval+for+monitoring+warfarin+therapy+once+therapeutic+levels+are+achieved%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeurer%26aufirst%3DL.%2BN.%26aulast%3DJamieson%26aufirst%3DB.%26atitle%3DWhat%2520is%2520the%2520interval%2520for%2520monitoring%2520warfarin%2520therapy%2520once%2520therapeutic%2520levels%2520are%2520achieved%253F%26jtitle%3DJ.%2520Fam.%2520Pract.%26date%3D2005%26volume%3D54%26spage%3D156%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roehrig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pernerstorfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinemer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perzborn, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5900</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1021/jm050101d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050101d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFShsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5900-5908&author=S.+Roehrigauthor=A.+Straubauthor=J.+Pohlmannauthor=T.+Lampeauthor=J.+Pernerstorferauthor=K.-H.+Schlemmerauthor=P.+Reinemerauthor=E.+Perzborn&title=Discovery+of+the+novel+antithrombotic+agent+5-chloro-N-%28%7B%285S%29-2-oxo-3-%5B4-%283-oxomorpholin-4-yl%29phenyl%5D-1%2C3-oxazolidin-5-yl%7Dmethyl%29thiophene-2-carboxamide+%28BAY+59-7939%29%3A+an+oral%2C+direct+factor+Xa+inhibitor&doi=10.1021%2Fjm050101d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor</span></div><div class="casAuthors">Roehrig, Susanne; Straub, Alexander; Pohlmann, Jens; Lampe, Thomas; Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Reinemer, Peter; Perzborn, Elisabeth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5900-5908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants.  The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-mol. inhibitors with good oral bioavailability.  We identified oxazolidinone derivs. as a new class of potent FXa inhibitors.  Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity.  The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity.  The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5.  Compd. 5 is currently under clin. development for the prevention and treatment of thromboembolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoreRYH8j2AErVg90H21EOLACvtfcHk0lhOrMdh4MiprQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFShsL0%253D&md5=034bd4efd9c8fbfeae95c230ac1c28a8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm050101d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050101d%26sid%3Dliteratum%253Aachs%26aulast%3DRoehrig%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DLampe%26aufirst%3DT.%26aulast%3DPernerstorfer%26aufirst%3DJ.%26aulast%3DSchlemmer%26aufirst%3DK.-H.%26aulast%3DReinemer%26aufirst%3DP.%26aulast%3DPerzborn%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520the%2520novel%2520antithrombotic%2520agent%25205-chloro-N-%2528%257B%25285S%2529-2-oxo-3-%255B4-%25283-oxomorpholin-4-yl%2529phenyl%255D-1%252C3-oxazolidin-5-yl%257Dmethyl%2529thiophene-2-carboxamide%2520%2528BAY%252059-7939%2529%253A%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5900%26epage%3D5908%26doi%3D10.1021%2Fjm050101d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwat, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallwood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5339</span>– <span class="NLM_lpage">5356</span>, <span class="refDoi"> DOI: 10.1021/jm070245n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070245n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5339-5356&author=D.+J.+P.+Pintoauthor=M.+J.+Orwatauthor=S.+Kochauthor=K.+A.+Rossiauthor=R.+A.+Alexanderauthor=A.+Smallwoodauthor=P.+C.+Wongauthor=A.+R.+Rendinaauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=K.+Heauthor=B.+Xinauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Discovery+of+1-%284-methoxyphenyl%29-7-oxo-6-%284-%282-oxopiperidin-1-yl%29phenyl%29-4%2C5%2C6%2C7-tetrahydro-1H-pyrazolo%5B3%2C4-c%5Dpyridine-3-carboxamide+%28Apixaban%2C+BMS-562247%29%2C+a+highly+potent%2C+selective%2C+efficacious%2C+and+orally+bioavailable+inhibitor+of+blood+coagulation+factor+Xa&doi=10.1021%2Fjm070245n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa</span></div><div class="casAuthors">Pinto, Donald J. P.; Orwat, Michael J.; Koch, Stephanie; Rossi, Karen A.; Alexander, Richard S.; Smallwood, Angela; Wong, Pancras C.; Rendina, Alan R.; Luettgen, Joseph M.; Knabb, Robert M.; He, Kan; Xin, Baomin; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5339-5356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efforts to identify a suitable follow-up compd. to razaxaban [i.e., 1-(3-amino-1,2-benzisoxazol-5-yl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide] focused on modification of a carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline.  Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained the potent factor Xa binding activity.  Exceptional potency of the series prompted an investigation of the neutral P1 moieties that resulted in the identification of the p-methoxyphenyl P1, which retained factor Xa binding affinity and good oral bioavailability.  Further optimization of the C-3 pyrazole position and replacement of the terminal P4 ring with a neutral heterocycle culminated in the discovery of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban).  Apixaban [i.e., 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide] exhibits a high degree of factor Xa potency, selectivity, and efficacy and has an improved pharmacokinetic profile relative to razaxaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbx6Ke9VLiirVg90H21EOLACvtfcHk0lhOrMdh4MiprQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF&md5=6620ac3af9109ab38bda8268d0ec446a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm070245n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070245n%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%2BA.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DDiscovery%2520of%25201-%25284-methoxyphenyl%2529-7-oxo-6-%25284-%25282-oxopiperidin-1-yl%2529phenyl%2529-4%252C5%252C6%252C7-tetrahydro-1H-pyrazolo%255B3%252C4-c%255Dpyridine-3-carboxamide%2520%2528Apixaban%252C%2520BMS-562247%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520efficacious%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520blood%2520coagulation%2520factor%2520Xa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5339%26epage%3D5356%26doi%3D10.1021%2Fjm070245n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauel, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priepke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassen, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienen, W.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of novel potent nonpeptide thrombin inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1021/jm0109513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0109513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1OgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1757-1766&author=N.+H.+Hauelauthor=H.+Narauthor=H.+Priepkeauthor=U.+Riesauthor=J.-M.+Stassenauthor=W.+Wienen&title=Structure-based+design+of+novel+potent+nonpeptide+thrombin+inhibitors&doi=10.1021%2Fjm0109513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of novel potent nonpeptide thrombin inhibitors</span></div><div class="casAuthors">Hauel, Norbert H.; Nar, Herbert; Priepke, Henning; Ries, Uwe; Stassen, Jean-Marie; Wienen, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1757-1766</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. syndromes of thromboembolism are evoked by an excessive stimulation of the coagulation cascade.  In this context, the serine protease thrombin plays a key role.  Considerable efforts have therefore been devoted to the discovery of safe, orally active inhibitors of this enzyme.  On the basis of the X-ray crystal structure of the peptidelike thrombin inhibitor NAPAP complexed with bovine thrombin, we have designed a new structural class of nonpeptidic inhibitors employing a 1,2,5-trisubstituted benzimidazole as the central scaffold.  Supported by a series of X-ray structure analyses, we optimized the activity of these compds.  Thrombin inhibition in the lower nanomolar range could be achieved although the binding energy mainly results from nonpolar, hydrophobic interactions.  To improve in vivo potency, we increased the overall hydrophilicity of the mols. by introducing carboxylate groups.  The very polar compd. BIBR 953 exhibited the most favorable activity profile in vivo.  This zwitterionic mol. was converted into the double-prodrug BIBR 1048, which showed strong oral activity in different animal species.  On the basis of these results, BIBR 1048 was chosen for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxoMVJTKRisLVg90H21EOLACvtfcHk0lgriGS7BFWubg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1OgsLs%253D&md5=d69204226d1d74aab2995a3465505eac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm0109513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0109513%26sid%3Dliteratum%253Aachs%26aulast%3DHauel%26aufirst%3DN.%2BH.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DPriepke%26aufirst%3DH.%26aulast%3DRies%26aufirst%3DU.%26aulast%3DStassen%26aufirst%3DJ.-M.%26aulast%3DWienen%26aufirst%3DW.%26atitle%3DStructure-based%2520design%2520of%2520novel%2520potent%2520nonpeptide%2520thrombin%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1757%26epage%3D1766%26doi%3D10.1021%2Fjm0109513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Briere, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauchier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taieb, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, O.</span></span> <span> </span><span class="NLM_article-title">Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review</span>. <i>Expert Rev. Pharmacoecon. Outcomes Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1080/14737167.2018.1518134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1080%2F14737167.2018.1518134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=30169975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BB3c3ktlSjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=27-36&author=J.+B.+Briereauthor=K.+Bowrinauthor=C.+Colemanauthor=L.+Fauchierauthor=P.+Levyauthor=K.+Folkertsauthor=M.+Toumiauthor=V.+Taiebauthor=A.+Millierauthor=O.+Wu&title=Real-world+clinical+evidence+on+rivaroxaban%2C+dabigatran%2C+and+apixaban+compared+with+vitamin+K+antagonists+in+patients+with+nonvalvular+atrial+fibrillation%3A+a+systematic+literature+review&doi=10.1080%2F14737167.2018.1518134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review</span></div><div class="casAuthors">Briere Jean-Baptiste; Bowrin Kevin; Coleman Craig; Fauchier Laurent; Levy Pierre; Folkerts Kerstin; Toumi Mondher; Taieb Vanessa; Millier Aurelie; Wu Olivia</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of pharmacoeconomics & outcomes research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Several comparative real-world effectiveness studies on direct oral anticoagulants (DOACs) have been conducted, but an overview of the available evidence remains to be developed, which could provide a better understanding of the value of DOACs relative to vitamin K antagonists (VKAs).  AREAS COVERED:  A systematic literature review was conducted on the available real-world evidence (RWE) of three DOACs (rivaroxaban, dabigatran, and apixaban) compared with VKAs (e.g. warfarin), in patients with nonvalvular atrial fibrillation (NVAF).This systematic literature review included RWE published up to December 2016.  Studies with > 50 patients reporting on incident and prevalent NVAF cases were included.  The following databases were searched: Medline, Embase, and the Cochrane Library.  Outcomes of interest included thromboembolic events, all-cause mortality, bleeding events, and nonpersistence.  Of the 562 RWE DOACs articles retrieved, 49 presented results for rivaroxaban versus VKAs, 79 for dabigatran versus VKAs, and 18 for apixaban versus VKAs.  Substantial heterogeneity was found across patient population, outcome definition, and follow-up period.  Major bleeding, ischemic stroke, and intracranial hemorrhage were the most frequent outcomes analyzed.  EXPERT COMMENTARY:  Overall, the RWE studies were aligned with the Phase 3 trials.  However, conflicting results were reported for several outcomes of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTb3fTuXcbWBJZoeNcnHOQ9fW6udTcc2eaR2ojP2OxlGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3ktlSjug%253D%253D&md5=018cba54845b88cdc80489b1b64d105d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1080%2F14737167.2018.1518134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737167.2018.1518134%26sid%3Dliteratum%253Aachs%26aulast%3DBriere%26aufirst%3DJ.%2BB.%26aulast%3DBowrin%26aufirst%3DK.%26aulast%3DColeman%26aufirst%3DC.%26aulast%3DFauchier%26aufirst%3DL.%26aulast%3DLevy%26aufirst%3DP.%26aulast%3DFolkerts%26aufirst%3DK.%26aulast%3DToumi%26aufirst%3DM.%26aulast%3DTaieb%26aufirst%3DV.%26aulast%3DMillier%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DO.%26atitle%3DReal-world%2520clinical%2520evidence%2520on%2520rivaroxaban%252C%2520dabigatran%252C%2520and%2520apixaban%2520compared%2520with%2520vitamin%2520K%2520antagonists%2520in%2520patients%2520with%2520nonvalvular%2520atrial%2520fibrillation%253A%2520a%2520systematic%2520literature%2520review%26jtitle%3DExpert%2520Rev.%2520Pharmacoecon.%2520Outcomes%2520Res.%26date%3D2019%26volume%3D19%26spage%3D27%26epage%3D36%26doi%3D10.1080%2F14737167.2018.1518134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangaralingham, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellolio, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBane, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noseworthy, P. A.</span></span> <span> </span><span class="NLM_article-title">Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation</span>. <i>J. Am. Heart Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e003725</span> <span class="refDoi"> DOI: 10.1161/JAHA.116.003725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2FJAHA.116.003725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=27412905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVWmsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=X.+Yaoauthor=N.+S.+Abrahamauthor=L.+R.+Sangaralinghamauthor=M.+F.+Bellolioauthor=R.+D.+McBaneauthor=N.+D.+Shahauthor=P.+A.+Noseworthy&title=Effectiveness+and+safety+of+dabigatran%2C+rivaroxaban%2C+and+apixaban+versus+warfarin+in+nonvalvular+atrial+fibrillation&doi=10.1161%2FJAHA.116.003725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation</span></div><div class="casAuthors">Yao, Xiaoxi; Abraham, Neena S.; Sangaralingham, Lindsey R.; Bellolio, Fernanda; McBane, Robert D.; Shah, Nilay D.; Noseworthy, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Heart Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e003725/1-e003725/18</span>CODEN:
                <span class="NLM_cas:coden">JAHABZ</span>;
        ISSN:<span class="NLM_cas:issn">2047-9980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background-The introduction of non-vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clin. trials may not translate to routine practice.  We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin.  Methods and Results-Using a large US insurance database, we identified privately insured and Medicare Advantage patients with nonvalvular atrial fibrillation who were users of apixaban, dabigatran, rivaroxaban, or warfarin between Oct. 1, 2010, and June 30, 2015.  We created 3 matched cohorts using 1:1 propensity score matching: apixaban vs. warfarin (n=15 390), dabigatran vs. warfarin (n=28 614), and rivaroxaban vs. warfarin (n=32 350).  Using Cox proportional hazards regression, we found that for stroke or systemic embolism, apixaban was assocd. with lower risk (hazard ratio [HR] 0.67, 95% CI 0.46-0.98, P=0.04), but dabigatran and rivaroxaban were assocd. with a similar risk (dabigatran: HR 0.98, 95% CI 0.76-1.26, P=0.98; rivaroxaban: HR 0.93, 95% CI 0.72-1.19, P=0.56).  For major bleeding, apixaban and dabigatran were assocd. with lower risk (apixaban: HR 0.45, 95% CI 0.34-0.59, P<0.001; dabigatran: HR 0.79, 95% CI 0.67-0.94, P<0.01), and rivaroxaban was assocd. with a similar risk (HR 1.04, 95% CI 0.90-1.20, P=0.60).  All non-vitamin K antagonist oral anticoagulants were assocd. with a lower risk of intracranial bleeding.  Conclusions-In patients with nonvalvular atrial fibrillation, apixaban was assocd. with lower risks of both stroke and major bleeding, dabigatran was assocd. with similar risk of stroke but lower risk of major bleeding, and rivaroxaban was assocd. with similar risks of both stroke and major bleeding in comparison to warfarin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYl1FAgjs16bVg90H21EOLACvtfcHk0li3g6eTBAbiSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVWmsrg%253D&md5=5088d522d513f981fa93d2b8935aef36</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1161%2FJAHA.116.003725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FJAHA.116.003725%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DX.%26aulast%3DAbraham%26aufirst%3DN.%2BS.%26aulast%3DSangaralingham%26aufirst%3DL.%2BR.%26aulast%3DBellolio%26aufirst%3DM.%2BF.%26aulast%3DMcBane%26aufirst%3DR.%2BD.%26aulast%3DShah%26aufirst%3DN.%2BD.%26aulast%3DNoseworthy%26aufirst%3DP.%2BA.%26atitle%3DEffectiveness%2520and%2520safety%2520of%2520dabigatran%252C%2520rivaroxaban%252C%2520and%2520apixaban%2520versus%2520warfarin%2520in%2520nonvalvular%2520atrial%2520fibrillation%26jtitle%3DJ.%2520Am.%2520Heart%2520Assoc.%26date%3D2016%26volume%3D5%26doi%3D10.1161%2FJAHA.116.003725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y.</span></span> <span> </span><span class="NLM_article-title">Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2298</span>– <span class="NLM_lpage">2307</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.055079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2FCIRCULATIONAHA.111.055079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=22514252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1arsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2298-2307&author=L.+Fribergauthor=M.+Rosenqvistauthor=G.+Y.+Lip&title=Net+clinical+benefit+of+warfarin+in+patients+with+atrial+fibrillation%3A+a+report+from+the+Swedish+atrial+fibrillation+cohort+study&doi=10.1161%2FCIRCULATIONAHA.111.055079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study</span></div><div class="casAuthors">Friberg, Leif; Rosenqvist, Marten; Lip, Gregory Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2298-2307</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: Known risk factors for bleeding during anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF).  Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding.  METHODS AND RESULTS: All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were studied for an av. of 1.5 years (260 000 patient-years at risk).  Patients were stratified according to risk scores with the use of historic International Classification of Disease diagnostic codes in the register.  Information about medication was obtained from the Swedish Drug Registry.  Our primary end point was net benefit defined as no. of avoided ischemic strokes with anticoagulation minus the no. of excess intracranial bleedings with a wt. of 1.5 to compensate for the generally more severe outcome with intracranial bleedings.  The adjusted net clin. benefit favored anticoagulation for almost all atrial fibrillation patients.  The exceptions were patients at very low risk of ischemic stroke with a CHA2DS2-VASc score of 0 and moderately elevated bleeding risk (-1.7%/y).  The results were broadly similar with CHADS2, except for patients with very low embolic risk; the CHA2DS2-VASc was able to identify those patients (n=6205, 3.9% of all patients) who had no net clin. benefit or even some disadvantage from anticoagulant treatment.  CONCLUSIONS: In almost all patients with atrial fibrillation, the risk of ischemic stroke without anticoagulant treatment is higher than the risk of intracranial bleeding with anticoagulant treatment.  Anal. of the net benefit indicates that more patients may benefit from anticoagulant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnotOpxLaJRbVg90H21EOLACvtfcHk0lgjtHKbr2wQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1arsr0%253D&md5=0622db049f66b613fc8f1101956996e2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.055079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.055079%26sid%3Dliteratum%253Aachs%26aulast%3DFriberg%26aufirst%3DL.%26aulast%3DRosenqvist%26aufirst%3DM.%26aulast%3DLip%26aufirst%3DG.%2BY.%26atitle%3DNet%2520clinical%2520benefit%2520of%2520warfarin%2520in%2520patients%2520with%2520atrial%2520fibrillation%253A%2520a%2520report%2520from%2520the%2520Swedish%2520atrial%2520fibrillation%2520cohort%2520study%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D2298%26epage%3D2307%26doi%3D10.1161%2FCIRCULATIONAHA.111.055079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bassand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Accetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzmaurice, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhaber, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misselwitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Cate, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheugt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkar, A. K.</span></span> <span> </span><span class="NLM_article-title">Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2882</span>– <span class="NLM_lpage">2889</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehw233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1093%2Feurheartj%2Fehw233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=27357359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltVSktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=2882-2889&author=J.+P.+Bassandauthor=G.+Accettaauthor=A.+J.+Cammauthor=F.+Coolsauthor=D.+A.+Fitzmauriceauthor=K.+A.+Foxauthor=S.+Z.+Goldhaberauthor=S.+Gotoauthor=S.+Haasauthor=W.+Hackeauthor=G.+Kayaniauthor=L.+G.+Mantovaniauthor=F.+Misselwitzauthor=H.+Ten+Cateauthor=A.+G.+Turpieauthor=F.+W.+Verheugtauthor=A.+K.+Kakkar&title=Two-year+outcomes+of+patients+with+newly+diagnosed+atrial+fibrillation%3A+results+from+GARFIELD-AF&doi=10.1093%2Feurheartj%2Fehw233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF</span></div><div class="casAuthors">Bassand Jean-Pierre; Bassand Jean-Pierre; Accetta Gabriele; Kayani Gloria; Kakkar Ajay K; Camm Alan John; Cools Frank; Fitzmaurice David A; Fox Keith A A; Goldhaber Samuel Z; Goto Shinya; Haas Sylvia; Hacke Werner; Mantovani Lorenzo G; Misselwitz Frank; Ten Cate Hugo; Turpie Alexander G G; Verheugt Freek W A; Verheugt Freek W A; Kakkar Ajay K</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">2882-2889</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year.  METHODS AND RESULTS:  GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF.  Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy.  The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy.  At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively.  Rates for all three major events were highest during the first 4 months.  Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%.  Anticoagulant treatment was associated with a 35% lower risk of death.  CONCLUSION:  The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation.  This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome.  This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death.  CLINICAL TRIAL REGISTRATION:  http://www.clinicaltrials.gov.  Unique identifier: NCT01090362.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqozCPMEXdb3O4gDb7JggCfW6udTcc2eZ-3aDciJaJQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltVSktw%253D%253D&md5=4a9eeb250adfc4ea4d20fb446b4e4750</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehw233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehw233%26sid%3Dliteratum%253Aachs%26aulast%3DBassand%26aufirst%3DJ.%2BP.%26aulast%3DAccetta%26aufirst%3DG.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DCools%26aufirst%3DF.%26aulast%3DFitzmaurice%26aufirst%3DD.%2BA.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DGoldhaber%26aufirst%3DS.%2BZ.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DHaas%26aufirst%3DS.%26aulast%3DHacke%26aufirst%3DW.%26aulast%3DKayani%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DL.%2BG.%26aulast%3DMisselwitz%26aufirst%3DF.%26aulast%3DTen%2BCate%26aufirst%3DH.%26aulast%3DTurpie%26aufirst%3DA.%2BG.%26aulast%3DVerheugt%26aufirst%3DF.%2BW.%26aulast%3DKakkar%26aufirst%3DA.%2BK.%26atitle%3DTwo-year%2520outcomes%2520of%2520patients%2520with%2520newly%2520diagnosed%2520atrial%2520fibrillation%253A%2520results%2520from%2520GARFIELD-AF%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D2882%26epage%3D2889%26doi%3D10.1093%2Feurheartj%2Fehw233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bane, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruberm, A.</span></span> <span> </span><span class="NLM_article-title">Factor XI and contact activation as targets for antithrombotic therapy</span>. <i>J. Thromb. Haemost.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1111/jth.13005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fjth.13005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=25976012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC2MfktVCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1383-1395&author=D.+Gailaniauthor=C.+E.+Baneauthor=A.+Gruberm&title=Factor+XI+and+contact+activation+as+targets+for+antithrombotic+therapy&doi=10.1111%2Fjth.13005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XI and contact activation as targets for antithrombotic therapy</span></div><div class="casAuthors">Gailani D; Bane C E; Gruber A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thrombosis and haemostasis : JTH</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1383-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The most commonly used anticoagulants produce therapeutic antithrombotic effects either by inhibiting thrombin or factor Xa (FXa) or by lowering the plasma levels of the precursors of these key enzymes, prothrombin and FX.  These drugs do not distinguish between thrombin generation contributing to thrombosis from thrombin generation required for hemostasis.  Thus, anticoagulants increase bleeding risk, and many patients who would benefit from therapy go untreated because of comorbidities that place them at unacceptable risk for hemorrhage.  Studies in animals demonstrate that components of the plasma contact activation system contribute to experimentally induced thrombosis, despite playing little or no role in hemostasis.  Attention has focused on FXII, the zymogen of a protease (FXIIa) that initiates contact activation when blood is exposed to foreign surfaces, and FXI, the zymogen of the protease FXIa, which links contact activation to the thrombin generation mechanism.  In the case of FXI, epidemiologic data indicate this protein contributes to stroke and venous thromboembolism, and perhaps myocardial infarction, in humans.  A phase 2 trial showing that reduction of FXI may be more effective than low molecular weight heparin at preventing venous thrombosis during knee replacement surgery provides proof of concept for the premise that an antithrombotic effect can be uncoupled from an anticoagulant effect in humans by targeting components of contact activation.  Here, we review data on the role of FXI and FXII in thrombosis and results of preclinical and human trials for therapies targeting these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFpzo98DHKlKx48Rj5GnGofW6udTcc2eZ-3aDciJaJQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfktVCmtw%253D%253D&md5=3a17ac6f58b2ab941bccbc6080a9ea27</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fjth.13005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13005%26sid%3Dliteratum%253Aachs%26aulast%3DGailani%26aufirst%3DD.%26aulast%3DBane%26aufirst%3DC.%2BE.%26aulast%3DGruberm%26aufirst%3DA.%26atitle%3DFactor%2520XI%2520and%2520contact%2520activation%2520as%2520targets%2520for%2520antithrombotic%2520therapy%26jtitle%3DJ.%2520Thromb.%2520Haemost.%26date%3D2015%26volume%3D13%26spage%3D1383%26epage%3D1395%26doi%3D10.1111%2Fjth.13005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of factor XI activity as a promising antithrombotic strategy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1435</span>– <span class="NLM_lpage">1439</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.drudis.2014.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=24794465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFerurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1435-1439&author=Z.+Chenauthor=D.+Seiffertauthor=B.+Hawes&title=Inhibition+of+factor+XI+activity+as+a+promising+antithrombotic+strategy&doi=10.1016%2Fj.drudis.2014.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Factor XI activity as a promising antithrombotic strategy</span></div><div class="casAuthors">Chen, Zhu; Seiffert, Dietmar; Hawes, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1435-1439</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Prevention and treatment of thromboembolic disorders with minimal bleeding risk remains a significant unmet medical need.  Studies in Factor XI (FXI)-deficient humans and exptl. animal models suggest that targeting FXI in humans provides antithrombotic benefits with reduced bleeding liability compared with current std. of care.  In this review, we describe an exciting era in the discovery and development of antithrombotic agents as multiple therapeutic modalities for FXI(a) inhibition progress through preclin. and clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUC5zfGWcW6LVg90H21EOLACvtfcHk0li7wM1kb8kFGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFerurg%253D&md5=2c492b2af52bc361025f028e3521b271</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSeiffert%26aufirst%3DD.%26aulast%3DHawes%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520factor%2520XI%2520activity%2520as%2520a%2520promising%2520antithrombotic%2520strategy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1435%26epage%3D1439%26doi%3D10.1016%2Fj.drudis.2014.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bane, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span> <span> </span><span class="NLM_article-title">Factor XI as a target for antithrombotic therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.drudis.2014.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=24886766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCitb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1454-1458&author=C.+E.+Baneauthor=D.+Gailani&title=Factor+XI+as+a+target+for+antithrombotic+therapy&doi=10.1016%2Fj.drudis.2014.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XI as a target for antithrombotic therapy</span></div><div class="casAuthors">Bane, Charles E., Jr.; Gailani, David</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1454-1458</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anticoagulants currently used in clin. practice to treat thromboembolic disorders are effective but increase the risk of severe bleeding because they target proteins that are essential for normal coagulation (hemostasis).  Drugs with better safety profiles are required for prevention and treatment of thromboembolic disease.  Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzzQ4yWZR1R7Vg90H21EOLACvtfcHk0li7wM1kb8kFGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCitb%252FE&md5=92c657d769a88603800bb29ca9340886</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DBane%26aufirst%3DC.%2BE.%26aulast%3DGailani%26aufirst%3DD.%26atitle%3DFactor%2520XI%2520as%2520a%2520target%2520for%2520antithrombotic%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1454%26epage%3D1458%26doi%3D10.1016%2Fj.drudis.2014.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, O.</span></span> <span> </span><span class="NLM_article-title">Congenital factor XI deficiency: an update</span>. <i>Semin. Thromb. Hemostasis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1353420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1055%2Fs-0033-1353420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=23929304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=621-631&author=S.+Dugaauthor=O.+Salomon&title=Congenital+factor+XI+deficiency%3A+an+update&doi=10.1055%2Fs-0033-1353420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Congenital factor XI deficiency: an update</span></div><div class="casAuthors">Duga, Stefano; Salomon, Ophira</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-631</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Severe factor XI (FXI) deficiency is an injury-related bleeding disorder, common in Ashkenazi Jews (with two mutations prevailing), but rare worldwide (with heterogeneous mutations).  In the past two decades, more than 220 mutations in the FXI gene have been reported in patients with FXI deficiency, of which 7 showed a founder effect.  Inhibitors to FXI were described in patients with null-allele mutations, following exposure to plasma, FXI concs., or anti-RhD Ig.  Treatment of patients with severe FXI deficiency remains challenging because factors influencing bleeding risks are still unknown.  The use of lower doses of recombinant activated factor VII in comparison with the doses commonly applied in hemophilia A or B seems promising also when assessed in vitro by thrombin generation test.  Recently, FXI has been shown to have a sep. role in hemostasis and in thrombosis.  In animal models, targeting FXI by knocking out the gene or by using FXI-neutralizing antibodies, antisense oligonucleotides, and peptidomimetic inhibitors, prevents arterial and vein thrombosis.  The homol. between human and murine FXI and the significant antithrombotic effect of FXI deficiency in animal models resulted in the development of a novel approach of targeting FXI for prevention of thrombosis without impairing hemostasis in high-risk patients.  The acceptance of FXI as a risk factor for thrombosis is a new concept, and patients with severe FXI deficiency might gain profit during life course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9p2sCb_-8EbVg90H21EOLACvtfcHk0li7wM1kb8kFGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2htLnN&md5=7bad95a2c1a4f6e30f7bdae6b1149cb4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1353420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1353420%26sid%3Dliteratum%253Aachs%26aulast%3DDuga%26aufirst%3DS.%26aulast%3DSalomon%26aufirst%3DO.%26atitle%3DCongenital%2520factor%2520XI%2520deficiency%253A%2520an%2520update%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2013%26volume%3D39%26spage%3D621%26epage%3D631%26doi%3D10.1055%2Fs-0033-1353420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Büller, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethune, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raskob, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhamme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Factor XI antisense oligonucleotide for prevention of venous thrombosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1405760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1056%2FNEJMoa1405760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=25482425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFSrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=232-240&author=H.+R.+B%C3%BCllerauthor=C.+Bethuneauthor=S.+Bhanotauthor=D.+Gailaniauthor=B.+P.+Moniaauthor=G.+E.+Raskobauthor=A.+Segersauthor=P.+Verhammeauthor=J.+I.+Weitz&title=Factor+XI+antisense+oligonucleotide+for+prevention+of+venous+thrombosis&doi=10.1056%2FNEJMoa1405760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XI antisense oligonucleotide for prevention of venous thrombosis</span></div><div class="casAuthors">Bueller, Harry R.; Bethune, Claudette; Bhanot, Sanjay; Gailani, David; Monia, Brett P.; Raskob, Gary E.; Segers, Annelise; Verhamme, Peter; Weitz, Jeffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-240/1-232-240/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Exptl. data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown.  FXI-ASO (ISIS 416858) is a second generation antisense oligonucleotide that specifically reduces factor XI levels.  We compared the efficacy and safety of FXI-ASO with those of enoxaparin in patients undergoing total knee arthroplasty.  Methods In this open-label, parallel-group study, we randomly assigned 300 patients who were undergoing elective primary unilateral total knee arthroplasty to receive one of two doses of FXI-ASO (200 mg or 300 mg) or 40 mg of enoxaparin once daily.  The primary efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral venog. or report of symptomatic events).  The principal safety outcome was major or clin. relevant nonmajor bleeding.  Results Around the time of surgery, the mean (±SE) factor XI levels were 0.38±0.01 units per mL in the 200-mg FXI-ASO group, 0.20±0.01 units per mL in the 300-mg FXI-ASO group, and 0.93±0.02 units per mL in the enoxaparin group.  The primary efficacy outcome occurred in 36 of 134 patients (27%) who received the 200-mg dose of FXI-ASO and in 3 of 71 patients (4%) who received the 300-mg dose of FXI-ASO, as compared with 21 of 69 patients (30 %) who received enoxaparin.  The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to enoxaparin (P<0.001).  Bleeding occurred in 3 %, 3 %, and 8 % of the patients in the three study groups, resp.  Conclusions This study showed that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients undergoing elective primary unilateral total knee arthroplasty was an effective method for its prevention and appeared to be safe with respect to the risk of bleeding. (Funded by Isis Pharmaceuticals; FXI-ASO TKA ClinicalTrials.gov no., NCT01713361.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIN16Q4zBOZLVg90H21EOLACvtfcHk0li7wM1kb8kFGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFSrsb4%253D&md5=dca68c696383ef3fdbf25b16f27e2989</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1405760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1405760%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCller%26aufirst%3DH.%2BR.%26aulast%3DBethune%26aufirst%3DC.%26aulast%3DBhanot%26aufirst%3DS.%26aulast%3DGailani%26aufirst%3DD.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DRaskob%26aufirst%3DG.%2BE.%26aulast%3DSegers%26aufirst%3DA.%26aulast%3DVerhamme%26aufirst%3DP.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DFactor%2520XI%2520antisense%2520oligonucleotide%2520for%2520prevention%2520of%2520venous%2520thrombosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D232%26epage%3D240%26doi%3D10.1056%2FNEJMoa1405760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallheer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span> <span> </span><span class="NLM_article-title">Factor XIa inhibitors as new anticoagulants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7425</span>– <span class="NLM_lpage">7447</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00173</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00173" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1yitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7425-7447&author=M.+L.+Quanauthor=D.+J.+P.+Pintoauthor=J.+M.+Smallheerauthor=W.+R.+Ewingauthor=K.+A.+Rossiauthor=J.+M.+Luettgenauthor=D.+A.+Seiffertauthor=R.+R.+Wexler&title=Factor+XIa+inhibitors+as+new+anticoagulants&doi=10.1021%2Facs.jmedchem.8b00173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XIa Inhibitors as New Anticoagulants</span></div><div class="casAuthors">Quan, Mimi L.; Pinto, Donald J. P.; Smallheer, Joanne M.; Ewing, William R.; Rossi, Karen A.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7425-7447</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved.  Early clin. and preclin. data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications.  This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrri7-BSbXNpLVg90H21EOLACvtfcHk0lj4xJGtcJ1PcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1yitL0%253D&md5=192aec0b37c394ffb790b874e34e79cf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00173%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DSmallheer%26aufirst%3DJ.%2BM.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DFactor%2520XIa%2520inhibitors%2520as%2520new%2520anticoagulants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7425%26epage%3D7447%26doi%3D10.1021%2Facs.jmedchem.8b00173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Horani, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, U. R.</span></span> <span> </span><span class="NLM_article-title">Factor XIa inhibitors: a review of patent literature</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1154045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1517%2F13543776.2016.1154045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=26881476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1Chtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=323-345&author=R.+A.+Al-Horaniauthor=U.+R.+Desai&title=Factor+XIa+inhibitors%3A+a+review+of+patent+literature&doi=10.1517%2F13543776.2016.1154045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Factor XIa inhibitors: A review of the patent literature</span></div><div class="casAuthors">Al-Horani, Rami A.; Desai, Umesh R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-345</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Anticoagulants are the mainstay for prevention and/or treatment of thrombotic disorders.  Each clin. used anticoagulant is assocd. with significant adverse consequences, esp. bleeding.  Factor XIa (FXIa), a key factor involved in the amplification of procoagulation signal, has been suggested as a major target for anticoagulant drug discovery because of reduced risk of bleeding.: Our literature search uncovered dozens of industrial and academic patents on the discovery of novel FXIa/FXI inhibitors.  Small peptidomimetics, sulfated glycosaminoglycan mimetics, polypeptides, antisense oligonucleotides, and monoclonal antibodies have been developed as inhibitors of FXIa.  Although many agents are in early discovery/development phases, the activity and safety of a few have been evaluated in various animal models and in humans.: FXIa is a promising drug target for development of effective anticoagulants with limited bleeding complications.  Literature reveals a major trend in the no. of patent applications over the last three years.  These inhibitors exploit different approaches for target inhibition.  Allosteric modulation of FXIa and biosynthetic inhibition of FXI are mechanistically unique.  Despite initial results in patients undergoing knee anthroplasty as with antisense oligonucleotides, major advances should be realized, particularly with respect to pharmacokinetics, for FXI/FXIa inhibitors to enter the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcAvCXF1PYbVg90H21EOLACvtfcHk0lj4xJGtcJ1PcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1Chtbw%253D&md5=647cc7fcd90903cf5fbacce6c733d280</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1154045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1154045%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Horani%26aufirst%3DR.%2BA.%26aulast%3DDesai%26aufirst%3DU.%2BR.%26atitle%3DFactor%2520XIa%2520inhibitors%253A%2520a%2520review%2520of%2520patent%2520literature%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D323%26epage%3D345%26doi%3D10.1517%2F13543776.2016.1154045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Mey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heubach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yassen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxnick, S.</span></span> <span> </span><span class="NLM_article-title">First evaluation of the safety, pharmacokinetics and pharmacodynamics of BAY1213790, a full human IgG1 antibody targeting coagulation factor XIa, in healthy young men</span>. <i>Res. Pract. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=392&author=D.+Thomasauthor=K.+Thelenauthor=D.+van+der%0AMeyauthor=S.+Schwersauthor=S.+Schifferauthor=J.+Ungerauthor=A.+Heubachauthor=A.+Yassenauthor=S.+Boxnick&title=First+evaluation+of+the+safety%2C+pharmacokinetics+and+pharmacodynamics+of+BAY1213790%2C+a+full+human+IgG1+antibody+targeting+coagulation+factor+XIa%2C+in+healthy+young+men"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DThelen%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BMey%26aufirst%3DD.%26aulast%3DSchwers%26aufirst%3DS.%26aulast%3DSchiffer%26aufirst%3DS.%26aulast%3DUnger%26aufirst%3DJ.%26aulast%3DHeubach%26aufirst%3DA.%26aulast%3DYassen%26aufirst%3DA.%26aulast%3DBoxnick%26aufirst%3DS.%26atitle%3DFirst%2520evaluation%2520of%2520the%2520safety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520BAY1213790%252C%2520a%2520full%2520human%2520IgG1%2520antibody%2520targeting%2520coagulation%2520factor%2520XIa%252C%2520in%2520healthy%2520young%2520men%26jtitle%3DRes.%2520Pract.%2520Thromb.%2520Haemostasis%26date%3D2017%26volume%3D1%26spage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">(Abstract PB 834)</p></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melkko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horny, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPetrillo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGagne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulmatycki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basson, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, R. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khder, Y.</span></span> <span> </span><span class="NLM_article-title">MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1516</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-10-880849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1182%2Fblood-2018-10-880849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=30692123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2019&pages=1507-1516&author=A.+W.+Kochauthor=N.+Schieringauthor=S.+Melkkoauthor=S.+Ewertauthor=J.+Salterauthor=Y.+Zhangauthor=P.+McCormackauthor=J.+Yuauthor=X.+Huangauthor=Y.+H.+Chiuauthor=Z.+Chenauthor=S.+Schleegerauthor=G.+Hornyauthor=K.+DiPetrilloauthor=L.+Mullerauthor=A.+Heinauthor=F.+Villardauthor=M.+Scharenbergauthor=P.+Ramageauthor=U.+Hassiepenauthor=S.+C%C3%B4t%C3%A9author=J.+DeGagneauthor=C.+Krantzauthor=J.+Ederauthor=B.+Stollauthor=K.+Kulmatyckiauthor=D.+L.+Feldmanauthor=P.+Hoffmannauthor=C.+T.+Bassonauthor=R.+J.+A.+Frostauthor=Y.+Khder&title=MAA868%2C+a+novel+FXI+antibody+with+a+unique+binding+mode%2C+shows+durable+effects+on+markers+of+anticoagulation+in+humans&doi=10.1182%2Fblood-2018-10-880849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans</span></div><div class="casAuthors">Koch, Alexander W.; Schiering, Nikolaus; Melkko, Samu; Ewert, Stefan; Salter, Janeen; Zhang, Yiming; McCormack, Peter; Yu, Jianying; Huang, Xueming; Chiu, Yu-Hsin; Chen, Zhiping; Schleeger, Simone; Horny, Geraldine; Dipetrillo, Keith; Muller, Lionel; Hein, Andreas; Villard, Frederic; Scharenberg, Meike; Ramage, Paul; Hassiepen, Ulrich; Cote, Serge; Degagne, Julie; Krantz, Carsten; Eder, Joerg; Stoll, Brian; Kulmatycki, Kenneth; Feldman, David L.; Hoffmann, Peter; Basson, Craig T.; Frost, Robert J. A.; Khder, Yasser</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1507-1516</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A large unmet medical need exists for safer antithrombotic drugs because all currently approved anticoagulant agents interfere with hemostasis, leading to an increased risk of bleeding.  Genetic and pharmacol. evidence in humans and animals suggests that reducing factor XI (FXI) levels has the potential to effectively prevent and treat thrombosis with a minimal risk of bleeding.  We generated a fully human antibody (MAA868) that binds the catalytic domain of both FXI (zymogen) and activated FXI.  Our structural studies show that MAA868 traps FXI and activated FXI in an inactive, zymogen-like conformation, explaining its equally high binding affinity for both forms of the enzyme.  This binding mode allows the enzyme to be neutralized before entering the coagulation process, revealing a particularly attractive anticoagulant profile of the antibody.  MAA868 exhibited favorable anticoagulant activity in mice with a dose-dependent protection from carotid occlusion in a ferric chloride-induced thrombosis model.  MAA868 also caused robust and sustained anticoagulant activity in cynomolgus monkeys as assessed by activated partial thromboplastin time without any evidence of bleeding.  Based on these preclin. findings, we conducted a first-in-human study in healthy subjects and showed that single s.c. doses of MAA868 were safe and well tolerated.  MAA868 resulted in dose- and time-dependent robust and sustained prolongation of activated partial thromboplastin time and FXI suppression for up to 4 wk or longer, supporting further clin. investigation as a potential once-monthly s.c. anticoagulant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEg6DvzFGi7Vg90H21EOLACvtfcHk0lg2cj-g_HEKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlSrtL8%253D&md5=69bf3a18273147a4b32c96be252c2d2c</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-10-880849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-10-880849%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BW.%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DMelkko%26aufirst%3DS.%26aulast%3DEwert%26aufirst%3DS.%26aulast%3DSalter%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMcCormack%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChiu%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSchleeger%26aufirst%3DS.%26aulast%3DHorny%26aufirst%3DG.%26aulast%3DDiPetrillo%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DHein%26aufirst%3DA.%26aulast%3DVillard%26aufirst%3DF.%26aulast%3DScharenberg%26aufirst%3DM.%26aulast%3DRamage%26aufirst%3DP.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DS.%26aulast%3DDeGagne%26aufirst%3DJ.%26aulast%3DKrantz%26aufirst%3DC.%26aulast%3DEder%26aufirst%3DJ.%26aulast%3DStoll%26aufirst%3DB.%26aulast%3DKulmatycki%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DD.%2BL.%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DBasson%26aufirst%3DC.%2BT.%26aulast%3DFrost%26aufirst%3DR.%2BJ.%2BA.%26aulast%3DKhder%26aufirst%3DY.%26atitle%3DMAA868%252C%2520a%2520novel%2520FXI%2520antibody%2520with%2520a%2520unique%2520binding%2520mode%252C%2520shows%2520durable%2520effects%2520on%2520markers%2520of%2520anticoagulation%2520in%2520humans%26jtitle%3DBlood%26date%3D2019%26volume%3D133%26spage%3D1507%26epage%3D1516%26doi%3D10.1182%2Fblood-2018-10-880849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corte, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspady, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neithnadka, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span> <span> </span><span class="NLM_article-title">Potent, orally bioavailable, and efficacious macrocyclic inhibitors of factor XIa. Discovery of pyridine-based macrocycles possessing phenylazole carboxamide P1 groups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=784-803&author=J.+R.+Corteauthor=D.+J.+P.+Pintoauthor=T.+Fangauthor=H.+Osunaauthor=W.+Yangauthor=Y.+Wangauthor=A.+Laiauthor=C.+G.+Clarkauthor=J.-H.+Sunauthor=R.+Rampullaauthor=A.+Mathurauthor=M.+Kaspadyauthor=P.+R.+Neithnadkaauthor=Y.-X.+C.+Liauthor=K.+A.+Rossiauthor=J.+E.+Myersauthor=S.+Sheriffauthor=Z.+Louauthor=T.+W.+Harperauthor=C.+Huangauthor=J.+J.+Zhengauthor=J.+M.+Bozarthauthor=Y.+Wuauthor=P.+C.+Wongauthor=E.+J.+Crainauthor=D.+A.+Seiffertauthor=J.+M.+Luettgenauthor=P.+Y.+S.+Lamauthor=R.+R.+Wexlerauthor=W.+R.+Ewing&title=Potent%2C+orally+bioavailable%2C+and+efficacious+macrocyclic+inhibitors+of+factor+XIa.+Discovery+of+pyridine-based+macrocycles+possessing+phenylazole+carboxamide+P1+groups&doi=10.1021%2Facs.jmedchem.9b01768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups</span></div><div class="casAuthors">Corte, James R.; Pinto, Donald J. P.; Fang, Tianan; Osuna, Honey; Yang, Wu; Wang, Yufeng; Lai, Amy; Clark, Charles G.; Sun, Jung-Hui; Rampulla, Richard; Mathur, Arvind; Kaspady, Mahammed; Neithnadka, Premsai Rai; Li, Yi-Xin Cindy; Rossi, Karen A.; Myers, Joseph E.; Sheriff, Steven; Lou, Zhen; Harper, Timothy W.; Huang, Christine; Zheng, Joanna J.; Bozarth, Jeffrey M.; Wu, Yiming; Wong, Pancras C.; Crain, Earl J.; Seiffert, Dietmar A.; Luettgen, Joseph M.; Lam, Patrick Y. S.; Wexler, Ruth R.; Ewing, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Factor XIa (FXIa) inhibitors are promising novel anticoagulants, which show excellent efficacy in preclin. thrombosis models with minimal effects on hemostasis.  The discovery of potent and selective FXIa inhibitors which are also orally bioavailable has been a challenge.  Here, we describe optimization of the imidazole-based macrocyclic series and our initial progress toward meeting this challenge.  A two-pronged strategy, which focused on replacement of the imidazole scaffold and the design of new P1 groups, led to the discovery of potent, orally bioavailable pyridine-based macrocyclic FXIa inhibitors.  Moreover, pyridine-based macrocycle 19, possessing the phenylimidazole carboxamide P1, exhibited excellent selectivity against relevant blood coagulation enzymes and displayed antithrombotic efficacy in a rabbit thrombosis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDJ6B4dsypXrVg90H21EOLACvtfcHk0lg2cj-g_HEKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrO&md5=c6443b52ba7e7c21ffe915d3f34ec736</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01768%26sid%3Dliteratum%253Aachs%26aulast%3DCorte%26aufirst%3DJ.%2BR.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DFang%26aufirst%3DT.%26aulast%3DOsuna%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DC.%2BG.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DKaspady%26aufirst%3DM.%26aulast%3DNeithnadka%26aufirst%3DP.%2BR.%26aulast%3DLi%26aufirst%3DY.-X.%2BC.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DHarper%26aufirst%3DT.%2BW.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DBozarth%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DCrain%26aufirst%3DE.%2BJ.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DPotent%252C%2520orally%2520bioavailable%252C%2520and%2520efficacious%2520macrocyclic%2520inhibitors%2520of%2520factor%2520XIa.%2520Discovery%2520of%2520pyridine-based%2520macrocycles%2520possessing%2520phenylazole%2520carboxamide%2520P1%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D784%26epage%3D803%26doi%3D10.1021%2Facs.jmedchem.9b01768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwat, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apedo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toussaint, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetsko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudmundsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a parenteral small molecule coagulation factor XIa inhibitor clinical candidate (BMS-962212)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9703</span>– <span class="NLM_lpage">9723</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01171</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01171" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslent7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9703-9723&author=D.+J.+P.+Pintoauthor=M.+J.+Orwatauthor=L.+M.+Smithauthor=M.+L.+Quanauthor=P.+Y.+S.+Lamauthor=K.+A.+Rossiauthor=A.+Apedoauthor=J.+M.+Bozarthauthor=Y.+Wuauthor=J.+J.+Zhengauthor=B.+Xinauthor=N.+Toussaintauthor=P.+Stetskoauthor=O.+Gudmundssonauthor=B.+Maxwellauthor=E.+J.+Crainauthor=P.+C.+Wongauthor=Z.+Louauthor=T.+W.+Harperauthor=S.+A.+Chackoauthor=J.+E.+Myersauthor=S.+Sheriffauthor=H.+Zhangauthor=X.+Houauthor=A.+Mathurauthor=D.+A.+Seiffertauthor=R.+R.+Wexlerauthor=J.+M.+Luettgenauthor=W.+R.+Ewing&title=Discovery+of+a+parenteral+small+molecule+coagulation+factor+XIa+inhibitor+clinical+candidate+%28BMS-962212%29&doi=10.1021%2Facs.jmedchem.7b01171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)</span></div><div class="casAuthors">Pinto, Donald J. P.; Orwat, Michael J.; Smith, Leon M.; Quan, Mimi L.; Lam, Patrick Y. S.; Rossi, Karen A.; Apedo, Atsu; Bozarth, Jeffrey M.; Wu, Yiming; Zheng, Joanna J.; Xin, Baomin; Toussaint, Nathalie; Stetsko, Paul; Gudmundsson, Olafur; Maxwell, Brad; Crain, Earl J.; Wong, Pancras C.; Lou, Zhen; Harper, Timothy W.; Chacko, Silvi A.; Myers, Joseph E.; Sheriff, Steven; Zhang, Huiping; Hou, Xiaoping; Mathur, Arvind; Seiffert, Dietmar A.; Wexler, Ruth R.; Luettgen, Joseph M.; Ewing, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9703-9723</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Factor XIa (FXIa) is a blood coagulation enzyme that is involved in the amplification of thrombin generation.  Mounting evidence suggests that direct inhibition of FXIa can block pathol. thrombus formation while preserving normal hemostasis.  Preclin. studies using a variety of approaches to reduce FXIa activity, including direct inhibitors of FXIa, have demonstrated good antithrombotic efficacy without increasing bleeding.  Based on this potential, the authors targeted the efforts at identifying potent inhibitors of FXIa with a focus on discovering an acute antithrombotic agent for use in a hospital setting.  Herein the authors describe the discovery of a potent FXIa clin. candidate, I (FXIa Ki = 0.7 nM), with excellent preclin. efficacy in thrombosis models and aq. soly. suitable for i.v. administration.  BMS-962212 is a reversible, direct, and highly selective small mol. inhibitor of FXIa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDjxJ_bitf6rVg90H21EOLACvtfcHk0lhLdHUI_y8z8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslent7bE&md5=8873c054b79778fe7c45daa2eda64084</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01171%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DApedo%26aufirst%3DA.%26aulast%3DBozarth%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DToussaint%26aufirst%3DN.%26aulast%3DStetsko%26aufirst%3DP.%26aulast%3DGudmundsson%26aufirst%3DO.%26aulast%3DMaxwell%26aufirst%3DB.%26aulast%3DCrain%26aufirst%3DE.%2BJ.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DHarper%26aufirst%3DT.%2BW.%26aulast%3DChacko%26aufirst%3DS.%2BA.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DDiscovery%2520of%2520a%2520parenteral%2520small%2520molecule%2520coagulation%2520factor%2520XIa%2520inhibitor%2520clinical%2520candidate%2520%2528BMS-962212%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9703%26epage%3D9723%26doi%3D10.1021%2Facs.jmedchem.7b01171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCreta, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSouza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirincione, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, R. J. A.</span></span> <span> </span><span class="NLM_article-title">First in human study to assess safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">876</span>, <span class="refDoi"> DOI: 10.1111/bcp.13520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fbcp.13520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=29346838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=876&author=V.+Pereraauthor=J.+M.+Luettgenauthor=Z.+Wangauthor=C.+E.+Frostauthor=C.+Yonesauthor=C.+Russoauthor=J.+Leeauthor=Y.+Zhaoauthor=F.+P.+LaCretaauthor=X.+Maauthor=R.+M.+Knabbauthor=D.+Seiffertauthor=M.+DeSouzaauthor=P.+Mugnierauthor=B.+Cirincioneauthor=T.+Uenoauthor=R.+J.+A.+Frost&title=First+in+human+study+to+assess+safety%2C+pharmacokinetics+and+pharmacodynamics+of+BMS-962212%2C+a+direct%2C+reversible%2C+small+molecule+factor+XIa+inhibitor+in+non-Japanese+and+Japanese+healthy+subjects&doi=10.1111%2Fbcp.13520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects</span></div><div class="casAuthors">Perera, Vidya; Luettgen, Joseph M.; Wang, Zhaoqing; Frost, Charles E.; Yones, Cynthia; Russo, Cesare; Lee, John; Zhao, Yue; La Creta, Frank P.; Ma, Xuewen; Knabb, Robert M.; Seiffert, Dietmar; De Souza, Mary; Mugnier, Pierre; Cirincione, Brenda; Ueno, Takayo; Frost, Robert J. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">876-887</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-962212, a first-in-class factor XIa inhibitor, in Japanese and non-Japanese healthy subjects.  Methods : This was a randomized, placebo-controlled, double-blind, sequential, ascending-dose study of 2-h (part A) and 5-day (part B) i.v. (IV) infusions of BMS-962212.  Part A used four doses (1.5, 4, 10 and 25 mg h-1) of BMS-962212 or placebo in a 6:2 ratio per dose.  Part B used four doses (1, 3, 9 and 20 mg h-1) enrolling Japanese (n = 4 active, n = 1 placebo) and non-Japanese (n = 4 active, n = 1 placebo) subjects per dose.  The PK, PD, safety and tolerability were assessed throughout the study.  Results : BMS-962212 was well tolerated; there were no signs of bleeding, and adverse events were mild.  In parts A and B, BMS-962212 demonstrated dose proportionality.  The mean half-life in parts A and B ranged from 2.04 to 4.94 h and 6.22 to 8.65 h, resp.  Exposure-dependent changes were obsd. in the PD parameters, activated partial thromboplastin time (aPTT) and factor XI clotting activity (FXI:C).  The max. mean aPTT and FXI:C change from baseline at 20 mg h-1 in part B was 92% and 90%, resp.  No difference was obsd. in wt.-cor. steady-state concns., aPTT or FXI:C between Japanese and non-Japanese subjects (P > 0.05).  Conclusion : BMS-962212 has tolerability, PK and PD properties suitable for investigational use as an acute antithrombotic agent in Japanese or non-Japanese subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9bWTBwIh5OLVg90H21EOLACvtfcHk0lhLdHUI_y8z8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGlsLY%253D&md5=30badec3a1c297fe1c85d37e22b821d3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13520%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DV.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DYones%26aufirst%3DC.%26aulast%3DRusso%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLaCreta%26aufirst%3DF.%2BP.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DSeiffert%26aufirst%3DD.%26aulast%3DDeSouza%26aufirst%3DM.%26aulast%3DMugnier%26aufirst%3DP.%26aulast%3DCirincione%26aufirst%3DB.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DFrost%26aufirst%3DR.%2BJ.%2BA.%26atitle%3DFirst%2520in%2520human%2520study%2520to%2520assess%2520safety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520BMS-962212%252C%2520a%2520direct%252C%2520reversible%252C%2520small%2520molecule%2520factor%2520XIa%2520inhibitor%2520in%2520non-Japanese%2520and%2520Japanese%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D876%26doi%3D10.1111%2Fbcp.13520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span>Oral factor XIa inhibitor for
the prevention of new ischemic stroke in patients receiving aspirin
and clopidogrel following acute ischemic stroke or transient ischemic
attack (TIA). <a href="https://clinicaltrials.gov/ct2/show/NCT03766581" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03766581</a> (accessed April 26, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+factor+XIa+inhibitor+for%0Athe+prevention+of+new+ischemic+stroke+in+patients+receiving+aspirin%0Aand+clopidogrel+following+acute+ischemic+stroke+or+transient+ischemic%0Aattack+%28TIA%29.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03766581+%28accessed+April+26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokesch, P. M.</span></span> <span> </span><span class="NLM_article-title">Abstract 13747: Phase 1a/1b study of EP-7041: a novel, potent, selective, small molecule FXIa inhibitor</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>, <span class="NLM_elocation-id">A13747</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&author=N.+J.+Haywardauthor=D.+I.+Goldbergauthor=E.+M.+Morrelauthor=P.+M.+Fridenauthor=P.+M.+Bokesch&title=Abstract+13747%3A+Phase+1a%2F1b+study+of+EP-7041%3A+a+novel%2C+potent%2C+selective%2C+small+molecule+FXIa+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DN.%2BJ.%26aulast%3DGoldberg%26aufirst%3DD.%2BI.%26aulast%3DMorrel%26aufirst%3DE.%2BM.%26aulast%3DFriden%26aufirst%3DP.%2BM.%26aulast%3DBokesch%26aufirst%3DP.%2BM.%26atitle%3DAbstract%252013747%253A%2520Phase%25201a%252F1b%2520study%2520of%2520EP-7041%253A%2520a%2520novel%252C%2520potent%252C%2520selective%252C%2520small%2520molecule%2520FXIa%2520inhibitor%26jtitle%3DCirculation%26date%3D2017%26volume%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sedrani, R.</span>; <span class="NLM_string-name">Hommel, U.</span>; <span class="NLM_string-name">Eder, J.</span></span> <span> </span><span class="NLM_article-title">Protease-Directed Drug Discovery</span>. In  <i>Gene Family Targeted Molecular Design</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>, Ed.; <span class="NLM_publisher-name">John Wiley and Sons</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2008</span>; Chapter 6, pp  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">197</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1002%2F9780470423936.ch6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=159-197&author=R.+Sedrani&author=U.+Hommel&author=J.+Ederauthor=K.+E.+Lackey&title=Gene+Family+Targeted+Molecular+Design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2F9780470423936.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470423936.ch6%26sid%3Dliteratum%253Aachs%26aulast%3DSedrani%26aufirst%3DR.%26atitle%3DProtease-Directed%2520Drug%2520Discovery%26btitle%3DGene%2520Family%2520Targeted%2520Molecular%2520Design%26aulast%3DLackey%26aufirst%3DK.%2BE.%26pub%3DJohn%2520Wiley%2520and%2520Sons%26date%3D2008%26spage%3D159%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renné, T.</span></span> <span> </span><span class="NLM_article-title">Human deficiencies in intrinsic cascade proteases FXII and plasma kallikrein (PKL) have not been strongly associated with antithrombotic protection or enhanced bleeding risk, see: Contact system revisited: an interface between inflammation, coagulation, and innate immunity</span>. <i>J. Thromb. Haemost.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1111/jth.13235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1111%2Fjth.13235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=26707513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BC28rltVSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=427-437&author=A.+T.+Longauthor=E.+Kenneauthor=R.+Jungauthor=T.+A.+Fuchsauthor=T.+Renn%C3%A9&title=Human+deficiencies+in+intrinsic+cascade+proteases+FXII+and+plasma+kallikrein+%28PKL%29+have+not+been+strongly+associated+with+antithrombotic+protection+or+enhanced+bleeding+risk%2C+see%3A+Contact+system+revisited%3A+an+interface+between+inflammation%2C+coagulation%2C+and+innate+immunity&doi=10.1111%2Fjth.13235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Contact system revisited: an interface between inflammation, coagulation, and innate immunity</span></div><div class="casAuthors">Long A T; Jung R; Fuchs T A; Renne T; Kenne E; Fuchs T A; Renne T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thrombosis and haemostasis : JTH</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The contact system is a plasma protease cascade initiated by factor XII (FXII) that activates the proinflammatory kallikrein-kinin system and the procoagulant intrinsic coagulation pathway.  Anionic surfaces induce FXII zymogen activation to form proteolytically active FXIIa.  Bacterial surfaces also have the ability to activate contact system proteins, indicating an important role for host defense using the cooperation of the inflammatory and coagulation pathways.  Recent research has shown that inorganic polyphosphate found in platelets activates FXII in vivo and can induce coagulation in pathological thrombus formation.  Experimental studies have shown that interference with FXII provides thromboprotection without a therapy-associated increase in bleeding, renewing interest in the FXIIa-driven intrinsic pathway of coagulation as a therapeutic target.  This review summarizes how the contact system acts as the cross-road of inflammation, coagulation, and innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQjjvqKO9Cintlzo9xastyfW6udTcc2ebneK-WVJpfe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rltVSntA%253D%253D&md5=7ef45350f96bacbde9109bd153bcccba</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fjth.13235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13235%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DA.%2BT.%26aulast%3DKenne%26aufirst%3DE.%26aulast%3DJung%26aufirst%3DR.%26aulast%3DFuchs%26aufirst%3DT.%2BA.%26aulast%3DRenn%25C3%25A9%26aufirst%3DT.%26atitle%3DHuman%2520deficiencies%2520in%2520intrinsic%2520cascade%2520proteases%2520FXII%2520and%2520plasma%2520kallikrein%2520%2528PKL%2529%2520have%2520not%2520been%2520strongly%2520associated%2520with%2520antithrombotic%2520protection%2520or%2520enhanced%2520bleeding%2520risk%252C%2520see%253A%2520Contact%2520system%2520revisited%253A%2520an%2520interface%2520between%2520inflammation%252C%2520coagulation%252C%2520and%2520innate%2520immunity%26jtitle%3DJ.%2520Thromb.%2520Haemost.%26date%3D2016%26volume%3D14%26spage%3D427%26epage%3D437%26doi%3D10.1111%2Fjth.13235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Coagulation Assays</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">e53</span>– <span class="NLM_lpage">e60</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.104.478222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1161%2Fcirculationaha.104.478222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=16043649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD2MzosFShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2005&pages=e53-e60&author=S.+M.+Batesauthor=J.+I.+Weitz&title=Coagulation+Assays&doi=10.1161%2FCIRCULATIONAHA.104.478222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Coagulation assays</span></div><div class="casAuthors">Bates Shannon M; Weitz Jeffrey I</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e53-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6m8OL_uszrDjk2McQZ6XmfW6udTcc2ebneK-WVJpfe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzosFShsA%253D%253D&md5=0a8f0f84d91fc2005b6d5f38b714ad3c</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1161%2Fcirculationaha.104.478222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fcirculationaha.104.478222%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DS.%2BM.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DCoagulation%2520Assays%26jtitle%3DCirculation%26date%3D2005%26volume%3D112%26spage%3De53%26epage%3De60%26doi%3D10.1161%2FCIRCULATIONAHA.104.478222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, S.</span>; <span class="NLM_string-name">McCraw, A.</span>; <span class="NLM_string-name">Echenagucia, M.</span></span> <i>Diagnosis of Hemophilia and Other Bleeding Disorders</i>, A Laboratory Manual, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_publisher-name">World Federation of Hemophilia</span>, <span class="NLM_year">2010</span>. <a href="http://www1.wfh.org/publication/files/pdf-1283.pdf" class="extLink">http://www1.wfh.org/publication/files/pdf-1283.pdf</a> (accessed April 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Kitchen&author=A.+McCraw&author=M.+Echenagucia&title=Diagnosis+of+Hemophilia+and+Other+Bleeding+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKitchen%26aufirst%3DS.%26btitle%3DDiagnosis%2520of%2520Hemophilia%2520and%2520Other%2520Bleeding%2520Disorders%26pub%3DWorld%2520Federation%2520of%2520Hemophilia%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prentiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradoux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Erkenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and preclinical characterization of selective factor D inhibitors targeting the alternative complement pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4656</span>– <span class="NLM_lpage">4668</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4656-4668&author=R.+G.+Karkiauthor=J.+Powersauthor=N.+Mainolfiauthor=K.+Andersonauthor=D.+B.+Belangerauthor=D.+Liuauthor=N.+Jiauthor=K.+Jendzaauthor=C.+F.+Gelinauthor=A.+Mac+Sweeneyauthor=C.+Solovayauthor=O.+Delgadoauthor=M.+Crowleyauthor=S.-M.+Liaoauthor=U.+A.+Argikarauthor=S.+Flohrauthor=L.+R.+La+Bonteauthor=E.+Lorthioisauthor=A.+Vulpettiauthor=A.+Brownauthor=D.+Longauthor=M.+Prentissauthor=N.+Gradouxauthor=A.+de+Erkenezauthor=F.+Cuminauthor=C.+Adamsauthor=B.+Jaffeeauthor=M.+Mogi&title=Design%2C+synthesis%2C+and+preclinical+characterization+of+selective+factor+D+inhibitors+targeting+the+alternative+complement+pathway&doi=10.1021%2Facs.jmedchem.9b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway</span></div><div class="casAuthors">Karki, Rajeshri G.; Powers, James; Mainolfi, Nello; Anderson, Karen; Belanger, David B.; Liu, Donglei; Ji, Nan; Jendza, Keith; Gelin, Christine F.; Mac Sweeney, Aengus; Solovay, Catherine; Delgado, Omar; Crowley, Maura; Liao, Sha-Mei; Argikar, Upendra A.; Flohr, Stefanie; La Bonte, Laura R.; Lorthiois, Edwige L.; Vulpetti, Anna; Brown, Ann; Long, Debby; Prentiss, Melissa; Gradoux, Nathalie; de Erkenez, Andrea; Cumin, Frederic; Adams, Christopher; Jaffee, Bruce; Mogi, Muneto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4656-4668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system.  Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria.  Previously, the authors have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (I and II) binding to the open active conformation of FD.  In continuation of the authors' drug discovery program, the authors designed compds. applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases.  The authors report herein the design, synthesis, and medicinal chem. optimization of the benzylamine series culminating in the discovery of (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid, an orally bioavailable and selective FD inhibitor.  (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5uolWfBzK7Vg90H21EOLACvtfcHk0lh8DAsJjoJwPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D&md5=a4a56886a758093516952737306a5d8a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00271%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DBelanger%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DN.%26aulast%3DJendza%26aufirst%3DK.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DSolovay%26aufirst%3DC.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DCrowley%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DLong%26aufirst%3DD.%26aulast%3DPrentiss%26aufirst%3DM.%26aulast%3DGradoux%26aufirst%3DN.%26aulast%3Dde%2BErkenez%26aufirst%3DA.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520preclinical%2520characterization%2520of%2520selective%2520factor%2520D%2520inhibitors%2520targeting%2520the%2520alternative%2520complement%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4656%26epage%3D4668%26doi%3D10.1021%2Facs.jmedchem.9b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Structure-based library design and fragment screening for the identification of reversible complement factor D protease inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1946-1958&author=A.+Vulpettiauthor=R.+Randlauthor=S.+R%C3%BCdisserauthor=N.+Ostermannauthor=P.+Erbelauthor=A.+Mac+Sweeneyauthor=T.+Zollerauthor=B.+Salemauthor=B.+Gerhartzauthor=F.+Cuminauthor=U.+Hommelauthor=C.+Dalvitauthor=E.+Lorthioisauthor=J.+Maibaum&title=Structure-based+library+design+and+fragment+screening+for+the+identification+of+reversible+complement+factor+D+protease+inhibitors&doi=10.1021%2Facs.jmedchem.6b01684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span></div><div class="casAuthors">Vulpetti, Anna; Randl, Stefan; Rudisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic dysregulation of alternative complement pathway activation has been assocd. with diverse clin. disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.  Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymic reaction of the amplification loop of the alternative pathway.  In this paper, the authors describe two hit finding approaches leading to the discovery of new chem. matter for this pivotal protease of the complement system: in silico active site mapping for hot spots identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries.  The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different sub-pockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPFgFvVDvCyrVg90H21EOLACvtfcHk0li5NjTuy8IiNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D&md5=179ea6dc5fb9ccb60931da60f23e6381</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01684%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DRandl%26aufirst%3DR.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DStructure-based%2520library%2520design%2520and%2520fragment%2520screening%2520for%2520the%2520identification%2520of%2520reversible%2520complement%2520factor%2520D%2520protease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1946%26epage%3D1958%26doi%3D10.1021%2Facs.jmedchem.6b01684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and design of first benzylamine-based ligands binding to an unlocked conformation of the complement factor D</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00104</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00104" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1Cjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=490-495&author=A.+Vulpettiauthor=N.+Ostermannauthor=S.+Randlauthor=T.+Yoonauthor=A.+Mac+Sweeneyauthor=F.+Cuminauthor=E.+Lorthioisauthor=S.+R%C3%BCdisserauthor=P.+Erbelauthor=J.+Maibaum&title=Discovery+and+design+of+first+benzylamine-based+ligands+binding+to+an+unlocked+conformation+of+the+complement+factor+D&doi=10.1021%2Facsmedchemlett.8b00104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D</span></div><div class="casAuthors">Vulpetti, Anna; Ostermann, Nils; Randl, Stefan; Yoon, Taeyoung; MacSweeney, Aengus; Cumin, Frederic; Lorthiois, Edwige; Rudisser, Simon; Erbel, Paul; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">490-495</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Complement Factor D, a serine protease of the S1 family and key component of the alternative pathway amplification loop, represents a promising target for the treatment of several prevalent and rare diseases linked to the innate immune system.  Previously reported FD inhibitors have been shown to bind to the FD active site in its self-inhibited conformation characterized by the presence of a salt bridge at the bottom of the S1 pocket between Asp189 and Arg218.  We report herein a new set of small-mol. FD ligands that harbor a basic S1 binding moiety directly binding to the carboxylate of Asp189, thereby displacing the Asp189-Arg218 ionic interaction and significantly changing the conformation of the self-inhibitory loop.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRdpNj9LCQYrVg90H21EOLACvtfcHk0li5NjTuy8IiNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1Cjs74%253D&md5=c24dccac197253f882e3a38a86a597ed</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00104%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DT.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520design%2520of%2520first%2520benzylamine-based%2520ligands%2520binding%2520to%2520an%2520unlocked%2520conformation%2520of%2520the%2520complement%2520factor%2520D%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D490%26epage%3D495%26doi%3D10.1021%2Facsmedchemlett.8b00104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, S. V.</span></span> <span> </span><span class="NLM_article-title">Complement factor D, a novel serine protease</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1002/pro.5560050401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1002%2Fpro.5560050401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=8845746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADyaK28XitFShu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1996&pages=553-564&author=J.+E.+Volanakisauthor=S.+V.+Narayana&title=Complement+factor+D%2C+a+novel+serine+protease&doi=10.1002%2Fpro.5560050401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Complement factor D, a novel serine protease</span></div><div class="casAuthors">Volanakis, John E.; Narayana, Sthanam V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-64</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review with many refs.  Factor D is unique among serine proteases in that it requires neither enzymic cleavage for expression of proteolytic activity nor inactivation by a serpin for its control.  Regulation of factor D activity is instead attained by a novel mechanism that depends on reversible conformational changes for expression and control of catalytic activity.  These conformational changes are believed to be induced by the single natural substrate, C3bB, and to result in realignment of the catalytic triad, the specificity pocket, and the nonspecific substrate binding site, all of which have atypical conformations.  Mutational studies have defined structural determinants responsible for these unique structural features of factor D and for the resultant low reactivity with synthetic esters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR-WO4fTyq7LVg90H21EOLACvtfcHk0li5NjTuy8IiNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitFShu7g%253D&md5=d55e7afa5c827b02023dd94994690eaa</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560050401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560050401%26sid%3Dliteratum%253Aachs%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26aulast%3DNarayana%26aufirst%3DS.%2BV.%26atitle%3DComplement%2520factor%2520D%252C%2520a%2520novel%2520serine%2520protease%26jtitle%3DProtein%2520Sci.%26date%3D1996%26volume%3D5%26spage%3D553%26epage%3D564%26doi%3D10.1002%2Fpro.5560050401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Design of small-molecule active-site inhibitors of the S1A family proteases as procoagulant and anticoagulant drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3799</span>– <span class="NLM_lpage">3822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00772</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00772" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3799-3822&author=P.+M.+Fischer&title=Design+of+small-molecule+active-site+inhibitors+of+the+S1A+family+proteases+as+procoagulant+and+anticoagulant+drugs&doi=10.1021%2Facs.jmedchem.7b00772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs</span></div><div class="casAuthors">Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3799-3822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Vitamin K antagonists (VKA) have long been the default drugs for anticoagulant management in venous thrombosis.  While efficacious, they are difficult to use due to interpatient dose-response variability and the risks of bleeding.  The approval of fondaparinux, a heparin-derived factor Xa (fXa) inhibitor, provided validation for the development of direct oral anticoagulants (DOAC), and currently such inhibitors of thrombin and fXa are in clin. use.  These agents can be used without regular coagulation monitoring, but the inherent risk of bleeding complications assocd. with blocking the common coagulation pathway remains.  Efforts are now underway to develop DOACs that inhibit components of the intrinsic and extrinsic coagulation cascades upstream of thrombin and fX.  Evidence from humans and from transgenic animal models suggests that this strategy may provide a better therapeutic margin between antithrombotic and antihemostatic effects.  Here the design of active-site inhibitors of S1A proteases involved in coagulation and fibrinolysis is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWkNuyZdaKyrVg90H21EOLACvtfcHk0lghHcU20Y1kxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaqu7bF&md5=9f213939b2bd2ef1a2d3c779096b5981</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00772%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDesign%2520of%2520small-molecule%2520active-site%2520inhibitors%2520of%2520the%2520S1A%2520family%2520proteases%2520as%2520procoagulant%2520and%2520anticoagulant%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3799%26epage%3D3822%26doi%3D10.1021%2Facs.jmedchem.7b00772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallheer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corte, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamurthy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1635</span>– <span class="NLM_lpage">1642</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2015.01.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=25728130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1635-1642&author=D.+J.+Pintoauthor=J.+M.+Smallheerauthor=J.+R.+Corteauthor=E.+J.+Austinauthor=C.+Wangauthor=T.+Fangauthor=L.+M.+Smithauthor=K.+A.+Rossiauthor=A.+R.+Rendinaauthor=J.+M.+Bozarthauthor=G.+Zhangauthor=A.+Weiauthor=V.+Ramamurthyauthor=S.+Sheriffauthor=J.+E.+Myersauthor=P.+E.+Morinauthor=J.+M.+Luettgenauthor=D.+A.+Seiffertauthor=M.+L.+Quanauthor=R.+R.+Wexler&title=Structure-based+design+of+inhibitors+of+coagulation+factor+XIa+with+novel+P1+moieties&doi=10.1016%2Fj.bmcl.2015.01.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties</span></div><div class="casAuthors">Pinto, Donald J. P.; Smallheer, Joanne M.; Corte, James R.; Austin, Erin J. D.; Wang, Cailan; Fang, Tianan; Smith, Leon M.; Rossi, Karen A.; Rendina, Alan R.; Bozarth, Jeffrey M.; Zhang, Ge; Wei, Anzhi; Ramamurthy, Vidhyashankar; Sheriff, Steven; Myers, Joseph E.; Morin, Paul E.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Quan, Mimi L.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1635-1642</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. 2 was previously identified as a potent inhibitor of factor XIa lacking oral bioavailability.  A structure-based approach was used to design analogs of 2 with novel P1 moieties with good selectivity profiles and oral bioavailability.  Further optimization of the P1 group led to the identification of a 4-chlorophenyltetrazole P1 analog, which when combined with further modifications to the linker and P2' group provided compd. 32 with FXIa Ki = 6.7 nM and modest oral exposure in dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTasnhdatPMrVg90H21EOLACvtfcHk0lghHcU20Y1kxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7g%253D&md5=c1d175da55f89b425610bcb2a1d0caa2</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.028%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DSmallheer%26aufirst%3DJ.%2BM.%26aulast%3DCorte%26aufirst%3DJ.%2BR.%26aulast%3DAustin%26aufirst%3DE.%2BJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DBozarth%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DRamamurthy%26aufirst%3DV.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DStructure-based%2520design%2520of%2520inhibitors%2520of%2520coagulation%2520factor%2520XIa%2520with%2520novel%2520P1%2520moieties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1635%26epage%3D1642%26doi%3D10.1016%2Fj.bmcl.2015.01.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleha, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (Razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1021/jm0497949</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0497949" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1729-1744&author=M.+L.+Quanauthor=P.+Y.+S.+Lamauthor=Q.+Hanauthor=D.+J.+P.+Pintoauthor=M.+Y.+Heauthor=R.+Liauthor=C.+D.+Ellisauthor=C.+G.+Clarkauthor=C.+A.+Telehaauthor=J.+H.+Sunauthor=R.+S.+Alexanderauthor=S.+Baiauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=P.+C.+Wongauthor=R.+R.+Wexler&title=Discovery+of+1-%283%E2%80%B2-aminobenzisoxazol-5%E2%80%B2-yl%29-3-trifluoromethyl-N-%5B2-fluoro-4-%5B%282%E2%80%B2-dimethylaminomethyl%29imidazol-1-yl%5Dphenyl%5D-1H-pyrazole-5-carboxyamide+hydrochloride+%28Razaxaban%29%2C+a+highly+potent%2C+selective%2C+and+orally+bioavailable+factor+Xa+inhibitor&doi=10.1021%2Fjm0497949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</span></div><div class="casAuthors">Quan, Mimi L.; Lam, Patrick Y. S.; Han, Qi; Pinto, Donald J. P.; He, Ming Y.; Li, Renhua; Ellis, Christopher D.; Clark, Charles G.; Teleha, Christopher A.; Sun, Jung-Hui; Alexander, Richard S.; Bai, Steve; Luettgen, Joseph M.; Knabb, Robert M.; Wong, Pancras C.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1729-1744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compds. with improved selectivity for factor Xa relative to trypsin and plasma kallikrein.  Further optimization of the P4 moiety led to compds. with enhanced permeability and reduced protein binding.  The SAR and pharmacokinetic profile of this series of compds. is described.  These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide (I), a potent, selective, and orally bioavailable inhibitor of factor Xa.  On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compd. was selected for clin. development as razaxaban (DPC 906, BMS-561389).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSs9m3fldmGbVg90H21EOLACvtfcHk0lghHcU20Y1kxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D&md5=c16a8d1ca98191a873f2e53cb0c5678c</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Fjm0497949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0497949%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DHe%26aufirst%3DM.%2BY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DC.%2BD.%26aulast%3DClark%26aufirst%3DC.%2BG.%26aulast%3DTeleha%26aufirst%3DC.%2BA.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DDiscovery%2520of%25201-%25283%25E2%2580%25B2-aminobenzisoxazol-5%25E2%2580%25B2-yl%2529-3-trifluoromethyl-N-%255B2-fluoro-4-%255B%25282%25E2%2580%25B2-dimethylaminomethyl%2529imidazol-1-yl%255Dphenyl%255D-1H-pyrazole-5-carboxyamide%2520hydrochloride%2520%2528Razaxaban%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520factor%2520Xa%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1729%26epage%3D1744%26doi%3D10.1021%2Fjm0497949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elrod, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirtley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span> <span> </span><span class="NLM_article-title">Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(01)00084-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS1074-5521%2801%2900084-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=11731301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1KmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=1107-1121&author=B.+A.+Katzauthor=P.+A.+Sprengelerauthor=C.+Luongauthor=E.+Vernerauthor=K.+Elrodauthor=M.+Kirtleyauthor=J.+Jancauthor=J.+R.+Spencerauthor=J.+G.+Breitenbucherauthor=H.+Huiauthor=D.+McGeeauthor=D.+Allenauthor=A.+Martelliauthor=R.+L.+Mackman&title=Engineering+inhibitors+highly+selective+for+the+S1+sites+of+Ser190+trypsin-like+serine+protease+drug+targets&doi=10.1016%2FS1074-5521%2801%2900084-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets</span></div><div class="casAuthors">Katz, Bradley A.; Sprengeler, Paul A.; Luong, Christine; Verner, Erik; Elrod, Kyle; Kirtley, Matt; Janc, James; Spencer, Jeffrey R.; Breitenbucher, J. Guy; Hui, Hon; McGee, Danny; Allen, Darin; Martelli, Arnold; Mackman, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Background: Involved or implicated in a wide spectrum of diseases, trypsin-like serine proteases comprise well studied drug targets and anti-targets that can be subdivided into two major classes.  In one class there is a serine at position 190 at the S1 site, as in urokinase type plasminogen activator (urokinase or uPA) and factor VIIa, and in the other there is an alanine at 190, as in tissue type plasminogen activator (tPA) and factor Xa.  A hydrogen bond unique to Ser190 protease-arylamidine complexes between OγSer190 and the inhibitor amidine confers an intrinsic preference for such inhibitors toward Ser190 proteases over Ala190 counterparts.  Results: Based on the structural differences between the S1 sites of Ser190 and Ala190 protease-arylamidine complexes, we amplified the selectivity of amidine inhibitors toward uPA and against tPA, by factors as high as 220-fold, by incorporating a halo group ortho to the amidine of a lead inhibitor scaffold.  Comparison of Ki values of such halo-substituted and parent inhibitors toward a panel of Ser190 and Ala190 proteases demonstrates pronounced selectivity of the halo analogs for Ser190 proteases over Ala190 counterparts.  Crystal structures of Ser190 proteases, uPA and trypsin, and of an Ala190 counterpart, thrombin, bound by a set of ortho (halo, amidino) aryl inhibitors and of non-halo parents reveal the structural basis of the exquisite selectivity and validate the design principle.  Conclusions: Remarkable selectivity enhancements of exceptionally small inhibitors are achieved toward the uPA target over the highly similar tPA anti-target through a single atom substitution on an otherwise relatively non-selective scaffold.  Overall selectivities for uPA over tPA as high as 980-fold at physiol. pH were realized.  The increase in selectivity results from the displacement of a single bound water mol. common to the S1 site of both the uPA target and the tPA anti-target because of the ensuing deficit in hydrogen bonding of the arylamidine inhibitor when bound in the Ala190 protease anti-target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjSa9M4EVJVrVg90H21EOLACvtfcHk0lhjqhGCZtRpdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1KmtLc%253D&md5=2c9f68fc584ac016ca320d0cfdf51027</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2801%2900084-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252801%252900084-9%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DElrod%26aufirst%3DK.%26aulast%3DKirtley%26aufirst%3DM.%26aulast%3DJanc%26aufirst%3DJ.%26aulast%3DSpencer%26aufirst%3DJ.%2BR.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DMcGee%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DD.%26aulast%3DMartelli%26aufirst%3DA.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26atitle%3DEngineering%2520inhibitors%2520highly%2520selective%2520for%2520the%2520S1%2520sites%2520of%2520Ser190%2520trypsin-like%2520serine%2520protease%2520drug%2520targets%26jtitle%3DChem.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D1107%26epage%3D1121%26doi%3D10.1016%2FS1074-5521%2801%2900084-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClellan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockway, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienaber, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3063</span>– <span class="NLM_lpage">3068</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(04)00530-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS0960-894X%2804%2900530-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15149645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktVektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=3063-3068&author=M.+D.+Wendtauthor=A.+Geyerauthor=W.+J.+McClellanauthor=T.+W.+Rockwayauthor=M.+Weitzbergauthor=X.+Zhaoauthor=R.+Manteiauthor=K.+Stewartauthor=V.+Nienaberauthor=V.+Klinghoferauthor=V.+L.+Giranda&title=Interaction+with+the+S1+beta-pocket+of+urokinase%3A+8-heterocycle+substituted+and+6%2C8-disubstituted+2-naphthamidine+urokinase+inhibitors&doi=10.1016%2FS0960-894X%2804%2900530-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction with the S1β-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors</span></div><div class="casAuthors">Wendt, Michael D.; Geyer, Andrew; McClellan, William J.; Rockway, Todd W.; Weitzberg, Moshe; Zhao, Xumiao; Mantei, Robert; Stewart, Kent; Nienaber, Vicki; Klinghofer, Vered; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3063-3068</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Several 8-substituted 2-naphthamidine-based inhibitors of the serine protease urokinase plasminogen activator (uPA) are described.  Direct attachment of five-membered satd. or unsatd. rings improved inhibitor performance; substitution with sulfones further improved binding profiles.  Combination of these substituents or of previously described NH-linked heteroarom. rings with 6-Ph amide substituents provided further enhancements to potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOGuP9062FOrVg90H21EOLACvtfcHk0lhjqhGCZtRpdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktVektb4%253D&md5=d680f577a48c809e875d5fe46cabbb8e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2804%2900530-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252804%252900530-X%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DRockway%26aufirst%3DT.%2BW.%26aulast%3DWeitzberg%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DNienaber%26aufirst%3DV.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DInteraction%2520with%2520the%2520S1%2520beta-pocket%2520of%2520urokinase%253A%25208-heterocycle%2520substituted%2520and%25206%252C8-disubstituted%25202-naphthamidine%2520urokinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D3063%26epage%3D3068%26doi%3D10.1016%2FS0960-894X%2804%2900530-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbucher, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span> <span> </span><span class="NLM_article-title">Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3856</span>– <span class="NLM_lpage">3871</span>, <span class="refDoi"> DOI: 10.1021/jm010244+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010244%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlWrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3856-3871&author=R.+L.+Mackmanauthor=B.+A.+Katzauthor=J.+G.+Breitenbucherauthor=H.+C.+Huiauthor=E.+Vernerauthor=C.+Luongauthor=L.+Liuauthor=P.+A.+Sprengeler&title=Exploiting+subsite+S1+of+trypsin-like+serine+proteases+for+selectivity%3A+potent+and+selective+inhibitors+of+urokinase-type+plasminogen+activator&doi=10.1021%2Fjm010244%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting Subsite S1 of Trypsin-Like Serine Proteases for Selectivity: Potent and Selective Inhibitors of Urokinase-Type Plasminogen Activator</span></div><div class="casAuthors">Mackman, Richard L.; Katz, Bradley A.; Breitenbucher, J. Guy; Hui, Hon C.; Verner, Erik; Luong, Christine; Liu, Liang; Sprengeler, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3856-3871</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A nonselective inhibitor of trypsin-like serine proteases, 2-(2-hydroxybiphenyl-3-yl)-1H-indole-5-carboxamidine (I) (Verner, E.; Katz, B. A.; Spencer, J.; Allen, D.; Hataye, J.; Hruzewicz, W.; Hui, H. C.; Kolesnikov, A.; Li, Y.; Luong, C.; Martelli, A.; Radika. K.; Rai, R.; She, M.; Shrader, W.; Sprengeler, P. A.; Trapp, S.; Wang, J.; Young, W. B.; Mackman, R. L. J. Med. Chem. 2001, 44, 2753-2771) has been optimized through minor structural changes on the S1 binding group to afford remarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA).  The trypsin-like serine proteases1 that comprise drug targets can be broadly categorized into two subfamilies, those with Ser190 and those with Ala190.  A single-atom modification, for example, replacement of hydrogen for chlorine at the 6-position of the 5-amidinoindole P1 group on I, generated ≤6700-fold selectivity toward the Ser190 enzymes and against the Ala190 enzymes.  The larger chlorine atom displaces a water mol. (H2O1S1) that binds near residue 190 in all the complexes of I, and related inhibitors, in uPA, thrombin, and trypsin.  The water mol., H2O1S1, in both the Ser190 or Ala190 enzymes, hydrogen bonds with the amidine N1 nitrogen of the inhibitor.  When it is displaced, a redn. in affinity toward the Ala190 enzymes is obsd. due to the amidine N1 nitrogen of the bound inhibitor being deprived of a key hydrogen-bonding partner.  In the Ser190 enzymes the affinity is maintained since the serine hydroxyl oxygen OγSer190 compensates for the displaced water mol.  High-resoln. crystallog. provided evidence for the displacement of the water mol. and validated the design rationale.  In summation, a novel and powerful method for engineering selectivity toward Ser190 proteases and against Ala190 proteases without substantially increasing mol. wt. is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxZsTVtV-cArVg90H21EOLACvtfcHk0lhjqhGCZtRpdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlWrt7Y%253D&md5=d431091b463a9168c4e7223b7f96f460</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm010244%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010244%252B%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26atitle%3DExploiting%2520subsite%2520S1%2520of%2520trypsin-like%2520serine%2520proteases%2520for%2520selectivity%253A%2520potent%2520and%2520selective%2520inhibitors%2520of%2520urokinase-type%2520plasminogen%2520activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3856%26epage%3D3871%26doi%3D10.1021%2Fjm010244%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="note"><p class="first last">Our subsequent efforts to target the S2′ pocket will be reported in due course.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">For examples of S1 serine protease inhibitors with acid-like motif interacting in the oxyanion hole:</p></div><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Huis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willardsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapundalo, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiya-Cork, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witlow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">mcKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaiz, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">light, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span> <span> </span><span class="NLM_article-title">The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4752</span>– <span class="NLM_lpage">4756</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.07.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2005.07.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=16125385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVanu7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=4752-4756&author=J.+T.+Kohrtauthor=K.+J.+Filipskiauthor=W.+L.+Codyauthor=C.+Caiauthor=D.+A.+Dudleyauthor=C.+A.+Van+Huisauthor=A.+Willardsenauthor=S.+T.+Rapundaloauthor=K.+Saiya-Corkauthor=R.+J.+Leadleyauthor=L.+Narasimhanauthor=E.+Zhangauthor=M.+Witlowauthor=M.+Adlerauthor=K.+McLeanauthor=Y.-L.+Chouauthor=C.+mcKnightauthor=D.+O.+Arnaizauthor=K.+J.+Shawauthor=D.+R.+lightauthor=J.+J.+Edmunds&title=The+discovery+of+fluoropyridine-based+inhibitors+of+the+factor+VIIa%2FTF+complex&doi=10.1016%2Fj.bmcl.2005.07.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex</span></div><div class="casAuthors">Kohrt, Jeffrey T.; Filipski, Kevin J.; Cody, Wayne L.; Cai, Cuiman; Dudley, Danette A.; Van Huis, Chad A.; Willardsen, J. Adam; Rapundalo, Stephen T.; Saiya-Cork, Kamlai; Leadley, Robert J.; Narasimhan, Lakshmi; Zhang, Erli; Whitlow, Marc; Adler, Marc; McLean, Kirk; Chou, Yuo-Ling; McKnight, Cecile; Arnaiz, Damian O.; Shaw, Kenneth J.; Light, David R.; Edmunds, Jeremy J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4752-4756</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The activated Factor VII/tissue factor complex (FVIIa/TF) plays a key role in the formation of blood clots.  Inhibition of this complex may lead to new antithrombotic drugs.  An X-ray crystal structure of a fluoropyridine-based FVIIa/TF inhibitor bound in the active site of the enzyme complex suggested that incorporation of substitution at the 5-position of the hydroxybenzoic acid side chain could lead to the formation of more potent inhibitors through interactions with the S1'/S2' pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPXXiEgbcYurVg90H21EOLACvtfcHk0lgSePvGiL_hXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVanu7zM&md5=e50b3a1dfc4f93a22f1f970a13907e0a</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.07.059%26sid%3Dliteratum%253Aachs%26aulast%3DKohrt%26aufirst%3DJ.%2BT.%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DCody%26aufirst%3DW.%2BL.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DVan%2BHuis%26aufirst%3DC.%2BA.%26aulast%3DWillardsen%26aufirst%3DA.%26aulast%3DRapundalo%26aufirst%3DS.%2BT.%26aulast%3DSaiya-Cork%26aufirst%3DK.%26aulast%3DLeadley%26aufirst%3DR.%2BJ.%26aulast%3DNarasimhan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DWitlow%26aufirst%3DM.%26aulast%3DAdler%26aufirst%3DM.%26aulast%3DMcLean%26aufirst%3DK.%26aulast%3DChou%26aufirst%3DY.-L.%26aulast%3DmcKnight%26aufirst%3DC.%26aulast%3DArnaiz%26aufirst%3DD.%2BO.%26aulast%3DShaw%26aufirst%3DK.%2BJ.%26aulast%3Dlight%26aufirst%3DD.%2BR.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520discovery%2520of%2520fluoropyridine-based%2520inhibitors%2520of%2520the%2520factor%2520VIIa%252FTF%2520complex%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D4752%26epage%3D4756%26doi%3D10.1016%2Fj.bmcl.2005.07.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">West, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaiz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualtieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukovich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltlow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span> <span> </span><span class="NLM_article-title">Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5712</span>– <span class="NLM_lpage">5715</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2009.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=19703768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFakur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5712-5715&author=C.+W.+Westauthor=M.+Adlerauthor=D.+Arnaizauthor=D.+Chenauthor=K.+Chuauthor=G.+Gualtieriauthor=E.+Hoauthor=C.+Huweauthor=D.+Lightauthor=G.+Phillipsauthor=R.+Pulkauthor=D.+Sukovichauthor=M.+Wiltlowauthor=S.+Yuanauthor=J.+Bryant&title=Identification+of+orally+bioavailable%2C+non-amidine+inhibitors+of+urokinase+plasminogen+activator+%28uPA%29&doi=10.1016%2Fj.bmcl.2009.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA)</span></div><div class="casAuthors">West, Christopher W.; Adler, Marc; Arnaiz, Danny; Chen, Deborah; Chu, Kieu; Gualtieri, Giovanna; Ho, Elena; Huwe, Christoph; Light, David; Phillips, Gary; Pulk, Rebecca; Sukovich, Drew; Whitlow, Marc; Yuan, Shendong; Bryant, Judi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5712-5715</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter the synthesis and evaluation of a series of non-amidine inhibitors of Urokinase Plasminogen Activator (uPA) are reported.  Starting from compd. I, a significant change provided compds. in which the amidine, binding in the S1 pocket, was replaced with a primary amine.  Further modifications led to the identification of potent, selective, and orally bioavailable uPA inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZYJuZGz1EJLVg90H21EOLACvtfcHk0lgSePvGiL_hXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFakur3P&md5=ca3529dc06e384edeea54b6b62b25252</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DC.%2BW.%26aulast%3DAdler%26aufirst%3DM.%26aulast%3DArnaiz%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DK.%26aulast%3DGualtieri%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DE.%26aulast%3DHuwe%26aufirst%3DC.%26aulast%3DLight%26aufirst%3DD.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DSukovich%26aufirst%3DD.%26aulast%3DWiltlow%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DBryant%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520orally%2520bioavailable%252C%2520non-amidine%2520inhibitors%2520of%2520urokinase%2520plasminogen%2520activator%2520%2528uPA%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5712%26epage%3D5715%26doi%3D10.1016%2Fj.bmcl.2009.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almond, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Garavilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savvides, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1727</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/jm0700619</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0700619" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivF2isb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1727-1730&author=M.+N.+Grecoauthor=M.+J.+Hawkinsauthor=E.+T.+Powellauthor=H.+R.+Almondauthor=L.+de+Garavillaauthor=J.+Hallauthor=L.+K.+Minorauthor=Y.+P.+Wangauthor=T.+W.+Corcoranauthor=E.+Di+Ceraauthor=A.+M.+Cantwellauthor=S.+N.+Savvidesauthor=B.+P.+Damianoauthor=B.+E.+Maryanoff&title=Discovery+of+potent%2C+selective%2C+orally+active%2C+nonpeptide+inhibitors+of+human+mast+cell+chymase&doi=10.1021%2Fjm0700619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37cR"><div class="casContent"><span class="casTitleNuber">37c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Selective, Orally Active, Nonpeptide Inhibitors of Human Mast Cell Chymase</span></div><div class="casAuthors">Greco, Michael N.; Hawkins, Michael J.; Powell, Eugene T.; Almond, Harold R., Jr.; De Garavilla, Lawrence; Hall, Jeffrey; Minor, Lisa K.; Wang, Yuanping; Corcoran, Thomas W.; Di Cera, Enrico; Cantwell, Angelene M.; Savvides, Savvas N.; Damiano, Bruce P.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1727-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of β-carboxamido-phosphon(in)ic acids, e.g., I, II, and III, was identified as a new structural motif for obtaining potent inhibitors of human mast cell chymase.  For example, 1-naphthyl deriv. I had an IC50 value of 29 nM and (E)-styryl deriv. II had an IC50 value of 3.5 nM.  An X-ray structure for I·chymase revealed key interactions within the enzyme active site.  I was selective for inhibiting chymase vs. eight serine proteases.  III was orally bioavailable in rats (F = 39%), and orally efficacious in a hamster model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcqGFCHhLjK7Vg90H21EOLACvtfcHk0ljj3nNXPiIoww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivF2isb0%253D&md5=f81cddf73934642d0ffad18cfe389c39</span></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=10.1021%2Fjm0700619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0700619%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DM.%2BN.%26aulast%3DHawkins%26aufirst%3DM.%2BJ.%26aulast%3DPowell%26aufirst%3DE.%2BT.%26aulast%3DAlmond%26aufirst%3DH.%2BR.%26aulast%3Dde%2BGaravilla%26aufirst%3DL.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DMinor%26aufirst%3DL.%2BK.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DCorcoran%26aufirst%3DT.%2BW.%26aulast%3DDi%2BCera%26aufirst%3DE.%26aulast%3DCantwell%26aufirst%3DA.%2BM.%26aulast%3DSavvides%26aufirst%3DS.%2BN.%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520orally%2520active%252C%2520nonpeptide%2520inhibitors%2520of%2520human%2520mast%2520cell%2520chymase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1727%26epage%3D1730%26doi%3D10.1021%2Fjm0700619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decock, A.</span>; <span class="NLM_string-name">Renatus, M.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Decock%2C+A.%3B+Renatus%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDecock%26aufirst%3DA." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span>The
assignment of the (S)-configured
absolute stereochemistry was not entirely unambiguous.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The%0Aassignment+of+the+%28S%29-configured%0Aabsolute+stereochemistry+was+not+entirely+unambiguous."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi-Sledeski, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minnich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sides, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, R. J.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and profiling of a β-tryptase inhibitor with a spiro-piperidineamide scaffold, benzylamnine P1 group, and a substituted indole P4 group</span>. <i>Med. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">794</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1039/c1md00104c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1039%2Fc1md00104c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=794-798&author=G.+Liangauthor=Y.+M.+Choi-Sledeskiauthor=G.+B.+Poliauthor=X.+Chenauthor=A.+Minnichauthor=Q.+Wangauthor=J.+Tsayauthor=K.+Sidesauthor=R.+J.+Vaz&title=Structure-based+design%2C+synthesis+and+profiling+of+a+%CE%B2-tryptase+inhibitor+with+a+spiro-piperidineamide+scaffold%2C+benzylamnine+P1+group%2C+and+a+substituted+indole+P4+group&doi=10.1039%2Fc1md00104c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1039%2Fc1md00104c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00104c%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DChoi-Sledeski%26aufirst%3DY.%2BM.%26aulast%3DPoli%26aufirst%3DG.%2BB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMinnich%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DTsay%26aufirst%3DJ.%26aulast%3DSides%26aufirst%3DK.%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520profiling%2520of%2520a%2520%25CE%25B2-tryptase%2520inhibitor%2520with%2520a%2520spiro-piperidineamide%2520scaffold%252C%2520benzylamnine%2520P1%2520group%252C%2520and%2520a%2520substituted%2520indole%2520P4%2520group%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D794%26epage%3D798%26doi%3D10.1039%2Fc1md00104c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espina, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.-S.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of benzylamine to reactive intermediates in rodents: formation of glutathione, glutamate, and peptide conjugates</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.1021/tx020063q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx020063q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt1Skur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=1190-1207&author=A.+E.+Mutlibauthor=P.+Dickensonauthor=S.-Y.+Chenauthor=R.+J.+Espinaauthor=J.+S.+Danielsauthor=L.-S.+Gan&title=Bioactivation+of+benzylamine+to+reactive+intermediates+in+rodents%3A+formation+of+glutathione%2C+glutamate%2C+and+peptide+conjugates&doi=10.1021%2Ftx020063q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of Benzylamine to Reactive Intermediates in Rodents: Formation of Glutathione, Glutamate, and Peptide Conjugates</span></div><div class="casAuthors">Mutlib, Abdul E.; Dickenson, Patricia; Chen, Shiang-Yuan; Espina, Robert J.; Daniels, J. Scott; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1190-1207</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vivo and in vitro disposition of benzylamine was investigated in rats.  Benzylamine was metabolized to only a small extent by rat liver subcellular fractions.  In contrast, it was extensively metabolized in vivo in rats.  In vivo studies performed with stable isotope-labeled benzylamine enabled rapid mass spectrometric identification of metabolites present in rat bile and urine.  The major metabolite of benzylamine was the hippuric acid formed by glycine conjugation of benzoic acid. LC/MS anal. of bile and urine obtained from rats dosed with 1:1 equimolar mixt. of either d0:d7- or d0:d2-benzylamine showed the presence of several glutathione adducts in addn. to the hippuric acid metabolite.  The presence of various glutathione adducts indicated that benzylamine was metabolized to a no. of reactive intermediates.  Various metabolic pathways, including those independent of P 450, were found to produce these intermediates.  A previously undocumented pathway included the formation of a new carbon-nitrogen bond that led to a potentially reactive intermediate, Ar-CH2-NH(CO)-X, capable of interacting with various nucleophiles.  The origin of this reactive intermediate is postulated to occur via the formation of either a formamide or carbamic acid metabolites.  Metabolites which were produced by the reaction of this intermediate, Ar-CH2-NH(CO)-X with nucleophiles included S-[benzylcarbamoyl]glutathione, N-acetyl-S-[benzylcarbamoyl]cysteine, S-[benzylcarbamoyl]cysteinylglycine, S-[benzylcarbamoyl]cysteinylglutamate, N-[benzylcarbamoyl]glutamate, and an oxidized glutathione adduct.  Bioactivation of amines via this pathway has not been previously described.  The oxidative deamination of benzylamine yielding the benzaldehyde was demonstrated to be a precursor to the hippuric acid metabolite and S-benzyl-L-glutathione.  The formation of the S-benzyl-L-glutathione conjugate showed that a net displacement of amine from benzylamine had taken place with a subsequent addn. of glutathione at the benzylic position.  In addn. to these novel pathways, a no. of other glutathione-derived adducts formed as a result of epoxide formation was characterized.  It was demonstrated that benzylamine was converted by rat P 450 2A1 and 2E1 to benzamide that was rapidly metabolized to an epoxide.  Mechanisms are proposed for the formation of various GSH adducts of benzylamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVVaqbZJzp9LVg90H21EOLACvtfcHk0ljj3nNXPiIoww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt1Skur0%253D&md5=338150cc6889accab3cf580cc76b8e9a</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1021%2Ftx020063q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx020063q%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDickenson%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DS.-Y.%26aulast%3DEspina%26aufirst%3DR.%2BJ.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DBioactivation%2520of%2520benzylamine%2520to%2520reactive%2520intermediates%2520in%2520rodents%253A%2520formation%2520of%2520glutathione%252C%2520glutamate%252C%2520and%2520peptide%2520conjugates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D1190%26epage%3D1207%26doi%3D10.1021%2Ftx020063q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espina, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shockcor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.-S.</span></span> <span> </span><span class="NLM_article-title">P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogues to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1021/tx0101189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0101189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVWitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=63-75&author=A.+E.+Mutlibauthor=S.-Y.+Chenauthor=R.+J.+Espinaauthor=J.+Shockcorauthor=S.+R.+Prakashauthor=L.-S.+Gan&title=P450-mediated+metabolism+of+1-%5B3-%28aminomethyl%29phenyl%5D-N-%5B3-fluoro-2%E2%80%B2-%28methylsulfonyl%29-%5B1%2C1%E2%80%B2-biphenyl%5D-4-yl%5D-3-%28trifluoromethyl%29-1H-pyrazole-+5-carboxamide+%28DPC+423%29+and+its+analogues+to+aldoximes.+Characterization+of+glutathione+conjugates+of+postulated+intermediates+derived+from+aldoximes&doi=10.1021%2Ftx0101189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)- [1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogs to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes</span></div><div class="casAuthors">Mutlib, Abdul E.; Chen, Shiang-Yuan; Espina, Robert J.; Shockcor, John; Prakash, Shimoga R.; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-75</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vivo and in vitro disposition of DPC 423, a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa, has recently been described.  Several metabolites, some of which were considered potentially reactive, were identified in rats.  A novel GSH adduct, the structure of which was not detd. conclusively, was isolated from bile of rats dosed with DPC 423.  Herein, we describe the complete structural elucidation of this unique GSH conjugate employing LC/MS and high-field NMR.  Similar GSH adducts of DPC 602, [13CD2]DPC 602, and SX 737, all structural analogs of DPC 423, were isolated, characterized spectroscopically, and shown to have identical mass fragmentation pathways.  The structures of these conjugates were initially suspected to be either an amide with N-S bond or a nitrogen-oxygen juxtaposed amide with a C-S bond.  Studies conducted with [13CD2]DPC 602 indicated an aldoxime structure.  The concluding evidence came from HMBC NMR spectrum of the conjugate, which showed strong correlation of the cysteine methylene protons with the imino carbon.  Further spectroscopic studies with chem. prepd. GSH adduct from benzaldehyde oxime confirmed this pattern of correlation.  In vivo and in vitro studies with the synthetic oxime intermediate from DPC 423 showed an adduct identical to the one isolated from the bile of rats dosed with DPC 423.  This supported the intermediacy of an aldoxime as a precursor to the GSH adducts.  It is postulated that the benzylamine moiety of DPC 423 (and its analogs) is oxidized to a hydroxylamine, which is subsequently converted to a nitroso intermediate.  Subsequent rearrangement of the nitroso leads to an aldoxime which in turn is metabolized by P 450 to a reactive intermediate.  The formation of oxime from DPC 423 (and its analogs) was found to be mediated by rat CYP 3A1/2, which were also responsible for converting the oxime to the GSH trappable reactive intermediate.  It is postulated that the aldoxime produces a radical or a nitrile oxide intermediate that reacts with GSH and hence produces this unusual GSH adduct.  On the basis of synthetic analogy, it is more likely that the nitrile oxide resulting from two-electron oxidn. of the aldoxime is the reactive intermediate.  Intramol. kinetic isotope effects were studied with [13CD2]DPC 602 to assess the importance of the metabolic cleavage of the aminomethyl carbon-hydrogen bond in forming this GSH adduct.  The lack of isotope effect in forming the aldoxime from [13CD2]DPC 602 suggests its formation does not occur through the imine intermediate.  Instead the data supports the postulated mechanism of hydroxylamine and nitroso intermediates as precursors to the aldoxime.  However, the formation of the GSH adduct from [13CD2]DPC 602 did show a significant intramol. kinetic isotope effect (kH/kD = 2.3) since a carbon-deuterium bond had to be broken on the aldoxime prior to the formation of the adduct.  A stable nitrile oxide derived from DPC 602 was postulated as the reactive intermediate responsible for forming this unique GSH adduct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosaKWZWKi61rVg90H21EOLACvtfcHk0li3WFvwgPLBsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVWitLg%253D&md5=dc073373f899d4189bfafba24e4fea8e</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1021%2Ftx0101189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0101189%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DChen%26aufirst%3DS.-Y.%26aulast%3DEspina%26aufirst%3DR.%2BJ.%26aulast%3DShockcor%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DS.%2BR.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DP450-mediated%2520metabolism%2520of%25201-%255B3-%2528aminomethyl%2529phenyl%255D-N-%255B3-fluoro-2%25E2%2580%25B2-%2528methylsulfonyl%2529-%255B1%252C1%25E2%2580%25B2-biphenyl%255D-4-yl%255D-3-%2528trifluoromethyl%2529-1H-pyrazole-%25205-carboxamide%2520%2528DPC%2520423%2529%2520and%2520its%2520analogues%2520to%2520aldoximes.%2520Characterization%2520of%2520glutathione%2520conjugates%2520of%2520postulated%2520intermediates%2520derived%2520from%2520aldoximes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D63%26epage%3D75%26doi%3D10.1021%2Ftx0101189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, D.</span>; <span class="NLM_string-name">Flohr, S.</span>; <span class="NLM_string-name">Gelin, C. F.</span>; <span class="NLM_string-name">Jendza, K.</span>; <span class="NLM_string-name">Ji, N.</span>; <span class="NLM_string-name">Karki, R. G.</span>; <span class="NLM_string-name">Liu, D.</span>; <span class="NLM_string-name">Lorthiois, E.</span>; <span class="NLM_string-name">Mainolfi, N.</span>; <span class="NLM_string-name">Powers, J. J.</span>; <span class="NLM_string-name">Vulpetti, A.</span></span> <span> </span><span class="NLM_article-title">Amidomethyl-biaryl Derivatives Complement Factor D Inhibitors and Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO2016/088082</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Belanger&author=S.+Flohr&author=C.+F.+Gelin&author=K.+Jendza&author=N.+Ji&author=R.+G.+Karki&author=D.+Liu&author=E.+Lorthiois&author=N.+Mainolfi&author=J.+J.+Powers&author=A.+Vulpetti&title=Amidomethyl-biaryl+Derivatives+Complement+Factor+D+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBelanger%26aufirst%3DD.%26atitle%3DAmidomethyl-biaryl%2520Derivatives%2520Complement%2520Factor%2520D%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="note"><p class="first last">The enantiomer of <b>6</b> with (<i>R</i>)-2,3-dihydrobenzofuranyl-3-amine P1 moiety was found significantly less potent with an IC<sub>50</sub> of 1.90 μM against FXIa.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span>Of note, for the
assessment of
FXIa inhibition in human plasma we chose to use only the catalytic
domain of FXIa to prevent FXIa activation of endogenous substrates
present in the plasma (e.g FIX) which could lead to unintended activation
of the fluorescent peptide substrates used in the assay. Based on
crystallographic data of the delineated inhibitors in this manuscript
we do not expect substantial differences in potency would arise due
to differences between full length and catalytic domain variants.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Of+note%2C+for+the%0Aassessment+of%0AFXIa+inhibition+in+human+plasma+we+chose+to+use+only+the+catalytic%0Adomain+of+FXIa+to+prevent+FXIa+activation+of+endogenous+substrates%0Apresent+in+the+plasma+%28e.g+FIX%29+which+could+lead+to+unintended+activation%0Aof+the+fluorescent+peptide+substrates+used+in+the+assay.+Based+on%0Acrystallographic+data+of+the+delineated+inhibitors+in+this+manuscript%0Awe+do+not+expect+substantial+differences+in+potency+would+arise+due%0Ato+differences+between+full+length+and+catalytic+domain+variants."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veloso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shilling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitch, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colman, R. W.</span></span> <span> </span><span class="NLM_article-title">Recent evolutionary divergence of plasma prekallikrein and factor XI</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/0049-3848(86)90056-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2F0049-3848%2886%2990056-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=3638032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADyaL28XltFWjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1986&pages=153-160&author=D.+Velosoauthor=J.+Shillingauthor=J.+Shineauthor=W.+M.+Fitchauthor=R.+W.+Colman&title=Recent+evolutionary+divergence+of+plasma+prekallikrein+and+factor+XI&doi=10.1016%2F0049-3848%2886%2990056-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Recent evolutionary divergence of plasma prekallikrein and factor XI</span></div><div class="casAuthors">Veloso, D.; Shilling, J.; Shine, J.; Fitch, W. M.; Colman, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-60</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    </div><div class="casAbstract">The evolution in mammals of the zymogens of the contact activation system of coagulation (prekallikrein and blood-coagulation factors XI and XII) was investigated.  The N-terminal sequences of human blood plasma prekallikrein and the heavy and light chain of kallikrein were detd. and compared with those of bovine prekallikrein and of human and bovine factors XI and XII.  The human and bovine N-terminal sequences of the light chains (catalytic polypeptide) showed striking similarities both among themselves and with those of the catalytic polypeptide chains of other coagulation and digestive proteases, indicating a common origin.  Comparison of the N-terminal sequences of human prekallikrein with those of the bovine prekallikrein and human and bovine factors XIa and XIIa indicated a common origin of the heavy chain of kallikrein and factor XIa, different from that of either factor XIIa or other known amino acid sequences.  Ancestral sequences for human and bovine prekallikrein and factor XI, deduced by genetic anal. of the min. no. of base changes indicated that the N-terminus of prekallikrein and factor XI evolved at about the same rate.  The estd. time for the gene duplication was ∼124 million years ago, a value consistent with the age of the mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokCak9CrFNw7Vg90H21EOLACvtfcHk0li3WFvwgPLBsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XltFWjsL0%253D&md5=a2efc5a4cdbeec168a18339af8a1a2b1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2F0049-3848%2886%2990056-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0049-3848%252886%252990056-3%26sid%3Dliteratum%253Aachs%26aulast%3DVeloso%26aufirst%3DD.%26aulast%3DShilling%26aufirst%3DJ.%26aulast%3DShine%26aufirst%3DJ.%26aulast%3DFitch%26aufirst%3DW.%2BM.%26aulast%3DColman%26aufirst%3DR.%2BW.%26atitle%3DRecent%2520evolutionary%2520divergence%2520of%2520plasma%2520prekallikrein%2520and%2520factor%2520XI%26jtitle%3DThromb.%2520Res.%26date%3D1986%26volume%3D43%26spage%3D153%26epage%3D160%26doi%3D10.1016%2F0049-3848%2886%2990056-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girolami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarparo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candeo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, A. M.</span></span> <span> </span><span class="NLM_article-title">Congenital prekallikrein deficiency</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">695</span>, <span class="refDoi"> DOI: 10.1586/ehm.10.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1586%2Fehm.10.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=21091145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGktr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=685-695&author=A.+Girolamiauthor=P.+Scarparoauthor=N.+Candeoauthor=A.+M.+Lombardi&title=Congenital+prekallikrein+deficiency&doi=10.1586%2Fehm.10.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Congenital prekallikrein deficiency</span></div><div class="casAuthors">Girolami, Antonio; Scarparo, Pamela; Candeo, Nicole; Lombardi, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-695</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4086</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The congenital deficiency of prekallikrein (PK) is a rare condition in which there is a peculiar discrepancy between a severe in vitro defect and absence of bleeding.  The gene controlling PK synthesis is located on chromosome 4 and consists of 14 exons and 15 introns.  Only approx. 80 cases of PK deficiency have been described in the literature.  Owing to the lack of bleeding, most cases go undetected or, if detected, go unreported.  Occasional bleeding or thrombosis have been reported in a few patients but this was only due to the presence of assocd. risk factors.  It is certain that the defect does not protect from thrombosis.  Diagnosis is based on the presence of a great prolongation of partial thromboplastin time and normal prothrombin time and thrombin time.  The long partial thromboplastin time is fully cor. by the addn. of normal plasma or normal serum and presents the unusual feature of shortening on long incubation times.  Platelet and vascular tests are normal.  Immunol. studies allow differentiation into two types, namely cases of true deficiency, which are approx. 70% of the total, and cases with abnormal forms.  PK is a glycoprotein synthesized in the liver as a single-chain peptide of 88000 Da.  It mostly circulates (∼75%) as a complex with high-mol.-wt. kininogen.  It is cleaved by FXIIa into a heavy chain and a light chain (catalytic domain), held together by disulfide bonds.  Mol. biol. techniques have so far only been applied to eleven families, and these studies do not yet allow definite phenotype/genotype conclusions.  The exons involved are 5, 8, 11, 14 and 15.  The noncoagulative effects of PK, mainly based on the effect of kallikrein, have been studied less, since they appear to be the result of the involvement of other components of the contact phase.  Kallikrein can mainly affect the formation of bradykinin from high-mol.-wt. kininogen and the activation of pro-urokinase to urokinase.  Bradykinin causes inflammation, vasodilatation and an increase in vessel permeability.  The activation of pro-urokinase results in enhanced fibrinolysis.  However, fibrinolysis has been reported to be normal or defective in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOHzI3XZCgnLVg90H21EOLACvtfcHk0li3WFvwgPLBsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGktr3K&md5=9ba709f3bd31daa3935f853bb855c95d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1586%2Fehm.10.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fehm.10.69%26sid%3Dliteratum%253Aachs%26aulast%3DGirolami%26aufirst%3DA.%26aulast%3DScarparo%26aufirst%3DP.%26aulast%3DCandeo%26aufirst%3DN.%26aulast%3DLombardi%26aufirst%3DA.%2BM.%26atitle%3DCongenital%2520prekallikrein%2520deficiency%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2010%26volume%3D3%26spage%3D685%26epage%3D695%26doi%3D10.1586%2Fehm.10.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="note"><p class="first last">The correlation of FXI activity to 2xaPTT was determined via a calibration curve using FXI depleted plasma. Please see the supporting information for details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span>One advantage of employing the
PT assay is that it provides a more comprehensive assessment of off-target
coagulation modulation by compounds, in particular those which may
inhibit more than one proteases in the cascade, which would be challenging
to asses by individual biochemical selectivity values alone.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=One+advantage+of+employing+the%0APT+assay+is+that+it+provides+a+more+comprehensive+assessment+of+off-target%0Acoagulation+modulation+by+compounds%2C+in+particular+those+which+may%0Ainhibit+more+than+one+proteases+in+the+cascade%2C+which+would+be+challenging%0Ato+asses+by+individual+biochemical+selectivity+values+alone."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, P. A.</span></span> <span> </span><span class="NLM_article-title">The maximal affinity of ligands</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">9997</span>– <span class="NLM_lpage">10002</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.18.9997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1073%2Fpnas.96.18.9997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10468550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=9997-10002&author=I.+D.+Kuntzauthor=K.+Chenauthor=K.+A.+Sharpauthor=P.+A.+Kollman&title=The+maximal+affinity+of+ligands&doi=10.1073%2Fpnas.96.18.9997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49aR"><div class="casContent"><span class="casTitleNuber">49a</span><div class="casTitle"><span class="NLM_cas:atitle">The maximal affinity of ligands</span></div><div class="casAuthors">Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9997-10002</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We explore the question of what are the best ligands for macromol. targets.  A survey of exptl. data on a large no. of the strongest-binding ligands indicates that the free energy of binding increases with the no. of nonhydrogen atoms with an initial slope of ≈-1.5 kcal/mol (1 cal = 4.18 J) per atom.  For ligands that contain more than 15 nonhydrogen atoms, the free energy of binding increases very little with relative mol. mass.  This nonlinearity is largely ascribed to nonthermodynamic factors.  An anal. of the dominant interactions suggests that van der Waals interactions and hydrophobic effects provide a reasonable basis for understanding binding affinities across the entire set of ligands.  Interesting outliers that bind unusually strongly on a per atom basis include metal ions, covalently attached ligands, and a few well known complexes such as biotin-avidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0L6KZhR0TxbVg90H21EOLACvtfcHk0li40b5J0N1kDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D&md5=46fe894b016f3041831a2f0b71f812b1</span></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.9997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.9997%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DI.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DK.%2BA.%26aulast%3DKollman%26aufirst%3DP.%2BA.%26atitle%3DThe%2520maximal%2520affinity%2520of%2520ligands%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D9997%26epage%3D10002%26doi%3D10.1073%2Fpnas.96.18.9997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit49b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eZXZmaVQMidJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit49c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency indices as guideposts for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03386-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+efficiency+indices+as+guideposts+for+drug+discovery&doi=10.1016%2FS1359-6446%2805%2903386-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49cR"><div class="casContent"><span class="casTitleNuber">49c</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2eZXZmaVQMidJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit49c&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520efficiency%2520indices%2520as%2520guideposts%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469%26doi%3D10.1016%2FS1359-6446%2805%2903386-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit49d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bembenek, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tounge, B. A.</span></span> <span> </span><span class="NLM_article-title">The role of molecular size in ligand efficiency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4258</span>– <span class="NLM_lpage">4261</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.05.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2007.05.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=17532632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVKntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4258-4261&author=C.+H.+Reynoldsauthor=S.+D.+Bembenekauthor=B.+A.+Tounge&title=The+role+of+molecular+size+in+ligand+efficiency&doi=10.1016%2Fj.bmcl.2007.05.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49dR"><div class="casContent"><span class="casTitleNuber">49d</span><div class="casTitle"><span class="NLM_cas:atitle">The role of molecular size in ligand efficiency</span></div><div class="casAuthors">Reynolds, Charles H.; Bembenek, Scott D.; Tounge, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4258-4261</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ligand efficiency is a simple metric for assessing whether a ligand derives its potency from optimal fit with the protein target or simply by virtue of making many contacts.  Comparison of protein-ligand binding affinities for over 8000 ligands with 28 protein targets shows conclusively that the av. ligand binding affinities are not linear with mol. size.  It is therefore important to scale ligand efficiencies by the size of the ligand, particularly where small ligands (e.g., fragments) are involved.  The authors propose a simple 'fit quality' metric that removes this dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnIaZs8-gK1rVg90H21EOLACvtfcHk0li40b5J0N1kDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVKntbo%253D&md5=2f95a0b64b1da0755d7f624dad18b2bc</span></div><a href="/servlet/linkout?suffix=cit49d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.05.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.05.038%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26aulast%3DBembenek%26aufirst%3DS.%2BD.%26aulast%3DTounge%26aufirst%3DB.%2BA.%26atitle%3DThe%2520role%2520of%2520molecular%2520size%2520in%2520ligand%2520efficiency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4258%26epage%3D4261%26doi%3D10.1016%2Fj.bmcl.2007.05.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug+like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50aR"><div class="casContent"><span class="casTitleNuber">50a</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljHVKkgC3lHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug%2520like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Perola, E.</span></span> <span> </span><span class="NLM_article-title">An analysis of binding efficiencies of drugs and their leads in successful drug discovery programs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2986</span>– <span class="NLM_lpage">2997</span>, <span class="refDoi"> DOI: 10.1021/jm100118x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100118x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2986-2997&author=E.+Perola&title=An+analysis+of+binding+efficiencies+of+drugs+and+their+leads+in+successful+drug+discovery+programs&doi=10.1021%2Fjm100118x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">An Analysis of the Binding Efficiencies of Drugs and their Leads in Successful Drug Discovery Programs</span></div><div class="casAuthors">Perola, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2986-2997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the evolution of binding efficiency in successful drug discovery programs, a data set of 60 lead/drug pairs with known binding affinities has been compiled and analyzed.  Low-end thresholds for the binding efficiencies of viable leads and drugs have been derived.  On av., the drugs in the set are significantly larger and more potent but have similar lipophilicity relative to their originating leads, suggesting that the ability to maintain low levels of lipophilicity while increasing mol. wt. is one of the keys to a successful drug discovery program.  A no. of examples demonstrate that large increases in binding efficiency from leads to more elaborate drugs sharing the same scaffold can be achieved.  The importance of dissecting a lead structure to identify the most efficient fragments and the option of sacrificing binding efficiency to optimize other properties are discussed, and relevant examples are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRqzYFBuX2Q7Vg90H21EOLACvtfcHk0ljHVKkgC3lHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D&md5=a7eaad792f1518d093588951df64d22f</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1021%2Fjm100118x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100118x%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26atitle%3DAn%2520analysis%2520of%2520binding%2520efficiencies%2520of%2520drugs%2520and%2520their%2520leads%2520in%2520successful%2520drug%2520discovery%2520programs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2986%26epage%3D2997%26doi%3D10.1021%2Fjm100118x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4406</span>– <span class="NLM_lpage">4409</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB2+agonists+using+parallel+synthesis+protocols%3A+a+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50cR"><div class="casContent"><span class="casTitleNuber">50c</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0ljHVKkgC3lHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit50c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB2%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520a%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The thermodynamic basis for the use of lipophilic efficiency in enthalpic optimization</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+thermodynamic+basis+for+the+use+of+lipophilic+efficiency+in+enthalpic+optimization&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50dR"><div class="casContent"><span class="casTitleNuber">50d</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0li4G-6LSVfsJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit50d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520thermodynamic%2520basis%2520for%2520the%2520use%2520of%2520lipophilic%2520efficiency%2520in%2520enthalpic%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Practical application of ligand efficiency metrics in lead optimisation</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3015</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1016%2Fj.bmc.2018.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=29655612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVent7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3006-3015&author=J.+S.+Scottauthor=M.+J.+Waring&title=Practical+application+of+ligand+efficiency+metrics+in+lead+optimisation&doi=10.1016%2Fj.bmc.2018.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50eR"><div class="casContent"><span class="casTitleNuber">50e</span><div class="casTitle"><span class="NLM_cas:atitle">Practical application of ligand efficiency metrics in lead optimisation</span></div><div class="casAuthors">Scott, James S.; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3006-3015</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of composite metrics that normalize biol. potency values in relation to markers of physicochem. properties, such as size or lipophilicity, has gained a significant amt. of traction with many medicinal chemists in recent years.  However, there is no consensus on best practice in the area and their application has attracted some criticism.  Here we present our approach to their application in lead optimization projects, provide an objective discussion of the principles we consider important and illustrate how our use of lipophilic ligand efficiency enabled the progression of a no. of our successful drug discovery projects.  We derive, from this and some recent literature highlights, a set of heuristic guidelines for lipophilicity based optimization that we believe are generally applicable across chem. series and protein targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrcXUmwxG8rVg90H21EOLACvtfcHk0li4G-6LSVfsJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVent7g%253D&md5=50bba76316f6f2ec3c89e06f6717c388</span></div><a href="/servlet/linkout?suffix=cit50e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DPractical%2520application%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520lead%2520optimisation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3006%26epage%3D3015%26doi%3D10.1016%2Fj.bmc.2018.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span>The absolute
stereochemistry
was confirmed by chemical correlation via asymmetric synthesis and
via X-ray co-crystal structure of <b>13</b> and FXIa (not shown).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+absolute%0Astereochemistry%0Awas+confirmed+by+chemical+correlation+via+asymmetric+synthesis+and%0Avia+X-ray+co-crystal+structure+of+13+and+FXIa+%28not+shown%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span>The (R)-isomer, proved
to be
the less active isomer with a FXIa IC<sub>50</sub> of 0.005 μM
and IC<sub>50</sub> in the presence of plasma of 0.42 μM.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+%28R%29-isomer%2C+proved%0Ato+be%0Athe+less+active+isomer+with+a+FXIa+IC50+of+0.005+%CE%BCM%0Aand+IC50+in+the+presence+of+plasma+of+0.42+%CE%BCM."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span>Structurally, the activity
of
the (S)-isomer correlated well with the active (R) conformation of
the fused 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine <b>13</b>, described earlier with the S benzylic
hydroxyl group of <b>23</b> lying in the same trajectory as
the C3 carbon of the 3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Structurally%2C+the+activity%0Aof%0Athe+%28S%29-isomer+correlated+well+with+the+active+%28R%29+conformation+of%0Athe+fused+3%2C4-dihydro-2H-benzo%5Bb%5D%5B1%2C4%5Doxazine+13%2C+described+earlier+with+the+S+benzylic%0Ahydroxyl+group+of+23+lying+in+the+same+trajectory+as%0Athe+C3+carbon+of+the+3%2C4-dihydro-2H-benzo%5Bb%5D%5B1%2C4%5Doxazine."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwat, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smallwood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5339</span>– <span class="NLM_lpage">5356</span>, <span class="refDoi"> DOI: 10.1021/jm070245n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070245n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5339-5356&author=D.+J.+P.+Pintoauthor=M.+J.+Orwatauthor=S.+Kochauthor=K.+A.+Rossiauthor=R.+S.+Alexanderauthor=A.+Smallwoodauthor=P.+C.+Wongauthor=A.+R.+Rendinaauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=K.+Heauthor=B.+Xinauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Discovery+of+1-%284-methoxyphenyl%29-7-oxo-6-%284-%282-oxopiperidin-1-yl%29phenyl%29-4%2C5%2C6%2C7-tetrahydro-1H-pyrazolo%5B3%2C4-c%5Dpyridine-3-carboxamide+%28apixaban%2C+BMS-562247%29%2C+a+highly+potent%2C+selective%2C+efficacious%2C+and+orally+bioavailable+inhibitor+of+blood+coagulation+factor+Xa&doi=10.1021%2Fjm070245n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa</span></div><div class="casAuthors">Pinto, Donald J. P.; Orwat, Michael J.; Koch, Stephanie; Rossi, Karen A.; Alexander, Richard S.; Smallwood, Angela; Wong, Pancras C.; Rendina, Alan R.; Luettgen, Joseph M.; Knabb, Robert M.; He, Kan; Xin, Baomin; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5339-5356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efforts to identify a suitable follow-up compd. to razaxaban [i.e., 1-(3-amino-1,2-benzisoxazol-5-yl)-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide] focused on modification of a carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline.  Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained the potent factor Xa binding activity.  Exceptional potency of the series prompted an investigation of the neutral P1 moieties that resulted in the identification of the p-methoxyphenyl P1, which retained factor Xa binding affinity and good oral bioavailability.  Further optimization of the C-3 pyrazole position and replacement of the terminal P4 ring with a neutral heterocycle culminated in the discovery of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban).  Apixaban [i.e., 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide] exhibits a high degree of factor Xa potency, selectivity, and efficacy and has an improved pharmacokinetic profile relative to razaxaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbx6Ke9VLiirVg90H21EOLACvtfcHk0li4G-6LSVfsJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSmsbnF&md5=6620ac3af9109ab38bda8268d0ec446a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm070245n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070245n%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DDiscovery%2520of%25201-%25284-methoxyphenyl%2529-7-oxo-6-%25284-%25282-oxopiperidin-1-yl%2529phenyl%2529-4%252C5%252C6%252C7-tetrahydro-1H-pyrazolo%255B3%252C4-c%255Dpyridine-3-carboxamide%2520%2528apixaban%252C%2520BMS-562247%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520efficacious%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520blood%2520coagulation%2520factor%2520Xa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5339%26epage%3D5356%26doi%3D10.1021%2Fjm070245n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Buck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the GastroPlus Advanced Compartmental and Transit (ACAT) model in early discovery</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1007/s11095-016-1951-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=10.1007%2Fs11095-016-1951-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=27278908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOrsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=2126-2139&author=N.+Gobeauauthor=R.+Stringerauthor=S.+De+Buckauthor=B.+Faller&title=Evaluation+of+the+GastroPlus+Advanced+Compartmental+and+Transit+%28ACAT%29+model+in+early+discovery&doi=10.1007%2Fs11095-016-1951-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the GastroPlus Advanced Compartmental and Transit (ACAT) Model in Early Discovery</span></div><div class="casAuthors">Gobeau, N.; Stringer, R.; De Buck, S.; Tuntland, T.; Faller, B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2126-2139</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The aim of this study was to evaluate the oral exposure predictions obtained early in drug discovery with a generic GastroPlus Advanced Compartmental And Transit (ACAT) model based on the in vivo i.v. blood concn.-time profile, in silico properties (lipophilicity, pKa) and in vitro high-throughput absorption-distribution-metab.-excretion (ADME) data (as detd. by PAMPA, soly., liver microsomal stability assays).  Methods: The model was applied to a total of 623 discovery mols. and their oral exposure was predicted in rats and/or dogs.  The predictions of Cmax, AUClast and Tmax were compared against the observations.  Results: The generic model proved to make predictions of oral Cmax, AUClast and Tmax within 3-fold of the observations for rats in resp. 65%, 68% and 57% of the 537 cases.  For dogs, it was resp. 77%, 79% and 85% of the 124 cases.  Statistically, the model was most successful at predicting oral exposure of Biopharmaceutical Classification System (BCS) class 1 compds. compared to classes 2 and 3, and was worst at predicting class 4 compds. oral exposure.  Conclusion: The generic GastroPlus ACAT model provided reasonable predictions esp. for BCS class 1 compds.  For compds. of other classes, the model may be refined by obtaining more information on soly. and permeability in secondary assays.  This increases confidence that such a model can be used in discovery projects to understand the parameters limiting absorption and extrapolate predictions across species.  Also, when predictions disagree with the observations, the model can be updated to test hypotheses and understand oral absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI6kj-cQp2LLVg90H21EOLACvtfcHk0ljve62ObGdeBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOrsrk%253D&md5=7314c07ecba5be0c58b48f45d3b9d781</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs11095-016-1951-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-016-1951-z%26sid%3Dliteratum%253Aachs%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DStringer%26aufirst%3DR.%26aulast%3DDe%2BBuck%26aufirst%3DS.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DEvaluation%2520of%2520the%2520GastroPlus%2520Advanced%2520Compartmental%2520and%2520Transit%2520%2528ACAT%2529%2520model%2520in%2520early%2520discovery%26jtitle%3DPharm.%2520Res.%26date%3D2016%26volume%3D33%26spage%3D2126%26epage%3D2139%26doi%3D10.1007%2Fs11095-016-1951-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molander, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trice, S. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S. M.</span></span> <span> </span><span class="NLM_article-title">Scope of the two-step, one-pot palladium-catalyzed borylation/Suzuki cross-coupling reaction utilizing bis-boronic acid</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">8678</span>– <span class="NLM_lpage">8688</span>, <span class="refDoi"> DOI: 10.1021/jo301642v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo301642v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=8678-8688&author=G.+A.+Molanderauthor=S.+L.+J.+Triceauthor=S.+M.+Kennedy&title=Scope+of+the+two-step%2C+one-pot+palladium-catalyzed+borylation%2FSuzuki+cross-coupling+reaction+utilizing+bis-boronic+acid&doi=10.1021%2Fjo301642v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Scope of the Two-Step, One-Pot Palladium-Catalyzed Borylation/Suzuki Cross-Coupling Reaction Utilizing Bis-Boronic Acid</span></div><div class="casAuthors">Molander, Gary A.; Trice, Sarah L. J.; Kennedy, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8678-8688</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of bis-boronic acid for the direct synthesis of boronic acids has greatly facilitated the two-step, one-pot borylation/Suzuki cross-coupling reaction between aryl and heteroaryl halides.  With use of Buchwald's second-generation XPhos preformed catalyst, high yields of cross-coupled products were obtained for most substrates.  The method also allows an efficient two-step, one-pot synthesis, providing access to three distinct cross-coupled products after column chromatog.  The method also provides a rapid and convenient route to teraryl compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDMxPPa0A15rVg90H21EOLACvtfcHk0ljve62ObGdeBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO&md5=80b369825dd060e4e3d243d3c85a9354</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjo301642v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo301642v%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DTrice%26aufirst%3DS.%2BL.%2BJ.%26aulast%3DKennedy%26aufirst%3DS.%2BM.%26atitle%3DScope%2520of%2520the%2520two-step%252C%2520one-pot%2520palladium-catalyzed%2520borylation%252FSuzuki%2520cross-coupling%2520reaction%2520utilizing%2520bis-boronic%2520acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D8678%26epage%3D8688%26doi%3D10.1021%2Fjo301642v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS4','PDB','6TS4'); return false;">PDB: 6TS4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QMT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QMT','PDB','6QMT'); return false;">PDB: 6QMT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS7','PDB','6TS7'); return false;">PDB: 6TS7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T7P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T7P','PDB','6T7P'); return false;">PDB: 6T7P</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS6','PDB','6TS6'); return false;">PDB: 6TS6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USY','PDB','6USY'); return false;">PDB: 6USY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS5','PDB','6TS5'); return false;">PDB: 6TS5</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00279">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23770"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00279?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00279</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis and characterization of compounds <b>4</b>, <b>25</b>, <b>26</b>, <b>28</b>, <b>29</b>, <b>40</b>, <b>41</b>, <b>47</b>, <b>48</b>, <b>51</b>, and <b>58</b>; crystallographic structure determination of PKL in complex with <b>4</b> and of fXIa in complex with compounds <b>2</b>, <b>3</b>, <b>7</b>, <b>15</b>, and <b>23</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_001.pdf">jm0c00279_si_001.pdf (421.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00279/suppl_file/jm0c00279_si_002.csv">jm0c00279_si_002.csv (1.87 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and structure factors for the crystal structures of PKL with compound <b>4</b> and of FXIa with compounds <b>2</b>, <b>3</b>, <b>7</b>, <b>15</b>, and <b>23</b> can be accessed using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T7P">6T7P</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS4">6TS4</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS7">6TS7</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS6">6TS6</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TS5">6TS5</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6USY">6USY</a>, respectively.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00279&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00279%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00279" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992fe4ce923d06","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
